CA2465247C - Benzimidazoles and analogues and their use as protein kinases inhibitors - Google Patents

Benzimidazoles and analogues and their use as protein kinases inhibitors Download PDF

Info

Publication number
CA2465247C
CA2465247C CA2465247A CA2465247A CA2465247C CA 2465247 C CA2465247 C CA 2465247C CA 2465247 A CA2465247 A CA 2465247A CA 2465247 A CA2465247 A CA 2465247A CA 2465247 C CA2465247 C CA 2465247C
Authority
CA
Canada
Prior art keywords
benzoimidazol
pyrazol
carboxylic acid
dimethyl
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2465247A
Other languages
French (fr)
Other versions
CA2465247A1 (en
Inventor
Michael Louis Edwards
Paul Joseph Cox
Shelley Amendola
Stephanie Daniele Deprets
Timothy Alan Gillespy
Christopher David Edlin
Andrew David Morley
Charles J. Gardner
Brian Pedgrift
Herve Bouchard
Didier Babin
Laurence Gauzy
Alain Le Brun
Tahir Nedeem Majid
John C. Reader
Lloyd J. Payne
Nawaz M. Khan
Michael Cherry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0113868A external-priority patent/FR2831537B1/en
Priority claimed from GB0206893A external-priority patent/GB0206893D0/en
Priority claimed from GB0206895A external-priority patent/GB0206895D0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CA2465247A1 publication Critical patent/CA2465247A1/en
Application granted granted Critical
Publication of CA2465247C publication Critical patent/CA2465247C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

THIS IS VOLUME OF

NOTE: For additional volumes please contact the Canadian Patent Office.

BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS
This invention is directed to benzimidazoles of formula (Ix), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases.
Such protein kinases belong especially to the following group: EGFR, Fak, FLK-1, FGFRl, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2, VEGFR, ITK and SYK.

Protein kinases are a family of enzymes that participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the etivironment. In general, these kinases fall into several groups; those which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues and those which preferentially catalyse the phosphorylation of hydroxy grbups of tyrosine residues [S.K.Hanks and T.Hunter, FASEB. J., 1995, 9, pages 576-596]. Such phosphorylations may greatly modify the function of the proteins; thus, protein kinases play an important role in regulating a wide variety of cell processes including, especially, metabolism, cell proliferation, cell differentiation or cell survival.
Ainong the various cellular functions in which the activity of a kinase protein is involved, certain processes represent attractive targets for treating certain diseases. As an example, mention may be made especially of angiogenesis and the control of the cell cycle, in which kinase proteins can play an essential role. These processes are essential for the growth of solid tumours and also for other diseases.
Angiogenesis or the formation of new blood vessels by sprouting from the preexisting vasculature is of central importance for embryonic development and organogenesis. Should the need arise, the vascular system has the potential to generate a network of new vessels so as to maintain the correct functioning of the tissues and organs. Angiogenesis is a complex multistage process which includes activation, migration, proliferation and survival of endothelial cells. In adults, angiogenesis is fairly limited, appearing mainly only in the processes of repair after an injury or of vascularization of the endometrium. (Merenmies et al., Cell Growth & Differentiation, 8, 3-10, 1997).
However, uncontrolled angiogenesis is found in certain pathologies such as retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration or cancer (solid tumours) (Folkman, Nature Med., 1, 27-31, 1995). The kinase proteins whose involvement it has been possible to demonstrate in the angiogenesis process include three members of the family of growth factor receptor tyrosine kinases: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR, kinase insert domain receptor, or FLK-1), FGF-R (fibroblast growth factor receptor) and TEK (also known as Tie-2).
In conjunction with other systems, the Vascular Endothelial Growth Factor receptors (VEGFRs) transmit signals involved in the migration, proliferation and survival of endothelial cells. The family VEGFR includes VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR3 (F1t4). The receptor VEGF-R2, which is expressed only in the endothelial cells, binds to the angiogenic growth factor VEGF, and thus serves as a transduction signal mediator via the activation of its intracellular kinase domain. Thus, the direct inhibition of the kinase activity of VEGF-R2 makes it possible to reduce the phenomenon of angiogenesis in the presence of exogenous VEGF (Strawn et al., Cancer Research, 56, 3540-3545, 1996), this process being demonstrated especially with the aid of VEGF-R2 mutants (Millauer et al., Cancer Research, 56, 1615-1620, 1996). The VEGF-R2 receptor appears to have no other function in adults than that associated with the angiogenic activity of VEGF. Thus, a selective inhibitor of the kinase activity of VEGF-R2 should show only little toxicity.

In addition to this central role in the dynamic angiogenic process, recent results suggest that the expression of VEGF contributes towards the survival of tumoral cells after chemotherapy and radiotherapy, underlining the potential synergism of KDR inhibitors with other agents (Lee C.G., Heijn M. et al., (2000), Cancer Research, 60 (19), 5565-70). The KDR inhibitors thus especially constitute anti-angiogenic agents and such agents might be used as a first line treatment against tlie emergence or regrowth of malignant tumours. The inhibition or regulation of VEGFR-2 (KDR) thus provides a powerful new mechanism of action for the treatment of a large number of solid tumours.

Extensive studies in the field of tumor angiogenesis in the past two decades have identified a number of therapeutic targets including kinases, proteases and integrins resulting in the discovery of many new anti-angiogenic agents, including KDR inhibitors some of which are currently under clinical evaluation (Jekunen, et al Cancer Treatment Rev. 1997 , 23, pages 263-286.).

The present patent application thus relates particularly to novel inhibitors of the VEGFR-2 (KDR) receptor that may be used especially for anti-angiogenic treatment in oncology.

The protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include for example, protein kinase C isoforms [A.C.Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cyclin-dependent kinases such as cdk2 [J.Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197]. The protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [S.Iwashita and M.Kobayashi, Cellular Signalling, 1992, 4, pages 123-132], and cytosolic non-receptor kinases such as p561ck, p59fYn, ZAP-70 and csk kinases [C.Chan et. al., Ann. Rev. Immunol., 1994,12, pages 555-592].
Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, for example by failure of the proper control mechanisms for the kinase, related for example to mutation, over-expression or inappropriate activation of the enzyme; or by over- or underproduction of cytokines or growth factors also participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.
SYK (Spleen Tyrosine Kinase) is a 72-kDa cytoplasmic protein tyrosine kinase that is expressed in a variety of hematopoietic cells and is an essential element in several cascades that couple antigen receptors to cellular responses. Thus, SYK plays a pivotal role in signalling of the high affinity IgE
receptor, FcgRl, in mast cells and in receptor antigen signalling in T and B
lymphocytes. The signal transduction pathways present in mast, T and B cells have common features. The ligand binding domain of the receptor lacks intrinsic tyrosine kinase activity. However, they interact with transducing subunits that contain immunoreceptor tyrosine based activation motifs (ITAMs) [M.Reth, Nature, 1989, 338, pages 383-384]. These motifs are present in both the (3 and y subunits of the FcERl, in the ~-subunit of the T cell receptor (TCR) and in the IgGa and IgG (3 subunits of the B cell receptor (BCR). [N.S.van Oers and A.Weiss, Seminars in Immunology, 1995, 7, pages 227-236] Upon binding of antigen and multimerization, the ITAM residues are phosphorylated by protein tyrosine kinases of the Src family. SYK belongs to a unique class of tyrosine kinases that have two tandem Src homology 2 (SH2) domains and a C terminal catalytic domain. These SH2 domains bind with high affinity to ITAMs and this SH2 -mediated association of SYK with an activated receptor stimulates SYK kinase activity and localises SYK to the plasma membrane.

In SYK deficient mice, mast cell degranulation is inhibited, suggesting that this is an important target for the development of mast cell stabilising agents [P.S.Costello, Oncogene, 1996, 13, pages 2595-2605]. Similar studies have demonstrated a critical role for SYK in BCR and TCR signalling [A.M.Cheng, Nature, 1995, 378, pages 303-306, (1995) and D.H.Chu et al., Immunological Reviews, 1998, 165, pages 167-180]. SYK also appears to be involved in eosinophil survival in response to IL-5 and GM-CSF [S.Yousefi et al., J. Exp. Med., 1996, 183, pages 1407-1414].
Despite the key role of SYK in mast cell, BCR and T cell signalling, little is known about the mechanism by which SYK
transmits downstream effectors. Two adaptor proteins, BLNK (B cell Linker protein, SLP-65) and SLP-76 have been shown to be substrates of SYK in B cells and mast cells respectively and'nave been postulated to interface SYK with downstream effectors [M.Ishiai et al., Immunity, 1999, 10, pages 117-125 and L.R.Hendricks-Taylor et al., J.Biol. Chem, 1997, 272, pages 1363-1367]. In addition SYK
appears to play an important role in the CD40 signalling pathway, which plays an important role in B
cell proliferation [M.Faris et al., J.Exp. Med., 1994, 179, pages 1923-1931].

SYK is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [F.Yanaga et al., Biochem. J., 1995, 311, (Pt. 2) pages 471-478].

ITK, is a T cell specific tyrosine kinase of the Tec family that is required for normal Th2 function.
Asthma is a disease characterised by increased Th2 cytokine production including IL-4. An inhibitor of ITK should therefore have an impact on disease progression in asthma through inhibition of Th2 cytokine production.

We have now found a novel group of benzimidazoles, which have valuable pharmaceutical properties, in particular, the ability to inhibit protein kinases, more particularly, the ability to inhibit the protein kinase SYK, the protein kinase KDR, the protein kinase tie2 or the protein kinase ITK.

Thus, in one aspect, the present invention is directed to pharmaceutical compositions comprising compounds of general formula (Ix):-Y N
II R
X~
W N

(Ix) wherein, for the purposes of (Ix):-X represents C-R2 and W, Y and Z, which may be identical or different, represent CH or CR3; or W represents CH, X represents N, Y represents CH or CR3, and Z represents CH
or CR3; or W represents N, X represents CH or CR2, Y represents CH and CR3, and Z
represents CH or CR3; or W represents N, X represents CH or CR2, Y represents N, and Z is CH or CR3; or W represents N, X represents CH or CR2, Y represents CH or CR3, and Z
represents N; or W represents N, X represents N, Y represents CH or CR3, and Z represents CH or CR3;
A5 represents H or alkyl;
Rl represents aryl or heteroaryl, each optionally substituted by one or more groups selected from carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NYlY2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NYIY2, -N(R6)C(=O)OR4, -N(R6)S02R4, -N(R6)SO2NYlY2, -NYlY2, -OR4, -OCF2H, -OCF3, -OC(=O)R4, -OC(=O)NYlY2, -OS(O)nR4, -S(O)nR4, -S(O)nNYlY2 and -S(O) nOR4;
R2 and R3 are such that:

R2 and R3, which may be identical or different, represent H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NYlY2, -C(=O)OR4, -NNYlY2, -N(R6)C(=O)R4, -N(R6)C(=0)NYlY2, -N(R6)C(=O)OR4, -N(R6)SO,R4, -N(R6)SO2NYlY2, -OR4, -OCF2H, -OCF3, -OC(=O)R4, -OC(=0)NYlY2, -S(O)nR4, -S(O)nNYlY2 or -S(O) nOR4; or R2 represents H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=0)NYlY2, -C(=O)OR4, -NYlY2, -N(R6)C(=O)R4, -N(R6)C(=O)NYlY2, -N(R6)C(=O)OR4, -N(R6)SO,,R4, -N(R6)SO2NY1Y2, -OR4, -OCF2H, -OCF3, -OC(=0)R4, -OC(=0)NYlY2, -S(O)nR4, -S(O)nNYlY2 or -S(O) nOR4 and R3 represents allcyl, haloalkyl, halogen and OR6; or R2 and R3 groups on adjacent carbon atoms may form a 5- to 6-membered carbon-based ring containing one or more heteroatoms, which may be identical or different, chosen from 0, N and S, and which may be optionally substituted by alkyl [examples include those where 0 and R3 form a group selected from -O-CH2-O-, -O-CH2-CH2-O-; -CH2-O-CH2-, -CH2-N(R14)-CH2-, -CH2-CH2-CH2-, -CH2-C(CH3)2-CH2-, -CH2-O-CH2-CH2-, -CH2-N(R14)-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-C(CH3)2-CH2-CH2-, -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-or -CH=CH-CH=N, in which R14 is H or a1ky1)];

R4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each optionally substituted with one or more substituents selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, halo, hydroxy, hydroxyalkyl, -C(=O)NY3Y4, -C(=0)OR6, -N(R6)C(=0)NYlY2, -NYlY2, -OR5 or alkyl substituted by -NY3y4;

R5 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R6 is chosen from the values of R5;
n is zero or an integer 1 or 2;

Yland Y2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, heterocycloalkylalkyl or alkyl optionally substituted by one or more groups selected from cyano, aryl, heteroaryl, hydroxy, -C(=O)OR6, -C(=O)NY3y4, -N-y3y4 or -OR5, or the group -NYlY2 may form a cyclic amine;

Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may form a cyclic amine;
all the alkyl (or alk, which represents alkyl), alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-COalk), -C(=O)OR6, -C(=O)R6, hydroxyalkyl, carboxyalkyl, S(O)n-alk, S(O)n-NH2, S(O)n NH(alk), S(O)ri N(alk)2, CF3, OCF3, NO2, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, -C(=O)-NY3Y4 and NY3Y4 radicals, the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(O)R5;
and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and their prodrugs, and their acid bioisosteres; together with one or more pharmaceutically acceptable carriers or excipients.

In another aspect, the invention concerns the compounds of formula (Ix) as defined above wherein Rl ~
is a pyrazolyl moiety in which R7 is hydrogen or alkyl, and R8 and R9 are N~N R~

independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NYlY2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -N(R6)SO2NYlY2, -NYlY2, -OR4, -OC(=O)R4, -OC(=O)NYlY2, -S(O)nR4 and -S(O)2NYlY2; or R8 and R9 together with the carbon atoms to which they are attached form (i) a 5 to 8 membered carbocyclic ring optionally substituted by one or more carbocyclic ring substituents; (ii) a phenyl ring optionally substituted by one or more aryl group substituents;
(iii) a 5 or 6 membered heteroaromatic ring in which one or more of the ring members is/are nitrogen, oxygen or sulfur (examples of such groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups) and which is optionally substituted by one or more groups selected from haloalkyl, hydroxy, halo, cyano, nitro, R4, -C(=O)NYlY2, -N(R6)C(=O)R4, -N(R6)C(=O)NYlY2, -N(R6)S02R4, -NYlY2 and -OR5; or (iv) a 5 or 6 membered heterocyclic ring optionally substituted by alkyl or oxo, and containing a heteroatom-containing group selected from 0, S, SO2, or NY5 (where Y5 is hydrogen, R4, -C(=O)R4, -C(=O)NYlY2, -C(=O)OR4 or -S02R4); but excluding the compounds:
2-(2H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-methyl-2H-pyrazol-3-yl)-1H-benzoimidazole; 5-methyl-6-[2-(2H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-4,5-dihydro-2H-pyridazin-3-one;
5-methyl-6-[2-(2H-pyrazol-3 -yl)- 1 H-benzoimidazol-4-yl] -4,5 -dihydro-2H-pyridazin-3 -one; 3,5-bis(benzimidazol-2-yl)-1H-pyrazole; 5,6-dimethyl-2-(5-methyl-lH-pyrazol-3-yl)-1H-benzoimidazole; 6-methyl-2-(5-methyl-lH-pyrazol-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(5-methyl-lH-pyrazole-3-yl)-1H-benzoimidazole; 5-nitro-2-(5-methyl-lH-pyrazole-3-yl)-1H-benzoimidazole; 2-(5-methyl-lH-pyrazole-3-yl)-1H-benzoimidazole-5-carboxylic acid; 2-(5-phenyl-lH-pyrazole-3-yl)-1H-benzoimidazole; 5,6-dimethyl-2-(5-phenyl-lH-pyrazole-3-yl)-1H-benzoimidazole; 5-methyl-2-(5-phenyl-lH-pyrazole-3-yl)-1H-benzoimidazole; 6-chloro-2-(5-methyl-lH-pyrazole-3-yl)-1H-benzoimidazole; 5-chloro-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(5-phenyl-lH-pyrazole-3-yl)-1H-benzoimidazole; N-[2-(5-isoquinolin-4-yl-lH-indazol-3-yl)-3H-benzoimidazol-5-yl]-methanesulfonamide; 3-(1H-benzoimidazol-2-yl)-5-(1H-indazol-4-yl)-1H-indazole, 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-2-methoxyphenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-5-yl]isoquinoline; 4-{3-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-indazol-5-yl}-isoquinoline; 4-[3-(4-chloro-lH-benzoimidazol-2-yl)-1H-indazol-5-yl]-isoquinoline; 4-[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-phenol; 3-[5-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole;
3-[5-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-[5-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-(1H-benzoimidazol-2-yl)-5-phenyl-lH-indazole; 2-(4-bromo-l-methyl-lH-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-tert-butyl-lH-pyrazol-3-yl)-1H-benzoimidazole; 3-(1H-benzoimidazol-2-yl)-6-(3-methoxy-phenyl)-1H-indazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid; 5-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-2-hydroxy-benzoic acid methyl ester; 5-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-f-uran-2-carboxylic acid methyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-4-methoxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (5-hydroxy-lH-pyrazol-3-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-pyrazol-3-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-[4-(2-hydroxy-ethyl)-piperidin-l-yl]-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (9H-purin-6-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid dimethylamide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-morpholin-4-yl-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyrazin-2-ylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid cyclohexylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-indazol-5-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-pyrrolidin-1-yl-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-indazol-5-yl)-amide; [3-(1H-benzoiinidazol-2-yl)-1H-indazol-6-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-(4-methyl-piperazin-1-yl)-methanone; 1-{4-[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-piperazin-l-yl}-ethanone; 3-(1H-benzoimidazol-2-yl).-1H-indazole-6-carboxylic acid (6-methoxy-pyridin-3-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyridin-4-ylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (2-hydroxy-ethyl)-methyl-amide; 3-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-butyric acid ethyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-propyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid phenylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyridin-3-ylamide; 3-(6-methoxy-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-6-pyridin-4-yl-lH-indazole; 3-(5-chloro-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-dimethoxy-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5-fluoro-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6-tert-butyl-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6,7-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-dichloro-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-difluoro-lH-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-fluoro-4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-2,3-dimethyl-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-2-methyl-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid cyclopropylamide; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-sulfonic acid amide; 4-[3-(6-dimethylamino-lH-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-carboxylic acid methylamide; 3-methoxy-4-{3-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-indazol-6-yl}-phenol; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 4-[3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-2-methoxy-phenol; 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3,5-dimethyl-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-phenoxy-phenol;
4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-benzene-1,3-diol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-2-methoxy-phenol;
N-{3-[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-phenyl}-benzamide; 6-[2-(1,5-dimethyl-1H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[2-(1-methyl-1H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-4,5-dihydro-2H-pyridazin-3-one;
8-(1,5-dimethyl-1H-pyrazol-3-yl)-7H-purine; 2-(1,5-dimethyl-lH-pyrazol-3-yl)-1H-imidazo[4,5-b]pyridine and 2-(5-methyl-lH-pyrazol-3-yl)-1H-imidazo[4,5-b]pyridine.

In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (Ix) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.
For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above for compounds of formula (Ix), and throughout the description of the invention hereinafter, the following terms unless otherwise indicated, shall be understood to have the following meanings:-"Patient" includes both human and other mammals.
"Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986,2l,p283 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995, pages 34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design";
Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include:
-C(=O)-NHOH, -C(=O)-CH2OH, -C(=O)-CH2SH, -C(=O)-NH-CN, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroarylsulfonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydoxy-l-methylpyrazolyl.

"Acyl" denotes a radical R-C(=O)- in which R represents a radical chosen from a hydrogen atom, linear or branched alkyl radicals containing not more than 6 carbon atoms;
optionally substituted amino; aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals, for example phenyl or pyrrolidinyl radicals: the term "acyl" thus especially denotes, for example, formyl radicals and acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, benzoyl and pyrrolidinylcarbonyl radicals.

"Acylainino" denotes -C(=O)-NH2, -C(O)-NH(alk) and -C(O)-N(alk)(alk) radicals:
in these radicals, NH(alk) and N(alk)(alk) have the meanings given hereinafter defined.

"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain and containing one or more double bonds. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. "Branched," as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain, which may be straight or branched.
Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl, decenyl, and 3,7-dimethyl-octa-2,6-dienyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein.
Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.
"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be a straight or branched chain having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl and dodecyl, and also the linear or branched positional isomers thereof. Exemplary alkyl groups substituted by one or more halogen atoms include trifluoromethyl, difluoromethyl, trifluoroethyl and difluoroethyl.
"Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

"Alkylenedioxy" means an -O-alkylene-O- group in which alkylene is as defined above. Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.

"Alkylsulfinyl" means an alkyl-SO- group in which the alkyl group is as previously described.
Preferred alkylsulfinyl groups are those in which the alkyl group is C1-4alkyl.

"Alkylsulfonyl" means an alkyl-S02- group in which the alkyl group is as previously described.
Preferred alkylsulfonyl groups are those in which the alkyl group is C1-4alkyl.
"Alkylsulfonylcarbamoyl" means an alkyl-S02-NH-C(=0)- group in which the alkyl group is as previously described. Preferred alkylsulfonylcarbamoyl groups are those in which the alkyl group is C 1-4alkyl.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, hexylthio, isohexylthio and heptylthio, and also the linear or branched positional isomers thereof. Preferred alkylthio groups have not more than 4 carbon atoms.

"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having about 2 to about 15 carbon atoms in the chain.
Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.
"Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which a monocyclic aromatic carbocyclic moiety and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Except where otherwise defined, aryl groups may be substituted with one or more aryl group substituents, which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylallcyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, -C(=O)NYlY2, -NY1-C(=O)alkyl, -NY1SO2alkyl, -NYlY2, -SO2NYlY2 or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, -C(=0)OR6, -C(=O)NYlY2, -NYlY2 or -OR5.
"Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C1-4alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl group is as previously described.
Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl group is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described.
An exemplary arylalkylthio group is benzylthio.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include phenoxy and naphthoxy, each optionally substituted.

"Aryloxycarbonyl" means an aryl-O-C(=O)- group in which the aryl group is as previously described.
Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

"Arylsulfinyl" means an aryl-SO- group in which the aryl group is as previously described.
"Arylsulfonyl" means an aryl-S02- group in which the aryl group is as previously described.
"Arylsulfonylcarbamoyl" means an aryl-S02-NH-C(=O)- group in which the aryl group is as previously described.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.

"Carbocyclic" means a saturated ring system comprising carbon atoms.

"Carbocyclic group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, -C(=O)NYlY2, -NYI-C(=O)alkyl, -NY1SO2all.yl, -NYlY2, -SO2NYlY2 or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, -C(=O)OR6, -C(=O)NYlY2, -NYlY2 or -OR5.

"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system wherein one of the ring carbon atoms is replaced by nitrogen and which (i) may also contain a further heteroatom-containing group selected from 0, S, SO2, or NY6 (where Y6 is hydrogen, alkyl, aryl, arylalkyl, -C(=0)R5, -C(=O)OR5, -C(=O)NYlY2 or -S02R5); and (ii) may be fused to additional aryl (e.g. phenyl), heteroaryl (e.g. pyridyl), heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system.
Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoline and the like groups.

"Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms.
Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cycloheptenyl.

"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms, optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C3-8cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.
"Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro, bromo and chloro.
"Haloalkyl" means an alkyl group having about 1 to about 6 carbon atoms in the chain and substituted by one or more halo atoms. Exemplary haloalkyl groups include trifluoromethyl.

"Heteroaroyl" means a heteroaryl-C(=O)- group in which the heteroaryl group is as described herein.
Exemplary heteroaryl groups include pyridylcarbonyl.

"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaryl moiety is as previously described.
"Heteroaryl" as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzoimidazolyl, benzothiazolyl, furyl, imidazolyl, indazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above except where otherwise defined); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a monocyclic heteroaromatic moiety and a cycloalkyl, cycloalkenyl or heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include tetrahydro-indazole, tetrahydro-pyrazolopyridine, 5-oxo-1,4,5,6,7,8,9,9a-octahydro-1,2,4,5a-tetraza-cyclopenta[a]naphthyl, optionally substituted by one or more "aryl group substituents" as defined above, except where otherwise defined). Optional substituents include one or more "aryl group substituents" as defined above, except where otherwise defined. When Rl is heteroaryl this may particularly represent pyrazolyl, triazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, imidazolyl, pyrrolyl, furanyl, thiophenyl, phenyl, pyridinyl, oxodihydropyridinyl, pyrimidinyl, indolyl, indazolyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, or oxodihydropyridinopyrazolyl.
"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties afe as previously described. Preferred heteroarylalkyl groups contain a C1-4alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.

"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.
"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.
"Heteroarylsulfonylcarbamoyl" means a heteroaryl-S02-NH-C(=0)- group in which the heteroaryl group is as previously described.

"Heterocycloalkyl" means: (i) a cycloalkyl group of about 3 to 10 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from 0, S and NY6 and may be optionally substituted by oxo (examples of such groups include hexahydropyran, pyrrolidinyl, piperidinyl, tetrahydropyranyl and octahydro-pyrido[1,2-c]pyrimidin-l-one); (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl) ring, each optionally substituted by one or more "aryl group substituents," and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).

"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.
"Hydroxyalkyl" means an alkyl group substituted by one or hydroxy groups.

"NH(alk)" and "N(alk)(alk)" denote an amino radical substituted, respectively, with one or two alkyl radicals, such alkyl radicals being linear or branched and chosen from alkyl radicals as defined above, preferably containing not more than 4 carbon atoms.

"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (Ix), including N-oxides thereof. For example an ester of a compound of formula (Ix) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively, an ester of a compound of formula (Ix) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
Suitable esters of compounds of formula (Ix) containing a hydroxy group are, for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-(3-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

Suitable esters of compounds of formula (Ix) containing a carboxy group are, for example, those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.
An especially useful class of esters of compounds of formula (Ix) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32 , pages 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an allcylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

Where the compound of the invention of formula (Ix) contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, omithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

Some of the compounds of the present invention of formula (Ix) are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.
Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when coinbined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, wlien the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobronudes, sulfates, phosphates, nitrates, sulfamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

As well as being useful in themselves as active compounds, salts of compounds of the invention of compounds of formula (Ix) are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

It will be appreciated that compounds of the present invention of formula (Ix) may contain asymmetric centres. These asymmetric centres may independently be in either the R or S
configuration. It will be apparent to those skilled in the art that certain conipounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (Ix) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates. Additionally, tautomers of the compounds of formula (Ix) are possible, and the present invention is intended to include all tautomeric forms of the compounds.
One subject of the present invention is thus the compounds of formula (I):

Y z N
11 \> Rl X~, W CN

A5 (I) in which:
X represents C-R' and W, Y and Z, which may be identical or different, represent CH or CR3;
R' represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno-pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydropyridinopyrazolyl radicals, all these radicals being optionally substituted with one or more radicals X', X2 or X3 chosen from H, halogen, haloalkyl, OH, W, NO2, CN, S(O)nR4, OR¾, NY'Y', COR4, -C(=0)NY'Y', -C(=O)OR4, -C(=O)OH, -N(R6)C(=O)R4, -N(R6)SO,R4, -N(R6)C(=O)NY'Y2, -N(R6)C(=O)OR4, -S(O)nOR¾, -S(O)õNY'Y', -OC.(=O)NY'Y', -OS(O)õR4, -OC(=O)R4 and optionally substituted thienyl, R' and R3 are such that:
either R' and R3, which may be identical or different, represent H, W, halogen, haloalkyl, OH, NO2,, CN, OR4, COR 4, S(O)õR4, -C(=O)NYIY', -C(=O)OR4, -C(=O)OH, -NY'Y', -N(R6)C(=O)R4, -N(R6)SO,R4, -N(R6)C(=O)NY'Y', -N(R6)C(=0)OR¾, -S(O)õOR4, -S(O)õNY'Y'', -OC(=0)NY'Y' and -OC(=O)R`' or R' represents H, R4, halogen, haloalkyl, OH, NO2), CN, OR¾, COR4, S(O)r,R4, -C(=O)NY'Y', -C(=O)OW, -C(=O)OH, -NY'Y2, -N(R6)C(=O)W, -N(W)SO'R4, -N(R6)C(=O)NY'Y2, -N(R6)C.(=O)OW, -S(O)nOR4, -S(O)õNY'Y2, -OC(=0)NY'Y2 and -OC(=O)R4 and R3 represents alkyl, haloalkyl, halogen and OW

or R' and R3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from 0, N and S, R4 represents alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl (optionally substituted), halogen, alkyl, hydroxyalkyl, OH, ORS, C(=O)NY3Y4, NY3Y4, alk-NY3Y4 and C(=0)OR6, RS represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.
Y' and Y' are such that: either Y' and Y2, which may be identical or different, represent H and optionally substituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, or Y' and Y2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical, Y3 and Y4 are such that: either Y3 and Y4, which may be identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y3 and Y4 form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical, A5 represents H or alkyl, R6 is chosen from the values of R5, all the alkyl (or alk, which represents alkyl), alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-COalk), -C(=0)OR6 , acyl -C(=O)R6, hydroxyalkyl, carboxyalkyl, S(O)n alk, S(O),,-NH2, S(O),,-NH(alk), S(O),,-N(alk)2, CF3, OCF3, NO2, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, -C(=0)-NY3Y4 and NY3Y4 radicals, the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(O)R5, the phenyl radicals furthermore being optionally substituted with a dioxole radical, n represents an integer from 0 to 2, it being understood that when R' represents an indazolyl radical to give the compounds of formula (F) below:
w \ N
X ' \N
~ N~ H
H (F) with X representing H, R' or R3 as defined above, then W necessarily represents H or unsubstituted alkyl, the said compounds of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compoundss of formula (I) as defined above corresponding to the formula (Ia):

Ya,Za N
I I ~>--- R,a Xa.Wa.

A5 (1a) in which:
Xa represents C-R2a and Wa, Ya and Za, which may be identical or different, represent CH or CR3a;
Rla represents aryl or heteroaryl chosen from pyrazolyl, triazolyl and indazolyl radicals, all these radicals being optionally substituted with one or more radicals X'a, X'a or X3a chosen from H, halogen, OH, R4a, OWa, NY'aY'a, S(O)õWa, -C(=O)NY'aY'a, -C(=O)OR4a, -N(R~a)C(=O)Wa, -N(R'a)SO-,R4a, -N(R6a)C(=O)NYIaY2a, -N(R6a)C(=O)OR¾a, -OC(=O)NYIaY'a, -OC(=0)R4a, -OS(O)õR4 a and thienyl optionally substituted with an alkyl radical, Wa and R3a are such that:
either Wa and R3a, which may be identical or different, represent H, R4a, halogen, OH, OR4a, C(=O)NY'aY2a, -C(=O)OR4a and -C(=O)OH, and R3a represents allcyl, halogen and OR6a, or Wa represents H, R4a, halogen, OH, OR4a, C(=O)NY'aY2a, -C(=O)OR4a and -C(=O)OH, and R3a represents alkyl, halogen and OR6a, or Wa and R3a together form an -O-CHZ-O- or -O-CH2-CH2,-O- ring, Wa represents allcyl, alkenyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl (optionally substituted), halogen, alkyl, hydroxyalkyl, OH, ORSa, C(=O)NY3aY4a, NY3aY4a, alk-NY3aY4a and C(=O)OR6a, RSa represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl, all these radicals being optionally substituted, Y'a and Y2a are such that: either Y'a and Y2a, which may be identical or different, represent H, alkyl, alkoxyalkyl, aryloxyalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted, or Yla and Y2a form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical, Y3a and Y4a are such that: either Y3a and Y¾a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl, or Y3a and Y¾a form, together with the nitrogen atom to which they are attached, a cyclic amino radical, A5 represents H or alkyl, all the alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-C(O)R6a), -C(=O)OR6a, acyl -C(=O)R6a, hydroxyalkyl, carboxyalkyl, S(O)n-alk, S(O)n NH,, S(O),,-NH(alk), S(O),,-N(alk)2, CF3, OCF3, NO7,, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, -C(=0)-NY3aY4 a and NY3aY4 a radicals, the latter radicals containing alkyl, aryl and heteroaryl themselves being optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, alkoxy radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(O)R6 a, the phenyl radicals furthermore being optionally substituted with a dioxole radical, R6a is chosen from the values of R5a, n represents an integer from 0 to 2, the said compounds of formula (Ia) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compounds of formula (I):
Y~'z N
I I ~>--- Rl X, W N

A5 (I) in which:
X represents C-R2 and W, Y and Z, which may be identical or different, represent CH or CR3;
R' represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno-pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyrano-pyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydro-pyridinopyrazolyl radicals, all these radicals optionally being substituted with one or more radicals Xl, X2 or X3 chosen from H, halogen, haloalkyl, OH, R4, NO2,, CN, S(O)õR4, OR4, NY'Y2, COR4, -C(=O)NY'Y2, -C(=O)OR4, -C(=O)OH, -N(R6)C(=O)R4, -N(R6)SO,W, -N(R6)C(=O)NY'Y', -N(R6)C(=O)OR4, -S(O)õOR4, -S(O)nNY'Y', -OC(=O)NY'Y', -OS(O) R4, -OC(=O)R4 and optionally substituted thienyl, W and R-' are such that:
either R' and R3, which may be identical or different, represent H, R4, halogen, haloalkyl, OH, NO', CN, OW, COR4, S(O),,W, -C(=O)NY'Y2, -C(=O)OW, -C(=O)OH, -NY'Y2, -N(R6)C(=O)R¾, -N(R6)SO2R4, -N(R6)C(=0)NY1Y2, -N(R6)C(=O)OR4, -S(O)nOR4, -S(O)nNY1Y2, -OC(=O)NY'Y' and -OC(=O)W
~
or R' represents H, R`', halogen, haloalkyl, OH, NOz, CN, OR4, COR¾, S(O)õR~, -C(=O)NY Y-, -C(=O)OR¾, -C(=O)OH, -NY'Y2, -N(R6)C(=O)W, -N(R6)SO,R4, -N(R6)C(=O)NY'Y', -N(R6)C(=O)OR¾, -S(O)"OR4, -S(O),'NYIY', -OC(=O)NY'Y'` and -OC(=O)R4 and R3 represents alkyl, haloalkyl, halogen and OR6 or R2 and R3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from 0, N and S, W represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, hetero-arylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, OR5, C(=O)NY3Y4, NY3Yd and C(=O)OR6, Rj represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylallcyl and heterocycloalkylalkyl.
R6 represents H and Cl-C4 alkyl, n represents an integer from 0 to 2 Y' and Y2 are such that: either Y' and Y2, which may be identical or different, represent H, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, all these radicals being optionally substituted with one or more radicals chosen from hydroxyl, -C(=O)-NY" Y4, -C(=O)OR6 and NY3Y4, or Y' and Y2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical, Y3 and Y4 are such that: either Y3 and Y4, which may be identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y3 and Y4 form, together with the nitrogen atom to which they are attached, a cyclic amino radical, A5 represents H or alkyl, it being understood that when R' represents an indazolyl radical to give the compounds of formula (F) below:

w ~ ~
X l ,N C N

N H
H (F) with X representing H, R2 or R3 as defined above, then W necessarily represents H or unsubstituted alkyl, the said compounds of formula (F) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.
It is obvious that, according to the ring represented by R' and its number of members, R' can comprise one, two or three substituents represented by X', X2 and X3.

One subject of the present invention is thus the compounds of formula (I) as defined above corresponding to the formula (1a):

Ya,Za N
.
II ~>--Ria Xa.Wa N

(Ia) in which:
Xa represents C-R'a and Wa, Ya and Za, which may be identical or different, represent CH or CR3a;
Rla represents aryl or heteroaryl chosen from pyrazolyl, triazolyl or indazolyl radicals, all these radicals being optionally substituted with one or more radicals X'a, X2a or X3a chosen from H, halogen, OH, R¾a, OR4a, NY'aY2a, S(O)nR4a, -C(=O)NY'aY2a, -C(=O)OR¾a, -N(R6a)C(=0)R4a, -N(R6a)SO,R'a, -N(R6a)C(=O)NY'aY'`a, -N(R6a)C(=0)OR4a, -OC(=O)NY'aY2a and -OC(=O)R4a, -OS(O)nR4a and thienyl optionally substituted with an alkyl radical, R''a and R3a are such that:
either RZa and R3a, which may be identical or different, represent H, R4a, halogen, OH, OR4a, C(=O)NYIaYZa, -C(=O)OR¾a, -C(=O)OH, and R3a represents alkyl, halogen and OR6a, or R2a represents H, R¾a, halogen, OH, OWa, C.(=O)NYlaY'a, -C(=O)OR4a, -C(=O)OH, and R3a represents alkyl, halogen and OR6, or R2a and R3a together form an -O-CH2,-O or -O-CH?-CH2-O- ring, R4a represents alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, heteroarylalkyl or arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, ORSa, C(=O)NY3aY4 a, NY3aY4 a and C(=O)OR6a, R5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylallcyl and heterocycloalkylalkyl, R6a represents H and C1-C4 alkyl, n represents an integer from 0 to 2, Y'a and Y'a are such that: either Y'a and Y2a, which may be identical or different, represent H, alkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted with one or more radicals chosen from hydroxyl, -C(=0)-NY3Y¾, -C(=O)OR6 and NY3Y4, or Y'a and Y2a form, together with the nitrogen atom to which they are attached, a cyclic amino radical, Y3a and Y4 a are such that: either Y3a and Y4a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl, or Y3a and Y4a form, together with the nitrogen atom to which they are attached, a cyclic amino radical, A5 represents H or alkyl, the said compounds of formula (Ia) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compounds of formula (1) as defined above corresponding to the formula (IA):

A, I ~>-A
A

A4 A5 (IA) in which A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from 0, N
and S, this heterocycle A being optionally substituted with one or more radicals XA1, XA2 or XA3 chosen from the values indicated hereinabove for the radicals X~, X2 or X3, Al, A, A3 and A4, which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, aryl, heteroaryl and aryloxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6A7 such that either A6 and A7, which may be identical or different, are chosen from a hydrogen atom and optionally substituted alkyl, alkoxyalkyl, phenoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl radicals, or A6 and A7 form, together with the nitrogen atom to which they are attached, an optionally substituted 5- or 6-membered cyclic radical, it being understood that two consecutive radicals among Al, A2, A3 and A4 can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more hetero atoms, wliich may be identical or different, chosen from 0, N
and S, A5 represents a hydrogen atom or an alkyl radical, R6b represents hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, phenylallcyl and cycloalkylalkyl, all the alkyl, alkenyl, aryl, heteroaryl, aryloxy, cycloalkyl and heterocycloalkyl radicals present in the above radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR), -C(=0)OR6b, acyl -C(=O)R6b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, S(O),,-alk, S(O)õNH,, S(O)õNH(alk), S(O)n N(alk)2, CF3, OCF3, NO-2, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=0)-NHZ, -C(=O)-NH(alk) and C(=O)-N(alk)2 radicals, all the above alkyl, alkenyl, alkoxy and alkylthio radicals being linear or branched and containing not more than 4 carbon atoms, all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical, n represents an integer from 0 to 2, the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).
A subject of the present invention is thus the compounds of formula (I) as defined above, corresponding to the formula (IAa):

A,a A2a N
I ~>-Aa A3a N
A4a A5a (IAa) in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA', XA' or XA3 chosen from the values indicated hereinabove for the radicals X', X' or X3, Aia, A2a, A3a and A4a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6 aA7 a such that either A6 a and A7a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A6a and A7a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl or phenyl radical, which are themselves optionally substituted, it being understood that two consecutive radicals from among Ala, A,a, A3a and A4a may form, with the benzimidazole radical to which they are attached, an optionally substituted 5- to 6-membered carbon-based ring containing one or two oxygen atoms, A5a represents a hydrogen atom or an alkyl radical, the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms, the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).

The substituents X', X2 and X3 as defined above are in particular such that one represents a hydrogen atom and the other two, which may be identical or different, are chosen from halogen atoms and OH, R4a, OR4a, CF3, OCF3, NO7, CN, NY'aY2a, acylamino (NH-COR6b), S(O)õalk, S(O)õNH,, S(O),,-NH(alk), S(O),,-N(alk)2, -C(=O)-NH2,, -C(=O)-NH(alk), C(=O)-N(alk)2, -C(=O)OR4a, -N(R'b)C(=O)Wa, -N(R6 b)SO,,R4a, -N(R6b)C(=0)NY'aY2a, -N(R~b)C(=O)OR4a, -OC(=O)NY'aY2a and thienyl radicals, the thienyl radical being optionally substituted with an alkyl radical, R4a, Y'a, Y2a and R6 b having the values defined above and alk representing a linear or branched allcyl radical including not more than 6 carbon atoms and optionally substituted as indicated above.

All the alkylthio radicals are such that the sulfur atom is optionally oxidized to sulfone or sulfoxide with one or two oxygen atoms.
Tables I, II and III described below give examples of compounds illustrating the present invention, with in particular substituents chosen from the values of Xl, X2 and X3 as defined above.
TABLE I

R

RB ""'". N
):D
`; 1 N
N H
H

o):=O o oo HN x HN ~ HN ~ Q
I DI 7 'N \ N HN v N N N
~ N H I ~ N ::c[N
N
~
N ~
H H H H H C H HN.
/
-N):=O H ~.N H

HN \ x HN ~ x HN ~CO x NN :)CrN N rm\'~ N ~N ~ ~
N H .N
N
H H H H
with X represents hydrogen, halogen or alkoxy as defined above.
TABLE II

R`
N-R
` N f N
I-' ti H
H

H N \N N
CI CI
N O / H N~ ~~N O CI
N N CI ~' ' N
N H ~ N H
H NN O H
N` H H
H H H N~
N I\NN N ~~N o I
N~"\N N H
~ N N H
::cc N H H
H H

N O H H N
)QN~NOC F\N I /
)NJNOC ~ H
H N H H
H
H
~ .S~ ~
N N N;S~ N
~~~ .y' NO OO IN ~ N N NH ~v N H )NJNd"b N
H H H H

HN
N
~ H N O O )XbocQ N~ ~
H H .y~N
H I N H
H
H ~
\ N ~ N; S CI
I ~NO O, CI
N H
H

in which NR'R represents NYIYZ as defined above.
TABLE III

R

N N
)(::CN H
H

OH NH2 HaN HO

x x x X
)C\'NN )I'NN ~ N. ~ N N\N
DCCN H
H H H H N
H

O O
....-x x x )(~c N N.N )00 N N QN)N
N N
H H H H
in which X represents hydrogen, alkynyl or NHCOCHZPh which is optionally substituted.

The subject of the present invention is thus the compounds of formula (I) as defined above in which the substituents of the said compounds of formula (I) have the any of the values indicated as defined hereinabove and in which the aryl radicals represent the phenyl and naphthyl radicals; the heteroaryl radicals represent the furyl, thienyl, benzothienyl, thianthrenyl, pyridyl, pyrazolyl, benzimidazolyl, benzofuran, isobenzof-uran and dihydrobenzofuran radicals; the cycloalkyl radicals represent a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical; the heterocycloalkyl radicals represent the hexahydropyran, piperidyl or morpholino radicals; the heterocycloalkylalkyl radicals represent the hexahydropyranylalkyl, piperidylallryl and morpholinoalkyl radicals; the arylalkyl radicals represent the phenylalkyl, ethylenedioxyphenylalkyl and naphthylalkyl radicals; the heteroarylalkyl radicals represent the thienylalkyl, pyridylalkyl, furylalkyl, pyrazolylalkyl, benzothienylalkyl, dihydrobenzofuranylalkyl and benzimidazolylalkyl radicals; the aryloxy radicals represent the phenoxy and naphthyloxy radicals; the arylalkoxy radicals represent the phenylalkoxy and naplithylalkoxy radicals; and the aryloxyalkyl radicals represent the phenoxyalkyl radical;
all these radicals being optionally substituted as indicated hereinabove.

One subject of the present invention is, more particularly, the compounds of formula (I) as defined above corresponding to the formula (IA):

A, I ~>--- A

A N
3 \

(IA) in which A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from 0, N and S, this heterocycle A optionally being substituted with one or more radicals XA', XA2 or XA3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals or thienyl radicals optionally substituted with an alkyl radical, Al, A2, A3 and A4, which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6A' such that either A6 and A7, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and heteroarylalkyl radicals, or A6 and A7 form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical, it being understood that two consecutive radicals among Al, A2, A3 and A4 can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from 0, N
and S, A5 represents a hydrogen atom or an alkyl radical, all the phenyl, phenoxy, cycloalkyl and heteroarylalkyl radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms, the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

A subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAb):
Alb Azb N
I \
Ab A3b N

A4b '45b (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, -OR6 b (including alkoxy), -COR6 b, -O-COR6 b, -OS(O) R6b, -O(CH,,)R CO-R6 b, phenyl, phenylalkyl, CF3, OCF3, NO2, CN, NY'bY2b, -NH-C(=O)NY'bY'b, acylamino (NH-CO-R6b), S(O)õalk, S(O)-NY'bY'b, -C(=O)-NY'bY2b, -C(=O)OR6 b, -NH-C(=O)R6 b, -NH-S(O)õR6b, -NH-C(=O)OR6b, -N(R6 b)C(=O)NY'bY'b, -OC(=O)NY'bY'b and thienyl radicals, all these radicals being optionally substituted, with NY'bY'b such that either Y'b and Y2b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Ylb and Y2b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical, Alb, A,b, A3b and A4b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, -OR6b (including alkoxy), -CO-R~b, -O-COR6 b, -OS(O)õR'b, -O(CH2)n CO-R6 b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6 bA7b such that either A6b and A7b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benz-imidazolylalkyl radicals, all these radicals being optionally substituted, or A6b and A7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted, it being understood that two consecutive radicals among Alb, A?b, A3b and A4b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimid-azole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical, A5b represents a hydrogen atom, all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR6 b), -C(=O)OR6b, acyl -C(=O)R6b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, S(O)õalk, S(O)õNH,, S(O), NH(alk), S(O)õ-N(alk),, CF3, OCF3, NO?, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylallcoxy, -C(=O)-NH?, -C(=O)-NH(alk) and C(=O)-N(alk)2 radicals, with n representing an integer from 0 to 2, and R6 b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, -NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF3, OCF3, alkyl, phenyl-S(O)n-alk-phenyl, alkoxy, NH,,, NHalk, N(alk)2, SO2INH.2, SO2Nalk or SO2N(alk)2 radical, all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms, all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical, the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

One subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, alkoxy, phenyl, phenylalkyl, CF3, OCF3, NO2, CN, NY'bY2b, -NH-C(=O)NY'bY'b, acylamino (NH-CO-R6b), S(O), alk, S(O),,-NY'bY'b, -C(=O)-NYIbY'b, -C(=O)ORbb, -NH-C(=O)R6b, -NH-S(O)õR6 b, -NH-C(=O)OR6 b, -N(R~b)C(=O)NY'bY'b, -OC(=O)NY'bY'b and thienyl radicals which are optionally substituted, with NY'bY'b such that either Y'b and Y2b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Ylb and Y2b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical, Aib, A?b, A3b and A4b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6 bA7 b such that either A6 b and A'b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A6 b and A'b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted, it being understood that two consecutive radicals among Alb, A,b, A3b and A4b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical, A5b represents a hydrogen atom, all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR6b), -C(=O)OR6b, acyl -C(=O)R6b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, S(O),; alk, S(O)õNH2, S(O)õNH(alk), S(O),,-N(alk)2, CF3, OCF3, NOz, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH2, -C(=O)-NH(alk) and C(=0)-N(alk)2 radicals, with n representing an integer from 0 to 2, and R~b representing hydrogen, allcyl, alkenyl, cycloalkyl, phenyl, phenylalkyl and cycloalkylalkyl, all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms, all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical, the said compounds of formula (lAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (lAb) in which Ab represents a pyrazolyl radical substituted with one or two radicals such that one is chosen from hydrogen, halogen atoms and alkyl, alkynyl, -COR6 b, phenyl, phenylalkyl, CF3, NO2, CN, NY'bY'b, -NH-C(=0)NY'bY2b, NH-CO-R6 b, S(O),,-alk, S(O),,-NY'bY'b, -C(=O)-NY'bY2b, -C(=O)OR6b, -NH-C(=O)R6b, -NH-S(O)õR6b, -NH-C(=O)OR6b, -N(R6 b)C(=O)NY'bY'b and thienyl radicals, all these radicals being optionally substituted, and the other is chosen from OH, -OR6b, -O-COR6 b, -OS(O),,R6b, -O(CHZ)n CO-R6b and -OC(=O)NY'bY'b radicals, all these radicals being optionally substituted, with NYIbY'b such that Y'b and Y2b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y'b and Y2b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical, Alb, A2b, A3b and A4b, which may be identical or different, are such that two of them represent hydrogen and the other two, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, -OR6 b (including alkoxy), -CO-R6b, -O-COR6b, -OS(O)õR6b, -O(CH,)R CO-R6b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6 bA7b such that either A6 b and A7b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benz-imidazolylalkyl radicals, all these radicals being optionally substituted, or A6b and A7b foim, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted, A5b represents a hydrogen atom, all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino (NH-COR6 b), -C(=O)OR6b, acyl -C(=O)R6b, hydroxyalkyl, carboxyalkyl, phenoxyallcyl, S(O), alk, S(O)õNH,, S(O),,-NH(alk), S(O),,-N(alk),, CF3, OCF3, NO2, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH2, -C(=O)-NH(alk) and C(=O)-N(alk)2 radicals, with n representing an integer from 0 to 2, and R6b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, -NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF3, OCF3, alkyl, phenyl-S(O)n-alk-phenyl, alkoxy, NH2, NHalk, N(alk)2, SO2NH2, SOzNalk or SO,N(alk), radical, all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms, all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical, the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of forrnula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals, Alb, A-,b, A3b and A4b, which may be identical or different, are chosen from a hydrogen atom;
halogen atoms; radicals of the following types: hydroxyl, alkyl, alkenyl optionally substituted with phenyl itself optionally substituted with one or more halogen atoms, alkoxy, nitro, cyano, furyl, thienyl optionally substituted with acyl COalk, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy which are optionally substituted; and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6 bA7 b such that either A6 b and A'b, which may be identical or different, are chosen from hydrogen and radicals of the following types : alkyl, alkoxyalkyl containing not more than 6 carbon atoms, phenoxyalkyl optionally substituted with acylamino NH-C(O)alk, phenyl, optionally substituted phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl optionally substituted with one or more alkyl radicals, naphthylalkyl, thienylalkyl optionally substituted with alkyl or thienyl, piperidylalkyl optionally substituted with a carboxyl radical which is free, salified or esterified with an alkyl radical, pyridylalkyl optionally substituted with one or more radicals chosen from halogen and CF3, benzothienylallcyl, pyrazolylalkyl optionally substituted with one or more alkyl radicals, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl, and benzimidazolylalkyl optionally substituted with one or more alkyl radicals, or A6 b and A7b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical, it being understood that two consecutive radicals among Aib, A,,b, A3b and A4b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical, A5a represents a hydrogen atom, the phenyl, phenoxy and phenylalkyl radicals above being optionally substituted with one or more radicals chosen from halogen atoms, hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and NH-COalk radicals, a carboxyl radical which is free, salified or esterified with an alkyl radical, and hydroxyalkyl, carboxyalkyl, phenoxyalkyl, alkylthio, SO2alk, SO-2NH2, S02-NH(alk), SO,,-N(alk)z, CF3, OCF3, NOZ, CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, -C(=O)-NH2, -C(=0)-NH(alk), C(=O)-N(alk)2 and C(O)CH3 radicals, all the allryl or alk, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 4 carbon atoms, all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical, the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab, Alb, A~b, A3b, A4b and A5b have any of the meanings indicated hereinabove, and when one of Alb, A2b, A3b and A4b represents a carboxyl radical amidated with a radical NA6 bA'b, then either one of A6 b and A'b represents a hydrogen atom or an alkyl radical and the other of A6 b and A'b is chosen from the values defined for A6 b and A'b, or A6 b and A7b form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical, the other substituents of the said compounds of formula (I) having the any of the values indicated hereinabove, the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above in which X, W, Y and Z are such that two or three of them represent CH and the others are chosen from the values of CR' or CR3 and, if appropriate, i.e., when two of them represent CH and CRZ and CR3 are adjacent to each other, can form a dioxole radical, R', R3 and the other substituents of the said compounds of formula (I) having any of the values as defined hereinabove, the said compounds of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (I).

The present invention thus relates in particular to the compounds of formula (IA) as defined above in which Al, & A3 and A4 are such that two or three of them represent a hydrogen atom and the others are chosen from the values of Al, A2, A3 and A4 and, if appropriate, i.e., when two of them represent a hydrogen atom and the other two are on adjacent carbons, can form a dioxole radical, the other substituents of the compounds of formula (IA) having any of the values as defined hereinabove, the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

A subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAa):

Ala A2a N
I \> Aa A3a N
A4a A5a (IAa) in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA1, XA2 or XA3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals and thienyl radicals optionally substituted with an alkyl radical, Ala, A,,a, A3a and A4a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA6 aA'a such that either A6 a and A7 a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A6a and A7a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl or phenyl radical, which are themselves optionally substituted, it being understood that two consecutive radicals from among Ala, A,,a, A3a and A4a may form, with the benzimidazole radical to which they are attached, an optionally substituted 5- to 6-membered carbon-based ring containing one or two oxygen atoms, A5a represents a hydrogen atom or an alkyl radical, the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms, the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).

One subject of the present invention is, more particularly, the compounds of formula (I) as defined above in which R represents a pyrazolyl or indazolyl radical, the other substituents having the values indicated above or below.
Among the preferred compounds that are particularly noted are the compounds of formula (I) in which Aa represents a pyrazolyl or indazolyl radical optionally substituted as indicated above and below, Ala, A?a, A3a and A4a are chosen from the following values:
- Aia represents hydrogen or carboxyl or forms a ring with the adjacent member A,,a - A4a represents hydrogen or carboxyl or forms a ring with the adjacent member A3a - A2a represents a carboxyl radical that is free, salified, esterified with an optionally substituted alkyl radical or an amidated carboxyl as indicated above or below, - A2a and A3a represent two optionally substituted alkyl radicals, A5 represents hydrogen.

One subject of the present invention is, even more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAb):
Al' b AP N
~}-- Ab y\
A3b A4b A5b (lAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals, Alb, A~b, A3b and A4b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl and alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical that is free, salified, esterified with an alkyl radical or amidated with a radical NA6 bA'b such that either A6 b and A7 b, which may be identical or different, are chosen from alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and furylalkyl radicals, or A6b and A'b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl radical, it being understood that two consecutive radicals from among Alb, A~b, A3b and A4b may form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or 4,5-methylenedioxybenzimidazole radical, A5b represents a hydrogen atom, the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and free, salified or esterified carboxyl radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 4 carbon atoms, the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer from, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).
With reference to formula (Ix) above, the following are particular and preferred groupings:

Rl may particularly represent optionally substituted heteroaryl. Exemplary optionally substituted heteroaryls include dihydrofuropyrazolyl, imidazolyl, indazolyl, indolyl, isoxazolyl, oxodihydropyridazinyl, oxodihydropyridinopyrazolyl, oxodihydropyridinyl, oxotetrahydropyrrolopyrazolyl, pyrazolyl, thiazolyl, thienopyrazolyl, tetrahydrocyclopentapyrazolyl, tetrahydroindazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, tetrahydropyrrolopyrazolyl or triazolyl. Optional substituents include one or more groups selected from carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NYlY2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NYlY2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -N(R6)SO2NYlY2, -NYlY2, -OR4, -OCF2H, -OCF3, -OC(=O)R4, -OC(=0)NYlY2, -S(O)nR4 and -S(0)2NYIY2. Rl Rs more preferably represents a heteroaryl moiety in which R7, R8 and R9 are as hereinbefore defined. It will be appreciated that compounds of formula (Ix) in which Rl represents a Rs heteroaryl moiety and R7 is hydrogen can exist in the tautomeric forms N'N R7 R9 ~
s R
Y N Z Rs jQNH W H X' W N N--NH

Z N Z 10 I and Y ~
W CN --N Xl- W N N' N
H H H

W may particularly represent CH when X is CR2, Y is CH or CR3 an.d Z are CH or CR3.
W may also particularly represent CH when X is N, Y is CH or CR3 and Z is CH
or CR3.

W may also particularly represent N when X is CH or CR2, Y is CH or CR3 and Z
is CH or CR3.
W may also particularly represent N when X is CH or CR2, Y is CH or CR3 and Z
is N.

It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.
A particular group of compounds of the invention are compounds of formula (Ixa):-Y C N Rs ~
~
W H N~N R7 (Ixa) in which W, X, Y, Z and R7 are as hereinbefore defined for compounds of formula (Ix), and R8 and R9 are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NYIY2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NYlY2, -N(R6)C(=O)OR4, -N(R6)S02R4, -NYlY2, -OR4, -OC(=O)R4, -OC(=O)NYlY2, -S(O)nR4 and -S(O)2NYlY2;
and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y
represents CH and Z
represents CH or C-CH3 are preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Z
represents CH and Y
represents:

(i) C-Cl-q.allcyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2];

(ii) C-aryl [e.g. C / \ , C / \ , C / \

CH3 , C / \ , C / \ , C / \ Cl , F O

-~
C / \ or C / O ,];
(iii) C-CN;
(iv) C-NO2;

(v) C-halo [e.g. C-Br, C-Cl or C-F];
(vi) C-haloalkyl [e.g. C-CF3];

N
(vii) C-heteroaryl [e.g. C / \N or C

(viii) C-OR4 [e.g. C-OCH3 , C-OCH2CH3 , C-OCHFZ , C-OCF3 , C-O / \
C-O-CH, or C-O-(CH2)2 N --~O

(ix) C-C.(=0)R4 [e.g. C-C(=0) o ];

(x) C-C=O)NYlY2 [e.g. C-C(=O)-NH-CH3 , C-C(=O)-N(CH3)z , C-C(=O)-NH-CH,CH3 , C-C(=O)-NH-CH(CH3)2 , C-C(=O)-NH-C(CH3),-CH,OH , C-C(=O)-NH-CH,CHZCN , C-C(=O)-NH-CH2CH,OCH3 , C-C(=O)-NH-CH2 ~

C-C(=O)-NH-CH, / \ , C-C(=O)-NH-CHZ / \ , C.-C(=O)-NH-CHZ / CH3 C-C(=O)-NH-CHz / \
N-C-C(=O)-NH-CH2 / \ C-C(=O)-NH-(CH2)2 / \
-N -C-C(=O)-NH-(CH,)Z N O, C-C(=O)-NH-(CH,)Z N , \-j H
N-- \
C-C(=O)-NH-(C,H,)<\ N , C-C(=O)-NH-(CH,)3 N
N/ ~N
O

C-C(=O)-NH-(CH,)3 N or C-C(=0)-NH
(xi) C-C(=O)OR4 [e.g. C-C(=0)OH or C-C(=O)OCH3];

(xii) C-NHC(=0)R4 [e.g. C-NHC(=O)CH3, C-NHC(=0)CH(CH3)2, C-NH-C(=O) o or C-NH-C(=O)-CH2 \ /]; or (xiii) C-CH(OH)aryl [e.g. C-CH(OH) \ / ];

(xiv) C-S(O)2NYlY2 [e.g. C-SO; NH-CHz (xv) C-S(O)nR4 [e.g. C-SO2CH3];

are also preferred.
Compounds of formula (Ixa) in which W represents CH, X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl, Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH` / \ and Z represents CH are also preferred.
Compounds of formula (Ixa) in which W represents CH, X represents CH, Y
represents C-CH3 and Z
represents C-CH3 are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-O-CH2-, and Z represents CH are also preferred.
Compounds of formula (Ixa) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH7)-CH2-CH2-, and Z represents CH are also preferred.
Compounds of formula (Ixa) in which R7 represents hydrogen are preferred.

Compounds of formula (Ixa) in which R8 represents:
(i) hydrogen;
(ii) C1-4alkyl [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)CH2CH3];
(iii) -SR`i [e.g. -S-CH3 , -S-CH2CH3 or -S-CH---a -S-CHz / \ , -S-CH2 O-OCH 3 , N S
-S-CH,-CH, / ~ , -S-CH, / ~ or -S-CH2 ~ I
(iv) -NYlY2 [e.g. or \-j (v) -OR5 [e.g. -OCH?CH3]

are preferred.

Compounds of formula (Ixa) in which R9 represents:
(i) hydrogen;
(ii) C1-7alkyl [e.g. -CH3, -CH2CH2CH3, -CH(CH3)2 or -CH2-CH2-CH(CH3)2];
(iii) aryl [e.g. phenyl];
(iv) -C(=O)NY'Y2 [e.g. -C(=O)-NH-CH2CH3 , -C(=O)-NH-CHzCH,CH3 , -C(=O)-NH-CHzCH(CH3)2 , -C(=O)-NH-CH(CH3), , -C(=O)-NH-C(CH3)3 , -C(=O)-NH-C(CH3)2CH2OH , -C(=O)-NH-CH2CH,OCH3 , -C(=O)-N(CH3)2 , -C(=O)-N(CH,CH3)Z , -C(=O)-NH--a I -C(=O)-NH-CHa or -C(=O)-NH O ];
(v) -N(R6)C(=O)R¾, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYlY2 or -OR5 [e.g.
-NH-C(=O)-CH3 , -NH-C(=O)-(CH,),CH3 , -NH-C(=O)-CH(CH3), , -NH-C(=O)-C(CH3)3 , -NH-C(=O)-CH2CH(CH3)1 , -NH-C(=O)-CH(CH3)CH,CH3 , -NH-C(=O)-CH2C(CH3)3 , -NH-C(=O)-CH2 -NH-C(=0)-CI z<
~- N
-NH-C(=O)-CH2 N/\ / N , -NH-C(=O)-CHZ N(CH3)2 , N

~
-NH-C(=O)-CHTN -NH-C(=O)-CHz N O or -NH-C(=O)-CHZOCH3 ], (b) R4 is aryl [e.g.

-NH-C(=O) \ / , -NH-C(=O) or -NH-C(=O) \ / CH3 ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)---<
or -NH-C(=O) ], (d) R4 is heteroaryl [e.g. -NH-C(=O) 0~/
O' H;C

O
-NH-C(=0) iN O
H C ' -NH-C(=0) /~ or -NH-C(=O) C\N ] or (e) heterocycloalkyl [e.g.
-NH-C(=O) O ];
(vi) -N(R6)C(=0)NYIY', particularly -NHC(=O)NY'Y' [e.g. -NH-C(=0)-NHCH3 , -NH-C(=0)-NHCH,CH3 , -NH-C(=0)-NHCH(CH3)2 ' -NH-C(=O)-NHCH,CH(CH3)Z ' -NH-C(=O)-NHC(CH3); ~
-NH-C(=O)-N(CH3)2 ' -NH-C(=O)-N(CH,CH3); 1 -NH-C(=0)-NH--a > -NH-C(=O)-NH-CH,a -NH-C(=0)-NH-CH:, / \ , -NH-C(=O)-NH / \ , -NH-C(=O)-N , -NH-C(=O)- N N-CH3 or -NH-C(=0)-N O ];

(vii) -NYlY2 [e.g. -NHZ]; or (viii) alkyl substituted by -N(R6)C(=O)NYlY2 [e.g. -CH2-NH-C(=O)-CH(CH3)2 or -CHz NH-C(=0)- O 1;

are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W
represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R7 represents hydrogen; R8 represents (i) hydrogen, (ii) C1-4alkyl [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)CH2CH3], (iii) -SR4 [e.g. -S-CH3 , -S-CH1CH3 or -S-CH---<

, -S-CH2/ \ , -S-CH2 / Y-OCH 3 , -S-CH2 CH2 01 N
-S-CHZ ~ ~ or -S-CHZ (iv) -NYlY2 [e.g. -N O ] or (v) -OR5 --[e.g. -OCH2CH3]; R9 represents (i) hydrogen; (ii) C1-7alkyl [e.g. -CH3, -CH2CH2CH3, -CH(CH3)2 or -CH2-CH2-CH(CH3)2]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NY'Y2 [e.g.
-C(=O)-NII-CH2CH3 , -C(=O)-NH-CH,CH,CH3 , -C(=O)-NH-CHZCH(CH)2 , -C(=O)-NH-CH(C.H3)21 -C(=O)-NH-C(CH3)3 1 -C(=O)-NH-C(CH3)2 CH,OH , -C(=O)-NH-CH,CH1OCH , -C(=O)-N(C.H3)Z , -C(=O)-N(CH,CH;), , -C(=O)-NH--a -C(=O)-NH-CH,< or --C(=0)-NH O

(v) -N(R6)C(=O)W, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYlY2 or -OR5 [e.g. -NH-C(=O)-CH3, -NH-C(=O)-(CH2)2 CH3 , -NH-C(=O)-CH(CH3), , -NH-C(=O)-C(C.H3)3 , -NH-C(=O)-CH2CH(CH3)2 , -NH-C(=O)-CH(CH3)CH,CH3 , -NH-C(=O)-CH,C(CH3)3 , -NH-C(=O)-CH2/ \ , -NH-C(=0)-CH2 < , ~-N
-NH-C(=O)-CH` N/\ / N , -NH-C.(=O)-CH; N(CH3)2, N

~
-NH-C(=0)-CH2 - N , -NH-C(=0)-CH2 -N 0 or -NH-C(=O)-CH2OCH3 ], (b) R4 is aryl [e.g.

-NH-C(=O) \ / , -NH-C(=O) or -NH-C(=O) \ / CH3 ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)--<j or -NH-C(=O) ], (d) R4 is heteroaryl O
-NH-C(=0) N

or [e.g. -NH-C(=0) N -NH-C(=0) ~O
p HC
-NH-C(=O) C\N ] or (e) heterocycloalkyl [e.g. -NH-C(=O) O ];
(vi) -N(R6)C(=O)NYIY', particularly -NHC(=O)NYiY' [e.g. -NH-C(=0)-NHCH3 , -NH-C(=O)-NHCH1CH3 , -Nff-C( O)-NHCH(CH3)z ~

~
-NH-C(=O)-NHCH,CH(CH;)1' -NH-C(=O)-NHC(CH3)3 ' -NH-C(=O)-N(CH3)1 -NH-C(=O)-N(CH,CH3)2, -NH-C(=0)-NH-a , -NH-C(=0)-NH-CHZa -NH-C(=O)-NH-CH2 / \ , -NH-C(=O)-NH / \

-NH-C(=0)-N , -NH-C(=0)-N N-CH; or -NH-C(=0)-N O ], (vii) -NYlY2 [e.g. -NH2] or (viii) alkyl substituted by -N(R6)C(=O)NYlY2 [e.g.
-CH2-NH-C(=O)-CH(CH3)2 or -CHNH-C(=O)- Oand their corresponding N-oxides, and their -prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are coinpounds of formula (Ixa) in which:- W
represents CH; X represents CH; Z represents CH; Y represents (i) C-C1-4alkyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2], (ii) C-aryl [e.g. C / \, C / \, O
CH3 CN CHib C / \ , C / \ CH3 , C / \ , C , F O~-I

C Cl, C / \ or C / O ], (iii) C-CN, (iv) C-N02, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF3], (vii) C-heteroaryl [e.g. C / \N or C (viii) C-OR4 [e.g. C-OCH3 , C-OCH2CH3 , C-OCHFZ , C-OCF3, C-0 C-O-C.Hz / \ or C-O-(CH2); N O], (ix) C-C(=0)R4 [e.g.
-C-C(=O) \ / ], (x) C-C=O)NYlY2 [e.g. C-C(=O)-NH-CH3 , C-C(=O)-N(CH3)2, C-C(=O)-NH-CH,CH3 , C-C.(=O)-NH-CH(CH3), , C-C(=O)-NH-C(CH3)2 -C.H2OH , C-C(=O)-NH-CHzCHZCN , C-C(=O)-NH-CH2CH2 OCH3 , C-C(=O)-NH-CH, / \ , C-C(=O)-NH-CH, / \ , C-C(=O)-NH-CH2 / \ , C-C(=O)-NH-CH2 O-CH 3 , C-C(=0)-NH-CHZ C-C(=0)-NH-CH, / \
-N
C-C(=O)-NH-(CHz), / \ , C-C(=O)-NH-(CH,)Z N 05 -~
C-C(=O)-NH-(CH,)y N , C-C(=O)-NH-(C.HZ)3 NN , H O
N--C-C(=O)-NH-(CHz)z ~ N, C-C(=O)-NH-(CH2)3 N N
N~
or C-C(=O)-NH \ /], (xi) C-C(=O)OR4 [e.g. C-C(=0)OH or C-C(=O)OCH3], (xii) C-NHC(=O)R4 [e.g. C-NHC(=O)CH3 or C-NHC(=0)CH(CH3)2, C-NH-C(=0) \ f or C-NH-C(=O)-C(=O)-CH, \ / ], (xiii) C-CH(OH)aryl [e.g. C-CH(OH) o ], (xiv) C-S(O)2NYIY2 [e.g. C-SO; NH-CHZ / \] or (xv) C S(O)nR4 [e.g. C-SO2CH3];

represents hydrogen; R8 represents (i) hydrogen, (ii) C.1-4alkyl [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)CH2 )CH3], (iii) -SR4 [e.g. -S-CH3 , -S-CHCH3 or -S-CHz---a -S-CH -S-CH2/ \ OCH3 , -S-CH` CHZ / \ , S
ON
-S-CH

or -S-CHZ ~ I ], (iv) -NYlY2 [e.g. -N O ] or (v) -OR5 [e.g. -OCH2CH3]; R9 represents (i) hydrogen; (ii) Cl-7alkyl [e.g. -CH3, -CH?CH2CH3, -CH(CH3)2 or -CH2-CH2-CH(CH3)2]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NYIY2 [e.g.
-C(=O)-NH-CH,CH3, -C(=O)-NH-CH,CHiCH, -C(=O)-NH-CH,CH(CH3)2, -C(=O)-NH-CH(CI~,), , -C.(=O)-NH-C(CH)3 1 -C(=O)-NH-C(CH3)ZCH,OH , -C(=O)-NH-CH,CH2OCH3 , -C(=O)-N(CH)21 -C(=O)-N(CH,CH: ), , -C(=O)-NH----a I -C(=O)-NH-CHa or -C(=0)-NH O

(v) -N(R6)C(=O)R4, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYlY2 or -OR5 [e.g. -NH-C(=0)-CH3 , -NH-C(=O)-(CH,),CH3 , -NH-C(=O)-CH(CH3)2 1 -NH-C(=O)-C(CH3)31 -NH-C(=O)-CH2CH(CH3)Z , -NH-C(=O)-CH(CH3)CH2CH3 , -NH-C(=O)-CHC(CH3)3 , -NH-C(=O)-CHZ / \ , -NH-C(=O)-CH,a , -N
-NH-C(=0)-CH; N/\ ~~N -NH-C(=O)-CHZ N(CH3)2 , N
-NH-C(=O)-CH,-N -NH-C(=O)-CH; N -\O or ~
-NH-C(=0)-CHOCH3 ], (b) R4 is aryl [e.g.

-NH-C(=O) \ / , -NH-C(=O) or -NH-C(=O) \ / CH3 ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)--a or -NH-C(=O) ], (d) R4 is O
-NH-C(=0) N
heteroaryl[e.g. -NH-C(=O) eFI N , , -NH-C(=0) O' H3 C

or -NH-C(=O) / \N ] or (e) heterocycloalkyl [e.g. -NH-C(=O) O ];
(vi) -N(R6)C(=O)NY'Y', particularly -NHC(=O)NY'Y2 [e.g. -NH-C(=O)-NHCH3 , -NH-C(=O)-NHCH2CH3 , -NI-I-C(=0)-NHCH(CH3)2' -NH-C(=O)-NHCH,CH(CH), ' -NII-C(=O)-NHC(CH3)3' -NH-C(=O)-N(CH3)2' -NH-C(=O)-N(CH,CH3), , -NH-C(=O)-NH--a , -NH-C(=O)-NH-CH. ,<
-NH-C(=O)-NH-CH2 -NH-C(=O)-NH 0 -NH-C(=O)-N , -NH-C(=O)-N N-CH3 or -NH-C(=O)-N O ], (vii) -NYlY2 [e.g. -NH2] or (viii) alkyl substituted by -N(R6)C(=O)NYlY2 [e.g.
-CH2-NH-C(=0)-CH(CH3)2 or -CH2 NH-C(=O)-N O]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.
A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W
represents CH; X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl; Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH, / \; Z represents CH; R7 represents hydrogen; R8 represents (i) hydrogen, (ii) Cl-q.alkyl [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)CH2CH3], (iii) -SR4 [e.g.
-S-CH3 , -S-CH,CH3 or -S-CH2 < , -S-CH 2 / \ , ON
-CH, / \ OCH3 , -S-CH; CHz / \ , -S-CH, or -S

S
-S-CHz \ I ], (iv) -NYlY2 [e.g. - ] or (v) -OR5 [e.g. -OCH2CH3]; R9 represents (i) hydrogen; (ii) C1-7alkyl [e.g. -CH3, -CH2CH2CH3, -CH(CH3)2 or -CH(CH3)2]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NY'Y' [e.g. -C(=O)-NH-CHCH3 , -C.(=O)-NH-CH,CHZCH , -C(=O)-NH-CH2CH(CI13)21 -C(=O)-NH-CH(CH3)2, -C(=O)-NH-C(CH3)3 , -C(=O)-NH-C(CH3),CH,OH , -C(=O)-NH-CHzCHzOCH3 , -C(=O)-N(CH3)z , -C(=O)-N(CH2CH3), , -C(=0)-NH-a -C(=O)-NH-CH,--a or -C(=O)-NH O ]; (v) -N(R6)C(=0)R4, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYlY2 or -OR5 [e.g. -NH-C(=O)-CH3, -NH-C(=O)-(CHz),CH3 , -NH-C(=O)-CH(CH3)2, -NH-C(=O)-C(CH3)3, -NH-C(=O)-CH2CH(CH3)2, -NH-C(=O)-CH(CH3)CH,CH3 , -NH-C(=O)-CH2C(CH3)3 , N
-NH-C(=0)-CH -NH-C =O -CH--a , / \
z ~ ( ) z -NH-C(=0)-CHZ N~ ~N i N
-NH-C(=O)-CH2-N(CH3)2 , -NH-C(=O)-CHZ N

-NH-C(=O)-CH2-N \O or -NH-C(=0)-CHZOC.H3 ], (b) R4 is aryl [e.g.
~

-NH-C(=O) \ / , -NH-C(=O) or -NH-C(=O) O CH3 ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)--a or -NH-C(=O) ], (d) R4 is O
-NH-C(=0) heteroaryl[e.g. -NH-C(=0) / N , , -NH-C(=0) O H3c or -NH-C(=O) C\N ] or (e) heterocycloalkyl [e.g. -NH-C(=O) O ];
(vi) -N(R')C(=O)NYIY', particularly -NHC(=O)NYIY' [e.g. -NH-C(=0)-NHCH3 , -NH-C(=O)-NHCH,CH3 , -N-H-C(=O)-NHCH(CH3)z ' -NH-C(=O)-NHCH,C.H(CH3)2' -NH-C(=O)-NHC(CH3)3 ' -NH-C(=O)-N(CH3)2 ~

, -NH-C(=0)-NH--a , -NH-C(=0)-NH-CH,a -NH-C(=O)-N(CH2CH~)2 -NH-C(=O)-NH-CH2 01 , -NH-C(=O)-NH / \ , /D , -NH-C(=0)-N N-CH3 or -NH-C(=O)- O ], (vii) -NYlY2 [e.g. -NH2] or (viii) alkyl substituted by -N(R6)C(=0)NYlY2 [e.g.
-CH?-NH-C(=O)-CH(CH3)2 or -CHNH-C(=0)- O]; and their corresponding N-oxides, and their _ prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W
represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R7 represents hydrogen;
R8 represents (i) hydrogen, (ii) CI-4alk-yl [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)CH2CH3], (iii) -SR4 [e.g. -S-CH3, -S-CH2CH3 or -S-CH,---a , -S-CH, / \

N
-S-CHZ / ]OCH3 , -S-CH7CH2/ \ , -S-CHZ / ~ or S
-S-CHZ 0 ], (lv) -NYlY2 [e.g. -N O ] or (v) -OR5 [e.g. -OCH2CH3]; R9 represents (i) hydrogen; (ii) C1-7alkyl [e.g. -CH3, -CH2CH2CH3, -CH(CH3)2 or -CH(CH3)2]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NYlY2 [e.g.

-C(=O)-NH-CH,CH , -C(=O)-NH-CH7C.H2CH3 , -C(=O)-NH-CH2CH(CH3)2, -C(=O)-NH-CH(CH)21 -C(=O)-NH-C(CH3)3 , -C(=O)-NH-C(CH3)2CHzOH , -C(=O)-NII-CH,CH,OCH3 , -C(=O)-N(CH)2 , -C(=O)-N(CH,CH)2, --C(=O)-NH---a ~ C(=O)-NH-CHa or -C(=O)-NH O ];

(v) -N(R6)C(=O)R4, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYIY2 or -OR5 [e.g. -NH-C(=0)-CH3 , -NH-C(=O)-(CH2)2 CH3 , -NH-C(=O)-CH(CH3)z , -NH-C(=O)-C(CH3)3, -NH-C(=O)-CHZCH(CH3)2, -NH-C(=O)-CH(CH3)CH2CH3 , -NH-C(=O)-CHZC(CH3)3 , -NH-C(=O)-CHZ -NH-C(=O)-CH--a , ~--N
-NH-C(=O)-CHZ ~~N ~ -NH-C(=O)-CH2 N(CH3)2 , N
-NH-C(=O)-CH; N -\O or -NH-C(=O)-CH2 N

-NH-C(=0)-CH,OCH3 ], (b) R4 is aryl [e.g.
H3C.
-NH-C(=O) \ / , -NH-C(=O) or -NH-C(=O) \ / CH3 ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)---a or -NH-C(=O) ], (d) 0 is I-~JC

O
-NH-C(=O) / f N
heteroaryl[e.g. -NH-C(=O) C~/11 , , -NT-I-C(=0) O' H3C

or -NH-C(=O) C\N ] or (e) heterocycloalkyl [e.g. -NH-C(=O) O ];
(vi) -N(R6)C(=O)NYlY2, particularly -NHC(=O)NYIY2 [e.g. -NH-C(=O)-NHCH3 , -NII-C(=O)-NHCH2CH31 -NH-C(=0)-NHCH(CH3)2 ' -NH-C(=O)-NHCHZCH(CH;), ' -NH-C(=O)-NHC(CH3)3' -NH-C(=O)-N(CH3)2' -NH-C(=O)-N(CH9CH3)2 , -NH-C(=0)-NH- < ? -NH-C(=0)-NH-CH,- a ~
-NH-C(=O)-NH-CH, / \ , -NH-C(=O)-NH / \ , -NH-C(=O)-N , -NH-C(=0)-N N-CH3 or -NH-C(=0)-N o (vii) NYlY2 [e.g. -NH2] or (viii) alkyl substituted by -N(R6)C(=O)NYlY2 [e.g. -CH7?-NH-C(=O)-CH(CH3)2 or -CHL NH-C(=0)- O]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.
A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W
represents CH; X represents CR2 and Y represents CR3 where R2 and R3 form the group -C.H2-O-CH2-; Z represents CH; R7 represents hydrogen; R8 represents (i) hydrogen, (ii) Cl_4alkyl [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)C.H2CH3], (iii) -SR4 [e.g. -S-CH3 , -S---or -S-CHa , -S-CH2 / \ , -S-CH2/ \ OCH3 , N S
-S-CHZ CH, / \ , -S-CH, / ~ or -S-CH2 (iv) -NYIY2 [e.g.

or (v) -OR5 [e.g. - ~ OCH~CH R9 represents (i) hydrogen; = ii (=~) C_ alkY1 [e.g. -CH3, 3]~ 1 7 3, -CH2CH2CH3, -CH(CH3)2 or -CH2-CH2-CH(CH3)2]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NY'Y' [e.g.
-C(=O)-NH-CH,CH , -C(=O)-NH-CHZCH2CH3 , -C(=O)-NH-CH,CH(CH3), , -C(=O)-NH-CH(CH3), , -C(=O)-NH-C(CH3)3, -C(=O)-NH-C(CH3)2CH,OH , -C(=O)-NH-CH2CH,OCH3, -C(=O)-N(CH,),, -C(=O)-N(CHCH3), , -C(=0)-NH-7a , -C(=0)-NH-CH,--a or -C(=0)-NH O ];

(v) -N(R6)C(=O)R4, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYlY2 or -OR5 [e.g. -NH-C(=O)-CH , -NH-C(=O)-(CH,)2CH3 , -NH-C(=O)-CH(CH3)2, -NH-C(=O)-C(CH3)3 1 -NH-C.(=O)-CH,CH(CH3)2, -NH-C(=O)-CH(CH3)CH2CH3 , -NH-C(=O)-CH2C(CH3)3 , -NH-C(=O)-CH2 01 , -NH-C(=O)-CH,a , -N
-NH-C(=0)-CHZ N ~ -NH-C(=O)-CH; N(CH3)Z , -NH-C(=0)-CH2 - N -NH-C(=O)-CHz N O or -NH-C(=O)-CH,OCH3 ], (b) R4 is aryl [e.g.

-NH-C(=O) \ / , -NH-C(=O) or -NH-C(=O) \ / CH ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)---a or -NH-C(=O) ], (d) R4 is O
-NH-C(=0) ~ O
heteroaryl[e.g. -NH-C(=0) / N , -NH-C(=0) O~ H3C ~
or -NH-C(=O) CN ] or (e) heterocycloalkyl [e.g. -NH-C(=O) O ];

(vi) -N(R6)C(=O)NYlY2, particularly -NHC(=O)NYlY2 [e.g. -NH-C(=O)-NHCH3 , -NH-C(=O)-NHCH,CH3 , -NH-C(=O)-NHCH(CH3)2 ' ~
-NH-C(=O)-NHCH,CH(CH3), ' -NH-C(=O)-NHC(CH)3 ' -NH-C(=O)-N(CH3)2 -NH-C(=O)-N(CH2CH)21 -NH-C(=O)-NH--a , -NH-C(=O)-NH-CH a ~
-NH-C(=O)-NH-CH2 -NH-C(=O)-NH / \

-NH-C(=O)-N , -NH-C(=O)-N N-CH3 or -NH-C(=0)- ], (vii) -NYlY2 [e.g. -NH2] or (viii) alkyl substituted by -N(R6)C(=0)NYlY2 [e.g.
-CH2-NH-C(=O)-CH(CH3)2 or -CH NH-C(=0)-N O]; and their corresponding _ N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.
A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W
represents CH; X represents CR2 and Y represents CR3 where R2 and R3 form the group -CH2-CH2-CH2- ; Z represents CH; R7 represents hydrogen; R8 represents (i) hydrogen, (ii) C1-4a1ky1 [e.g. CH3, CH2CH3, CH(CH3)2 or CH(CH3)CH2CH3], (iii) -SR4 [e.g. -S-CH3, -S-or -S-CH--a , -S-CH2 / \ , -S-CH2 O-OCH31 N S
-S-CH; CHZ / \ , -S-CH, / ~ or -S-CHZ \ I ], (iv) -NYlY2 [e.g.
-N p] or (v) -OR5 [e.g. -OCH2)CH3]; R9 represents (i) hydrogen; O ii C1_7a1kY1 [e.g. -CH3, 3~
-CH2CH2CH3, -CH(CH3)2 or -CH2-CH,)-CH(CH3)2]; (iii) aryl [e.g. phenyl]; (iv) -C(=O)NY'Y2 [e.g.
-C(=O)-NH-CH2CH; , -C(=O)-NH-CH2CH7CH3 , -C(=O)-NH-CH2CH(CH)2 , -C(=O)-NH-CH(CH3)Z , -C(=O)-NH-C(CH3)3 , -C(=O)-NH-C(CH3),CH,OH , -C(=O)-NH-CH,CH,OCH3, -C(=O)-N(CH;), , -C(=O)-N(CH,CH)2 , -C.(=O)-NH---< I -C(=O)-NH-CH2 < or -C(=O)-NH O ];

(v) -N(R6)C(=O)R4, particularly -NHC(=O)R4, in which (a) R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NYlY2 or -OR5 [e.g. -NH-C(=O)-CH3 , -NH-C(=O)-(CHZ)2 CH3 1 -NH-C(=O)-CH(CH3)z , -NH-C(=O)-C(CH3)3 1 -NH-C(=O)-CH2CH(CH3)21 -NH-C(=0)-CH(CH3)CH,CH3 , -NH-C(=O)-CH2C(CH3)3, -NH-C(=O)-CHz / \ , -NH-C(=O)-CH< , -N
-NH-C(=O)-CH7-N/\ //N , -NH-C(=O)-CHZ N(CH3)2 , N

-NH-C(=0)-CH2 - N -NH-C(=0)-CH2 -N O or -NH-C(=O)-CH2OCH3 ], (b) R4 is aryl [e.g.
HC

-NH-C(=O) \ / , -NH-C(=O) \ / or -NH-C(=O) \ / CH3 ], (c) R4 is cycloalkyl [e.g. -NH-C(=O)--< or -NH-C(=O) ], (d) R4 is O
-NH-C(=O) heteroaryl[e.g. -NH-C(=0) / N , -NH-C(=0) O-~ H 3 or -NH-C(=O) CN ] or (e) heterocycloallcyl [e.g. -NH-C(=O) O ];
(vi) -N(R6)C(=O)NYIY2, particularly -NHC(=O)NYlY2 [e.g. -NH-C(=O)-NHCH3 , -NH-C(=O)-NHCH,CH 1 -NH-C(=0)-NHCH(CH3)Z ~
-NH-C(=O)-NHCH,CH(CH3), -NH-C(=O)-NHC(CH)3 ' -NH-C(=O)-N(CH3)2' -NH-C(=O)-N(CH2CH3), , -NH-C(=O)-NH-< -NH-C(=O)-NH-CHa -NH-C(=O)-NH-CH2 -NH-C(=O)-NH / \

-NH-C(=O)-N , -NH-C(=0)- N-CH3 or -NH-C(=O)-N O
(vii) -NYIY2 [e.g. -NH2] or (viii) alkyl substituted by -N(R6)C(=O)NYIY2 [e.g.
-CH2-NH-C(=O)-CH(CH3)2 or -C.H2 NH-C(=0)- O]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixa) in which R8 is hydrogen or -CH3 and R9 is -CH2-CH2-CH(CH3)2, -C(=O)-NH-CH2CH3 , -C(=O)-NH-CHZCH,CH3, -C(=O)-NH-CH(CH3), , -C(=O)-NH-C(CH3)3 1 -C(=O)-NH-C(CH),CHOH, -C(=O)-NH---a -C(=O)-NH-CHZCH,OCH , -C(=O)-N(CH)1 , -C(=O)-N(CH,CH3), , -C(=O)-NH O , -NH-C(=O)-CH3, -NI-I-C(=O)-(CH,)zCH3 , -NH-C(=O)-CH(CH3), , -NH-C(=O)-C(CH3)3 , -NH-C(=O)-CH,C.H(CH3)Z , -NH-C(=O)-CH(CH3)CH2CH3, -NH-C(=O)-CH2C(CH3)3 , N
-NH-C(=O)-CHZ -NH-C(=0)-CH2- < , -NH-C(=O)-CH2-N/\ N ~
-NH-C(=O)-CH2 -N(CH3)2 , -NH-C(=0)-CH2 -N

-NH-C(=O)-CH, N , -NH-C(=O)-CH,OCH3 , -NH-C(=0) `
\ ~
HC

-NH-C(=O) -NH-C(=O) O CH3 , -NH-C(=O)--<l , H~IC
O
-NH-C(=O) , -NH-C(=O) -NH-C(=O) I, ON N

-NH-C(=O) o\N , -NH-C(=0) // I -NH-C(=O)-NHCH3 , -NH-C(=O)-NHCH2CH3 , -NH-C(=O)-NHCH(CH3)2 5 -NH-C(=0)-NHC(CH)3 ' -NH-C(=O)-N(CH3)2 1 -NH-C(=O)-N(CH2 CH3)2 , -NH-C(=O)-NH-a -NH-C(=O)-NH-CHa , -NH-C(=0)-NH-CH2 / \ , -NH-C(=O)-NH / \ , -NH-C(=O)-N

-NH-C(=O)-N N-CH3 -NH-C(=0)-N O -CH2-NH-C(=0) CH(CH3)) or -CHZ NH-C(=0)-N j are particularly preferred.

Compounds of formula (Ixa) in which R9 represents hydrogen and R8 represents -CH(CH3)2, -S-CH3 ,-S-CH1CH3 or -S-CH--~ are also particularly preferred.
Compounds of formula (Ixa) in which W is CH, X is CH, Y is CH, C-CH,)CH3, C-CH2CH2CH3, CN F O~
~
C / , C / \ , C / \ , C , C-CN, C-Br, C-CF3, N
C / \N , C / ~ , C-OCH3 , C-OCH,CH3 , C-OCHF, , C-OCF3 , C-O-CHZ / \ , C-C(=O)-NH-CH3 , C-C(=O)-NH-CH,CH3, C-C(=O)-NH-CH(CH3)Z , C-C(=O)-NH-C(CH3)2-CH,OH , C-C(=O)-NH-CH2CH2CN , C-C(=O)-NH-CHCH2OCH3 , C-C(=0)-NH-CH / \ , C-C(=O)-NH-CH2 C-C(=O)-NH-CH2 / \ , C-C(=0)-NH-CH CH3 1 C-C(=O)-NH-(CH,)2 0 1 C-C(=O)-NH-(CH,); N --~O , C-C(=O)-NH-(CH,), N

N
C-C(-O)-~-(CH~~~ 11 ~
C-C(=0)-NH-(CH,)3 ~N N--N
C-C(=0)-NH-CH, / \ ? C-C(=O)-NH-CHZ O-N O

C-C(=O)-NH-(CH,)3 N , C-C(=O)-NH \ /, C-C(=O)OCH3, C-C(=O)OH, C-CH(OH) \ /, C-SO2CH3 or C-SO; NH-CH2 / \ and Z is CH are particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-CH3 or C-CH2CH3, Y is C-CH3, C-CH2CH3, C-CH(CH3)2, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH, / \, and Z is CH
are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH3, Y is CH, C-CH3, C-CH2CH3, C-Cl or C-OCH3 and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH2CH3, Y is C-F and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 atoms form the group -CH2-CH2-CH2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-O-CH?-, and Z represents CH are also particularly preferred.
Compounds of formula (Ixa) in which R8 is hydrogen or -CH3 and R9 is -C(=O)-NH-CHzCH3 , -C.(=O)-NH-CHCH,CH3 , -C(=O)-NH-CH(CH3), , -C(=O)-NH-CH2CH(CH3)2 , -C(=O)-NH-C(CH3)3 1 -C(=O)-NH-C(CH3),CH,OH , -C(=O)-N(CH,CH), , -C(=O)-NH--< I -C(=O)-NH-CHa ~ -C(=O)-NH O , -C(=O)-NH-CHCH7OCH3, -NH-C(=O) O , -NH-C(=O)-(CH2),CH3 , -NH-C(=O)-CH(C.H3), , -NH-C(=0)-C(CH3)3 , -NH-C(=O)-CH2CH(CH3)2 , -NH-C(=O)-CH(CH3)CH,CH3, -NH-C(=O)-CH2C(CH3)3 , -NH-C(=O)-CH,--a , N
-NH-C(=0)-CHi N //N , -NH-C(=O)-CH` N O\ /, -NH-C(=O)-CH,OCH3 , N -/
-NH-C(=O) \ / , -NH-C(=O)-a , -NH-C(=O) , -NH-C(=O) / /N, -NH-C(=0) ~ \N, -NH-C(=0) O
O -O
-NH-C(=0) N , -NH-C(=O)-NHCH3 , -NH-C(=O)-NHCH,CH3 , zI3C

-NH-C(=0)-NHCH(CH3)2 . -NH-C(=O)-NHC(CH)3 , -NH-C(=O)-N(CH3)Z , -NH-C(=O)-N(CH2CH3)z , -NH-C(=O)-NH-a , -NH-C(=O)-NH-CH< ~
-NH-C(=O)-NH-CH2 / \ , -NH-C(=O)-NH / \ , -NH-C(=0)-N -NH-C(=0)- N N-CH3 or -NH-C(=0)- 0 are especially preferred.
Compounds of formula (Ixa) in which W is CH, X is CH, Y is C OCH3, C-OCH2CH3, C-OCHF2, d Z is CH are an C-CF3, C-C(=O)-NH-CH, / \ or C-C(=O)-NH-CH2 O-N
- especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C-CH3 or C-CH2CH3, Y is C-CH3 or C-CH2CH3, C-Cl or C-F and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH3, Y is C-CH3, C-CH2CH3, C-Cl, C-F or C-OCH3 and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH2CH3, Y is C-Cl or C-F
and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-CH2-CH2-, and Z represents CH are also especially preferred.
Compounds of formula (Ixa) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2)-O-CH2-, and Z represents CH are also especially preferred.
Another particular group of compounds of the invention are compounds of formula (Ix) wherein Rl is a heteroaryl moiety in which R8 and R9 together with the carbon atoms to which they are attached form an optionally substituted phenyl ring, i.e. compounds of formula (Ixb):-4 O 6 (R10)P

Y Z N \ 7 1 \
I \
X" W H ~N le (Ixb) in which W, X, Y, Z and R7 are as hereinbefore defined for compounds of formula (Ix); RlO is carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NYlY2, -C(=0)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NYlY2, -N(R6)C(=0)0R4, -N(R6)S02R4, -N(R6)SO2NYlY2, -NYlY2, -OR4, -OCF2H, -OCF3, -OC(=0)R4, -OC(=0)NYlY2, -S(O)nR4 or -S(O)2NYlY2;
and p is zero, or an integer 1; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.
hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Y
represents CH and Z
represents CH or C-CH3 are preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Z
represents CH and Y
represents:

(i) C-C1-4alkyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2];

(ii) C-aryl [e.g. C / \ , C / \ , C / \ , C / \ CH3 C / \ IC / \ ~
F 0`
C Cl,C / \ orC 0 01;
(iii) C-CN;
(iv) C-N02;

(v) C-halo [e.g. C-Br, C-Cl or C-F];
(vi) C-haloalkyl [e.g. C-CF3];
\
(vii) C-heteroaryl [e.g. C / N or C / ~];
(viii) C-OR4 [e.g. C-OCH3 , C-OCH,CH3, C-OCHFZ , C-OCF3 , C-O / \ C-O-C.H, / \
or C-O-(CH,); N ~O ];

~
(ix) C-C(=0)R4 [e.g. C-C(=O) o ];

(x) C-C=O)NYlY2 [e.g. C-C,(=O)-NH-CH3, C-C(=O)-N(CH3), C-C(=O)-NH-CH,CH3 , C-C(=O)-NH-CH(CH3)2 , C-C(=O)-NH-C(CH3)2-CHzOH , C-C(=O)-NH-CH2CH2CN , C-C(=O)-NH-CH2CH,OCH3 , C-C(=0)-NH-CH2 / \ , C-C(=0)-NH-CH2 CH3 C-C(=O)-NH-CH, / \ , C-C(=O)-NH-CH, CH3 , C-C(=O)-NH-CH, O-N
C-C(=O)-NH-CH, ON-\

C(=O)-NH-(CH2)z 0 , C-C(=O)-rH-(CHz), N o , C-N
C-C(=O)-NH-(CH2)2 N , C-C(=0)-NH-(CH2)--C~ --N , N

~
C-C(=O)-NH-(CH2)3 N, C-C(=O)-NH-(CH,)3 N or C-C(=O)-NH \ / ];
(xi) C-C(=O)OR4 [e.g. C-C(=O)OH or C-C(=O)OCH3];

(xii) C-NHC(=O)R`l [e.g. C-NHC(=0)CH3, C-NHC(=0)CH(CH3)2, C-NH-C(=O) \ / or C-NH-C(=O)-CH, (xiii) C-CH(OH)aryl [e.g. C-CH(OH) \ / ];

(xiv) C-S(O)2NYlY2 [e.g. C-SO; NH-CHi or (xv) C-S(O)nR4 [e.g. C-SO2CH3];

are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents C-CH3, C-CH2C.H3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl, Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH, / \. and Z represents CH are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Y
represents C-CH3 and Z
represents C-CH3 are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR2 and Y
represents CR3 where R'~ and R3 form the group -CH?-O-CH2-, and Z represents CH are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-CH2-CH2-, and Z represents CH are also preferred.
Compounds of formula (Ixb) in which R7 represents hydrogen are preferred.

Compounds of formula (Ixb) in which p is zero or one are preferred.
Compounds of formula (Ixb) in which RIO represents:
(i) cyano (ii) halo [e.g. chloro, fluoro];
(iii) C1-4alkyl [e.g. methyl, (iv) -OR4 [e.g. -OCH3, -OCH2CH3]; or (v) -C(=O)NYlY2 [e.g. -C(=O)-NH2, -C(=0)-NHCH(CH3)2, -C(=O)-N(CH3)2 are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R7 represents hydrogen; R10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) Cl-q.alkyl [e.g. metliyl], (iv) -OR4 [e.g. -OCH3 or -OCH2CH3] or (v) -C(=O)NYlY2 [e.g. -C(=O)-NH2, -C(=O)-NHCH(CH3)2 or -C(=O)-N(CH3)2]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres;
and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CH; Z represents CH; Y represents (i) C-C14alkyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2], (ii) C-aryl [e.g. C / \, C / \

C / \ , C/ \ CH3,C / \ ,C / \ , F O`

C / \ C1, C / \ or C / \ O], (iii) C-CN, (iv) C-NO2, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF3], (vii) C-heteroaryl [e.g. C / \N or N
C / ~ ], (viii) C-OR4 [e.g. C-OCH3 , C-OCH2C.H3 3 C-OCHF, , C-OCF3 , C-O / \ , C-O-CH, / \ or C-O-(CH,)-N O ], (ix) C-C(=O)R4 [e.g.
- 2 \-/

C-C(=O) \ / ], (x) C-C=O)NYlY-[e.g. C-C(=O)-NH-CH3, C-C(=O)-N(CH3)2, C-C(=O)-NH-CH2CH3, C-C(=O)-NH-CH(CH3)2, C-C(=O)-NH-C(CH3)2-CH2OH, C-C(=O)-NH-CHZCH2CN, C-C(=O)-NH-CH,CH2OCH3 , C-C(=O)-NH-C.H2 / \ , C-C(=O)-NH-CH, C.-C(=O)-NH-CHZ / \ , C-C(=O)-NH-CH, O-CH 3 , C-C(=O)-NH-CH, ON-\ C-C(=O)-NH-CO-N
C-C(=O)-NH-(CH,), / \ C-C(=O)-NH-(CH2); N o -~
C-C(=O)-NH-(CH2); N , C-C(=O)-NH-(CH,)3 NN, N
C-C(=0)-NH-(CHZ)--C~ N, C-C(=0)-NH-(CH2)3 N

N,or C-C(=0)-NH 0 ], (xi) -C(=0)OR4 [e.g. C-C(=0)OH or C-C(=0)OCH3], (xii) C-NHC(=0)R4 [e.g. C-NHC(=0)CH3 or C-NHC(=0)CH(CH3)2, C-NH-C(=0) \ / or C-NH-C(=O)-CH2 \ / ], (xiii) C-CH(OH)aryl [e.g. C-CH(OH) \ / ], (xiv) C S(O)2NYIY2 [e.g. C-SO--NH-CH, / \] or (xv) C-S(O)nR4 [e.g. C-SO2CH3]; R7 represents hydrogen; p is zero or one; R10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) -OR4 [e.g. -OCH3 or -OCH2CH3] or (v) -C(=0)NYIY2 [e.g.
-C(=O)-NH2,-C(=O)-NHCH(CH3)2 or -C(=O)-N(CH3)2]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.
hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl; Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH, Z represents CH; R7 represents hydrogen; p is zero or one; RIO
represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g.
methyl], (iv) -OR4 [e.g. -OCH3 or -OCH2CH3] or (v) -C(=O)NYlY2 [e.g. -C(=O)-NH2, -C(=O)-NHCH(CH3)2 or -C(=O)-N(CH3)2];

and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R7 represents hydrogen; p is zero or one; R10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) -OR4 [e.g. -OCH3 or -OCH2CH3] or (v) -C(=O)NYlY2 [e.g. -C(=0)-NH2, -C(=O)-NHCH(CH3)2 or -C(=O)-N(CH3)2]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres;
and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CR2 and Y represents CR3 where R2 and R3 form the group -CH2-O-CH2-; Z represents CH; R7 represents hydrogen; p is zero or one; R10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) Cl-4alkyl [e.g. methyl], (iv) -OR4 [e.g. -OCH3 or -OCH2CH3] or (v) -C(=O)NYlY2 [e.g. -C.(=O)-NH2, -C.(=O)-NHCH(CH3)2 or -C(=0)-N(CH3)2]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CR2 and Y represents CR3 where R2 and R3 form the group -CH2-CH2-CH2- ; Z represents CH; R7 represents hydrogen; p is zero or one; R10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) -OR4 [e.g. -OCH3 or -OCH2CH3] or (v) -C(=O)NYlY2 [e.g. -C(=0)-NH2, -C(=0)-NHCH(CH3)2 or -C(=0)-N(CH3)2];
and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixb) in wllich R7 represents hydrogen and p is zero are particularly preferred.
Compounds of formula (Ixb) in which R7 represents hydrogen; p is one and R10 represents cyano, chloro, fluoro, methyl, -OCH3, -OCH2CH3, -C(=O) NH2, -C(=O)-NHCH(CH3)2 or -C(=0)-N(CH3)2 are also particularly preferred.

Compounds of formula (Ixb) in wllich W is CH, X is CH, Y is CH, C-CH2CH3, C-CH2CH2CH3, C O , C C3, C b , C (2 0 , C-CN, C-Br, C-CF3, N
C / \N , C C-OCH3, C-OCHZCI I3 , C-OCHF, , C-OCF3, C-O-CHz C-C(=O)-NH-CH3, C-C(=O)-NH-CH,CH3 , C-C.(=O)-NH-CH(CH3)2' C-C(=O)-NH-C(CH3)2-CH20H , C-C(=O)-NH-CHZCHZCN , ~
C-C(=O)-NH-CH,CH,OCH3, C-C(=O)-NH-CH2 C-C(=O)-NH-CHZ C-C(=O)-NH-CH, C-C(=O)-NH-CH, O-CH3, C-C(=O)-NH-(CH2)Z
C-C(=O)-NH-(CH2)2 d-\O, C-C(=O)-NH-(CH2)2 N
~

N
~ , C-C(=0)-NH-(CHz)~ N ~
C-C(=0)-NH-(CH2)3 NN N--C-C(=O)-NH-CHZ C-C(=O)-NH H
-C, O-N - O

C-C(=O)-NH-(CH,)3 N , C-C(=O)-NH \ /, C-C(=O)OCH3 C-C(=O)OH
C-CH(OH) O , C-SO2CH3 or C-SO2 NH-CH2 / \ and Z is CH are particularly preferred.
Compounds of formula (Ixb) in which W is CH, X is C-CH3 or C-CH2CH3, Y is C-CH3, C-CH2CH3, C-CH(CH3)2, C-Br, C-Cl, C-F, C / \, C-C(=O)-NH-CH2 / \, and Z is CH are also particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is C-OCH3, Y is CH, C-CH3, C-CH2CH3, C-Cl or C-OCH3 and Z is CH are also particularly preferred.
Compounds of formula (Ixb) in which W is CH, X is C-OCH2CH3, Y is C-F and Z is CH are also particularly preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-CH2-CH2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-O-CH2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixb) in which R7 represents hydrogen and p is zero are especially preferred.
Compounds of formula (Ixb) in which R7 represents hydrogen; p is one and RlO
represents -OCH3, -OCH7)CH3 or -C(=O)-NHCH(CH3)2 attached to position 5 of the indazolyl ring are also especially preferred.

Compounds of formula (Ixb) in which W is CH, X is C-CH3 or C-CH2CH3, Y is C-CH3 or C-CH-)CH3 and Z is CH are also especially preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein Rl is a pyrazolyl moiety in which R8 and R9 together with the carbon atoms to which they are attached form an optionally substituted C5-8cycloalkyl ring, i.e.
compounds of formula (Ixc):-(Ri2) q A
Y ~ N
I
W H N'N R 7 (Ixc) in which W, X, Y, Z, X and p are as hereinbefore defined for compounds of formula (Ix), A is a C5-8cycloalkyl ring and R12 is acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, -C(=O)NYlY2, -NYI-C(=0)alkyl, -NYISO2alkyl, -NYlY2, -SO2NYlY2 or alkyl, alkenyl or allcynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, -C(=O)OR6, -C(=O)NYlY2, -NYlY2 or -OR5; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Y
represents CH and Z
represents CH or C-CH3 are preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Z
represents CH and Y
represents:

(i) C-C1-4alkyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2];

(ii) C-aryl [e.g. C / \ , C / \ , C / \ , C / \ CH3 , C / \ , C / \ , F O'~
C Cl, C / \ or C / \ O ];
(iii) C-CN;
(iv) C-N02;

(v) C-halo [e.g. C-Br, C-Cl or C-F];
(vi) C-haloalkyl [e.g. C-CF3];
N
(vii) C-heteroaryl [e.g. C / \N or C

(viii) C-OR4 [e.g. C-OCH3 , C-OCII2CH3 , C-OCHF,, C-OCF~ , C-O / \
C-O-CHZ / \ or C-O-(CHz); N -\O ];
-(ix) C-C(=0)R4 [e.g. C-C(=0) G ];

(x) C-C=O)NYIY2 [e.g. C-C(=O)-NH-CH3 , C-C(=O)-N(CH3); ~
C-C(=O)-NH-CH,CH3 ) C-C(=O)-NH-CH(CH3), , C-C(=O)-NH-C(CH3)2-CH2 OH , C-C(=O)-NH-CH,CH,CN, C-C(=O)-NH-CH,CH,OCH3 ' C-C(=O)-NH-CHZ / \ , C-C(=O)-NH-CHz / \ , C-C(=O)-NH-CH2 C-C(=O)-NH-CH2 O-CH 3 , C-C(=0)-NH-CHZ C-C(=0)-NH-CH2 / \
-N
C-C(=O)-NH-(CHZ)Z C-C(=O)-NH-(CH2)2 N O, - ~~
N~N
C-C(=0)-NH-(CH,), N , C-G(=0)-NH-(CH,)--C~ /N, N
O
~
C-C(=O)-NH-(CH,)3 N N ~ C-C(=0)-NH-(CH,)3 N or C-C(=O)-NH 0 ];

(xi) C-C(=O)OR4 [e.g. C-C(=O)OH or C-C(=O)OCH3];

(xii) C-NHC(=0)R4 [e.g. C-NHC(=0)CH3, C-NHC(=O)CH(CH3)2, C-NH-C(=O) \ / or C-NH-C(=O)-CH, or (xiii) C-CH(OH)aryl [e.g. C-CH(OH) o (xiv) C-S(O)2NYlY2 [e.g. C.-SO; NH-CH2 / \ ];
(xv) C-S(O)nR4 [e.g. C-SO2CH3];

are also preferred.
Compounds of formula (Ixc) in which W represents CH, X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl, Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH2 Q and Z represents CH are also preferred.
Compounds of formula (Ixc) in which W represents CH, X represents CH, Y
represents C-CH3 and Z
represents C-CH3 are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-O-CH2-, and Z represents CH are also preferred.
Compounds of formula (Ixc) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH7)-CH2-CH7)-, and Z represents CH are also preferred.
Compounds of formula (Ixc) in which R7 represents hydrogen are preferred.

Compounds of formula (Ixc) in which A represents a cyclopentyl, cyclohexyl and cycloheptyl, especially cyclohexyl, ring are preferred.

Compounds of formula (Ixc) in which q is zero are preferred.
A preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W
represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Lxc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W
represents CH; X represents CH; Z represents CH; Y represents (i) C-C1-4alkyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2], (ii) C-aryl [e.g. C / \, C / \, C / CH3 1 C / \ , C / \ , F O\

C Cl, C / \ or C / 0 ], (iii) C-CN, (iv) C-NO2, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF3], (vii) C-heteroaryl [e.g. C / \N or N
C (viii) C-OR4 [e.g. C-OCH3, C-OCH,CH3 , C-OCHF,, C-OCFj , C-O , C-O-CHZ o or C-O-(CH,)2 N - ~O ], (ix) C-C(=O)R4 [e.g.
\-/
C-C(=0) \ / ], (x) C-C=0)NYlY2 [e.g. C'-C(=O)-NH-CH3 , C-C(=O)-N(C.H3)2 , C-C(=O)-NH-CH,CH3 , C-C(=O)-NH-CH(CH3), , C-C(=O)-NH-C(CH3)2-CH2OH , C-C(=O)-NH-CHZCH,CN, C-C(=O)-NH-CH,CH2OCH3 ' C-C(=O)-NH-CH, C-C(=O)-NH-CHZ / \ , C-C(=O)-NH-CH2 / \ , C-C(=O)-NH-CHZ O-CH 3 , C-C(=O)-NH-CH, C-C(=O)-NH-CH2 O-N 10 C-C(=O)-NH-(CH,), / \, C-C(=O)-NH-(CHZ);
N o ~
C-C(=O)-NH-(CH2)2 N , C-C(=O)-NH-(CH,)3 N , \5:- N
\

C.-C(=O)-NH-(CHz);<\ N , C-C(=O)-NH-(CH2)3 N
N~

or C-C.(=O)-NH \ / ], (xi) -C(=O)OR4 [e.g. C-C(=O)OH or C-C(=0)OCH3], (xii) C-NHC(=0)R4 [e.g. C-NHC(=O)CH3 or C-NHC(=0)CH(CH3)2, C-NH-C(=O) \ / or C-NH-C(=O)-CH, \ / ], (xiii) C-CH(OH)aryl [e.g. C-CH(OH) (xiv) C-S(O)2NYlY2 [e.g. C-SO; NH-CH2 / \] or (xv) C-S(O)nR4 [e.g. C-SO2CH3]; R7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres;
and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W
represents CH; X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl; Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH, Z represents CH; R7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:-W
represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R7 represents hydrogen;
A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.
A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CR9- and Y represents CR3 where R-9 and R3 form the group -CH2-O-CH?-; Z represents CH; R7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W
represents CH; X represents CR2 and Y represents CR3 where R-9 and R3 form the group -CH2-CH2-CH2-; Z represents CH; R7 represents hydrogen; A represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixc) in which R7 represents hydrogen and p is zero are particularly preferred.
Compounds of formula (Ixc) in which W is CH, X is C-CH3, Y is C-CH3 and Z is CH are also particularly preferred.

Compounds of formula (Ixc) in which A is a cyclopentyl ring are particularly preferred.
Another particular group of compounds of the invention are compounds of formula (Ix) wherein RI is a Rs pyrazolyl moiety in which R8 and R9 together with the carbon atoms to which they N',N R7 are attached form an optionally substituted heterocycloalkyl ring, i.e.
compounds of formula (Ixd):-(R131r Y ~ N
\ /
\
I \
W H N~N R7 (Ixd) in which W, X, Y, Z and X are as hereinbefore defined for compounds of formula (Ix), Xl is 0, S, S02, or NY5 (where Y5 is hydrogen, R4, -C(=0)R4, -C(=O)NYIY2, -C(=0)OR4 or -S02R4), r is zero or an integer one or two and R13 is alkyl or two R13 groups attached to the same carbon atom form an oxo group; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres;
and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
Compounds of formula (Ixd) in which W represents CH, X represents CH, Y
represents CH and Z
represents CH or C-CH3 are preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CH, Z
represents CH and Y
represents:

(i) C-C1-4alkyl [e.g. C-CH3, C-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2];

(ii) C-aryl [e.g. C / \ , C / \ , C / \ , C / \ CH3 , C / \ , C / \ , C / \ Cl , F O`

C / \ or C / O ];
(iii) C-CN;
(iv) C-NO2;

(v) C-halo [e.g. C-Br, C-Cl or C-F];
(vi) C-haloalkyl [e.g. C-CF3];
(vii) C-heteroaryl [e.g. C / \N or C

(viii) C-OR4 [e.g. C-OCH3 , C-OCH,CH3 , C-OCHFZ , C-OCF3, C-O / \ I
C-O-CHZ / \ or C-O-(CHZ) N \O ];
~
(ix) C-C(=0)R4 [e.g. C-C(=0) \ / ];

(x) C-C=O)NYlY2 [e.g. C-C(=O)-NH-CH3 , C-C(=O)-N(CH3),, C-C(=O)-NH-CH2CH3 , C-C(=O)-NH-CH(CH3), , C-C(=O)-NH-C(CH3),-CH2OH , C-C(=O)-NH-CHzCH,CN , C-C(=O)-NH-CH,CH2OCH3 , C.-C(=O)-NH-CH, / \ , C-C(=O)-NH-CH~ C-C(=O)-NH-CH2 / \ , C-C(=O)-NH-CHZ CH3 , C-C(=O)-NH-CH, / \ , N-C
-C(=O)-NH-(CH,)Z / \ -C-C(=O)-NH-CH2 O-N

C-C(=O)-NH-(CH2)2 N O, C-C(=O)-NH-(CH2)2 N , ~

N
C-C(=O)-NH-(CHZ)-C~ ~N
N
O
~
C-C(=O)-NH-(CH`)3 NN , C-C(=O)-NH-(CHZ)3 N or C-C(=O)-NH \ / ];

(xi) C-C(=O)OR4 [e.g. C-C(=O)OH or C-C(=O)OCH3];

(xii) C-NHC(=0)R4 [e.g. C-NHC(=O)CH3, C-NHC(=0)CH(CH3)2, C-NH-C(=O) o or C-NH-C(=O)-CHz 0 ];
(xiii) C-CH(OH)aryl [e.g. C-CH(OH) \ / ];

(xiv) C-S(O)2NYlY2 [e.g. C.-SOf NH-CHZ or (xv) C-S(O)nR4 [e.g. C-SO2CH3];

are also preferred.
Compounds of formula (Ixd) in which W represents CH, X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl, Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH, / \ and Z represents CH are also preferred.
Compounds of formula (Ixa) in wliich W represents CH, X represents CH, Y
represents C-CH3 and Z
represents C-CH3 are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-O-CH2-, and Z represents CH are also preferred.
Compounds of formula (Ixd) in which W represents CH, X represents CR9- and Y
represents CR3 where R2 and R3 form the group -CH2-CH2-CH2-, and Z represents CH are also preferred.
Compounds of formula (Ixd) in which R7 represents hydrogen are preferred.

Compounds of formula (Ixd) in which Xl is:
(i) 0;

(ii) N-C(=0)R4 [e.g. N-C(=O)CH3, N-C(=0)CH2CH(CH3)2, N-C(=0)CH(CH3)2, or N-C(=0)C(CH3)3 or N-(C=0)--a ];

(iii) N-C(=0)NYlY2 [e.g. N-C(=0)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=0)N(CH2CH3)2 N-(C=0)-N , N-(C=0)-N or N-(C=0)- O];

(iv) N-C.(=0)OR4 [e.g. N-C(=0)OCH3 or N-C(=0)OCH2CH3]; or (v) N-S02R4 [e.g. N-SO2CH3 or N-SO2CH(CH3)21;

are preferred.
Compounds of formula (Ixd) in which r is zero are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W
represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R7 represents hydrogen; Xl is (i) 0; (ii) N-C(=0)R4 [e.g. N-C(=0)CH3, N-C(=0)CH2CH(CH3)2, N-C(=0)CH(CH3)2, or N-C(=0)C(CH3)3 or N-(C=0)--a ]; (iii) N-C(=0)NYlY2 [e.g.
N-C(=0)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=0)N(CH2CH3)2 N-(C=0)-N , N-(C=0)-N or N-(C=0)- O]; (iv) N-C(=0)OR4 [e.g. N-C(=0)OCH3 or N-C(=0)OCH2CH3]; or (v) N-S02R4 [e.g. N-SO2CH3 or N-SO2CH(CH3)2] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W
represents CH; X represents CH; Z represents CH; Y represents (i) C-C1-4a1ky1 [e.g. C-CH3, C.-CH2CH3'C-CH2CH2CH3 or C-CH(CH3)2], (ii) C-aryl [e.g. C

C / \ , C CH3 , C / \ , C / \ , F O
Cl, C. b or C 6 0 ], (iii) C-CN, (iv) C-NO2, (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF3], (vii) C-heteroaryl [e.g. C / \ N or C (viii) C-OR4 [e.g. C-OC.H3 , C-OCH,Cl~,, C-OCHF2 , C-OCF3 , C-0 / \ , C-O-CH2 / \ or C-O-(CH2)N~O ], (ix) C-C(=O)R4 [e.g.
-C-C(=0) \ / ], (x) C-C=O)NYlY2 [e.g. C-C(=O)-NH-CH3, C-C(=O)-N(CH3); ~
C-C(=O)-NH-CHZCH3 , C-C(=O)-NH-CH(CH3)2, C-C(=O)-NH-C(CH3),-CH2OH , C-C(=O)-NH-CH2CH2CN, C-C(=O)-NH-CH2CH2OCH3 C-C(=O)-NH-CH, / \ , C-C(=O)-NH-CH, / \ , C-C(=O)-NH-CH2 / \ , C-C(=O)-NH-CHz / \ CH3 , c-c(=o)-NH-cH, ~ ~ C-C(=O)-rrH-CH, N-C-C(=O)-NH-(CH,)Z C-C(=O)-NH-(CH,); N\

~
C-C(=0)-NH-(CH2); N O , C-C(=O)-NH-(CH,)3 ~N , O
N
C-C(=O)-NH-(CH2)2 N , C-C(=0)-NH-(CH2)3 N

or C-C(=O)-NH (xi) -C(=0)OR4 [e.g. C-C(=0)OH or C-C(=0)OCH3], (xii) C-NHC(=O)R4 [e.g. C-NHC(=O)CH3 or C-NHC(=0)CH(CH3)2, C-NH-C(=O) \ / or C-NH-C(=O)-CH2 \ / ], (xiii) C-CH(OH)aryl [e.g. C-CH(OH) \ / ], (xiv) NH-CH2 ] or (xv) C-S(O)nR4 [e.g. C-S02CH3]; R7 C-S(O)2NYlY2 [e.g. C-SO; / \

represents hydrogen; Xl is (i) 0; (ii) N-C(=0)R4 [e.g. N-C(=0)CH3, N-C(=0)CH2CH(CH3)2, N-C(=O)CH(CH3)2, or N-C(=O)C(CH3)3 or N-(C=O)--a ]; (iii) N-C(=0)NYlY2 [e.g.
N-C(=0)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=O)N(CH2CH3)2 N-(C=0)-N , N-(C=0)-N or N-(C=0)-N p]; (iv) N-C(=0)OR4 [e.g. N-C(=0)OCH3 or \--j N-C(=0)OCH2CH3]; or (v) N-S02R4 [e.g. N-SO2CH3 or N-SO2CH(CH3)2] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W
represents CH; X represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl; Y represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, C / \ or C-C(=O)-NH-CH2 Z represents CH; R7 represents hydrogen; XI is (i) 0; (ii) N-C(=0)R4 [e.g. N-C(=0)CH3, N-C(=0)CH2CH(CH3)2, N-C(=0)CH(CH3)2, or N-C(=0)C(CH3)3 or N-(C=0)--a ]; (iii) N-C(=0)NYlY2 [e.g. N-C(=0)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=0)N(CH2CH3)2 N-(C=O)-N , N-(C=0)-N or N-(C=0)- O];
(iv) N-C(=0)OR4 [e.g. N-C(=0)OCH3 or N-C(=O)OCH2CH3]; or (v) N-S02R4 [e.g. N-S02CH3 or N-S02CH(CH3)2] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.
hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:-W
represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R7 represents hydrogen;
Xl is (i) 0; (ii) N-C(=0)R4 [e.g. N-C(=0)CH3, N-C(=0)CH2CH(CH3)2, N-C(=0)CH(CH3)2, or N-C(=0)C(CH3)3 or N-(C=O)---a ]; (iii) N-C(=0)NYlY2 [e.g. N-C(=0)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=O)N(C.H2CH3)2 N-(C=O)-N , N-(C=0)-N or N-(C=O)-N O]; (iv) N-C(=O)OR`I [e.g. N-C(=0)OCH3 or N-C(=0)OCH2CH3]; or (v) N-S02R4 [e.g. N-S02CH3 or N-S02CH(CH3)2] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.
hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:-W
represents CH; X represents CR2 and Y represents CR3 where R2 and R3 form the group -CH2-O-CH2-; Z represents CH; R7 represents hydrogen; Xl is (i) 0; (ii) N-C(=0)R4 [e.g. N-C(=0)CH3, N-C(=0)CH2CH(CH3)2, N-C(=0)CH(CH3)2, or N-C(=0)C(CH3)3 or N-(C=0)--a ]; (iii) N-C(=0)NYlY2 [e.g. N-C(=0)N(CH3)2, N-C(=0)NCH(C.H3)2, N-C(=0)N(CH2CH3)2 N-(C=0)-N , N-(C=0)-N or N-(C=0)- O];
(iv) N-C(=0)OR4 [e.g. N-C(=O)OCH3 or N-C(=0)OCH2CH3]; or (v) N-S02R4 [e.g. N-S02CH3 or N-SO,)CH(CH3)2] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.
hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:-W
represents CH; X represents CR-9 and Y represents CR3 where 10 and R3 form the group -CH2-CH2-CH2)-; Z represents CH; R7 represents hydrogen; Xl is (i) 0; (ii) N-C(=0)R4 [e.g. N-C(=0)CH3, N-C(=0)CH2CH(CH3)2, N-C(=0)CH(CH3)2, or N-C(=0)C(CH3)3 or N-(C=0)--< ]; (iii) N-C(=0)NYIY2 [e.g. N-C(=0)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=0)N(CH2CH3)2, N-(C=0)-N , N-(C=0)-N or N-(C=0)- O];
~-~
(iv) N-C(=0)OR4 [e.g. N-C(=O)OCH3 or N-C(=O)OCH2CH3]; or (v) N-S02R4 [e.g. N-S02CH3 or N-S02CH(CH3)2] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g.
hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixd) in which Xl is N-C(=O)CH(CH3)2, N-C(=0)CH2CH(CH3)2, N-C(=0)C(CH3)3; N-(C=O)--< , N-C(=O)N(CH3)2, N-C(=0)NCH(CH3)2, N-C(=O)N(CH2CH3)2, N-(C=O)-N , N-(C=O)-N , N-(C=0)-N O, N-C(=0)OCH3 or N-C(=O)OCH2CH3and r is zero are particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is CH, Y is CH, C-CH2CH3, C-CH2CH2CH3, CN F O
\ \ \ , C / , C ~ \ , C / , C / , C-CN, C-Br, C-CF3, N
C / \ N , C-OCH3 , C-OCH2CH3, C-OCHF,, C-OCF3, C-O-CH, C,-C(=O)-NH-CH3 , C-C(=O)-NH-CH,CH3 , C-C(=O)-NH-CH(CH3), , C-C(=O)-NH-C(CH3),-CHZOH , C-C(=O)-NH-CH,CH,CN , C-C(=O)-NH-C.H,CH,OCH3 , C-C(=O)-NH-CHZ 0 , C-C(=O)-NH-CH, C-C(=O)-NH-CH, C-C(=O)-NH-CH, CH3 1 C.-C(=O)-NH-(CH,)`
C-C(=O)-NH-(CH2)2 N O, C-C(=O)-NH-(CHZ)TN
N~N
C-C(=O)-NH-(CH,)-C~ II , G-C(=0)-NH-(CH,)3N \ ~N , N--N
C-C(=O)-NH-CHZ / \ C-C(=O)-NH-CH` / \ `-N
O

C-C(=O)-NH-(CH,)3 N , C-C(=O)-NH o , C-C(=O)OCH3 C-C(=O)OH
C-CH(OH) \ /, C-SO2CH3 or C-SOz NH-CH2 / \ and Z is CH are particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is C-CH3 or C-CH2CH3, Y is C-CH3, C-CH2CH3, C-CH(CH3)2, C-Br, C-Cl, C-F, C C-C(=O)-NH-CH, / \, and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C-OCH3, Y is CH, C-CH3, C-CH-)CH3, C-Cl or C-OCH3 and Z is CH are also particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is C-OCH2CH3, Y is C-F and Z is CH are also particularly preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-CH2-CH2-, and Z represents CH are also particularly preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR2 and Y
represents CR3 where R2 and R3 form the group -CH2-O-CH2-, and Z represents CH are also particularly preferred.
Compounds of formula (Ixd) in which Xl is N-(C=O)--< , N-C(=0)N(CH3)2, N-C(=0)NC.H(CH3)2, N-C(=0)N(CH2CH3)2, N-(C=O)-N or N-(C=O)-N and r is zero are especially preferred.
Compounds of formula (Ixd) in which W represents CH, X represents C-CH3, Y
represents C-CH3 or C-Cl and Z represents CH are especially preferred.

Particular compounds of the invention of formula (Ix) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to Al 10) shown in Table 1 to the carbon atom (*C) in the heteroaryl moiety of one of the fragments (B 1 to B
168) shown in Table 2.

Particular compounds of the invention of formula (Ixa) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to A110) shown in Table 1 to the carbon atom (*C) in the pyrazole ring of one of the fragments (B 1 to B48, B74 to B 107, B 124 to B 127, 130 to 142 or 144 to 150) shown in Table 2.

Particular compounds of the invention of formula (Ixb) are also selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B63 to B73, B108 to B 114, B128 or B151) shown in Table 2.

Particular compounds of the invention of formula (Ixc) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to Al 10) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B56, B59 or B129) shown in Table 2.

Particular compounds of the invention of formula (Ixd) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B 115 to B
123 or B 157) shown in Table 2.
Al Nv A2 CH3 ai~ Nv cc* A3 CH; A4 CFs N
\\
i*
N\%*

A5 OH A6 CH3ON\
c*
N C* I/ H

A8 F N\
A7 cI N\\ C
C
A9 CH; \ N\ A10 0 *
C
CH3 C Ns \ / N
All e.1 N~ A12 CH3 N
v C* c CI Cl A13 tCH_;)3C \ N~ A14 0 / NC HO N~
H I / N/

C.H3NH N\ CH3(CH2)3NH NC*
C

A17 0 A18 0 s0 I\ ~ I\ N c HzN~s N ~, A 19 A20 \ 0 N\
C*
O N / N
j '* H ,-c C
A21 CH3O I\ N c* A22 0 N / cQc*

N
A23 CH3O\ N A24 (CH;)ZN N\
::jj C* %

A26 N~
A25 (CH3)2N N\ N
%* CN NC
CH; N H
A27 CH3CH2 N\ ~g CH3CH,CHz N\
\C* C
H H

A29 N/\/O N~ A30 F~CH O N\
~* I 1 ;
O F N
N H
H

r N\ .C
~
A31 CF3O1:~,-N
H.

A33 NC \ N A34 OH
l / j * / \ N\
%

N CH;CH,~ N
CH3O\\C * H I \\C*

(CH3)zCH,H N ~ HsC~N N~
\ %

N
I/ H I/ N C* I
/ H I/ C*
N
H
o A42 0 ~\ H I\ H3C
N C* I\ H I\ N C*
N
H H

I\ H N C* I\ H I\ N C*
HC / H
s H
A45 c A46 c NN \ N~ CH;O(CH,)-HI N C
H I C*
/ N
H

C
A47 0 o A48 0 N~/\N N \--\N N
H C* H C*
H H

4 N N~ NC-(CH,),-NH
(\/ H C* ~
N
H
A51 o A52 0 I \ N
H I\ N C* H \C
N
H
A53 0 A54 (cH02CH v Nv c*
(CH3)ZCHNH N C CH I/ N

F H

A55 CH3CH, \ N A56 CH3CH, N\
I ~C* C
CI=I3 / CH3CH, A57 A58 CH3 \ N\
~/c*
N
\ Br C CH3 H
DO, A59 cH3 A60 /

H3C N\ N
C* \\
j *
H H

A61 A62 H3C H3C \ I\ N C* \ I\ N c H

A63 CH3 A64 cl \ I \ N C * \ I \ NC*
/ rj / H
A65 p A66 O o N

N C* O I \ C*
F N N
H H
A67 / A68 101-C:Q \ I N~C N
C \C*
OCHs H

N
\ \ N \c I \ ~C
O \% 'N
H H

A71 Hi C N N A72 (CH3),CH N N
C* C*
~ \\ ~ \\
O O
H

NC* \ I O /
I
H

\ \ NN
/ N
H
A77 N A78 H~C CH 0 \ ~ \ N~ HOCH,H N c*
%*

j~,~
~ \ N C* I D-_- H I~*

(CH3)2CHCH,,, N
N \C
\
I N/* I H

~ I\ N\ C*
O
H H
A85 0 o A86 N N-I N 0 N \N " N \ N\
H C* H I C*
H
N /
H

A87 x;c cx, 0 A88 0 HOCH N I \ \\ ~N\N \
x N H3C CH3x / N C*
H H

A89 o A90 0 H3C a S N\ C*

CH3 A91 o A92 0 J I C*
CjC* \ N\ ~N \ N\
N O\/ / 1`j H H

N
N
H
NC
CH N
;/ N
H;C H

N \ N~ (CH3),CHNH N~
I j j A97 0 A98 o H * I\ I I\ N C
O \H I
\ NC
s C 3 N N

A99 cF3 N\ A100 0 \ N~
C* C
N
F O H
A101 A102 ~ x ~
CC*
O rJ ):::c H

z I \ N *
A103 Ox A104 HOCx /
I \ ~C* x3C
/
HOCHz H
A105 N N A106 H3C~ I \ N~ (CH3),CH y ):),N
~C*
O / N~C ~
H
A107 N ~ A108 N
\~
C~ C* C
N ~ / N ~ N
N H H
A109 N % N~ A110 N N\
c*
i ~
~N H N H

B 1 ~ B2 CH, *CNH
N *C\~ NH
B3 ~CH,CH3 B4 ~CH,OH
*C~~ NH *C'Nz NH

B5 CF3 B6 ~NH, *C\~ ~NH *C~~ " NH
N N

B7 CD B8 OCHzCH;
*C~~N' NH
~ =
*C\~ " NH
N
B9 ~SCH3 B 10 SCH,CH3 C\IN ~NH *C~~ NH

B11 \ B12 s \
s._/y s *C ~ ~NH
*C~NZNH
B13 / ~ B 14 s *C-~ ~NH
N
*C\I oNH
N
B15 B16 CH3~
N
s / ~ N
- *C~ ~NH
F-~
*C\~N/NH
B17 HOCH, B18 HOCH,CH,~
,NH *C~~ NH
*C N

B 19 CH3OCH, B20 *C~ ~NH
~N

*C\~ NI-I
N B

*C~~ ~NH
*C\~ " NH
N
B23 (CH3)7 B24 NH(CHZ)zOH
O

*C~~ NH *C.\~ NH
N N
C(CH3)2CH,OH B26 N
B25 O o *C"N' NH O

*C'N~NH
B27 Hz \/}- B28 (CH3)2CHNH~
~\
*C -'N'~ NH *C'~"Ni HN
HN
*C\~ "NH
N *C\~V NH
B31 p CH3 B32 HN
'\ HN
~
*C~~ " NH *C \N/NH
N ~

B33 p *C~ NH *C~~ NH
N N

B35 p o\-HN p *C~\N/NH HN \
r--\
*C~~ z NH
N
B37 B38 0 )__NHCH3 O HN HN
*C\\ NH
J~ N
*C/\~ NH

~-H 0 HN
HN
*C\~ NH
*C\,N,,NH
B41 B42 p~ ~p ~IN SLCH3 p~}--~
HN C"'N NH
*C\~ ZNH
N
B43 cx,cH,o B44 ~
~
*C~~ NH -*C~~NNH

B45 CH3,,SC.H3 B46 CH3C.H2CH2,,SCH3 *CNH *C
B47 ocx3 B48 / \

(CH3)2CI ~S
P
CH;CH,CH,~S
*C\~ ZNH
*C~~ " NH N
N
B49 ~SCH, B50 SCH3 %~
*C\\ C *CNH

B51 SCHzCH3 B52 ~ N_~ ~

*C-- ZNH N
N

B53 H,N B54 *c *CNH N
O
B55 o B56 *c~ A
~N-H
*C\~ ~NH
B57 o B58 ~ S
HN
*C--N IINH
*C\~ ZNH
N

*C~~ ~NH *C\\ ~NH
N N
HN
HN
*C~~ ~NH
N *C, NH
"Z N

- ~ ~
*c ~NH ^
N *C\~ ~NH
B65 cH.3 B66 CF3 *C\~ NH *C\~ NH
N N

*C~N N ~NH *C\~ NoNH

*C\~ NH *C\~ ~NH
N N

*C\~ N NH *C\~ NH
B73 CN B74 cH3s~
*C ,NH
\ ~
N
*C~~ ~NH
N
B75 0 B76 0NHcx3 cH
r 3 0 \ N14 NH
~--~ ~
*C\~ ~NH
*C NH
N N
/ \ CH3~N
O O
NH
*C"'N ~NH
*C\~ NH

B79 ~ H3 B80 HOCHz HN \ CH3 *C"' ~NH - 0 N
*C\~ NH

S HN
O
*C~~ NH
*C"' NH
N
B83 cH(cH3)2 B84 *C~~N" NH

*C~~ NH
B85 o\\ B86 0)-CH,CH(CH3), -CH(CH3), HN ~

*C"' ~NH *C\ NH
N ~N
B87 0\\ B88 :--NNNH *C~" NH
N

HN
MN
*C~~
N *C~~ NH
HN
HN
kC ~NiNH *C ~~ ~--A
z NH
N

B93 0~ B94 0 0 HN
HN
*C NH
*C-N ZNH
B95 N_ B96 \ -I
~-j HN
HN
*C, NH
*C~~ NH B97 ~ N~N

N
O N.J O
~-j HN HN
*C~~N~NH *C'-~NH
N

B99 B 100 c o 0 N_J) O, N O~
HN HN
*C~~ ~NH *C~~ ~NH
N N

o ~\ /
HN

*C~~ NH N *C~~ ~NH
N

o r --~I

- H
HN
*C~~ NH
*C-'~NH
N
B 105 N 11 B106 HCH(CH;)z _~I O
O
*C sNH
*C~~ z NH
N
B107 NH(CH3)1 B108 HO
o CH3 *C~~ ~NH
*C\~ NH
B109 cI B110 F/ \
*C\~ ~NH
*C\~ ~NH
N
B i l l P B112 EtO
cI

*C IINH
*C"' NH
N
B113 NHz B114 N(CH3)2 *C ~NH *C"'N "INH
N

B115 cR B116 CH3 *C-'N *C\~ N ' NH
Q-IINH
B 117 0=< CH(CH3), B 118 0=< CH2CH(CH3)2 N

p p *C\~N" NH *C~~NeNH
B 119 0~ N(CH3)2 B120 0~ OCH

N N
*C\-N ~NH *C\X N INH
B121 <NHCH(CHI)2 B122 N O
N
*C\~ NH
C\~ N
B 123 C(CH3)3 B 124 0 O-( ~-N V
HN
*C~~ NH
*C~~ ,NH
N
NI-IC(CH3)3 B126 0 B 125 )_N(CH.
O
HN
*C~~ NH
*C~~ ~NH
N
B127 B128 NHCH(CI I3), p~-No O
FrN

*C NH
*C~~ NH

s *C~~ ~NH *C~~ ~NH
N
B131 Br B132 O j H3 *C\\ N ~NH FfN OH

*C~~N "INH

\/ ~ ~-aOH
HN H
NH
*C\\N ~NH CN
~~n H

*C~~ NH H

*C~~N ~NH
B137 \\ B138 H3C
O
y-No HN/
HN
*C~~ NH
N *C\~ ' NH
N

YNO-OH YND
HN ~ CH3 *c NH *C1`j NH
~
B141 0 B142 N(CH3)2 y N~ y *CNH *CNH
B143 YNW B 144 NHC(CH3)2CH,OH
O
HN*C~~ NH
*C~~ NH

B145 NHCHzC(CH3)20H B146 NHC(CH3)3 O
*C~~ NH *C--N IINH

B147 H~ B148 N
O

*C~~ z NH O N
N
*C~~ ~NH
N
B 149 B 150 Co NJ
O
O
- *C-- ~NH
N
*C\~ NH

B 151 NHCH2C(CH3)2OH B 152 3 O /\
N~ S
>==<
I
- *C' NI
N
*C~~ NH

IIN O
HN O
*C~~ " NH
N

*C "NH
B155 CH; B156 N, o H3C O ~CH3 -~HN
r *C~o NH
~N *C~ H
N
B157 N B158 pN

*C NH *C-N ~NH

~ B160 0 ~-- ~--N-H3C - (CH3)zCH
*C\~ eNE *C\~ NH
N N
B 161 --~N(CH3)2 B 162 NH
O
NH
*C/
\N ~ \
*C
O \ N
O O
B 163 (CHa)aN B 164 CH3CH,NH
HN
C/
~N H

O
H(CH,)Z
B165 B166 ~H

N
N
O

OC
HN ~\N
O
C\
x N-H

B167 NHCHzCH(CH;)z B168 O
O *C/
*C N
\N-H

*C 0-1 Particular compounds of the invention of formula (Ix) denoted as the product of the combination of group Al to Al 10 in Table 1 with B 1 to B 169 in Table 2 are illustrated below:

A1-B1; Al-B2; A1-B3; A1-B4; Al-B5; A1-B6;
A1-B7; A1-B8; Al-B9; Al-BlO; A1-B11; A1-B12;
Al-B13; A1-B14; A1-B15; A1-B16; A1-B17; A1-B18;
Al-B19; A1-B20; A1-B21; A1-B22; A1-B23; A1-B24;
Al-B25; A1-B26; A1-B27; Al-B28; Al-B29; Al-B30;
A1-B31; A1-B32; A1-B33; Al-B34; A1-B35; Al-B36;
A1-B37; Al-B38; Al-B39; Al-B40; Al-B41; Al-B42;
A1-B43; Al-B44; A1-B45; A1-B46; Al-B47; A1-B48;
Al-B49; Al-B50; A1-B51; Al-B52; A1-B53; A1-B54;
A1-B55; A1-B56; A1-B57; Al-B58; A1-B59; A1-B60;
A1-B61; Al-B62; Al-B63; A1-B64; Al-B65; A1-B66;
Al-B67; Al-B68; Al-B69; A1-B70; Al-B71; A1-B72;
Al-B73; A1-B74; A1-B75; Al-B76; Al-B77; Al-B78;
Al-B79; A1-B80; Al-B81; A1-B82; A1-B83; Al-B84;
Al-B85; A1-B86; A1-B87; A1-B88; Al-B89; A1-B90;
Al-B91; Al-B92; Al-B93; A1-B94; Al-B95; Al-B96;
A1-B97; Al-B98; A1-B99; A1-B100; A1-B101; A1-B102;
Al-B103; A1-B104; A1-B105; A1-B106; A1-B107; A1-B108;
A1-B109; Al-B110; A1-B111; Al-B112; Al-B113; Al-B114;
A1-B115; Al-B116; A1-B117; A1-B118; A1-B119; A1-B120;
Al-B121; A1-B122; Al-B123; Al-B124; A1-B125; A1-B126;
Al-B127; Al-B128; Al-B129; Al-B130; A1-B131; A1-B132;
Al-B133; Al-B134; Al-B135; A1-B136; A1-B137; Al-B138;
Al-B139; Al-B140; Al-B141; Al-B142; A1-B143; A1-B144;
A1-B145; Al-B146; Al-B147; A1-B148; Al-B149; Al-B150;
A1-B151; Al-B152; Al-B153; Al-B154; Al-B155; A1-B156;
Al-B157; Al-B158; A1-B159; Al-B160; Al-B161; Al-B162;
Al-B163; Al-B164; A1-B165; A1-B166; A1-B167; Al-B168;
A1-B169; A2-B1; A2-B2; A2-B3; A2-B4; A2-B5;
A2-B6; A2-B7; A2-B8; A2-B9; A2-B10; A2-B11;
A2-B 12; A2-B 13; A2-B 14; A2-B 15; A2-B 16; A2-B 17;
A2-B 18; A2-B 19; A2-B20; A2-B21; A2-B22; A2-B23;
A2-B24; A2-B25; A2-B26; A2-B27; A2-B28; A2-B29;
A2-B30; A2-B31; A2-B32; A2-B33; A2-B34; A2-B35;
A2-B37; A2-B38; A2-B39; A2-B40; A2-B41;
A2-B36;
A2-B42; A2-B43; A2-B44; A2-B45; A2-B46; A2-B47;
A2-B48; A2-B49; A2-B50; A2-B51; A2-B52; A2-B53;
A2-B54; A2-B55; A2-B56; A2-B57; A2-B58; A2-B59;
A2-B60; A2-B61; A2-B62; A2-B63; A2-B64; A2-B65;
A2-B66; A2-B67; A2-B68; A2-B69; A2-B70; A2-B71;
A2-B72; A2-B73; A2-B74; A2-B75; A2-B76; A2-B77;
A2-B78; A2-B79; A2-B80; A2-B81; A2-B82; A2-B83;
A2-B84; A2-B85; A2-B86; A2-B87; A2-B88; A2-B89;
A2-B90; A2-B91; A2-B92; A2-B93; A2-B94; A2-B95;
A2-B96; A2-B97; A2-B98; A2-B99; A2-B100; A2-B101;
A2-B 102; A2-B 103; A2-B 104; A2-B 105; A2-B 106; A2-B 107;
A2-B108; A2-B 109; A2-B 110; A2-B 111; A2-B 112; A2-B 113;
A2-B 114; A2-B 115; A2-B 116; A2-B 117; A2-B 118; A2-B 119;
A2-B 120; A2-B 121; A2-B 122; A2-B 123; A2-B 124; A2-B 125;
A2-B 126; A2-B 127; A2-B 128; A2-B 129; A2-B 130; A2 B 131;
A2-3132; A2-B 133; A2-B 134; A2-B 135; A2-B 136; A2-B 137;
A2-B138; A2-B 139; A2-B 140; A2-B 141; A2-B 142; A2-B 143;
A2-B 144; A2-B 145; A2-B 146; A2-B 147; A2-B 148; A2-B 149;
A2-B150; A2-B151; A2-B152; A2-B153; A2-B154; A2-B155;
A2-B 156; A2-B 157; A2-B158; A2-B 159; A2-B160; A2-B 161;
A2-B 162; A2-B 163; A2-B 164; A2-B 165; A2-B 166; A2-B 167;
A2-B 168; A2-B 169; A3-B 1; A3-B2; A3-B3; A3-B4;
A3-B5; A3-B6; A3-B7; A3-B8; A3-B9; A3-B 10;
A3-B11; A3-B12; A3-B13; A3-B14; A3-B15; A3-B16;
A3-B 17; A3-B 18; A3-B 19; A3-B20; A3-B21; A3-B22;
A3-B23; A3-B24; A3-B25; A3-B26; A3-B27; A3-B28;
A3-B29; A3-B30; A3-B31; A3-B32; A3-B33; A3-B34;
A3-B35; A3-B36; A3-B37; A3-B38; A3-B39; A3-B40;
A3-B41; A3-B42; A3-B43; A3-B44; A3-B45; A3-B46;
A3-B47; A3-B48; A3-B49; A3-B50; A3-B51; A3-B52;
A3-B53; A3-B54; A3-B55; A3-B56; A3-B57; A3-B58;
A3-B59; A3-B60; A3-B61; A3-B62; A3-B63; A3-B64;
A3-B65; A3-B66; A3-B67; A3-B68; A3-B69; A3-B70;
A3-B71; A3-B72; A3-B73; A3-B74; A3-B75; A3-B76;
A3-B77; A3-B78; A3-B79; A3-B80; A3-B81; A3-B82;
A3-B83; A3-B84; A3-B85; A3-B86; A3-B87; A3-B88;
A3-B89; A3-B90; A3-B91; A3-B92; A3-B93; A3-B94;
A3-B95; A3-B96; A3-B97; A3-B98; A3-B99; A3-B100;
A3-B 101; A3-B 102; A3-B 103; A3-B 104; A3-B 105; A3-B 106;
A3-B107; A3-B108; A3-B109; A3-B110; A3-B111; A3-13112;
A3-B 113; A3-B 114; A3-B 115; A3-B 116; A3-B 117; A3-B 118;
A3-B 119; A3-B 120; A3-B 121; A3-B 122; A3-B 123; A3-B 124;
A3-B 125; A3-B 126; A3-B 127; A3-B 128; A3-B 129; A3-B 130;
A3-B131; A3-B132; A3-B133; A3-B134; A3-B135; A3-B136;
A3-B137; A3-B138; A3-B139; A3-B140; A3-B141; A3-B142;
A3-B143; A3-B 144; A3-B 145; A3-B 146; A3-B 147; A3-B 148;
A3-B 149; A3-B 150; A3-B 151; A3-B 152; A3-B 153; A3-B 154;
A3-B155; A3-B156; A3-B157; A3-B158; A3-B159; A3-B160;
A3-B161; A3-B162; A3-B163; A3-B164; A3-B165; A3-B166;
A3-B167; A3-B168; A3-B169; A4-B1; A4-B2; A4-B3;
A4-B4; A4-B5; A4-B6; A4-B7; A4-B8; A4-B9;
A4-B 10; A4-B 11; A4-B12; A4-B13; A4-B14; A4-B 15;
A4-B16; A4-B 17; A4-B 18; A4-B 19; A4-B20; A4-B21;
A4-B22; A4-B23; A4-B24; A4-B25; A4-B26; A4-B27;
A4-B28; A4-B29; A4-B30; A4-B31; A4-B32; A4-B33;
A4-B34; A4-B35; A4-B36; A4-B37; A4-B38; A4-B39;
A4-B40; A4-B41; A4-B42; A4-B43; A4-B44; A4-B45;
A4-B46; A4-B47; A4-B48; A4-B49; A4-B50; A4-B51;
A4-B52; A4-B53; A4-B54; A4-B55; A4-B56; A4-B57;
A4-B58; A4-B59; A4-B60; A4-B61; A4-B62; A4-B63;
A4-B64; A4-B65; A4-B66; A4-B67; A4-B68; A4-B69;
A4-B70; A4-B71; A4-B72; A4-B73; A4-B74; A4-B75;
A4-B76; A4-B77; A4-B78; A4-B79; A4-B80; A4-B81;
A4-B82; A4-B83; A4-B84; A4-B85; A4-B86; A4-B87;
A4-B88; A4-B89; A4-B90; A4-B91; A4-B92; A4-B93;
A4-B94; A4-B95; A4-B96; A4-B97; A4-B98; A4-B99;
A4-B 100; A4-B 101; A4-B 102; A4-B 103; A4-B 104; A4-B 105;
A4-B 106; A4-B 107; A4-B 108; A4-B 109; A4-B 110; A4-B 111;
A4-B 112; A4-B 113; A4-B 114; A4-B 115; A4-B 116; A4-B 117;
A4-B 118; A4-B 119; A4-B 120; A4-B 121; A4-B 122; A4-B 123;
A4-B 124; A4-B 125; A4-B 126; A4-B 127; A4-B 128; A4-B129;
A4-B 130; A4-B 131; A4-B 132; A4-B 133; A4-B 134; A4-B 13 5;
A4-B136; A4-B137; A4-B138; A4-B139; A4-B140; A4-B141;
A4-B 142; A4-B 143; A4-B 144; A4-B 145; A4-B 146; A4-B 147;
A4-B 148; A4-B 149; A4-B 150; A4-B 151; A4-B 152; A4-B 153;
A4-B 154; A4-B155; A4-B156; A4-B 157; A4-B158; A4-B 159;
A4-B 160; A4-B 161; A4-B 162; A4-B 163; A4-B 164; A4-B 165;
A4-B 166; A4-B 167; A4-B 168; A4-B 169; A5-B 1; A5-B2;
A5-B3; A5-B4; A5-B5; A5-B6; A5-B7; A5-B8;
A5-B9; A5-B10; A5-B11; A5-B12; A5-B13; A5-B14;
A5-B 15; A5-B 16; A5-B 17; A5-B 18; A5-B 19; A5-B20;
A5-B21; A5-B22; A5-B23; A5-B24; A5-B25; A5-B26;
A5-B27; A5-B28; A5-B29; A5-B30; A5-B31; A5-B32;
A5-B33; A5-B34; A5-B35; A5-B36; A5-B37; A5-B38;
A5-B39; A5-B40; A5-B41; A5-B42; A5-B43; A5-B44;
A5-B45; A5-B46; A5-B47; A5-B48; A5-B49; A5-B50;
A5-B51; A5-B52; A5-B53; A5-B54; A5-B55; A5-B56;
A5-B57; A5-B58; A5-B59; A5-B60; A5-B61; A5-B62;
A5-B63; A5-B64; A5-B65; A5-B66; A5-B67; A5-B68;
A5-B69; A5-B70; A5-B71; A5-B72; A5-B73; A5-B74;
A5-B75; A5-B76; A5-B77; A5-B78; A5-B79; A5-B80;
A5-B81; A5-B82; A5-B83; A5-B84; A5-B85; A5-B86;
A5-B87; A5-B88; A5-B89; A5-B90; A5-B91; A5-B92;
A5-B93; A5-B94; A5-B95; A5-B96; A5-B97; A5-B98;
A5-B99; A5-B 100; A5-B 101; A5-B 102; A5-B103; A5-B 104;
A5-B 105; A5-B 106; A5-B 107; A5-B 108; A5-B 109; A5-B 110;
A5-B111; A5-B112; A5-B113; A5-B114; A5-B115; A5-B116;
A5-B 117; A5-B 118; A5-B 119; A5-B 120; A5-B 121; A5-B 122;
A5-B123; A5-B124; A5-B125; A5-B126; A5-B127; A5-B128;
A5-B129; A5-B130; A5-B131; A5-B132; A5-B133; A5-B134;
A5-B135; A5-B136; A5-B137; A5-B138; A5-B139; A5-B140;
A5-B 141; A5-B 142; A5-B 143; A5-B 144; A5-B 145; A5-B 146;
A5-B 147; A5-B148; A5-B 149; A5-B 150; A5-B 151; A5-B 152;
A5-B 153; A5-B 154; A5-B155; A5-B 156; A5-B 157; A5-B 15 8;
A5-B 159; A5-B 160; A5-B 161; A5-B 162; A5-B 163; A5-B 164;
A5-B 165; A5-B 166; A5-B 167; A5-B 168; A5-B169; A6-B 1;
A6-B2; A6-B3; A6-B4; A6-B5; A6-B6; A6-B7;
A6-B8; A6-B9; A6-B 10; A6-B 11; A6-B 12; A6-B 13;
A6-B 14; A6-B 15; A6-B 16; A6-B 17; A6-B 18; A6-B 19;
A6-B20; A6-B21; A6-B22; A6-B23; A6-B24; A6-B25;
A6-B26; A6-B27; A6-B28; A6-B29; A6-B30; A6-B31;
A6-B32; A6-B33; A6-B34; A6-B35; A6-B36; A6-B37;
A6-B38; A6-B39; A6-B40; A6-B41; A6-B42; A6-B43;
A6-B44; A6-B45; A6-B46; A6-B47; A6-B48; A6-B49;
A6-B50; A6-B51; A6-B52; A6-B53; A6-B54; A6-B55;
A6-B56; A6-B57; A6-B58; A6-B59; A6-B60; A6-B61;
A6-B62; A6-B63; A6-B64; A6-B65; A6-B66; A6-B67;
A6-B68; A6-B69; A6-B70; A6-B71; A6-B72; A6-B73;
A6-B74; A6-B75; A6-B76; A6-B77; A6-B78; A6-B79;
A6-B80; A6-B81; A6-B82; A6-B83; A6-B84; A6-B85;
A6-B86; A6-B87; A6-B88; A6-B89; A6-B90; A6-B91;
A6-B92; A6-B93; A6-B94; A6-B95; A6-B96; A6-B97;
A6-B98; A6-B99; A6-B 100; A6-B 101; A6-B 102; A6-B 103;
A6-B 104; A6-B 105; A6-B 106; A6-B 107; A6-B 108; A6-B 109;
A6-B 110; A6-B 111; A6-B 112; A6-B 113; A6-B 114; A6-B 115;
A6-B 116; A6-B 117; A6-B 118; A6-B 119; A6-B 120; A6-B 121;
A6-B 122; A6-B 123; A6-B 124; A6-B 125; A6-B 126; A6-B 127;
A6-B 128; A6-B 129; A6-B 130; A6-B 131; A6-B 132; A6-B 133;
A6-B 134; A6-B 135; A6-B 136; A6-B 137; A6-B 138; A6-B 139;
A6-B 140; A6-B 141; A6-B 142; A6-B 143; A6-B 144; A6-B 145;
A6-B 146; A6-B 147; A6-B 148; A6-B 149; A6-B 150; A6-B 151;
A6-B 152; A6-B 153; A6-B 154; A6-B 155; A6-B 156; A6-B 157;
A6-B 158; A6-B 159; A6-B 160; A6-B 161; A6-B 162; A6-B 163;
A6-B 164; A6-B 165; A6-B 166; A6-B 167; A6-B 168; A6-B 169;
A7-B1; A7-B2; A7-B3; A7-B4; A7-B5; A7-B6;
A7-B7; A7-B8; A7-B9; A7-B10; A7-B11; A7-B12;
A7-B 13; A7-B 14; A7-B 15; A7-B 16; A7-B17; A7-B 18;
A7-B19; A7-B20; A7-B21; A7-B22; A7-B23; A7-B24;
A7-B25; A7-B26; A7-B27; A7-B28; A7-B29; A7-B30;
A7-B31; A7-B32; A7-B33; A7-B34; A7-B35; A7-B36;
A7-B37; A7-B38; A7-B39; A7-B40; A7-B41; A7-B42;
A7-B43; A7-B44; A7-B45; A7-B46; A7-B47; A7-B48;
A7-B49; A7-B50; A7-B51; A7-B52; A7-B53; A7-B54;
A7-B55; A7-B56; A7-B57; A7-B58; A7-B59; A7-B60;
A7-B61; A7-B62; A7-B63; A7-B64; A7-B65; A7-B66;
A7-B67; A7-B68; A7-B69; A7-B70; A7-B71; A7-B72;
A7-B73; A7-B74; A7-B75; A7-B76; A7-B77; A7-B78;
A7-B79; A7-B80; A7-B81; A7-B82; A7-B83; A7-B84;
A7-B85; A7-B86; A7-B87; A7-B88; A7-B89; A7-B90;
A7-B91; A7-B92; A7-B93; A7-B94; A7-B95; A7-B96;
A7-B97; A7-B98; A7-B99; A7-B100; A7-B101; A7-B102;
A7-B 103; A7-B 104; A7-B 105; A7-B 106; A7-B 107; A7-B 108;
A7-B 109; A7-B 110; A7-B 111; A7-B 112; A7-B 113; A7-B 114;
A7-B 115; A7-B 116; A7-B 117; A7-B 118; A7-B 119; A7-B 120;
A7-B 121; A7-B122; A7-B 123; A7-B 124; A7-B 125; A7-B126;
A7-B 127; A7-B 128; A7-B 129; A7-B130; A7-B 131; A7-B132;
A7-B 133; A7-B 134; A7-B 135; A7-B 136; A7-B 137; A7-B 138;
A7-B139; A7-B 140; A7-B 141; A7-B 142; A7-B 143; A7-B 144;
A7-B 145; A7-B 146; A7-B 147; A7-B 148; A7-B 149; A7-B 150;
A7-B 151; A7-B 152; A7-B 153; A7-B 154; A7-B 155; A7-B156;
A7-B157; A7-B158; A7-B159; A7-B160; A7-B161; A7-B162;
A7-B 163; A7-B 164; A7-B 165; A7-B 166; A7-B167; A7-B 168;
A7-B169; A8-B1; A8-B2; A8-B3; A8-B4; A8-B5;
A8-B6; A8-B7; A8-B8; A8-B9; A8-B10; A8-B11;
A8-B 12; A8-B 13; A8-B 14; A8-B 15; A8-B 16; A8-B 17;
A8-B 18; A8-B 19; A8-B20; A8-B21; A8-B22; A8-B23;
A8-B24; A8-B25; A8-B26; A8-B27; A8-B28; A8-B29;
A8-B30; A8-B31; A8-B32; A8-B33; A8-B34; A8-B35;
A8-B36; A8-B37; A8-B38; A8-B39; A8-B40; A8-B41;
A8-B42; A8-B43; A8-B44; A8-B45; A8-B46; A8-B47;
A8-B48; A8-B49; A8-B50; A8-B51; A8-B52; A8-B53;
A8-B54; A8-B55; A8-B56; A8-B57; A8-B58; A8-B59;
A8-B60; A8-B61; A8-B62; A8-B63; A8-B64; A8-B65;
A8-B66; A8-B67; A8-B68; A8-B69; A8-B70; A8-B71;
A8-B72; A8-B73; A8-B74; A8-B75; A8-B76; A8-B77;
A8-B78; A8-B79; A8-B80; A8-B81; A8-B82; A8-B83;
A8-B84; A8-B85; A8-B86; A8-B87; A8-B88; A8-B89;
A8-B90; A8-B91; A8-B92; A8-B93; A8-B94; A8-B95;
A8-B96; A8-B97; A8-B98; A8-B99; A8-B100; A8-B101;
A8-B 102; A8-B 103; A8-B 104; A8-B 105; A8-B 106; A8-B 107;
A8-B 108; A8-B 109; A8-B 110; A8-B 111; A8-B 112; A8-B 113;
A8-B 114; A8-B 115; A8-B 116; A8-B 117; A8-B 118; A8-B 119;
A8-B 120; A8-B 121; A8-B 122; A8-B 123; A8-B 124; A8-B 125;
A8-B 126; A8-B 127; A8-B 128; A8-B 129; A8-B 130; A8-B 131;
A8-B 132; A8-B133; A8-B 134; A8-B 135; A8-B 136; A8-B 137;
A8-B138; A8-B139; A8-B 140; A8-B 141; A8-B 142; A8-B 143;
A8-B 144; A8-B 145; A8-B 146; A8-B147; A8-B 148; A8-B 149;
A8-B 150; A8-B 151; A8-B 152; A8-B 153; A8-B 154; A8-B 155;
A8-B 156; A8-B 157; A8-B 158; A8-B 159; A8-B 160; A8-B161;
A8-B 162; A8-B 163; A8-B 164; A8-B 165; A8-B 166; A8-B 167;
A8-B168; A8-B 169; A9-B 1; A9-B2; A9-B3; A9-B4;
A9-B5; A9-B6; A9-B7; A9-B8; A9-B9; A9-B10;
A9-B 11; A9-B 12; A9-B 13; A9-B 14; A9-B 15; A9-B 16;
A9-B 17; A9-B 18; A9-B 19; A9-B20; A9-B21; A9-B22;
A9-B23; A9-B24; A9-B25; A9-B26; A9-B27; A9-B28;
A9-B29; A9-B30; A9-B31; A9-B32; A9-B33; A9-B34;
A9-B35; A9-B36; A9-B37; A9-B38; A9-B39; A9-B40;
A9-B41; A9-B42; A9-B43; A9-B44; A9-B45; A9-B46;
A9-B47; A9-B48; A9-B49; A9-B50; A9-B51; A9-B52;
A9-B53; A9-B54; A9-B55; A9-B56; A9-B57; A9-B58;
A9-B59; A9-B60; A9-B61; A9-B62; A9-B63; A9-B64;
A9-B65; A9-B66; A9-B67; A9-B68; A9-B69; A9-B70;
A9-B71; A9-B72; A9-B73; A9-B74; A9-B75; A9-B76;
A9-B77; A9-B78; A9-B79; A9-B80; A9-B81; A9-B82;
A9-B83; A9-B84; A9-B85; A9-B86; A9-B87; A9-B88;
A9-B89; A9-B90; A9-B91; A9-B92; A9-B93; A9-B94;
A9-B95; A9-B96; A9-B97; A9-B98; A9-B99; A9-B 100;
A9-B 101; A9-B 102; A9-B 103; A9-B 104; A9-B 105; A9-B 106;
A9-B 107; A9-B 108; A9-B 109; A9-B 110; A9-B 111; A9-B 112;
A9-B 113; A9-B 114; A9-B 115; A9-B 116; A9-B 117; A9-B 118;
A9-B 119; A9-B 120; A9-B 121; A9-B 122; A9-B 123; A9-B 124;
A9-B 125; A9-B 126; A9-B 127; A9-B 128; A9-B 129; A9-B130;
A9-B131; A9-B132; A9-B133; A9-B134; A9-B135; A9-B136;
A9-B 137; A9-B 138; A9-B 139; A9-B 140; A9-B 141; A9-B 142;
A9-B 143; A9-B 144; A9-B 145; A9-B 146; A9-B147; A9-B 148;
A9-B 149; A9-B 150; A9-B 151; A9-B152; A9-B153; A9-B 154;
A9-B 155; A9-B156; A9-B 157; A9-B 158; A9-B159; A9-B 160;
A9-B161; A9-B 162; A9-B 163; A9-B 164; A9-B 165; A9-B 166;
A9-B167; A9-B168; A9-B169; A10-Bl; A10-B2; A10-B3;
A10-B4; A10-B5; A10-B6; A10-B7; Al0-B8; A10-B9;
A10-B10; A10-B11; A10-B12; A10-B13; A10-B14; Al -B15;
A10-B16; A10-B17; A10-B18; A10-B19; A10-B20; A10-B21;
A10-B22; A10-B23; A10-B24; A10-B25; A10-B26; A10-B27;
A10-B28; A10-B29; A10-B30; A10-B31; A10-B32; A10-B33;
A10-B34; A10-B35; Al0-B36; A10-B37; A10-B38; A10-B39;
A10-B40; A10-B41; A10-B42; A10-B43; A10-B44; A10-B45;
A10-B46; A10-B47; A10-B48; A10-B49; A10-B50; A10-B51;
A10-B52; A10-B53; A10-B54; A10-B55; A10-B56; A10-B57;
A10-B58; A10-B59; A10-B60; A10-B61; A10-B62; A10-B63;
A10-B64; A10-B65; A10-B66; A10-B67; A10-B68; A10-B69;
A10-B70; A10-B71; A10-B72; A10-B73; A10-B74; A10-B75;
A10-B76; A10-B77; A10-B78; A10-B79; A10-B80; A10-B81;
A10-B82; A10-B83; A10-B84; A10-B85; A10-B86; A10-B87;
A10-B88; A10-B89; A10-B90; A10-B91; A10-B92; A10-B93;
A10-B94; A10-B95; A10-B96; A10-B97; A10-B98; A10-B99;
A10-B100; A10-B101; A10-B102; A10-B103; A10-B104; A10-B105;
A10-B106; A10-B107; A10-B108; A10-B109; A10-B110; A10-B111;
A10-B112; A10-B113; A10-B114; A10-B115; A10-B116; A10-B117;
A10-B118; A10-B119; A10-B120; A10-B121; A10-B122; A10-B123;
A10-B124; A10-B125; A10-B126; A10-B127; A10-B128; A10-B129;
A10-B130; A10-B131; A10-B132; A10-B133; A10-B134; A10-B135;
A10-B136; A10-B137; A10-B138; A10-B139; A10-B140; A10-B141;
A10-B142; A10-B143; A10-B144; A10-B145; A10-B146; A10-B147;
A10-B148; A10-B149; A10-B150; A10-B151; A10-B152; A10-B153;
A10-B154; A10-B155; A10-B156; A10-B157; A10-B158; A10-B159;
A10-B160; A10-B161; A10-B162; A10-B163; A10-B164; A10-B165;
A10-B166; A10-B167; A10-B168; A10-B169; A1l-Bl; A11-B2;
A11-B3; A11-B4; A11-B5; A11-B6; All-B7; All-B8;
A11-B9; All-B10; All-B11; A11-B12; A11-B13; A11-B14;
A11-B15; A11-B16; A11-B17; A11-B18; A11-B19; A11-B20;
A11-B21; A11-B22; A11-B23; A11-B24; A11-B25; A11-B26;
A11-B27; A11-B28; A11-B29; A11-B30; A11-B31; All-B32;
A11-B33; A11-B34; A11-B35; All-B36; All-B37; All-B38;
A11-B39; All-B40; A11-B41; All-B42; A11-B43; A11-B44;
A11-B45; A11-B46; Al1-B47; All-B48; A11-B49; All-B50;
All-B51; All-B52; A11-B53; A11-B54; A11-B55; All-B56;
A11-B57; A11-B58; A11-B59; A11-B60; All-B61; All-B62;
All-B63; A11-B64; A11-B65; A11-B66; All-B67; All-B68;
A11-B69; A11-B70; All-B71; A11-B72; A11-B73; A11-B74;
A11-B75; A11-B76; A11-B77; A11-B78; All-B79; A11-B80;
A11-B81; All-B82; All-B83; All-B84; A1l-B85; A11-B86;
All-B87; All-B88; A11-B89; A11-B90; All-B91; A11-B92;
A11-B93; All-B94; All-B95; All-B96; All-B97; All-B98;
A11-B99; All-B100; All-Bl01; A11-B102; A11-B103; All-B104;
A11-B105; All-B106; All-B107; A11-B108; A11-B109; A1l-B110;
A1l-B111; A11-B112; A11-B113; A11-B114; A11-B115; A11-B116;
A11-B117; A11-B118; A11-B119; All-B120; A11-B121; A11-B122;
A1l-B123; A11-B124; A11-B125; All-B126; A11-B127; A11-B128;
All-B129; A11-B130; A11-B131; A11-B132; A11-B133; All-B134;
A11-B135; All-B136; All-B137; All-B138; A11-B139; A11-B140;
A11-B141; All-B142; All-B143; All-B144; All-B145; All-B146;
A11-B147; A11-B148; All-B149; All-B150; A11-B151; All-B152;
A11-B153; A11-B154; A11-B155; A1l-B156; All-B157; A11-B158;
A11-B159; A11-B160; A1l-B161; All-B162; All-B163; All-B164;
A11-B165; All-B166; A11-B167; A11-B168; A11-B169; A12-Bl;
A12-B2; A12-B3; A12-B4; A12-B5; A12-B6; A12-B7;
A12-B8; A12-B9; A12-B10; A12-B11; A12-B12; A12-B13;
A12-B14; A12-B15; A12-B16; A12-B17; A12-B18; A12-B19;
A12-B20; A12-B21; A12-B22; A12-B23; A12-B24; A12-B25;
A12-B26; A12-B27; A12-B28; A12-B29; A12-B30; A12-B31;
A12-B32; A12-B33; A12-B34; A12-B35; A12-B36; A12-B37;
A12-B38; A12-B39; A12-B40; A12-B41; A12-B42; A12-B43;
A12-B44; A12-B45; A12-B46; A12-B47; A12-B48; A12-B49;
A12-B50; A12-B51; A12-B52; A12-B53; A12-B54; A12-B55;
A12-B56; A12-B57; A12-B58; A12-B59; A12-B60; A12-B61;
A12-B62; A12-B63; A12-B64; A12-B65; A12-B66; A12-B67;
A12-B68; A12-B69; A12-B70; A12-B71; A12-B72; A12-B73;
A12-B74; A12-B75; A12-B76; A12-B77; A12-B78; A12-B79;
A12-B80; A12-B81; A12-B82; A12-B83; A12-B84; A12-B85;
A12-B86; A12-B87; A12-B88; A12-B89; A12-B90; A12-B91;
A12-B92; A12-B93; A12-B94; A12-B95; A12-B96; A12-B97;
A12-B98; A12-B99; A12-B100; A12-B101; A12-B102; A12-B103;
A12-B104; A12-B105; A12-B106; A12-B107; A12-B108; A12-B109;
A12-B110; A12-B111; A12-B112; A12-B113; A12-B114; A12-B115;
A12-B116; A12-B117; A12-B118; A12-B119; A12-B120; A12-B121;
A12-B122; A12-B123; A12-B124; A12-B125; A12-B126; A12-B127;
A12-B128; A12-B129; A12-B130; A12-B131; A12-B132; A12-B133;
A12-B134; A12-B135; A12-B136; A12-B137; A12-B138; A12-B139;
A12-B140; A12-B141; A12-B142; A12-B143; A12-B144; A12-B145;
A12-B146; A12-B147; A12-B148; A12-B149; A12-B150; A12-B151;
A12-B152; A12-B153; A12-B154; A12-B155; A12-B156; A12-B157;
A12-B158; A12-B159; A12-B160; A12-B161; A12-B162; A12-B163;
A12-B164; A12-B165; A12-B166; A12-B167; A12-B168; A12-B169;
A13-B1; A13-B2; A13-B3; A13-B4; A13-B5; A13-B6;
A13-B7; A13-B8; A13-B9; A13-B10; A13-B11; A13-B12;
A13-B13; A13-B14; A13-B15; A13-B16; A13-B17; A13-B18;
A13-B19; A13-B20; A13-B21; A13-B22; A13-B23; A13-B24;
A13-B25; A13-B26; A13-B27; A13-B28; A13-B29; A13-B30;
A13-B31; A13-B32; A13-B33; A13-B34; A13-B35; A13-B36;
A13-B37; A13-B38; A13-B39; A13-B40; A13-B41; A13-B42;
A13-B43; A13-B44; A13-B45; A13-B46; A13-B47; A13-B48;
A13-B49; A13-B50; A13-B51; A13-B52; A13-B53; A13-B54;
A13-B55; A13-B56; A13-B57; A13-B58; A13-B59; A13-B60;
A13-B61; A13-B62; A13-B63; A13-B64; A13-B65; A13-B66;
A13-B67; A13-B68; A13-B69; A13-B70; A13-B71; A13-B72;
A13-B73; A13-B74; A13-B75; A13-B76; A13-B77; A13-B78;
A13-B79; A13-B80; A13-B81; A13-B82; A13-B83; A13-B84;
A13-B85; A13-B86; A13-B87; A13-B88; A13-B89; A'13-B90;
A13-B91; A13-B92; A13-B93; A13-B94; A13-B95; A13-B96;
A13-B97; A13-B98; A13-B99; A13-B100; A13-B101; A13-B102;
A13-B103; A13-B104; A13-B105; A13-B106; A13-B107; A13-B108;
A13-B109; A13-B110; A13-B111; A13-B112; A13-B113; A13-B114;
A13-B115; A13-B116; A13-B117; A13-B118; A13-B119; A13-B120;
A13-B121; A13-B122; A13-B123; A13-B124; A13-B125; A13-B126;
A13-B127; A13-B128; A13-B129; A13-B130; A13-B131; A13-B132;
A13-B133; A13-B134; A13-B135; A13-B136; A13-B137; A13-B138;
A13-B139; A13-B140; A13-B141; A13-B142; A13-B143; A13-B144;
A13-B145; A13-B146; A13-B147; A13-B148; A13-B149; A13-B150;
A13-B 151; A13-B 152; A13-B 153; A13-B 154; A13-B155; A13-B 156;
A13-B157; A13-B158; A13-B159; A13-B160; A13-B161; A13-B162;
A13-B 163; A13-B 164; A13-B 165; A13-B 166; A13-B 167; A13-B 168;
A13-B169; A14-B1; A14-B2; A14-B3; A14-B4; A14-B5;
A14-B6; A14-B7; A14-B8; A14-B9; A14-B10; A14-B11;
A14-B12; A14-B13; A14-B14; A14-B15; A14-B16; A14-B17;
A14-B18; A14-B19; A14-B20; A14-B21; A14-B22; A14-B23;
A14-B24; A14-B25; A14-B26; A14-B27; A14-B28; A14-B29;
A14-B30; A14-B31; A14-B32; A14-B33; A14-B34; A14-B35;
A14-B36; A14-B37; A14-B38; A14-B39; A14-B40; A14-B41;
A14-B42; A14-B43; A14-B44; A14-B45; A14-B46; A14-B47;
A14-B48; A14-B49; A14-B50; A14-B51; A14-B52; A14-B53;
A14-B54; A14-B55; A14-B56; A14-B57; A14-B58; A14-B59;
A14-B60; A14-B61; A14-B62; A14-B63; A14-B64; A14-B65;
A14-B66; A14-B67; A14-B68; A14-B69; A14-B70; A14-B71;
A14-B72; A14-B73; A14-B74; A14-B75; A14-B76; A14-B77;
A14-B78; A14-B79; A14-B80; A14-B81; A14-B82; A14-B83;
A14-B84; A14-B85; A14-B86; A14-B87; A14-B88; A14-B89;
A14-B90; A14-B91; A14-B92; A14-B93; A14-B94; A14-B95;
A14-B96; A14-B97; A14-B98; A14-B99; A14-B100; A14-B101;
A14-B102; A14-B103; A14-B104; A14-B105; A14-B106; A14-B107;
A14-B108; A14-B109; A14-B110; A14-B111; A14-B112; A14-B113;
A14-B114; A14-B115; A14-B116; A14-B117; A14-B118; A14-B119;
A14-B120; A14-B121; A14-B122; A14-B123; A14-B124; A14-B125;
A14-B126; A14-B127; A14-B128; A14-B129; A14-B130; A14-B131;
A14-B132; A14-B133; A14-B134; A14-B135; A14-B136; A14-B137;
A14-B138; A14-B139; A14-B140; A14-B141; A14-B142; A14-B143;
A14-B144; A14-B145; A14-B146; A14-B147; A14-B148; A14-B149;
A14-B150; A14-B151; A14-B152; A14-B153; A14-B154; A14-B155;
A14-B156; A14-B157; A14-B158; A14-B159; A14-B160; A14-B161;
A14-B162; A14-B163; A14-B164; A14-B165; A14-B166; A14-B167;
A14-B168; A14-B169; A15-B1; A15-B2; A15-B3; A15-B4;
A15-B5; A15-B6; A15-B7; A15-B8; A15-B9; A15-B10;
A15-B11; A15-B12; A15-B13; A15-B14; A15-B15; A15-B16;
A15-B17; A15-B18; A15-B19; A15-B20; A15-B21; A15-B22;
A15-B23; A15-B24; A15-B25; A15-B26; A15-B27; A15-B28;
A15-B29; A15-B30; A15-B31; A15-B32; A15-B33; A15-B34;
A15-B35; A15-B36; A15-B37; A15-B38; A15-B39; A15-B40;
A15-B41; A15-B42; A15-B43; A15-B44; A15-B45; A15-B46;
A15-B47; A15-B48; A15-B49; A15-B50; A15-B51; A15-B52;
A15-B53; A15-B54; A15-B55; A15-B56; A15-B57; A15-B58;
A15-B59; A15-B60; A15-B61; A15-B62; A15-B63; A15-B64;
A15-B65; A15-B66; A15-B67; A15-B68; A15-B69; A15-B70;
A15-B71; A15-B72; A15-B73; A15-B74; A15-B75; A15-B76;
A15-B77; A15-B78; A15-B79; A15-B80; A15-B81; A15-B82;
A15-B83; A15-B84; A15-B85; A15-B86; A15-B87; A15-B88;
A15-B89; A15-B90; A15-B91; A15-B92; A15-B93; A15-B94;
A15-B95; A15-B96; A15-B97; A15-B98; A15-B99; A15-B100;
A15-B101; A15-B102; A15-B103; A15-B104; A15-B105; A15-B106;
A15-B107; A15-B108; A15-B109; A15-B110; A15-B111; A15-B112;
A15-B113; A15-B114; A15-B115; A15-B116; A15-B117; A15-B118;
A15-B119; A15-B120; A15-B121; A15-B122; A15-B123; A15-B124;
A15-B125; A15-B126; A15-B127; A15-B128; A15-B129; A15-B130;
A15-B131; A15-B132; A15-B133; A15-B134; A15-B135; A15-B136;
A15-B137; A15-B138; A15-B139; A15-B140; A15-B141; A15-B142;
A15-B143; A15-B144; A15-B145; A15-B146; A15-B147; A15-B148;
A15-B149; A15-B150; A15-B151; A15-B152; A15-B153; A15-B154;
A15-B155; A15-B156; A15-B157; A15-B158; A15-B159; A15-B160;
A15-B161; A15-B162; A15-B163; A15-B164; A15-B165; A15-B166;
A15-B167; A15-B168; A15-B169; A16-Bl; A16-B2; A16-B3;
A16-B4; A16-B5; A16-B6; A16-B7; A16-B8; A16-B9;
A16-B10; A16-B11; A16-B12; A16-B13; A16-B14; A16-B15;
A16-B16; A16-B17; A16-B18; A16-B19; A16-B20; A16-B21;
A16-B22; A16-B23; A16-B24; A16-B25; A16-B26; A16-B27;
A16-B28; A16-B29; A16-B30; A16-B31; A16-B32; A16-B33;
A16-B34; A16-B35; A16-B36; A16-B37; A16-B38; A16-B39;
A16-B40; A16-B41; A16-B42; A16-B43; A16-B44; A16-B45;
A16-B46; A16-B47; A16-B48; A16-B49; A16-B50; A16-B51;
A16-B52; A16-B53; A16-B54; A16-B55; A16-B56; A16-B57;
A16-B58; A16-B59; A16-B60; A16-B61; A16-B62; A16-B63;
A16-B64; A16-B65; A16-B66; A16-B67; A16-B68; A16-B69;
A16-B70; A16-B71; A16-B72; A16-B73; A16-B74; A16-B75;
A16-B76; A16-B77; A16-B78; A16-B79; A16-B80; A16-B81;
A16-B82; A16-B83; A16-B84; A16-B85; A16-B86; A16-B87;
A16-B88; A16-B89; A16-B90; A16-B91; A16-B92; A16-B93;
A16-B94; A16-B95; A16-B96; A16-B97; A16-B98; A16-B99;
A16-B100; A16-B101; A16-B102; A16-B103; A16-B104; A16-B105;
A16-B106; A16-B107; A16-B108; A16-B109; A16-B110; A16-B111;
A16-B112; A16-B113; A16-B114; A16-B115; A16-B116; A16-B117;
A16-B118; A16-B119; A16-B120; A16-B121; A16-B122; A16-B123;
A16-B124; A16-B125; A16-B126; A16-B127; A16-B128; A16-B129;
A16-B130; A16-B131; A16-B132; A16-B133; A16-B134; A16-B135;
A16-B136; A16-B137; A16-B138; A16-B139; A16-B140; A16-B141;
A16-B142; A16-B143; A16-B144; A16-B145; A16-B146; A16-B147;
A16-B148; A16-B149; A16-B150; A16-B151; A16-B152; A16-B153;
A16-B154; A16-B155; A16-B156; A16-B157; A16-B158; A16-B159;
A16-B160; A16-B161; A16-B162; A16-B163; A16-B164; A16-B165;
A16-B166; A16-B167; A16-B168; A16-B169; A17-B1; A17-B2;
A17-B3; A17-B4; A17-B5; A17-B6; A17-B7; A17-B8;
A17-B9; A17-B10; A17-B11; A17-B12; A17-B13; A17-B14;
A17-B15; A17-B16; A17-B17; A17-B18; A17-B19; A17-B20;
A17-B21; A17-B22; A17-B23; A17-B24; A17-B25; A17-B26;
A17-B27; A17-B28; A17-B29; A17-B30; A17-B31; A17-B32;
A17-B33; A17-B34; A17-B35; A17-B36; A17-B37; A17-B38;
A17-B39; A17-B40; A17-B41; A17-B42; A17-B43; A17-B44;
A17-B45; A17-B46; A17-B47; A17-B48; A17-B49; A17-B50;
A17-B51; A17-B52; A17-B53; A17-B54; A17-B55; A17-B56;
A17-B57; A17-B58; A17-B59; A17-B60; A17-B61; A17-B62;
A17-B63; A17-B64; A17-B65; A17-B66; A17-B67; A17-B68;
A17-B69; A17-B70; A17-B71; A17-B72; A17-B73; A17-B74;
A17-B75; A17-B76; A17-B77; A17-B78; A17-B79; A17-B80;
A17-B81; A17-B82; A17-B83; A17-B84; A17-B85; A17-B86;
A17-B87; A17-B88; A17-B89; A17-B90; A17-B91; A17-B92;
A17-B93; A17-B94; A17-B95; A17-B96; A17-B97; A17-B98;
A17-B99; A17-B 100; A17-B 101; A17-B102; A17-B 103; A17-B104;
A17-B105; A17-B106; A17-B107; A17-B108; A17-B109; A17-B110;
A17-B111; A17-B112; A17-B113; A17-B114; A17-B115; A17-B116;
A17-B117; A17-B118; A17-B119; A17-B120; A17-B121; A17-B122;
A17-B123; A17-B124; A17-B125; A17-B126; A17-B127; A17-B128;
A17-B129; A17-B130; A17-B131; A17-B132; A17-B133; A17-B134;
A17-B135; A17-B136; A17-B137; A17-B138; A17-B139; A17-B140;
A17-B141; A17-B142; A17-B143; A17-B144; A17-B145; A17-B146;
A17-B147; A17-B148; A17-B149; A17-B150; A17-B151; A17-B152;
A17-B153; A17-B154; A17-B155; A17-B156; A17-B157; A17-B158;
A17-B159; A17-B160; A17-B161; A17-B162; A17-B163; A17-B164;
A17-B165; A17-B166; A17-B167; A17-B168; A17-B169; A18-B1;
A18-B2; A18-B3; A18-B4; A18-B5; A18-B6; A18-B7;
A18-B8; A18-B9; A18-B10; A18-B11; A18-B12; A18-B13;
A18-B14; A18-B15; A18-B16; A18-B17; A18-B18; A18-B19;
A18-B20; A18-B21; A18-B22; A18-B23; A18-B24; A18-B25;
A18-B26; A18-B27; A18-B28; A18-B29; A18-B30; A18-B31;
A18-B32; A18-B33; A18-B34; A18-B35; A18-B36; A18-B37;
A18-B38; A18-B39; A18-B40; A18-B41; A18-B42; A18-B43;
A18-B44; A18-B45; A18-B46; A18-B47; A18-B48; A18-B49;
A18-B50; A18-B51; A18-B52; A18-B53; A18-B54; A18-B55;
A18-B56; A18-B57; A18-B58; A18-B59; A18-B60; A18-B61;
A18-B62; A18-B63; A18-B64; A18-B65; A18-B66; A18-B67;
A18-B68; A18-B69; A18-B70; A18-B71; A18-B72; A18-B73;
A18-B74; A18-B75; A18-B76; A18-B77; A18-B78; A18-B79;
A18-B80; A18-B81; A18-B82; A18-B83; A18-B84; A18-B85;
A18-B86; A18-B87; A18-B88; A18-B89; A18-B90; A18-B91;
A18-B92; A18-B93; A18-B94; A18-B95; A18-B96; A18-B97;
A18-B98; A18-B99; A18-B100; A18-B101; A18-B102; A18-B103;
A 18-B 104; A18-B 105; A18-B106; A18-B107; A 18-B 108; A 18-B 109;
A18-B110; A18-B111; A18-B112; A18-B113; A18-B114; A18-B115;
A18-B116; A18-B117; A18-B118; A18-B119; A18-B120; A18-B121;
A18-B122; A18-B123; A18-B124; A18-B125; A18-B126; A18-B127;
A18-B 128; A18-B 129; A18-B130; A18-B 131; A18-B 132; A18-B 133;
A18-B134; A18-B135; A18-B136; A18-B137; A18-B138; A18-B139;
A18-B140; A18-B141; A18-B142; A18-B143; A18-B144; A18-B145;
A18-B146; A18-B147; A18-B148; A18-B149; A18-B150; A18-B151;
A18-B152; A18-B153; A18-B154; A18-B155; A18-B156; A18-B157;
A18-B158; A18-B159; A18-B160; A18-B161; A18-B162; A18-B163;
A18-B164; A18-B165; A18-B166; A18-B167; A18-B168; A18-B169;
A19-Bl; A19-B2; A19-B3; A19-B4; A19-B5; A19-B6;
A19-B7; A19-B8; A19-B9; A19-B10; A19-B11; A19-B12;
A19-B13; A19-B14; A19-B15; A19-B16; A19-B17; A19-B18;
A19-B19; A19-B20; A19-B21; A19-B22; A19-B23; A19-B24;
A19-B25; A19-B26; A19-B27; A19-B28; A19-B29; A19-B30;
A19-B31; A19-B32; A19-B33; A19-B34; A19-B35; A19-B36;
A19-B37; A19-B38; A19-B39; A19-B40; A19-B41; A19-B42;
A19-B43; A19-B44; A19-B45; A19-B46; A19-B47; A19-B48;
A19-B49; A19-B50; A19-B51; A19-B52; A19-B53; A19-B54;
A19-B55; A19-B56; A19-B57; A19-B58; A19-B59; A19-B60;
A19-B61; A19-B62; A19-B63; A19-B64; A19-B65; A19-B66;
A19-B67; A19-B68; A19-B69; A19-B70; A19-B71; A19-B72;
A19-B73; A19-B74; A19-B75; A19-B76; A19-B77; A19-B78;
A19-B79; A19-B80; A19-B81; A19-B82; A19-B83; A19-B84;
A19-B85; A19-B86; A19-B87; A19-B88; A19-B89; A19-B90;
A19-B91; A19-B92; A19-B93; A19-B94; A19-B95; A19-B96;
A19-B97; A19-B98; A19-B99; A19-B100; A19-B101; A19-B102;
A19-B103; A19-B104; A19-B105; A19-B106; A19-B107; A19-B108;
A19-B109; A19-B110; A19-B111; A19-B112; A19-B113; A19-B114;
A19-B115; A19-B116; A19-B117; A19-B118; A19-B119; A19-B120;
A19-B121; A19-B122; A19-B123; A19-B124; A19-B125; A19-B126;
A19-B127; A19-B128; A19-B129; A19-B130; A19-B131; A19-B132;
A19-B133; A19-B134; A19-B135; A19-B136; A19-B137; A19-B138;
A19-B139; A19-B140; A19-B141; A19-B142; A19-B143; A19-B144;
A19-B145; A19-B146; A19-B147; A19-B148; A19-B149; A19-B150;
A19-B151; A19-B152; A19-B153; A19-B154; A19-B155; A19-B156;
A19-B157; A19-B158; A19-B159; A19-B160; A19-B161; A19-B162;
A19-B163; A19-B164; A19-B165; A19-B166; A19-B167; A19-B168;
A19-B169; A20-B1; A20-B2; A20-B3; A20-B4; A20-B5;
A20-B6; A20-B7; A20-B8; A20-B9; A20-B10; A20-B11;
A20-B12; A20-B 13; A20-B 14; A20-B 15; A20-B 16; A20-B 17;
A20-B18; A20-B19; A20-B20; A20-B21; A20-B22; A20-B23;
A20-B24; A20-B25; A20-B26; A20-B27; A20-B28; A20-B29;
A20-B30; A20-B31; A20-B32; A20-B33; A20-B34; A20-B35;
A20-B36; A20-B37; A20-B38; A20-B39; A20-B40; A20-B41;
A20-B42; A20-B43; A20-B44; A20-B45; A20-B46; A20-B47;
A20-B48; A20-B49; A20-B50; A20-B51; A20-B52; A20-B53;
A20-B54; A20-B55; A20-B56; A20-B57; A20-B58; A20-B59;
A20-B60; A20-B61; A20-B62; A20-B63; A20-B64; A20-B65;
A20-B66; A20-B67; A20-B68; A20-B69; A20-B70; A20-B71;
A20-B72; A20-B73; A20-B74; A20-B75; A20-B76; A20-B77;
A20-B78; A20-B79; A20-B80; A20-B81; A20-B82; A20-B83;
A20-B84; A20-B85; A20-B86; A20-B87; A20-B88; A20-B89;
A20-B90; A20-B91; A20-B92; A20-B93; A20-B94; A20-B95;
A20-B96; A20-B97; A20-B98; A20-B99; A20-B100; A20-B101;
A20-B 102; A20-B 103; A20-B 104; A20-B 105; A20-B 106; A20-B 107;
A20-B 108; A20-B 109; A20-B 110; A20-B 11 1; A20-B 112; A20-B 113;
A20-B 114; A20-B 115; A20-B 116; A20-B 117; A20-B 118; A20-B 119;
A20-B 120; A20-B 121; A20-B 122; A20-B123; A20-B 124; A20-B125;
A20-B 126; A20-B 127; A20-B 128; A20-B 129; A20-B130; A20-B 13 1;
A20-B 132; A20-B133; A20-B 134; A20-B 135; A20-B 136; A20-B 137;
A20-B 138; A20-B 139; A20-B 140; A20-B 141; A20-B 142; A20-B 143;
A20-B 144; A20-B 145; A20-B 146; A20-B 147; A20-B 148; A20-B 149;
A20-B 150; A20-B 15 1; A20-B 152; A20-B153; A20-B 154; A20-B 155;
A20-B156; A20-B 157; A20-B 158; A20-B159; A20-B 160; A20-B 161;
A20-B 162; A20-B 163; A20-B 164; A20-B 165; A20-B 166; A20-B 167;
A20-B168; A20-B169; A21-B1; A21-B2; A21-B3; A21-B4;
A21-B5; A21-B6; A21-B7; A21-B8; A21-B9; A21-B10;
A21-B11; A21-B12; A21-B13; A21-B14; A21-B15; A21-B16;
A21-B17; A21-B18; A21-B19; A21-B20; A21-B21; A21-B22;
A21-B23; A21-B24; A21-B25; A21-B26; A21-B27; A21-B28;
A21-B29; A21-B30; A21-B31; A21-B32; A21-B33; A21-B34;
A21-B35; A21-B36; A21-B37; A21-B38; A21-B39; A21-B40;
A21-B41; A21-B42; A21-B43; A21-B44; A21-B45; A21-B46;
A21-B47; A21-B48; A21-B49; A21-B50; A21-B51; A21-B52;
A21-B53; A21-B54; A21-B55; A21-B56; A21-B57; A21-B58;
A21-B59; A21-B60; A21-B61; A21-B62; A21-B63; A21-B64;
A21-B65; A21-B66; A21-B67; A21-B68; A21-B69; A21-B70;
A21-B71; A21-B72; A21-B73; A21-B74; A21-B75; A21-B76;
A21-B77; A21-B78; A21-B79; A21-B80; A21-B81; A21-B82;
A21-B83; A21-B84; A21-B85; A21-B86; A21-B87; A21-B88;
A21-B89; A21-B90; A21-B91; A21-B92; A21-B93; A21-B94;
A21-B95; A21-B96; A21-B97; A21-B98; A21-B99; A21-B100;
A21-B101; A21-B102; A21-B103; A21-B104; A21-B105; A21-B106;
A21-B107; A21-B108; A21-B109; A21-B110; A21-B111; A21-B112;
A21-B113; A21-B114; A21-B115; A21-B116; A21-B117; A21-B118;
A21-B119; A21-B120; A21-B121; A21-B122; A21-B123; A21-B124;
A21-B125; A21-B126; A21-B127; A21-B128; A21-B129; A21-B130;
A21-B131; A21-B132; A21-B133; A21-B134; A21-B135; A21-B136;
A21-B137; A21-B138; A21-B139; A21-B140; A21-B141; A21-B142;
A21-B143; A21-B144; A21-B145; A21-B146; A21-B147; A21-B148;
A21-B149; A21-B150; A21-B151; A21-B152; A21-B153; A21-B154;
A21-B155; A21-B156; A21-B157; A21-B158; A21-B159; A21-B160;
A21-B161; A21-B162; A21-B163; A21-B164; A21-B165; A21-B166;
A21-B 167; A21-B 168; A21-B 169; A22-B 1; A22-B2; A22-B3;
A22-B4; A22-B5; A22-B6; A22-B7; A22-B8; A22-B9;
A22-B 10; A22-B 11; A22-B 12; A22-B 13; A22-B 14; A22-B 15;
A22-B 16; A22-B 17; A22-B 18; A22-B 19; A22-B20; A22-B2 1;
A22-B22; A22-B23; A22-B24; A22-B25; A22-B26; A22-B27;
A22-B28; A22-B29; A22-B30; A22-B31; A22-B32; A22-B33;
A22-B34; A22-B35; A22-B36; A22-B37; A22-B38; A22-B39;
A22-B40; A22-B41; A22-B42; A22-B43; A22-B44; A22-B45;
A22-B46; A22-B47; A22-B48; A22-B49; A22-B50; A22-B51;
A22-B52; A22-B53; A22-B54; A22-B55; A22-B56; A22-B57;
A22-B58; A22-B59; A22-B60; A22-B61; A22-B62; A22-B63;
A22-B64; A22-B65; A22-B66; A22-B67; A22-B68; A22-B69;
A22-B70; A22-B71; A22-B72; A22-B73; A22-B74; A22-B75;
A22-B76; A22-B77; A22-B78; A22-B79; A22-B80; A22-B81;
A22-B82; A22-B83; A22-B84; A22-B85; A22-B86; A22-B87;
A22-B88; A22-B89; A22-B90; A22-B91; A22-B92; A22-B93;
A22-B94; A22-B95; A22-B96; A22-B97; A22-B98; A22-B99;
A22-B 100; A22-B 101; A22-B 102; A22-B 103; A22-B 104; A22-B105;
A22-B 106; A22-B107; A22-B 108; A22-B 109; A22-B 110; A22-B 111;
A22-B 112; A22-B 113; A22-B 114; A22-B 115; A22-B 116; A22-B 117;
A22-B 118; A22-B 119; A22-B 120; A22-B 121; A22-B 122; A22-B123;
A22-B 124; A22-B 125; A22-B126; A22-B 127; A22-B 128; A22-B 129;
A22-B 130; A22-B 131; A22-B 132; A22-B 133; A22-B 134; A22-B 135;
A22-B136; A22-B 137; A22-B 138; A22-B139; A22-B 140; A22-B 141;
A22-B 142; A22-B 143; A22-B 144; A22-B 145; A22-B 146; A22-B 147;
A22-B148; A22-B 149; A22-B 150; A22-B 151; A22-B 152; A22-B 153;
A22-B 154; A22-B 155; A22-B 156; A22-B 157; A22-B158; A22-B 159;
A22-B 160; A22-B 161; A22-B 162; A22-B 163; A22-B 164; A22-B 165;
A22-B166; A22-B167; A22-B168; A22-B169; A23-B1; A23-B2;
A23-B3; A23-B4; A23-B5; A23-B6; A23-B7; A23-B8;
A23-B9; A23-B10; A23-B11; A23-B12; A23-B13; A23-B14;
A23-B 15; A23-B 16; A23-B 17; A23-B 18; A23-B 19; A23-B20;
A23-B21; A23-B22; A23-B23; A23-B24; A23-B25; A23-B26;
A23-B27; A23-B28; A23-B29; A23-B30; A23-B31; A23-B32;
A23-B33; A23-B34; A23-B35; A23-B36; A23-B37; A23-B38;
A23-B39; A23-B40; A23-B41; A23-B42; A23-B43; A23-B44;
A23-B45; A23-B46; A23-B47; A23-B48; A23-B49; A23-B50;
A23-B51; A23-B52; A23-B53; A23-B54; A23-B55; A23-B56;
A23-B57; A23-B58; A23-B59; A23-B60; A23-B61; A23-B62;
A23-B63; A23-B64; A23-B65; A23-B66; A23-B67; A23-B68;
A23-B69; A23-B70; A23-B71; A23-B72; A23-B73; A23-B74;
A23-B75; A23-B76; A23-B77; A23-B78; A23-B79; A23-B80;
A23-B81; A23-B82; A23-B83; A23-B84; A23-B85; A23-B86;
A23-B87; A23-B88; A23-B89; A23-B90; A23-B91; A23-B92;
A23-B93; A23-B94; A23-B95; A23-B96; A23-B97; A23-B98;
A23-B99; A23-B 100; A23-B 101; A23-B 102; A23-B103; A23-B104;
A23-B 105; A23-B106; A23-B107; A23-B 108; A23-B109; A23-B 110;
A23-B 111; A23-B 112; A23-B 113; A23-B114; A23-B 115; A23-B 116;
A23-B117; A23-B118; A23-B119; A23-B120; A23-B121; A23-B122;
A23-B 123; A23-B 124; A23-B 125; A23-B 126; A23-B 127; A23-B 128;
A23-B 129; A23-B 130; A23-B 131; A23-B 132; A23-B 133; A23-B134;
A23-B135; A23-B136; A23-B137; A23-B138; A23-B139; A23-B140;
A23-B141; A23-B142; A23-B143; A23-B144; A23-B145; A23-B146;
A23-B147; A23-B148; A23-B149; A23-B150; A23-B151; A23-B152;
A23-B 153; A23-B 154; A23-B155; A23-B 156; A23-B 157; A23-B 158;
A23-B159; A23-B 160; A23-B 161; A23-B 162; A23-B 163; A23-B 164;
A23-B 165; A23-B 166; A23-B 167; A23-B168; A23-B 169; A24-B 1;
A24-B2; A24-B3; A24-B4; A24-B5; A24-B6; A24-B7;
A24-B8; A24-B9; A24-B 10; A24-B 11; A24-B 12; A24-B 13;
A24-B 14; A24-B 15; A24-B 16; A24-B 17; A24-B 18; A24-B 19;
A24-B20; A24-B21; A24-B22; A24-B23; A24-B24; A24-B25;
A24-B26; A24-B27; A24-B28; A24-B29; A24-B30; A24-B31;
A24-B32; A24-B33; A24-B34; A24-B35; A24-B36; A24-B37;
A24-B38; A24-B39; A24-B40; A24-B41; A24-B42; A24-B43;
A24-B44; A24-B45; A24-B46; A24-B47; A24-B48; A24-B49;
A24-B50; A24-B51; A24-B52; A24-B53; A24-B54; A24-B55;
A24-B56; A24-B57; A24-B58; A24-B59; A24-B60; A24-B61;
A24-B62; A24-B63; A24-B64; A24-B65; A24-B66; A24-B67;
A24-B68; A24-B69; A24-B70; A24-B71; A24-B72; A24-B73;
A24-B74; A24-B75; A24-B76; A24-B77; A24-B78; A24-B79;
A24-B80; A24-B81; A24-B82; A24-B83; A24-B84; A24-B85;
A24-B86; A24-B87; A24-B88; A24-B89; A24-B90; A24-B91;
A24-B92; A24-B93; A24-B94; A24-B95; A24-B96; A24-B97;
A24-B98; A24-B99; A24-B 100; A24-B 101; A24-B 102; A24-B 103;
A24-B 104; A24-B 105; A24-B 106; A24-B 107; A24-B 108; A24-B 109;
A24-B 110; A24-B 111; A24-B 112; A24-B 113; A24-B 114; A24-B 115;
A24-B 116; A24-B 117; A24-B 118; A24-B 119; A24-B 120; A24-B 121;
A24-B 122; A24-B 123; A24-B 124; A24-B 125; A24-B 126; A24-B 127;
A24-B128; A24-B 129; A24-B 130; A24-B 13 1; A24-B 132; A24-B 133;
A24-B 134; A24-B 13 5; A24-B 136; A24-B 137; A24-B 13 8; A24-B139;
A24-B 140; A24-B 141; A24-B 142; A24-B 143; A24-B144; A24-B 145;
A24-B 146; A24-B 147; A24-B148; A24-B 149; A24-B 150; A24-B 151;
A24-B 152; A24-B 153; A24-B 154; A24-B 155; A24-B 156; A24-B 157;
A24-B 158; A24-B 159; A24-B 160; A24-B 161; A24-B 162; A24-B 163;
A24-B 164; A24-B 165; A24-B 166; A24-B 167; A24-B 168; A24-B 169;
A25-Bl; A25-B2; A25-B3; A25-B4; A25-B5; A25-B6;
A25-B7; A25-B8; A25-B9; A25-B 10; A25-B 11; A25-B 12;
A25-B13; A25-B14; A25-B15; A25-B16; A25-B17; A25-B18;
A25-B19; A25-B20; A25-B21; A25-B22; A25-B23; A25-B24;
A25-B25; A25-B26; A25-B27; A25-B28; A25-B29; A25-B30;
A25-B31; A25-B32; A25-B33; A25-B34; A25-B35; A25-B36;
A25-B37; A25-B38; A25-B39; A25-B40; A25-B41; A25-B42;
A25-B43; A25-B44; A25-B45; A25-B46; A25-B47; A25-B48;
A25-B49; A25-B50; A25-B51; A25-B52; A25-B53; A25-B54;
A25-B55; A25-B56; A25-B57; A25-B58; A25-B59; A25-B60;
A25-B61; A25-B62; A25-B63; A25-B64; A25-B65; A25-B66;
A25-B67; A25-B68; A25-B69; A25-B70; A25-B71; A25-B72;
A25-B73; A25-B74; A25-B75; A25-B76; A25-B77; A25-B78;
A25-B79; A25-B80; A25-B81; A25-B82; A25-B83; A25-B84;
A25-B85; A25-B86; A25-B87; A25-B88; A25-B89; A25-B90;
A25-B91; A25-B92; A25-B93; A25-B94; A25-B95; A25-B96;
A25-B97; A25-B98; A25-B99; A25-B 100; A25-B 101; A25-B102;
A25-B 103; A25-B 104; A25-B105; A25-B 106; A25-B 107; A25-B 108;
A25-B109; A25-B110; A25-B111; A25-B112; A25-B113; A25-B114;
A25-B 115; A25-B 116; A25-B 117; A25-B 118; A25-B 119; A25-B 120;
A25-B 121; A25-B 122; A25-B 123; A25-B 124; A25-B 125; A25-B126;
A25-B127; A25-B128; A25-B 129; A25-B 130; A25-B 131; A25-B 132;
A25-B133; A25-B134; A25-B135; A25-B136; A25-B137; A25-B138;
A25-B139; A25-B 140; A25-B 141; A25-B 142; A25-B143; A25-B144;
A25-B145; A25-B 146; A25-B 147; A25-B 148; A25-B 149; A25-B150;
A25-B151; A25-B152; A25-B153; A25-B154; A25-B155; A25-B156;
A25-B157; A25-B158; A25-B159; A25-B 160; A25-B161; A25-B162;
A25-B 163; A25-B 164; A25-B 165; A25-B 166; A25-B 167; A25-B168;
A25-B169; A26-B1; A26-B2; A26-B3; A26-B4; A26-B5;
A26-B6; A26-B7; A26-B8; A26-B9; A26-B10; A26-B11;
A26-B 12; A26-B 13; A26-B 14; A26-B 15; A26-B16; A26-B 17;
A26-B18; A26-B19; A26-B20; A26-B21; A26-B22; A26-B23;
A26-B24; A26-B25; A26-B26; A26-B27; A26-B28; A26-B29;
A26-B30; A26-B31; A26-B32; A26-B33; A26-B34; A26-B35;
A26-B36; A26-B37; A26-B38; A26-B39; A26-B40; A26-B41;
A26-B42; A26-B43; A26-B44; A26-B45; A26-B46; A26-B47;
A26-B48; A26-B49; A26-B50; A26-B51; A26-B52; A26-B53;
A26-B54; A26-B55; A26-B56; A26-B57; A26-B58; A26-B59;
A26-B60; A26-B61; A26-B62; A26-B63; A26-B64; A26-B65;
A26-B66; A26-B67; A26-B68; A26-B69; A26-B70; A26-B71;
A26-B72; A26-B73; A26-B74; A26-B75; A26-B76; A26-B77;
A26-B78; A26-B79; A26-B80; A26-B81; A26-B82; A26-B83;
A26-B84; A26-B85; A26-B86; A26-B87; A26-B88; A26-B89;
A26-B90; A26-B91; A26-B92; A26=B93; A26-B94; A26-B95;
A26-B96; A26-B97; A26-B98; A26-B99; A26-B100; A26-B101;
A26-B 102; A26-B103; A26-B104; A26-B 105; A26-B 106; A26-B 107;
A26-B 108; A26-B 109; A26-B 110; A26-B 111; A26-B 112; A26-B 113;
A26-B 114; A26-B 115; A26-B116; A26-B 117; A26-B 118; A26-B 119;
A26-B 120; A26-B 121; A26-B122; A26-B 123; A26-B124; A26-B 125;
A26-B 126; A26-B 127; A26-B 128; A26-B 129; A26-B 130; A26-B 13 1;
A26-B 132; A26-B 133; A26-B 134; A26-B135; A26-B 136; A26-B 137;
A26-B 138; A26-B 139; A26-B140; A26-B 141; A26-B 142; A26-B 143;
A26-B 144; A26-B 145; A26-B146; A26-B 147; A26-B 148; A26-B 149;
A26-B 150; A26-B 151; A26-B 152; A26-B 153; A26-B 154; A26-B 155;
A26-B156; A26-B 157; A26-B 158; A26-B 159; A26-B 160; A26-B 161;
A26-B 162; A26-B 163; A26-B 164; A26-B 165; A26-B 166; A26-B167;
A26-B 168; A26-B 169; A27-B 1; A27-B2; A27-B3; A27-B4;
A27-B5; A27-B6; A27-B7; A27-B8; A27-B9; A27-B10;
A27-B 11; A27-B 12; A27-B 13; A27-B 14; A27-B 15; A27-B 16;
A27-B 17; A27-B 18; A27-B 19; A27-B20; A27-B21; A27-B22;
A27-B23; A27-B24; A27-B25; A27-B26; A27-B27; A27-B28;
A27-B29; A27-B30; A27-B31; A27-B32; A27-B33; A27-B34;
A27-B35; A27-B36; A27-B37; A27-B38; A27-B39; A27-B40;
A27-B41; A27-B42; A27-B43; A27-B44; A27-B45; A27-B46;
A27-B47; A27-B48; A27-B49; A27-B50; A27-B51; A27-B52;
A27-B53; A27-B54; A27-B55; A27-B56; A27-B57; A27-B58;
A27-B59; A27-B60; A27-B61; A27-B62; A27-B63; A27-B64;
A27-B65; A27-B66; A27-B67; A27-B68; A27-B69; A27-B70;
A27-B71; A27-B72; A27-B73; A27-B74; A27-B75; A27-B76;
A27-B77; A27-B78; A27-B79; A27-B80; A27-B81; A27-B82;
A27-B83; A27-B84; A27-B85; A27-B86; A27-B87; A27-B88;
A27-B89; A27-B90; A27-B91; A27-B92; A27-B93; A27-B94;
A27-B95; A27-B96; A27-B97; A27-B98; A27-B99; A27-B100;
A27-B 101; A27-B 102; A27-B 103; A27-B 104; A27-B 105; A27-B 106;
A27-B 107; A27-B 108; A27-B 109; A27-B 110; A27-B 111; A27-B 112;
A27-B 113; A27-B 114; A27-B 115; A27-B 116; A27-B 117; A27-B 118;
A27-B 119; A27-B 120; A27-B 121; A27-B 122; A27-B123; A27-B 124;
A27-B 125; A27-B 126; A27-B 127; A27-B 128; A27-B 129; A27-B130;
A27-B 131; A27-B 132; A27-B133; A27-B 134; A27-B 135; A27-B136;
A27-B 137; A27-B 138; A27-B 139; A27-B 140; A27-B 141; A27-B 142;
A27-B 143; A27-B 144; A27-B 145; A27-B 146; A27-B 147; A27-B 148;
A27-B 149; A27-B 150; A27-B 151; A27-B 152; A27-B 153; A27-B 154;
A27-B155; A27-B156; A27-B157; A27-B158; A27-B159; A27-B160;
A27-B 161; A27-B 162; A27-B 163; A27-B 164; A27-B 165; A27-B 166;
A27-B167; A27-B168; A27-B169; A28-B1; A28-B2; A28-B3;
A28-B4; A28-B5; A28-B6; A28-B7; A28-B8; A28-B9;
A28-B10; A28-B11; A28-B12; A28-B13; A28-B14; A28-B15;
A28-B 16; A28-B 17; A28-B 18; A28-B19; A28-B20; A28-B21;
A28-B22; A28-B23; A28-B24; A28-B25; A28-B26; A28-B27;
A28-B28; A28-B29; A28-B30; A28-B31; A28-B32; A28-B33;
A28-B34; A28-B35; A28-B36; A28-B37; A28-B38; A28-B39;
A28-B40; A28-B41; A28-B42; A28-B43; A28-B44; A28-B45;
A28-B46; A28-B47; A28-B48; A28-B49; A28-B50; A28-B51;
A28-B52; A28-B53; A28-B54; A28-B55; A28-B56; A28-B57;
A28-B58; A28-B59; A28-B60; A28-B61; A28-B62; A28-B63;
A28-B64; A28-B65; A28-B66; A28-B67; A28-B68; A28-B69;
A28-B70; A28-B71; A28-B72; A28-B73; A28-B74; A28-B75;
A28-B76; A28-B77; A28-B78; A28-B79; A28-B80; A28-B81;
A28-B82; A28-B83; A28-B84; A28-B85; A28-B86; A28-B87;
A28-B88; A28-B89; A28-B90; A28-B91; A28-B92; A28-B93;
A28-B94; A28-B95; A28-B96; A28-B97; A28-B98; A28-B99;
A28-B 100; A28-B 101; A28-B 102; A28-B 103; A28-B 104; A28-B 105;
A28-B 106; A28-B 107; A28-B 108; A28-B109; A28-B 110; A28-B 111;
A28-B112; A28-B113; A28-B114; A28-B115; A28-B116; A28-B117;
A28-B 118; A28-B 119; A28-B120; A28-B121; A28-B 122; A28-B123;
A28-B124; A28-B125; A28-B126; A28-B127; A28-B128; A28-B129;
A28-B130; A28-B131; A28-B132; A28-B133; A28-B134; A28-B135;
A28-B136; A28-B137; A28-B138; A28-B139; A28-B140; A28-B141;
A28-B142; A28-B143; A28-B144; A28-B145; A28-B146; A28-B147;
A28-B148; A28-B149; A28-B150; A28-B151; A28-B152; A28-B153;
A28-B154; A28-B155; A28-B156; A28-B157; A28-B158; A28-B159;
A28-B160; A28-B161; A28-B162; A28-B163; A28-B164; A28-B165;
A28-B 166; A28-B 167; A28-B 168; A28-B 169; A29-B l; A29-B2;
A29-B3; A29-B4; A29-B5; A29-B6; A29-B7; A29-B8;
A29-B9; A29-B 10; A29-B 11; A29-B 12; A29-B 13; A29-B 14;
A29-B 15; A29-B 16; A29-B 17; A29-B 18; A29-B 19; A29-B20;
A29-B21; A29-B22; A29-B23; A29-B24; A29-B25; A29-B26;
A29-B27; A29-B28; A29-B29; A29-B30; A29-B31; A29-B32;
A29-B33; A29-B34; A29-B35; A29-B36; A29-B37; A29-B38;
A29-B39; A29-B40; A29-B41; A29-B42; A29-B43; A29-B44;
A29-B45; A29-B46; A29-B47; A29-B48; A29-B49; A29-B50;
A29-B51; A29-B52; A29-B53; A29-B54; A29-B55; A29-B56;
A29-B57; A29-B58; A29-B59; A29-B60; A29-B61; A29-B62;
A29-B63; A29-B64; A29-B65; A29-B66; A29-B67; A29-B68;
A29-B69; A29-B70; A29-B71; A29-B72; A29-B73; A29-B74;
A29-B75; A29-B76; A29-B77; A29-B78; A29-B79; A29-B80;
A29-B81; A29-B82; A29-B83; A29-B84; A29-B85; A29-B86;
A29-B87; A29-B88; A29-B89; A29-B90; A29-B91; A29-B92;
A29-B93; A29-B94; A29-B95; A29-B96; A29-B97; A29-B98;
A29-B99; A29-B 100; A29-B 101; A29-B 102; A29-B 103; A29-B104;
A29-B 105; A29-B 106; A29-B 107; A29-B 108; A29-B 109; A29-B 110;
A29-B 111; A29-B 112; A29-B 113; A29-B 114; A29-B 115; A29-B 116;
A29-B117; A29-B118; A29-B119; A29-B120; A29-B121; A29-B122;
A29-B 123; A29-B 124; A29-B125; A29-B 126; A29-B 127; A29-B 128;
A29-B129; A29-B130; A29-B 131; A29-B 132; A29-B 133; A29-B 134;
A29-B135; A29-B136; A29-B137; A29-B138; A29-B139; A29-B 140;
A29-B 141; A29-B 142; A29-B 143; A29-B 144; A29-B 145; A29-B 146;
A29-B 147; A29-B 148; A29-B 149; A29-B150; A29-B 151; A29-B 152;
A29-B153; A29-B 154; A29-B 15 5; A29-B 156; A29-B 157; A29-B 15 8;
A29-B159; A29-B 160; A29-B 161; A29-B 162; A29-B 163; A29-B 164;
A29-B165; A29-B 166; A29-B 167; A29-B168; A29-B 169; A30-B 1;
A30-B2; A30-B3; A30-B4; A30-B5; A30-B6; A30-B7;
A30-B8; A30-B9; A30-B10; A30-B11; A30-B12; A30-B13;
A30-B 14; A30-B15; A30-B 16; A30-B17; A30-B18; A30-B19;
A30-B20; A30-B21; A30-B22; A30-B23; A30-B24; A30-B25;
A30-B26; A30-B27; A30-B28; A30-B29; A30-B30; A30-B31;
A30-B32; A30-B33; A30-B34; A30-B35; A30-B36; A30-B37;
A30-B38; A30-B39; A30-B40; A30-B41; A30-B42; A30-B43;
A30-B44; A30-B45; A30-B46; A30-B47; A30-B48; A30-B49;
A30-B50; A30-B51; A30-B52; A30-B53; A30-B54; A30-B55;
A30-B56; A30-B57; A30-B58; A30-B59; A30-B60; A30-B61;
A30-B62; A30-B63; A30-B64; A30-B65; A30-B66; A30-B67;
A30-B68; A30-B69; A30-B70; A30-B71; A30-B72; A30-B73;
A30-B74; A30-B75; A30-B76; A30-B77; A30-B78; A30-B79;
A30-B80; A30-B81; A30-B82; A30-B83; A30-B84; A30-B85;
A30-B86; A30-B87; A30-B88; A30-B89; A30-B90; A30-B91;
A30-B92; A30-B93; A30-B94; A30-B95; A30-B96; A30-B97;
A30-B98; A30-B99; A30-B 100; A30-B 101; A30-B102; A30-B103;
A30-B 104; A30-B 105; A30-B 106; A30-B 107; A30-B 108; A30-B 109;
A30-B 110; A30-B 111; A30-B 112; A30-B 113; A30-B 114; A30-B 115;
A3 0-B 116; A30-B 117; A30-B 118; A30-B 119; A30-B 120; A30-B 121;
A30-B 122; A30-B 123; A30-B 124; A30-B 125; A30-B 126; A30-B 127;
A30-B 128; A30-B129; A30-B 130; A30-B 131; A30-B 132; A30-B133;
A30-B 134; A30-B 135; A30-B136; A30-B 137; A30-B 138; A30-B 139;
A30-B 140; A30-B 141; A30-B142; A30-B 143; A30-B144; A30-B 145;
A30-B 146; A30-B 147; A30-B 148; A30-B 149; A30-B 150; A30-B 151;
A30-B 152; A30-B 153; A30-B 154; A30-B155; A30-B156; A30-B 157;
A30-B 158; A30-B 159; A30-B 160; A30-B 161; A30-B162; A30-B 163;
A30-B 164; A30-B165; A30-B 166; A30-B 167; A30-B 168; A30-B 169;
A31-B1; A31-B2; A31-B3; A31-B4; A31-B5; A31-B6;
A31-B7; A31-B8; A31-B9; A31-B10; A31-B11; A31-B12;
A31-B13; A31-B14; A31-B15; A31-B16; A31-B17; A31-B18;
A31-B19; A31-B20; A31-B21; A31-B22; A31-B23; A31-B24;
A31-B25; A31-B26; A31-B27; A31-B28; A31-B29; A31-B30;
A31-B31; A31-B32; A31-B33; A31-B34; A31-B35; A31-B36;
A31-B37; A31-B38; A31-B39; A31-B40; A31-B41; A31-B42;
A31-B43; A31-B44; A31-B45; A31-B46; A31-B47; A31-B48;
A31-B49; A31-B50; A31-B51; A31-B52; A31-B53; A31-B54;
A31-B55; A31-B56; A31-B57; A31-B58; A31-B59; A31-B60;
A31-B61; A31-B62; A31-B63; A31-B64; A31-B65; A31-B66;
A31-B67; A31-B68; A31-B69; A31-B70; A31-B71; A31-B72;
A31-B73; A31-B74; A31-B75; A31-B76; A31-B77; A31-B78;
A31-B79; A31-B80; A31-B81; A31-B82; A31-B83; A31-B84;
A31-B85; A31-B86; A31-B87; A31-B88; A31-B89; A31-B90;
A31-B91; A31-B92; A31-B93; A31-B94; A31-B95; A31-B96;
A31-B97; A31-B98; A31-B99; A31-B100; A31-B101; A31-B102;
A31-B103; A31-B104; A31-B105; A31-B106; A31-B107; A31-B108;
A31-B109; A31-B110; A31-B111; A31-B112; A31-B113; A31-B114;
A31-B115; A31-B116; A31-B117; A31-B118; A31-B119; A31-B120;
A31-B121; A31-B122; A31-B123; A31-B124; A31-B125; A31-B126;
A31-B127; A31-B128; A31-B129; A31-B130; A31-B131; A31-B132;
A31-B133; A31-B134; A31-B135; A31-B136; A31-B137; A31-B138;
A31-B139; A31-B140; A31-B141; A31-B142; A31-B143; A31-B144;
A31-B145; A31-B146; A31-B147; A31-B148; A31-B149; A31-B150;
A31-B151; A31-B152; A31-B153; A31-B154; A31-B155; A31-B156;
A31-B157; A31-B158; A31-B159; A31-B160; A31-B161; A31-B162;
A31-B 163; A31-B164; A31-B 165; A31-B 166; A31-B 167; A31-B 168;
A31-B169; A32-B1; A32-B2; A32-B3; A32-B4; A32-B5;
A32-B6; A32-B7; A32-B8; A32-B9; A32-B10; A32-B11;
A32-B 12; A32-B 13; A32-B 14; A32-B 15; A32-B 16; A32-B 17;
A32-B18; A32-B 19; A32-B20; A32-B21; A32-B22; A32-B23;
A32-B24; A32-B25; A32-B26; A32-B27; A32-B28; A32-B29;
A32-B30; A32-B31; A32-B32; A32-B33; A32-B34; A32-B35;
A32-B36; A32-B37; A32-B38; A32-B39; A32-B40; A32-B41;
A32-B42; A32-B43; A32-B44; A32-B45; A32-B46; A32-B47;
A32-B48; A32-B49; A32-B50; A32-B51; A32-B52; A32-B53;
A32-B54; A32-B55; A32-B56; A32-B57; A32-B58; A32-B59;
A32-B60; A32-B61; A32-B62; A32-B63; A32-B64; A32-B65;
A32-B66; A32-B67; A32-B68; A32-B69; A32-B70; A32-B71;
A32-B72; A32-B73; A32-B74; A32-B75; A32-B76; A32-B77;
A32-B78; A32-B79; A32-B80; A32-B81; A32-B82; A32-B83;
A32-B84; A32-B85; A32-B86; A32-B87; A32-B88; A32-B89;
A32-B90; A32-B91; A32-B92; A32-B93; A32-B94; A32-B95;
A32-B96; A32-B97; A32-B98; A32-B99; A32-B100; A32-B101;
A32-B102; A32-B 103; A32-B 104; A32-B 105; A32-B106; A32-B 107;
A32-B 108; A32-B 109; A32-B 110; A32-B 111; A32-B 112; A32-B 113;
A32-B 114; A32-B 115; A32-B 116; A32-B117; A32-B 118; A32-B 119;
A32-B 120; A32-B 121; A32-B 122; A32-B123; A32-B 124; A32-B 125;
A32-B 126; A32-B 127; A32-B 128; A32-B 129; A32-B 130; A32-B 131;
A32-B 132; A32-B 133; A32-B 134; A32-B135; A32-B136; A32-B 137;
A32-B 13 8; A32-B 13 9; A32-B 140; A32-B 141; A32-B 142; A32-B 143;
A32-B144; A32-B 145; A32-B 146; A32-B 147; A32-B 148; A32-B 149;
A32-B 150; A32-B 151; A32-B 152; A32-B153; A32-B 154; A32-B 155;
A32-B 156; A32-B 157; A32-B 158; A32-B159; A32-B 160; A32-B 161;
A32-B162; A32-B 163; A32-B 164; A32-B 165; A32-B 166; A32-B 167;
A32-B168; A32-B169; A33-B1; A33-B2; A33-B3; A33-B4;
A33-B5; A33-B6; A33-B7; A33-B8; A33-B9; A33-B10;
A33-B11; A33-B12; A33-B13; A33-B14; A33-B15; A33-B16;
A33-B17; A33-B18; A33-B19; A33-B20; A33-B21; A33-B22;
A33-B23; A33-B24; A33-B25; A33-B26; A33-B27; A33-B28;
A33-B29; A33-B30; A33-B31; A33-B32; A33-B33; A33-B34;
A33-B35; A33-B36; A33-B37; A33-B38; A33-B39; A33-B40;
A33-B41; A33-B42; A33-B43; A33-B44; A33-B45; A33-B46;
A33-B47; A33-B48; A33-B49; A33-B50; A33-B51; A33-B52;
A33-B53; A33-B54; A33-B55; A33-B56; A33-B57; A33-B58;
A33-B59; A33-B60; A33-B61; A33-B62; A33-B63; A33-B64;
A33-B65; A33-B66; A33-B67; A33-B68; A33-B69; A33-B70;
A33-B71; A33-B72; A33-B73; A33-B74; A33-B75; A33-B76;
A33-B77; A33-B78; A33-B79; A33-B80; A33-B81; A33-B82;
A33-B83; A33-B84; A33-B85; A33-B86; A33-B87; A33-B88;
A33-B89; A33-B90; A33-B91; A33-B92; A33-B93; A33-B94;
A33-B95; A33-B96; A33-B97; A33-B98; A33-B99; A33-B100;
A33-B101; A33-B102; A33-B103; A33-B104; A33-B105; A33-B106;
A33-B107; A33-B108; A33-B109; A33-B110; A33-B111; A33-B112;
A33-B 113; A33-B 114; A33-B 115; A33-B 116; A33-B 117; A33-B 118;
A33-B119; A33-B120; A33-B121; A33-B122; A33-B123; A33-B124;
A33-B125; A33-B126; A33-B127; A33-B128; A33-B129; A33-B130;
A33-B131; A33-B 132; A33-B133; A33-B134; A33-B135; A33-B 136;
A33-B137; A33-B138; A33-B139; A33-B140; A33-B141; A33-B142;
A33-B 143; A33-B 144; A33-B 145; A33-B 146; A33-B 147; A33-B 148;
A33-B149; A33-B 150; A33-B 151; A33-B 152; A33-B 153; A33-B 154;
A33-B155; A33-B156; A33-B157; A33-B158; A33-B159; A33-B160;
A33-B 161; A33-B 162; A33-B 163; A33-B 164; A33-B 165; A33-B 166;
A33-B 167; A33-B 168; A33-B 169; A34-B 1; A34-B2; A34-B3;
A34-B4; A34-B5; A34-B6; A34-B7; A34-B8; A34-B9;
A34-B 10; A34-B 11; A34-B 12; A34-B 13; A34-B 14; A34-B 15;
A34-B 16; A34-B 17; A34-B 18; A34-B 19; A34-B20; A34-B21;
A34-B22; A34-B23; A34-B24; A34-B25; A34-B26; A34-B27;
A34-B28; A34-B29; A34-B30; A34-B31; A34-B32; A34-B33;
A34-B34; A34-B35; A34-B36; A34-B37; A34-B38; A34-B39;
A34-B40; A34-B41; A34-B42; A34-B43; A34-B44; A34-B45;
A34-B46; A34-B47; A34-B48; A34-B49; A34-B50; A34-B51;
A34-B52; A34-B53; A34-B54; A34-B55; A34-B56; A34-B57;
A34-B58; A34-B59; A34-B60; A34-B61; A34-B62; A34-B63;
A34-B64; A34-B65; A34-B66; A34-B67; A34-B68; A34-B69;
A34-B70; A34-B71; A34-B72; A34-B73; A34-B74; A34-B75;
A34-B76; A34-B77; A34-B78; A34-B79; A34-B80; A34-B81;
A34-B82; A34-B83; A34-B84; A34-B85; A34-B86; A34-B87;
A34-B88; A34-B89; A34-B90; A34-B91; A34-B92; A34-B93;
A34-B94; A34-B95; A34-B96; A34-B97; A34-B98; A34-B99;
A34-B 100; A34-B 101; A34-B 102; A34-B 103; A34-B 104; A34-B 105;
A34-B 106; A34-B 107; A34-B 108; A34-B 109; A34-B 110; A34-B 111;
A34-B 112; A34-B 113; A34-B 114; A34-B 115; A34-B 116; A34-B 117;
A34-B 118; A34-B 119; A34-B 120; A34-B 121; A34-B 122; A34-B 123;
A34-B 124; A34-B125; A34-B 126; A34-B 127; A34-B128; A34-B 129;
A34-B 130; A34-B 131; A34-B 132; A34-B 133; A34-B 134; A34-B135;
A34-B 136; A34-B 137; A34-B 13 8; A34-B 13 9; A34-B 140; A34-B 141;
A34-B 142; A34-B 143; A34-B 144; A34-B 145; A34-B 146; A34-B 147;
A34-B 148; A34-B149; A34-B 150; A34-B 151; A34-B 152; A34-B 153;
A34-B 154; A34-B155; A34-B 156; A34-B 157; A34-B 158; A34-B159;
A34-B 160; A34-B 161; A34-B 162; A34-B 163; A34-B 164; A34-B 165;
A34-B 166; A34-B 167; A34-B 168; A34-B 169; A35-B 1; A35-B2;
A35-B3; A35-B4; A35-B5; A35-B6; A35-B7; A35-B8;
A35-B9; A35-B10; A35-B11; A35-B12; A35-B13; A35-B14;
A35-B15; A35-B 16; A35-B 17; A35-B 18; A35-B 19; A35-B20;
A35-B21; A35-B22; A35-B23; A35-B24; A35-B25; A35-B26;
A35-B27; A35-B28; A35-B29; A35-B30; A35-B31; A35-B32;
A35-B33; A35-B34; A35-B35; A35-B36; A35-B37; A35-B38;
A35-B39; A35-B40; A35-B41; A35-B42; A35-B43; A35-B44;
A35-B45; A35-B46; A35-B47; A35-B48; A35-B49; A35-B50;
A35-B51; A35-B52; A35-B53; A35-B54; A35-B55; A35-B56;
A35-B57; A35-B58; A35-B59; A35-B60; A35-B61; A35-B62;
A35-B63; A35-B64; A35-B65; A35-B66; A35-B67; A35-B68;
A35-B69; A35-B70; A35-B71; A35-B72; A35-B73; A35-B74;
A35-B75; A35-B76; A35-B77; A35-B78; A35-B79; A35-B80;
A35-B81; A35-B82; A35-B83; A35-B84; A35-B85; A35-B86;
A35-B87; A35-B88; A35-B89; A35-B90; A35-B91; A35-B92;
A35-B93; A35-B94; A35-B95; A35-B96; A35-B97; A35-B98;
A35-B99; A35-B100; A35-B101; A35-B102; A35-B103; A35-B104;
A35-B 105; A35-B 106; A35-B 107; A35-B 108; A35-B 109; A35-B 110;
A35-B 111; A35-B 112; A35-B 113; A35-B 114; A35-B 115; A35-B116;
A35-B117; A35-B118; A35-B119; A35-B120; A35-B121; A35-B122;
A35-B123; A35-B124; A35-B125; A35-B126; A35-B127; A35-B128;
A35-B129; A35-B130; A35-B131; A35-B132; A35-B133; A35-B134;
A35-B135; A35-B136; A35-B137; A35-B138; A35-B139; A35-B140;
A35-B141; A35-B142; A35-B 143; A35-B 144; A35-B145; A35-B 146;
A35-B147; A35-B148; A35-B149; A35-B150; A35-B151; A35-B152;
A35-B153; A35-B154; A35-B155; A35-B156; A35-B157; A35-B158;
A35-B159; A35-B160; A35-B161; A35-B162; A35-B163; A35-B164;
A35-B165; A35-B166; A35-B167; A35-B168; A35-B169; A36-Bl;
A36-B2; A36-B3; A36-B4; A36-B5; A36-B6; A36-B7;
A36-B8; A36-B9; A36-B10; A36-B11; A36-B12; A36-B13;
A36-B 14; A36-B15; A36-B 16; A36-B 17; A36-B 18; A36-B 19;
A36-B20; A36-B21; A36-B22; A36-B23; A36-B24; A36-B25;
A36-B26; A36-B27; A36-B28; A36-B29; A36-B30; A36-B31;
A36-B32; A36-B33; A36-B34; A36-B35; A36-B36; A36-B37;
A36-B38; A36-B39; A36-B40; A36-B41; A36-B42; A36-B43;
A36-B44; A36-B45; A36-B46; A36-B47; A36-B48; A36-B49;
A36-B50; A36-B51; A36-B52; A36-B53; A36-B54; A36-B55;
A36-B56; A36-B57; A36-B58; A36-B59; A36-B60; A36-B61;
A36-B62; A36-B63; A36-B64; A36-B65; A36-B66; A36-B67;
A36-B68; A36-B69; A36-B70; A36-B71; A36-B72; A36-B73;
A36-B74; A36-B75; A36-B76; A36-B77; A36-B78; A36-B79;
A36-B80; A36-B81; A36-B82; A36-B83; A36-B84; A36-B85;
A36-B86; A36-B87; A36-B88; A36-B89; A36-B90; A36-B91;
A36-B92; A36-B93; A36-B94; A36-B95; A36-B96; A36-B97;
A36-B98; A36-B99; A36-B 100; A36-B 101; A36-B 102; A36-B 103;
A36-B104; A36-B105; A36-B106; A36-B107; A36-B108; A36-B109;
A36-B 110; A36-B 111; A36-B 112; A36-B 113; A36-B 114; A36-B 115;
A36-B 116; A36-B 117; A36-B 118; A36-B 119; A36-B120; A36-B 121;
A36-B 122; A36-B 123; A36-B 124; A36-B 125; A36-B126; A36-B 127;
A36-B128; A36-B129; A36-B130; A36-B131; A36-B132; A36-B133;
A36-B134; A36-B135; A36-B136; A36-B137; A36-B138; A36-B139;
A36-B 140; A36-B 141; A36-B 142; A36-B 143; A36-B 144; A36-B 145;
A36-B146; A36-B147; A36-B148; A36-B149; A36-B150; A36-B151;
A36-B152; A36-B153; A36-B154; A36-B155; A36-B156; A36-B157;
A36-B158; A36-B159; A36-B160; A36-B161; A36-B162; A36-B163;
A36-B 164; A36-B165; A36-B 166; A36-B 167; A36-B 168; A36-B 169;
A37-B 1; A37-B2; A37-B3; A37-B4; A37-B5; A37-B6;
A37-B7; A37-B8; A37-B9; A37-B 10; A37-B 11; A37-B 12;
A37-B 13; A37-B 14; A37-B 15; A37-B 16; A37-B 17; A37-B 18;
A37-B 19; A37-B20; A37-B21; A37-B22; A37-B23; A37-B24;
A37-B25; A37-B26; A37-B27; A37-B28; A37-B29; A37-B30;
A37-B31; A37-B32; A37-B33; A37-B34; A37-B35; A37-B36;
A37-B37; A37-B38; A37-B39; A37-B40; A37-B41; A37-B42;
A37-B43; A37-B44; A37-B45; A37-B46; A37-B47; A37-B48;
A37-B49; A37-B50; A37-B51; A37-B52; A37-B53; A37-B54;
A37-B55; A37-B56; A37-B57; A37-B58; A37-B59; A37-B60;
A37-B61; A37-B62; A37-B63; A37-B64; A37-B65; A37-B66;
A37-B67; A37-B68; A37-B69; A37-B70; A37-B71; A37-B72;
A37-B73; A37-B74; A37-B75; A37-B76; A37-B77; A37-B78;
A37-B79; A37-B80; A37-B81; A37-B82; A37-B83; A37-B84;
A37-B85; A37-B86; A37-B87; A37-B88; A37-B89; A37-B90;
A37-B91; A37-B92; A37-B93; A37-B94; A37-B95; A37-B96;
A37-B97; A37-B98; A37-B99; A37-B100; A37-B101; A37-B102;
A37-B103; A37-B 104; A37-B 105; A37-B 106; A37-B 107; A37-B 108;
A37-B 109; A37-B 110; A37-B 111; A37-B 112; A37-B 113; A37-B 114;
A37-B 115; A37-B 116; A37-B 117; A37-B 118; A37-B 119; A37-B 120;
A37-B 121; A37-B 122; A37-B 123; A37-B 124; A37-B 125; A37-B 126;
A37-B127; A37-B128; A37-B129; A37-B130; A37-B131; A37-B132;
A37-B133; A37-B134; A37-B135; A37-B136; A37-B137; A37-B138;
A37-B 139; A37-B 140; A37-B 141; A37-B 142; A37-B 143; A37-B144;
A37-B 145; A37-B 146; A37-B 147; A37-B 148; A37-B149; A37-B 150;
A37-B 15 1; A37-B 152; A37-B153; A37-B 154; A37-B 155; A37-B156;
A37-B157; A37-B158; A37-B159; A37-B160; A37-B161; A37-B162;
A37-B163; A37-B 164; A37-B 165; A37-B 166; A37-B 167; A37-B 168;
A37-B169; A38-B1; A38-B2; A38-B3; A38-B4; A38-B5;
A38-B6; A38-B7; A38-B8; A38-B9; A38-B10; A38-B11;
A38-B12; A38-B13; A38-B14; A38-B15; A38-B16; A38-B17;
A38-B18; A38-B19; A38-B20; A38-B21; A38-B22; A38-B23;
A38-B24; A38-B25; A38-B26; A38-B27; A38-B28; A38-B29;
A38-B30; A38-B31; A38-B32; A38-B33; A38-B34; A38-B35;
A38-B36; A38-B37; A38-B38; A38-B39; A38-B40; A38-B41;
A38-B42; A38-B43; A38-B44; A38-B45; A38-B46; A38-B47;
A38-B48; A38-B49; A38-B50; A38-B51; A38-B52; A38-B53;
A38-B54; A38-B55; A38-B56; A38-B57; A38-B58; A38-B59;
A38-B60; A38-B61; A38-B62; A38-B63; A38-B64; A38-B65;
A38-B66; A38-B67; A38-B68; A38-B69; A38-B70; A38-B71;
A38-B72; A38-B73; A38-B74; A38-B75; A38-B76; A38-B77;
A38-B78; A38-B79; A38-B80; A38-B81; A38-B82; A38-B83;
A38-B84; A38-B85; A38-B86; A38-B87; A38-B88; A38-B89;
A38-B90; A38-B91; A38-B92; A38-B93; A38-B94; A38-B95;
A38-B96; A38-B97; A38-B98; A38-B99; A38-B100; A38-B101;
A38-B102; A38-B103; A38-B104; A38-B105; A38-B106; A38-B107;
A38-B108; A38-B109; A38-B110; A38-B111; A38-B112; A38-B113;
A38-B114; A38-B115; A38-B116; A38-B117; A38-B118; A38-B119;
A38-B120; A38-B121; A38-B122; A38-B123; A38-B124; A38-B125;
A38-B126; A38-B127; A38-B128; A38-B129; A38-B130; A38-B131;
A38-B132; A38-B133; A38-B134; A38-B135; A38-B136; A38-B137;
A38-B138; A38-B139; A38-B140; A38-B141; A38-B142; A38-B143;
A38-B144; A38-B145; A38-B146; A38-B147; A38-B148; A38-B149;
A38-B150; A38-B151; A38-B152; A38-B153; A38-B154; A38-B155;
A38-B156; A38-B157; A38-B158; A38-B159; A38-B160; A38-B161;
A38-B162; A38-B163; A38-B164; A38-B165; A38-B166; A38-B167;
A38-B168; A38-B169; A39-Bl; A39-B2; A39-B3; A39-B4;
A39-B5; A39-B6; A39-B7; A39-B8; A39-B9; A39-B10;
A39-B11; A39-B12; A39-B13; A39-B14; A39-B15; A39-B16;
A39-B17; A39-B18; A39-B 19; A39-B20; A39-B21; A39-B22;
A39-B23; A39-B24; A39-B25; A39-B26; A39-B27; A39-B28;
A39-B29; A39-B30; A39-B31; A39-B32; A39-B33; A39-B34;
A39-B35; A39-B36; A39-B37; A39-B38; A39-B39; A39-B40;
A39-B41; A39-B42; A39-B43; A39-B44; A39-B45; A39-B46;
A39-B47; A39-B48; A39-B49; A39-B50; A39-B51; A39-B52;
A39-B53; A39-B54; A39-B55; A39-B56; A39-B57; A39-B58;
A39-B59; A39-B60; A39-B61; A39-B62; A39-B63; A39-B64;
A39-B65; A39-B66; A39-B67; A39-B68; A39-B69; A39-B70;
A39-B71; A39-B72; A39-B73; A39-B74; A39-B75; A39-B76;
A39-B77; A39-B78; A39-B79; A39-B80; A39-B81; A39-B82;
A39-B83; A39-B84; A39-B85; A39-B86; A39-B87; A39-B88;
A39-B89; A39-B90; A39-B91; A39-B92; A39-B93; A39-B94;
A39-B95; A39-B96; A39-B97; A39-B98; A39-B99; A39-B100;
A39-B101; A39-B102; A39-B103; A39-B104; A39-B105; A39-B106;
A39-B107; A39-B 108; A39-B 109; A39-B 110; A39-B 111; A39-B 112;
A39-B113; A39-B114; A39-B115; A39-B116; A39-B117; A39-B118;
A39-B119; A39-B120; A39-B121; A39-B122; A39-B123; A39-B124;
A39-B 125; A39-B 126; A39-B127; A39-B 128; A39-B 129; A39-B130;
A39-B131; A39-B132; A39-B133; A39-B134; A39-B135; A39-B136;
A39-B137; A39-B138; A39-B139; A39-B140; A39-B141; A39-B142;
A39-B143; A39-B144; A39-B145; A39-B146; A39-B147; A39-B148;
A39-B149; A39-B150; A39-B151; A39-B152; A39-B153; A39-B154;
A39-B155; A39-B156; A39-B157; A39-B158; A39-B159; A39-B160;
A39-B161; A39-B162; A39-B163; A39-B164; A39-B165; A39-B166;
A39-B167; A39-B168; A39-B169; A40-B1; A40-B2; A40-B3;
A40-B4; A40-B5; A40-B6; A40-B7; A40-B8; A40-B9;
A40-B 10; A40-B 11; A40-B 12; A40-B 13; A40-B 14; A40-B 15;
A40-B 16; A40-B 17; A40-B 18; A40-B 19; A40-B20; A40-B21;
A40-B22; A40-B23; A40-B24; A40-B25; A40-B26; A40-B27;
A40-B28; A40-B29; A40-B30; A40-B31; A40-B32; A40-B33;
A40-B34; A40-B35; A40-B36; A40-B37; A40-B38; A40-B39;
A40-B40; A40-B41; A40-B42; A40-B43; A40-B44; A40-B45;
A40-B46; A40-B47; A40-B48; A40-B49; A40-B50; A40-B51;
A40-B52; A40-B53; A40-B54; A40-B55; A40-B56; A40-B57;
A40-B58; A40-B59; A40-B60; A40-B61; A40-B62; A40-B63;
A40-B64; A40-B65; A40-B66; A40-B67; A40-B68; A40-B69;
A40-B70; A40-B71; A40-B72; A40-B73; A40-B74; A40-B75;
A40-B76; A40-B77; A40-B78; A40-B79; A40-B80; A40-B81;
A40-B82; A40-B83; A40-B84; A40-B85; A40-B86; A40-B87;
A40-B88; A40-B89; A40-B90; A40-B91; A40-B92; A40-B93;
A40-B94; A40-B95; A40-B96; A40-B97; A40-B98; A40-B99;
A40-B 100; A40-B 101; A40-B 102; A40-B 103; A40-B 104; A40-B 105;
A40-B 106; A40-B 107; A40-B 108; A40-B 109; A40-B 110; A40-B 111;
A40-B 112; A40-B 113; A40-B 114; A40-B 115; A40-B 116; A40-B 117;
A40-B 118; A40-B 119; A40-B 120; A40-B 121; A40-B 122; A40-B123;
A40-B 124; A40-B 125; A40-B 126; A40-B 127; A40-B 128; A40-B 129;
A40-B130; A40-B131; A40-B132; A40-B133; A40-B134; A40-B135;
A40-B136; A40-B137; A40-B138; A40-B139; A40-B 140; A40-B141;
A40-B 142; A40-B 143; A40-B 144; A40-B 145; A40-B 146; A40-B 147;
A40-B148; A40-B 149; A40-B 150; A40-B 151; A40-B152; A40-B153;
A40-B154; A40-B155; A40-B156; A40-B157; A40-B158; A40-B159;
A40-B 160; A40-B 16 1; A40-B 162; A40-B 163; A40-B 164; A40-B165;
A40-B166; A40-B167; A40-B168; A40-B169; A41-Bl; A41-B2;
A41-B3; A41-B4; A41-B5; A41-B6; A41-B7; A41-B8;
A41-B9; A41-B10; A41-B11; A41-B12; A41-B13; A41-B14;
A41-B15; A41-B16; A41-B17; A41-B18; A41-B19; A41-B20;
A41-B21; A41-B22; A41-B23; A41-B24; A41-B25; A41-B26;
A41-B27; A41-B28; A41-B29; A41-B30; A41-B31; A41-B32;
A41-B33; A41-B34; A41-B35; A41-B36; A41-B37; A41-B38;
A41-B39; A41-B40; A41-B41; A41-B42; A41-B43; A41-B44;
A41-B45; A41-B46; A41-B47; A41-B48; A41-B49; A41-B50;
A41-B51; A41-B52; A41-B53; A41-B54; A41-B55; A41-B56;
A41-B57; A41-B58; A41-B59; A41-B60; A41-B61; A41-B62;
A41-B63; A41-B64; A41-B65; A41-B66; A41-B67; A41-B68;
A41-B69; A41-B70; A41-B71; A41-B72; A41-B73; A41-B74;
A41-B75; A41-B76; A41-B77; A41-B78; A41-B79; A41-B80;
A41-B81; A41-B82; A41-B83; A41-B84; A41-B85; A41-B86;
A41-B87; A41-B88; A41-B89; A41-B90; A41-B91; A41-B92;
A41-B93; A41-B94; A41-B95; A41-B96; A41-B97; A41-B98;
A41-B99; A41-B100; A41-B101; A41-B102; A41-B103; A41-B104;
A41-B105; A41-B106; A41-B107; A41-B108; A41-B109; A41-B110;
A41-B111; A41-B112; A41-B113; A41-B114; A41-B115; A41-B116;
A41-B117; A41-B118; A41-B119; A41-B120; A41-B121; A41-B122;
A41-B123; A41-B124; A41-B125; A41-B126; A41-B127; A41-B128;
A41-B129; A41-B130; A41-B131; A41-B132; A41-B133; A41-B134;
A41-B135; A41-B136; A41-B137; A41-B138; A41-B139; A41-B140;
A41-B141; A41-B142; A41-B143; A41-B144; A41-B145; A41-B146;
A41-B147; A41-B148; A41-B149; A41-B150; A41-B151; A41-B152;
A41-B153; A41-B154; A41-B155; A41-B156; A41-B157; A41-B158;
A41-B159; A41-B160; A41-B161; A41-B162; A41-B163; A41-B164;
A41-B165; A41-B166; A41-B167; A41-B168; A41-B169; A42-B1;
A42-B2; A42-B3; A42-B4; A42-B5; A42-B6; A42-B7;
A42-B8; A42-B9; A42-B 10; A42-B 11; A42-B 12; A42-B13;
A42-B 14; A42-B 15; A42-B 16; A42-B 17; A42-B 18; A42-B19;
A42-B20; A42-B21; A42-B22; A42-B23; A42-B24; A42-B25;
A42-B26; A42-B27; A42-B28; A42-B29; A42-B30; A42-B31;
A42-B32; A42-B33; A42-B34; A42-B35; A42-B36; A42-B37;
A42-B38; A42-B39; A42-B40; A42-B41; A42-B42; A42-B43;
A42-B44; A42-B45; A42-B46; A42-B47; A42-B48; A42-B49;
A42-B50; A42-B51; A42-B52; A42-B53; A42-B54; A42-B55;
A42-B56; A42-B57; A42-B58; A42-B59; A42-B60; A42-B61;
A42-B62; A42-B63; A42-B64; A42-B65; A42-B66; A42-B67;
A42-B68; A42-B69; A42-B70; A42-B71; A42-B72; A42-B73;
A42-B74; A42-B75; A42-B76; A42-B77; A42-B78; A42-B79;
A42-B80; A42-B81; A42-B82; A42-B83; A42-B84; A42-B85;
A42-B86; A42-B87; A42-B88; A42-B89; A42-B90; A42-B91;
A42-B92; A42-B93; A42-B94; A42-B95; A42-B96; A42-B97;
A42-B98; A42-B99; A42-B 100; A42-B 101; A42-B 102; A42-B 103;
A42-B 104; A42-B 105; A42-B 106; A42-B 107; A42-B 108; A42-B 109;
A42-B 110; A42-B 111; A42-B 112; A42-B 113; A42-B 114; A42-B 115;
A42-B 116; A42-B 117; A42-B 118; A42-B 119; A42-B 120; A42-B 121;
A42-B 122; A42-B 123; A42-B 124; A42-B 125; A42-B126; A42-B 127;
A42-B128; A42-B 129; A42-B 130; A42-B 131; A42-B 132; A42-B 133;
A42-B 134; A42-B135; A42-B136; A42-B 137; A42-B 138; A42-B139;
A42-B 140; A42-B 141; A42-B 142; A42-B 143; A42-B 144; A42-B 145;
A42-B 146; A42-B 147; A42-B 148; A42-B 149; A42-B 150; A42-B 151;
A42-B 152; A42-B 153; A42-B 154; A42-B 155; A42-B 156; A42-B 157;
A42-B 158; A42-B 159; A42-B 160; A42-B 161; A42-B 162; A42-B 163;
A42-B 164; A42-B 165; A42-B166; A42-B 167; A42-B 168; A42-B 169;
A43-Bl; A43-B2; A43-B3; A43-B4; A43-B5; A43-B6;
A43-B7; A43-B8; A43-B9; A43-B10; A43-B11; A43-B12;
A43-B13; A43-B 14; A43-B 15; A43-B 16; A43-B 17; A43-B 18;
A43-B19; A43-B20; A43-B21; A43-B22; A43-B23; A43-B24;
A43-B25; A43-B26; A43-B27; A43-B28; A43-B29; A43-B30;
A43-B31; A43-B32; A43-B33; A43-B34; A43-B35; A43-B36;
A43-B37; A43-B38; A43-B39; A43-B40; A43-B41; A43-B42;
A43-B43; A43-B44; A43-B45; A43-B46; A43-B47; A43-B48;
A43-B49; A43-B50; A43-B51; A43-B52; A43-B53; A43-B54;
A43-B55; A43-B56; A43-B57; A43-B58; A43-B59; A43-B60;
A43-B61; A43-B62; A43-B63; A43-B64; A43-B65; A43-B66;
A43-B67; A43-B68; A43-B69; A43-B70; A43-B71; A43-B72;
A43-B73; A43-B74; A43-B75; A43-B76; A43-B77; A43-B78;
A43-B79; A43-B80; A43-B81; A43-B82; A43-B83; A43-B84;
A43-B85; A43-B86; A43-B87; A43-B88; A43-B89; A43-B90;
A43-B91; A43-B92; A43-B93; A43-B94; A43-B95; A43-B96;
A43-B97; A43-B98; A43-B99; A43-B 100; A43-B 101; A43-B 102;
A43-B103; A43-B104; A43-B105; A43-B106; A43-B107; A43-B108;
A43-B109; A43-B110; A43-B111; A43-B112; A43-B113; A43-B114;
A43-B 115; A43-B 116; A43-B 117; A43-B 118; A43-B 119; A43-B120;
A43-B 121; A43-B122; A43-B 123; A43-B 124; A43-B 125; A43-B 126;
A43-B127; A43-B128; A43-B129; A43-B130; A43-B131; A43-B132;
A43-B 133; A43-B 134; A43-B 135; A43-B 136; A43-B 137; A43-B 138;
A43-B 139; A43-B 140; A43-B 141; A43-B 142; A43-B 143; A43-B 144;
A43-B 145; A43-B 146; A43-B 147; A43-B148; A43-B 149; A43-B 150;
A43-B151; A43-B 152; A43-B153; A43-B 154; A43-B 155; A43-B156;
A43-B 157; A43-B 158; A43-B 159; A43-B 160; A43-B 161; A43-B 162;
A43-B 163; A43-B 164; A43-B 165; A43-B 166; A43-B 167; A43-B 168;
A43-B169; A44-B1; A44-B2; A44-B3; A44-B4; A44-B5;
A44-B6; A44-B7; A44-B8; A44-B9; A44-B10; A44-B11;
A44-B 12; A44-B 13; A44-B 14; A44-B 15; A44-B 16; A44-B 17;
A44-B 18; A44-B 19; A44-B20; A44-B21; A44-B22; A44-B23;
A44-B24; A44-B25; A44-B26; A44-B27; A44-B28; A44-B29;
A44-B30; A44-B31; A44-B32; A44-B33; A44-B34; A44-B35;
A44-B36; A44-B37; A44-B38; A44-B39; A44-B40; A44-B41;
A44-B42; A44-B43; A44-B44; A44-B45; A44-B46; A44-B47;
A44-B48; A44-B49; A44-B50; A44-B51; A44-B52; A44-B53;
A44-B54; A44-B55; A44-B56; A44-B57; A44-B58; A44-B59;
A44-B60; A44-B61; A44-B62; A44-B63; A44-B64; A44-B65;
A44-B66; A44-B67; A44-B68; A44-B69; A44-B70; A44-B71;
A44-B72; A44-B73; A44-B74; A44-B75; A44-B76; A44-B77;
A44-B78; A44-B79; A44-B80; A44-B81; A44-B82; A44-B83;
A44-B84; A44-B85; A44-B86; A44-B87; A44-B88; A44-B89;
A44-B90; A44-B91; A44-B92; A44-B93; A44-B94; A44-B95;
A44-B96; A44-B97; A44-B98; A44-B99; A44-B100; A44-B101;
A44-B 102; A44-B 103; A44-B 104; A44-B 105; A44-B 106; A44-B 107;
A44-B 108; A44-B 109; A44-B 110; A44-B 111; A44-B 112; A44-B 113;
A44-B 114; A44-B 115; A44-B 116; A44-B 117; A44-B 118; A44-B 119;
A44-B 120; A44-B 121; A44-B122; A44-B 123; A44-B 124; A44-B 125;
A44-B 126; A44-B 127; A44-B128; A44-B 129; A44-B 130; A44-B 131;
A44-B 132; A44-B133; A44-B 134; A44-B135; A44-B136; A44-B 137;
A44-B 13 8; A44-B 139; A44-B 140; A44-B 141; A44-B 142; A44-B143;
A44-B 144; A44-B 145; A44-B 146; A44-B 147; A44-B 148; A44-B 149;
A44-B150; A44-B 151; A44-B 152; A44-B 153; A44-B 154; A44-B 155;
A44-B 156; A44-B 157; A44-B 158; A44-B159; A44-B 160; A44-B 161;
A44-B 162; A44-B 163; A44-B 164; A44-B 165; A44-B 166; A44-B 167;
A44-B168; A44-B169; A45-Bl; A45-B2; A45-B3; A45-B4;
A45-B5; A45-B6; A45-B7; A45-B8; A45-B9; A45-B10;
A45-B 11; A45-B 12; A45-B 13; A45-B 14; A45-B 15; A45-B16;
A45-B 17; A45-B18; A45-B 19; A45-B20; A45-B21; A45-B22;
A45-B23; A45-B24; A45-B25; A45-B26; A45-B27; A45-B28;
A45-B29; A45-B30; A45-B31; A45-B32; A45-B33; A45-B34;
A45-B35; A45-B36; A45-B37; A45-B38; A45-B39; A45-B40;
A45-B41; A45-B42; A45-B43; A45-B44; A45-B45; A45-B46;
A45-B47; A45-B48; A45-B49; A45-B50; A45-B51; A45-B52;
A45-B53; A45-B54; A45-B55; A45-B56; A45-B57; A45-B58;
A45-B59; A45-B60; A45-B61; A45-B62; A45-B63; A45-B64;
A45-B65; A45-B66; A45-B67; A45-B68; A45-B69; A45-B70;
A45-B71; A45-B72; A45-B73; A45-B74; A45-B75; A45-B76;
A45-B77; A45-B78; A45-B79; A45-B80; A45-B81; A45-B82;
A45-B83; A45-B84; A45-B85; A45-B86; A45-B87; A45-B88;
A45-B89; A45-B90; A45-B91; A45-B92; A45-B93; A45-B94;
A45-B95; A45-B96; A45-B97; A45-B98; A45-B99; A45-B100;
A45-B 101; A45-B 102; A45-B 103; A45-B104; A45-B105; A45-B 106;
A45-B 107; A45-B 108; A45-B 109; A45-B 110; A45-B 111; A45-B 112;
A45-B 113; A45-B 114; A45-B 115; A45-B 116; A45-B117; A45-B 118;
A45-B 119; A45-B 120; A45-B 121; A45-B 122; A45-B 123; A45-B124;
A45-B125; A45-B 126; A45-B 127; A45-B 128; A45-B 129; A45-B130;
A45-B 131; A45-B132; A45-B 133; A45-B 134; A45-B 135; A45-B136;
A45-B 137; A45-B 138; A45-B 139; A45-B 140; A45-B 141; A45-B142;
A45-B 143; A45-B 144; A45-B 145; A45-B 146; A45-B 147; A45-B 148;
A45-B149; A45-B150; A45-B151; A45-B152; A45-B153; A45-B154;
A45-B 155; A45-B 156; A45-B 157; A45-B 158; A45-B 159; A45-B160;
A45-B161; A45-B162; A45-B163; A45-B 164; A45-B 165; A45-B 166;
A45-B167; A45-B168; A45-B169; A46-B1; A46-B2; A46-B3;
A46-B4; A46-B5; A46-B6; A46-B7; A46-B8; A46-B9;
A46-B 10; A46-B 11; A46-B12; A46-B 13; A46-B14; A46-B 15;
A46-B 16; A46-B 17; A46-B 18; A46-B 19; A46-B20; A46-B21;
A46-B22; A46-B23; A46-B24; A46-B25; A46-B26; A46-B27;
A46-B28; A46-B29; A46-B30; A46-B31; A46-B32; A46-B33;
A46-B34; A46-B35; A46-B36; A46-B37; A46-B38; A46-B39;
A46-B40; A46-B41; A46-B42; A46-B43; A46-B44; A46-B45;
A46-B46; A46-B47; A46-B48; A46-B49; A46-B50; A46-B51;
A46-B52; A46-B53; A46-B54; A46-B55; A46-B56; A46-B57;
A46-B58; A46-B59; A46-B60; A46-B61; A46-B62; A46-B63;
A46-B64; A46-B65; A46-B66; A46-B67; A46-B68; A46-B69;
A46-B70; A46-B71; A46-B72; A46-B73; A46-B74; A46-B75;
A46-B76; A46-B77; A46-B78; A46-B79; A46-B80; A46-B81;
A46-B82; A46-B83; A46-B84; A46-B85; A46-B86; A46-B87;
A46-B88; A46-B89; A46-B90; A46-B91; A46-B92; A46-B93;
A46-B94; A46-B95; A46-B96; A46-B97; A46-B98; A46-B99;
A46-B 100; A46-B 101; A46-B 102; A46-B 103; A46-B 104; A46-B 105;
A46-B 106; A46-B 107; A46-B 10S; A46-B 109; A46-B 110; A46-B 111;
A46-B 112; A46-B 113; A46-B 114; A46-B 115; A46-B 116; A46-B 117;
A46-B 118; A46-B 119; A46-B 120; A46-B 121; A46-B 122; A46-B 123;
A46-B 124; A46-B 125; A46-B 12 6; A46-B 127; A46-B 128; A46-B129;
A46-B 130; A46-B 131; A46-B 132; A46-B 133; A46-B 134; A46-B 135;
A46-B136; A46-B137; A46-B138; A46-B139; A46-B140; A46-B141;
A46-B 142; A46-B 143; A46-B 144; A46-B 145; A46-B 146; A46-B 147;
A46-B 148; A46-B 149; A46-B 150; A46-B 151; A46-B 152; A46-B 153;
A46-B 154; A46-B 155; A46-B 156; A46-B 157; A46-B 158; A46-B 159;
A46-B 160; A46-B 161; A46-B 162; A46-B 163; A46-B 164; A46-B 165;
A46-B 166; A46-B 167; A46-B 168; A46-B 169; A47-B 1; A47-B2;
A47-B3; A47-B4; A47-B5; A47-B6; A47-B7; A47-B8;
A47-B9; A47-B 10; A47-B 11; A47-B 12; A47-B 13; A47-B 14;
A47-B 15; A47-B 16; A47-B 17; A47-B 18; A47-B 19; A47-B20;
A47-B21; A47-B22; A47-B23; A47-B24; A47-B25; A47-B26;
A47-B27; A47-B28; A47-B29; A47-B30; A47-B31; A47-B32;
A47-B33; A47-B34; A47-B35; A47-B36; A47-B37; A47-B38;
A47-B39; A47-B40; A47-B41; A47-B42; A47-B43; A47-B44;
A47-B45; A47-B46; A47-B47; A47-B48; A47-B49; A47-B50;
A47-B51; A47-B52; A47-B53; A47-B54; A47-B55; A47-B56;
A47-B57; A47-B58; A47-B59; A47-B60; A47-B61; A47-B62;
A47-B63; A47-B64; A47-B65; A47-B66; A47-B67; A47-B68;
A47-B69; A47-B70; A47-B71; A47-B72; A47-B73; A47-B74;
A47-B75; A47-B76; A47-B77; A47-B78; A47-B79; A47-B80;
A47-B81; A47-B82; A47-B83; A47-B84; A47-B85; A47-B86;
A47-B87; A47-B88; A47-B89; A47-B90; A47-B91; A47-B92;
A47-B93; A47-B94; A47-B95; A47-B96; A47-B97; A47-B98;
A47-B99; A47-B 100; A47-B 101; A47-B 102; A47-B 103; A47-B 104;
A47-B 105; A47-B 106; A47-B 107; A47-B 108; A47-B 109; A47-B 110;
A47-B 111; A47-B 112; A47-B 113; A47-B 114; A47-B 115; A47-B 116;
A47-B 117; A47-B 118; A47-B 119; A47-B 120; A47-B 121; A47-B 122;
A47-B 123; A47-B 124; A47-B 125; A47-B 126; A47-B 127; A47-B 128;
A47-B 129; A47-B130; A47-B 131; A47-B 132; A47-B 133; A47-B 134;
A47-B 135; A47-B136; A47-B 137; A47-B 138; A47-B 139; A47-B 140;
A47-B 141; A47-B 142; A47-B 143; A47-B 144;, A47-B 145; A47-B 146;
A47-B 147; A47-B 148; A47-B 149; A47-B 150; A47-B 151; A47-B 152;
A47-B 153; A47-B 154; A47-B155; A47-B156; A47-B 157; A47-B158;
A47-B 159; A47-B 160; A47-B 161; A47-B 162; A47-B 163; A47-B 164;
A47-B 165; A47-B 166; A47-B 167; A47-B 168; A47-B 169; A48-B 1;
A48-B2; A48-B3; A48-B4; A48-B5; A48-B6; A48-B7;
A48-B8; A48-B9; A48-B 10; A48-B 11; A48-B12; A48-B 13;
A48-B 14; A48-B 15; A48-B 16; A48-B17; A48-B 18; A48-B 19;
A48-B20; A48-B21; A48-B22; A48-B23; A48-B24; A48-B25;
A48-B26; A48-B27; A48-B28; A48-B29; A48-B30; A48-B31;
A48-B32; A48-B33; A48-B34; A48-B35; A48-B36; A48-B37;
A48-B38; A48-B39; A48-B40; A48-B41; A48-B42; A48-B43;
A48-B44; A48-B45; A48-B46; A48-B47; A48-B48; A48-B49;
A48-B50; A48-B51; A48-B52; A48-B53; A48-B54; A48-B55;
A48-B56; A48-B57; A48-B58; A48-B59; A48-B60; A48-B61;
A48-B62; A48-B63; A48-B64; A48-B65; A48-B66; A48-B67;
A48-B68; A48-B69; A48-B70; A48-B71; A48-B72; A48-B73;
A48-B74; A48-B75; A48-B76; A48-B77; A48-B78; A48-B79;
A48-B80; A48-B81; A48-B82; A48-B83; A48-B84; A48-B85;
A48-B86; A48-B87; A48-B88; A48-B89; A48-B90; A48-B91;
A48-B92; A48-B93; A48-B94; A48-B95; A48-B96; A48-B97;
A48-B98; A48-B99; A48-B100; A48-B101; A48-B102; A48-B103;
A48-B 104; A48-B105; A48-B 106; A48-B 107; A48-B 108; A48-B 109;
A48-B 110; A48-B 111; A48-B 112; A48-B113; A48-B114; A48-B115;
A48-B116; A48-B117; A48-B118; A48-B119; A48-B120; A48-B121;
A48-B 122; A48-B 123; A48-B 124; A48-B 125; A48-B 126; A48-B 127;
A48-B128; A48-B 129; A48-B 130; A48-B 131; A48-B 132; A48-B 133;
A48-B 134; A48-B135; A48-B 136; A48-B 137; A48-B138; A48-B139;
A48-B140; A48-B 141; A48-B 142; A48-B143; A48-B 144; A48-B 145;
A48-B 146; A48-B 147; A48-B 148; A48-B 149; A48-B 150; A48-B 151;
A48-B152; A48-B153; A48-B154; A48-B155; A48-B156; A48-B 157;
A48-B158; A48-B159; A48-B160; A48-B161; A48-B162; A48-B163;
A48-B164; A48-B165; A48-B 166; A48-B167; A48-B168; A48-B169;
A49-B1; A49-B2; A49-B3; A49-B4; A49-B5; A49-B6;
A49-B7; A49-B8; A49-B9; A49-B10; A49-B11; A49-B12;
A49-B 13; A49-B 14; A49-B 15; A49-B 16; A49-B 17; A49-B 18;
A49-B 19; A49-B20; A49-B21; A49-B22; A49-B23; A49-B24;
A49-B25; A49-B26; A49-B27; A49-B28; A49-B29; A49-B30;
A49-B31; A49-B32; A49-B33; A49-B34; A49-B35; A49-B36;
A49-B37; A49-B38; A49-B39; A49-B40; A49-B41; A49-B42;
A49-B43; A49-B44; A49-B45; A49-B46; A49-B47; A49-B48;
A49-B49; A49-B50; A49-B51; A49-B52; A49-B53; A49-B54;
A49-B55; A49-B56; A49-B57; A49-B58; A49-B59; A49-B60;
A49-B61; A49-B62; A49-B63; A49-B64; A49-B65; A49-B66;
A49-B67; A49-B68; A49-B69; A49-B70; A49-B71; A49-B72;
A49-B73; A49-B74; A49-B75; A49-B76; A49-B77; A49-B78;
A49-B79; A49-B80; A49-B81; A49-B82; A49-B83; A49-B84;
A49-B85; A49-B86; A49-B87; A49-B88; A49-B89; A49-B90;
A49-B91; A49-B92; A49-B93; A49-B94; A49-B95; A49-B96;
A49-B97; A49-B98; A49-B99; A49-B 100; A49-B 101; A49-B 102;
A49-B 103; A49-B 104; A49-B 105; A49-B 106; A49-B 107; A49-B 108;
A49-B 109; A49-B 110; A49-B 111; A49-B 112; A49-B 113; A49-B 114;
A49-B 115; A49-B 116; A49-B 117; A49-B 118; A49-B 119; A49-B 120;
A49-B 121; A49-B 122; A49-B 123; A49-B 124; A49-B 125; A49-B 126;
A49-B 127; A49-B 128; A49-B 129; A49-B 130; A49-B 131; A49-B132;
A49-B 133; A49-B 134; A49-B 135; A49-B 136; A49-B 137; A49-B138;
A49-B 139; A49-B 140; A49-B141; A49-B 142; A49-B 143; A49-B 144;
A49-B 145; A49-B 146; A49-B 147; A49-B 148; A49-B 149; A49-B 150;
A49-B 151; A49-B 152; A49-B 153; A49-B 154; A49-B 155; A49-B 156;
A49-B 157; A49-B158; A49-B 159; A49-B 160; A49-B 161; A49-B162;
A49-B 163; A49-B164; A49-B 165; A49-B 166; A49-B 167; A49-B168;
A49-B 169; A50-B 1; A50-B2; A50-B3; A50-B4; A50-B5;
A50-B6; A50-B7; A50-B8; A50-B9; A50-B10; A50-B11;
A50-B12; A50-B13; A50-B 14; A50-B 15; A50-B 16; A50-B 17;
A50-B18; A50-B19; A50-B20; A50-B21; A50-B22; A50-B23;
A50-B24; A50-B25; A50-B26; A50-B27; A50-B28; A50-B29;
A50-B30; A50-B31; A50-B32; A50-B33; A50-B34; A50-B35;
A50-B36; A50-B37; A50-B38; A50-B39; A50-B40; A50-B41;
A50-B42; A50-B43; A50-B44; A50-B45; A50-B46; A50-B47;
A50-B48; A50-B49; A50-B50; A50-B51; A50-B52; A50-B53;
A50-B54; A50-B55; A50-B56; A50-B57; A50-B58; A50-B59;
A50-B60; A50-B61; A50-B62; A50-B63; A50-B64; A50-B65;
A50-B66; A50-B67; A50-B68; A50-B69; A50-B70; A50-B71;
A50-B72; A50-B73; A50-B74; A50-B75; A50-B76; A50-B77;
A50-B78; A50-B79; A50-B80; A50-B81; A50-B82; A50-B83;
A50-B84; A50-B85; A50-B86; A50-B87; A50-B88; A50-B89;
A50-B90; A50-B91; A50-B92; A50-B93; A50-B94; A50-B95;
A50-B96; A50-B97; A50-B98; A50-B99; A50-B100; A50-B101;
A50-B 102; A50-B 103; A50-B 104; A50-B 105; A50-B 106; A50-B 107;
A50-B 108; A50-B 109; A50-B 110; A50-B 111; A50-B 112; A50-B 113;
A50-B 114; A50-B 115; A50-B 116; A50-B 117; A50-B118; A50-B 119;
A50-B 120; A50-B121; A50-B 122; A50-B123; A50-B 124; A50-B 125;
A50-B 126; A50-B 127; A50-B 128; A50-B 129; A50-B 130; A50-B 131;
A50-B132; A50-B 133; A50-B 134; A50-B 135; A50-B136; A50-B 137;
A50-B 138; A50-B 139; A50-B 140; A50-B141; A50-B 142; A50-B 143;
A50-B 144; A50-B 145; A50-B146; A50-B 147; A50-B148; A50-B 149;
A50-B 150; A50-B 15 1; A50-B 152; A50-B 153; A50-B 154; A50-B 155;
A50-B 156; A50-B157; A50-B158; A50-B 159; A50-B 160; A50-B161;
A50-B 162; A50-B 163; A50-B 164; A50-B 165; A50-B166; A50-B167;
A50-B168; A50-B169; A51-Bl; A51-B2; A51-B3; A51-B4;
A51-B5; A51-B6; A51-B7; A51-B8; A51-B9; A51-B10;
A51-B11; A51-B12; A51-B13; A51-B14; A51-B15; A51-B16;
A51-B17; A51-B18; A51-B19; A51-B20; A51-B21; A51-B22;
A51-B23; A51-B24; A51-B25; A51-B26; A51-B27; A51-B28;
A51-B29; A51-B30; A51-B31; A51-B32; A51-B33; A51-B34;
A51-B35; A51-B36; A51-B37; A51-B38; A51-B39; A51-B40;
A51-B41; A51-B42; A51-B43; A51-B44; A51-B45; A51-B46;
A51-B47; A51-B48; A51-B49; A51-B50; A51-B51; A51-B52;
A51-B53; A51-B54; A51-B55; A51-B56; A51-B57; A51-B58;
A51-B59; A51-B60; A51-B61; A51-B62; A51-B63; A51-B64;
A51-B65; A51-B66; A51-B67; A51-B68; A51-B69; A51-B70;
A51-B71; A51-B72; A51-B73; A51-B74; A51-B75; A51-B76;
A51-B77; A51-B78; A51-B79; A51-B80; A51-B81; A51-B82;
A51-B83; A51-B84; A51-B85; A51-B86; A51-B87; A51-B88;
A51-B89; A51-B90; A51-B91; A51-B92; A51-B93; A51-B94;
A51-B95; A51-B96; A51-B97; A51-B98; A51-B99; A51-B100;
A51-B101; A51-B102; A51-B103; A51-B104; A51-B105; A51-B106;
A51-B107; A51-B108; A51-B109; A51-B110; A51-B111; A51-B112;
A51-B113; A51-B114; A51-B115; A51-B116; A51-B117; A51-B118;
A51-B119; A51-B120; A51-B121; A51-B122; A51-B123; A51-B124;
A51-B125; A51-B126; A51-B127; A51-B128; A51-B129; A51-B130;
A51-B131; A51-B132; A51-B133; A51-B134; A51-B135; A51-B136;
A51-B137; A51-B138; A51-B139; A51-B140; A51-B141; A51-B142;
A51-B143; A51-B144; A51-B145; A51-B146; A51-B147; A51-B148;
A51-B149; A51-B150; A51-B151; A51-B152; A51-B153; A51-B154;
A51-B155; A51-B156; A51-B157; A51-B158; A51-B159; A51-B160;
A51-B161; A51-B162; A51-B163; A51-B164; A51-B165; A51-B166;
A51-B167; A51-B168; A51-B169; A52-B1; A52-B2; A52-B3;
A52-B4; A52-B5; A52-B6; A52-B7; A52-B8; A52-B9;
A52-B 10; A52-B 11; A52-B 12; A52-B 13; A52-B 14; A52-B 15;
A52-B 16; A52-B 17; A52-B 18; A52-B 19; A52-B20; A52-B21;
A52-B22; A52-B23; A52-B24; A52-B25; A52-B26; A52-B27;
A52-B28; A52-B29; A52-B30; A52-B31; A52-B32; A52-B33;
A52-B34; A52-B35; A52-B36; A52-B37; A52-B38; A52-B39;
A52-B40; A52-B41; A52-B42; A52-B43; A52-B44; A52-B45;
A52-B46; A52-B47; A52-B48; A52-B49; A52-B50; A52-B51;
A52-B52; A52-B53; A52-B54; A52-B55; A52-B56; A52-B57;
A52-B58; A52-B59; A52-B60; A52-B61; A52-B62; A52-B63;
A52-B64; A52-B65; A52-B66; A52-B67; A52-B68; A52-B69;
A52-B70; A52-B71; A52-B72; A52-B73; A52-B74; A52-B75;
A52-B76; A52-B77; A52-B78; A52-B79; A52-B80; A52-B81;
A52-B82; A52-B83; A52-B84; A52-B85; A52-B86; A52-B87;
A52-B88; A52-B89; A52-B90; A52-B91; A52-B92; A52-B93;
A52-B94; A52-B95; A52-B96; A52-B97; A52-B98; A52-B99;
A52-B 100; A52-B 101; A52-B102; A52-B 103; A52-B 104; A52-B 105;
A52-B 106; A52-B 107; A52-B 108; A52-B 109; A52-B 110; A52-B 111;
A52-B 112; A52-B 113; A52-B 114; A52-B 115; A52-B116; A52-B 117;
A52-B 118; A52-B 119; A52-B 120; A52-B 121; A52-B 122; A52-B 123;
A52-B 124; A52-B125; A52-B 126; A52-B 127; A52-B 128; A52-B 129;
A52-B 130; A52-B 131; A52-B132; A52-B133; A52-B 134; A52-B 135;
A52-B136; A52-B137; A52-B138; A52-B139; A52-B140; A52-B141;
A52-B 142; A52-B 143; A52-B144; A52-B 145; A52-B 146; A52-B 147;
A52-B 148; A52-B 149; A52-B 150; A52-B 151; A52-B 152; A52-B153;
A52-B 154; A52-B155; A52-B 156; A52-B 157; A52-B 158; A52-B 159;
A52-B 160; A52-B 161; A52-B 162; A52-B 163; A52-B 164; A52-B 165;
A52-B 166; A52-B 167; A52-B 168; A52-B 169; A53-B l; A53-B2;
A53-B3; A53-B4; A53-B5; A53-B6; A53-B7; A53-B8;
A53-B9; A53-B10; A53-B11; A53-B12; A53-B13; A53-B14;
A53-B 15; A53-B 16; A53-B 17; A53-B 18; A53-B19; A53-B20;
A53-B21; A53-B22; A53-B23; A53-B24; A53-B25; A53-B26;
A53-B27; A53-B28; A53-B29; A53-B30; A53-B31; A53-B32;
A53-B33; A53-B34; A53-B35; A53-B36; A53-B37; A53-B38;
A53-B39; A53-B40; A53-B41; A53-B42; A53-B43; A53-B44;
A53-B45; A53-B46; A53-B47; A53-B48; A53-B49; A53-B50;
A53-B51; A53-B52; A53-B53; A53-B54; A53-B55; A53-B56;
A53-B57; A53-B58; A53-B59; A53-B60; A53-B61; A53-B62;
A53-B63; A53-B64; A53-B65; A53-B66; A53-B67; A53-B68;
A53-B69; A53-B70; A53-B71; A53-B72; A53-B73; A53-B74;
A53-B75; A53-B76; A53-B77; A53-B78; A53-B79; A53-B80;
A53-B81; A53-B82; A53-B83; A53-B84; A53-B85; A53-B86;
A53-B87; A53-B88; A53-B89; A53-B90; A53-B91; A53-B92;
A53-B93; A53-B94; A53-B95; A53-B96; A53-B97; A53-B98;
A53-B99; A53-B 100; A53-B 101; A53-B 102; A53-B 103; A53-B 104;
A53-B 105; A53-B 106; A53-B 107; A53-B 108; A53-B 109; A53-B 110;
A53-B111; A53-B112; A53-B113; A53-B114; A53-B115; A53-B116;
A53-B117; A53-B118; A53-B119; A53-B120; A53-B121; A53-B122;
A53-B 123; A53-B 124; A53-B 125; A53-B 126; A53-B 127; A53-B 128;
A53-B129; A53-B130; A53-B131; A53-B132; A53-B133; A53-B134;
A53-B135; A53-B136; A53-B137; A53-B138; A53-B139; A53-B140;
A53-B141; A53-B142; A53-B143; A53-B144; A53-B145; A53-B146;
A53-B147; A53-B148; A53-B149; A53-B150; A53-B151; A53-B 152;
A53-B153; A53-B154; A53-B155; A53-B156; A53-B157; A53-B158;
A53-B 159; A53-B 160; A53-B 161; A53-B 162; A53-B 163; A53-B 164;
A53-B165; A53-B166; A53-B167; A53-B168; A53-B169; A54-B1;
A54-B2; A54-B3; A54-B4; A54-B5; A54-B6; A54-B7;
A54-B8; A54-B9; A54-B 10; A54-B 11; A54-B 12; A54-B 13;
A54-B 14; A54-B 15; A54-B 16; A54-B 17; A54-B 18; A54-B 19;
A54-B20; A54-B21; A54-B22; A54-B23; A54-B24; A54-B25;
A54-B26; A54-B27; A54-B28; A54-B29; A54-B30; A54-B31;
A54-B32; A54-B33; A54-B34; A54-B35; A54-B36; A54-B37;
A54-B38; A54-B39; A54-B40; A54-B41; A54-B42; A54-B43;
A54-B44; A54-B45; A54-B46; A54-B47; A54-B48; A54-B49;
A54-B50; A54-B51; A54-B52; A54-B53; A54-B54; A54-B55;
A54-B56; A54-B57; A54-B58; A54-B59; A54-B60; A54-B61;
A54-B62; A54-B63; A54-B64; A54-B65; A54-B66; A54-B67;
A54-B68; A54-B69; A54-B70; A54-B71; A54-B72; A54-B73;
A54-B74; A54-B75; A54-B76; A54-B77; A54-B78; A54-B79;
A54-B80; A54-B81; A54-B82; A54-B83; A54-B84; A54-B85;
A54-B86; A54-B87; A54-B88; A54-B89; A54-B90; A54-B91;
A54-B92; A54-B93; A54-B94; A54-B95; A54-B96; A54-B97;
A54-B98; A54-B99; A54-B 100; A54-B 101; A54-B 102; A54-B 103;
A54-B 104; A54-B 105; A54-B 106; A54-B 107; A54-B 108; A54-B 109;
A54-B 110; A54-B 111; A54-B 112; A54-B 113; A54-B 114; A54-B 115;
A54-B 116; A54-B 117; A54-B 118; A54-B 119; A54-B120; A54-B 121;
A54-B 122; A54-B 123; A54-B 124; A54-B 125; A54-B 126; A54-B 127;
A54-B 128; A54-B 129; A54-B130; A54-B 131; A54-B 132; A54-B 133;
A54-B 134; A54-B 135; A54-B 136; A54-B137; A54-B 138; A54-B 139;
A54-B 140; A54-B 141; A54-B 142; A54-B143; A54-B144; A54-B145;
A54-B 146; A54-B 147; A54-B148; A54-B149; A54-B150; A54-B 151;
A54-B 152; A54-B 153; A54-B 154; A54-B 155; A54-B 156; A54-B 157;
A54-B 158; A54-B159; A54-B 160; A54-B161; A54-B 162; A54-B163;
A54-B 164; A54-B 165; A54-B 166; A54-B 167; A54-B 168; A54-B 169;
A55-B1; A55-B2; A55-B3; A55-B4; A55-B5; A55-B6;
A55-B7; A55-B8; A55-B9; A55-B10; A55-B11; A55-B12;
A55-B 13; A55-B14; A55-B 15; A55-B 16; A55-B 17; A55-B 18;
A55-B19; A55-B20; A55-B21; A55-B22; A55-B23; A55-B24;
A55-B25; A55-B26; A55-B27; A55-B28; A55-B29; A55-B30;
A55-B31; A55-B32; A55-B33; A55-B34; A55-B35; A55-B36;
A55-B37; A55-B38; A55-B39; A55-B40; A55-B41; A55-B42;
A55-B43; A55-B44; A55-B45; A55-B46; A55-B47; A55-B48;
A55-B49; A55-B50; A55-B51; A55-B52; A55-B53; A55-B54;
A55-B55; A55-B56; A55-B57; A55-B58; A55-B59; A55-B60;
A55-B61; A55-B62; A55-B63; A55-B64; A55-B65; A55-B66;
A55-B67; A55-B68; A55-B69; A55-B70; A55-B71; A55-B72;
A55-B73; A55-B74; A55-B75; A55-B76; A55-B77; A55-B78;
A55-B79; A55-B80; A55-B81; A55-B82; A55-B83; A55-B84;
A55-B85; A55-B86; A55-B87; A55-B88; A55-B89; A55-B90;
A55-B91; A55-B92; A55-B93; A55-B94; A55-B95; A55-B96;
A55-B97; A55-B98; A55-B99; A55-B 100; A55-B 101; A55-B 102;
A55-B103; A55-B104; A55-B105; A55-B106; A55-B107; A55-B108;
A55-B109; A55-B110; A55-B111; A55-B112; A55-B113; A55-B114;
A55-B115; A55-B116; A55-B117; A55-B118; A55-B119; A55-B120;
A55-B121; A55-B122; A55-B123; A55-B124; A55-B125; A55-B126;
A55-B127; A55-B128; A55-B129; A55-B130; A55-B131; A55-B132;
A55-B133; A55-B134; A55-B135; A55-B136; A55-B137; A55-B138;
A55-B139; A55-B140; A55-B141; A55-B142; A55-B143; A55-B144;
A55-B145; A55-B146; A55-B147; A55-B148; A55-B149; A55-B150;
A55-B151; A55-B152; A55-B153; A55-B154; A55-B155; A55-B156;
A55-B157; A55-B 158; A55-B159; A55-B160; A55-B 161; A55-B 162;
A55-B163; A55-B164; A55-B165; A55-B166; A55-B167; A55-B168;
A55-B169; A56-B1; A56-B2; A56-B3; A56-B4; A56-B5;
A56-B6; A56-B7; A56-B8; A56-B9; A56-B10; A56-B11;
A56-B 12; A56-B 13; A56-B 14; A56-B 15; A56-B 16; A56-B17;
A56-B18; A56-B19; A56-B20; A56-B21; A56-B22; A56-B23;
A56-B24; A56-B25; A56-B26; A56-B27; A56-B28; A56-B29;
A56-B30; A56-B31; A56-B32; A56-B33; A56-B34; A56-B35;
A56-B36; A56-B37; A56-B38; A56-B39; A56-B40; A56-B41;
A56-B42; A56-B43; A56-B44; A56-B45; A56-B46; A56-B47;
A56-B48; A56-B49; A56-B50; A56-B51; A56-B52; A56-B53;
A56-B54; A56-B55; A56-B56; A56-B57; A56-B58; A56-B59;
A56-B60; A56-B61; A56-B62; A56-B63; A56-B64; A56-B65;
A56-B66; A56-B67; A56-B68; A56-B69; A56-B70; A56-B71;
A56-B72; A56-B73; A56-B74; A56-B75; A56-B76; A56-B77;
A56-B78; A56-B79; A56-B80; A56-B81; A56-B82; A56-B83;
A56-B84; A56-B85; A56-B86; A56-B87; A56-B88; A56-B89;
A56-B90; A56-B91; A56-B92; A56-B93; A56-B94; A56-B95;
A56-B96; A56-B97; A56-B98; A56-B99; A56-B100; A56-B101;
A56-B102; A56-B103; A56-B104; A56-B105; A56-B106; A56-B107;
A56-B 108; A56-B 109; A56-B 110; A56-B 111; A56-B 112; A56-B 113;
A56-B114; A56-B 115; A56-B 116; A56-B117; A56-B 118; A56-B 119;
A56-B120; A56-B121; A56-B122; A56-B123; A56-B124; A56-B125;
A56-B126; A56-B 127; A56-B 128; A56-B 129; A56-B 130; A56-B 131;
A56-B132; A56-B133; A56-B134; A56-B135; A56-B136; A56-B137;
A56-B138; A56-B139; A56-B140; A56-B141; A56-B142; A56-B143;
A56-B144; A56-B145; A56-B146; A56-B147; A56-B148; A56-B149;
A56-B150; A56-B151; A56-B152; A56-B153; A56-B154; A56-B155;
A56-B156; A56-B157; A56-B158; A56-B159; A56-B160; A56-B161;
A56-B 162; A56-B 163; A56-B164; A56-B 165; A56-B 166; A56-B 167;
A56-B168; A56-B169; A57-B1; A57-B2; A57-B3; A57-B4;
A57-B5; A57-B6; A57-B7; A57-B8; A57-B9; A57-B10;
A57-B 11; A57-B12; A57-B 13; A57-B 14; A57-B 15; A57-B 16;
A57-B17; A57-B 18; A57-B 19; A57-B20; A57-B21; A57-B22;
A57-B23; A57-B24; A57-B25; A57-B26; A57-B27; A57-B28;
A57-B29; A57-B30; A57-B31; A57-B32; A57-B33; A57-B34;
A57-B35; A57-B36; A57-B37; A57-B38; A57-B39; A57-B40;
A57-B41; A57-B42; A57-B43; A57-B44; A57-B45; A57-B46;
A57-B47; A57-B48; A57-B49; A57-B50; A57-B51; A57-B52;
A57-B53; A57-B54; A57-B55; A57-B56; A57-B57; A57-B58;
A57-B59; A57-B60; A57-B61; A57-B62; A57-B63; A57-B64;
A57-B65; A57-B66; A57-B67; A57-B68; A57-B69; A57-B70;
A57-B71; A57-B72; A57-B73; A57-B74; A57-B75; A57-B76;
A57-B77; A57-B78; A57-B79; A57-B80; A57-B81; A57-B82;
A57-B83; A57-B84; A57-B85; A57-B86; A57-B87; A57-B88;
A57-B89; A57-B90; A57-B91; A57-B92; A57-B93; A57-B94;
A57-B95; A57-B96; A57-B97; A57-B98; A57-B99; A57-B100;
A57-B 101; A57-B 102; A57-B 103; A57-B 104; A57-B 105; A57-B 106;
A57-B107; A57-B 108; A57-B 109; A57-B 110; A57-B 111; A57-B 112;
A57-B 113; A57-B 114; A57-B 115; A57-B 116; A57-B 117; A57-B 118;
A57-B 119; A57-B 120; A57-B 121; A57-B 122; A57-B 123; A57-B 124;
A57-B 125; A57-B 126; A57-B 127; A57-B 128; A57-B 129; A57-B 130;
A57-B131; A57-B 132; A57-B 133; A57-B 134; A57-B 135; A57-B136;
A57-B137; A57-B138; A57-B139; A57-B140; A57-B141; A57-B 142;
A57-B143; A57-B 144; A57-B 145; A57-B 146; A57-B 147; A57-B 148;
A57-B 149; A57-B150; A57-B 151; A57-B 152; A57-B 153; A57-B 154;
A57-B 155; A57-B156; A57-B 157; A57-B 158; A57-B159; A57-B 160;
A57-B161; A57-B 162; A57-B 163; A57-B 164; A57-B165; A57-B166;
A57-B167; A57-B168; A57-B169; A58-Bl; A58-B2; A58-B3;
A58-B4; A58-B5; A58-B6; A58-B7; A58-B8; A58-B9;
A58-B10; A58-B11; A58-B12; A58-B13; A58-B14; A58-B15;
A58-B16; A58-B17; A58-B18; A58-B19; A58-B20; A58-B21;
A58-B22; A58-B23; A58-B24; A58-B25; A58-B26; A58-B27;
A58-B28; A58-B29; A58-B30; A58-B31; A58-B32; A58-B33;
A58-B34; A58-B35; A58-B36; A58-B37; A58-B38; A58-B39;
A58-B40; A58-B41; A58-B42; A58-B43; A58-B44; A58-B45;
A58-B46; A58-B47; A58-B48; A58-B49; A58-B50; A58-B51;
A58-B52; A58-B53; A58-B54; A58-B55; A58-B56; A58-B57;
A58-B58; A58-B59; A58-B60; A58-B61; A58-B62; A58-B63;
A58-B64; A58-B65; A58-B66; A58-B67; A58-B68; A58-B69;
A58-B70; A58-B71; A58-B72; A58-B73; A58-B74; A58-B75;
A58-B76; A58-B77; A58-B78; A58-B79; A58-B80; A58-B81;
A58-B82; A58-B83; A58-B84; A58-B85; A58-B86; A58-B87;
A58-B88; A58-B89; A58-B90; A58-B91; A58-B92; A58-B93;
A58-B94; A58-B95; A58-B96; A58-B97; A58-B98; A58-B99;
A58-B100; A58-B101; A58-B102; A58-B103; A58-B104; A58-B105;
A58-B106; A58-B107; A58-B108; A58-B109; A58-B110; A58-B111;
A58-B112; A58-B113; A58-B114; A58-B115; A58-B116; A58-B117;
A58-B118; A58-B119; A58-B120; A58-B121; A58-B122; A58-B123;
A58-B 124; A58-B 125; A58-B126; A58-B 127; A58-B 128; A58-B 129;
A58-B130; A58-B131; A58-B132; A58-B133; A58-B134; A58-B135;
A58-B136; A58-B137; A58-B138; A58-B139; A58-B140; A58-B141;
A58-B142; A58-B143; A58-B144; A58-B145; A58-B146; A58-B147;
A58-B148; A58-B149; A58-B150; A58-B151; A58-B152; A58-B153;
A58-B154; A58-B155; A58-B156; A58-B157; A58-B158; A58-B159;
A58-B160; A58-B161; A58-B162; A58-B163; A58-B164; A58-B165;
A58-B166; A58-B167; A58-B168; A58-B169; A59-B1; A59-B2;
A59-B3; A59-B4; A59-B5; A59-B6; A59-B7; A59-B8;
A59-B9; A59-B10; A59-B11; A59-B12; A59-B13; A59-B14;
A59-B 15; A59-B16; A59-B 17; A59-B 18; A59-B 19; A59-B20;
A59-B21; A59-B22; A59-B23; A59-B24; A59-B25; A59-B26;
A59-B27; A59-B28; A59-B29; A59-B30; A59-B31; A59-B32;
A59-B33; A59-B34; A59-B35; A59-B36; A59-B37; A59-B38;
A59-B39; A59-B40; A59-B41; A59-B42; A59-B43; A59-B44;
A59-B45; A59-B46; A59-B47; A59-B48; A59-B49; A59-B50;
A59-B51; A59-B52; A59-B53; A59-B54; A59-B55; A59-B56;
A59-B57; A59-B58; A59-B59; A59-B60; A59-B61; A59-B62;
A59-B63; A59-B64; A59-B65; A59-B66; A59-B67; A59-B68;
A59-B69; A59-B70; A59-B71; A59-B72; A59-B73; A59-B74;
A59-B75; A59-B76; A59-B77; A59-B78; A59-B79; A59-B80;
A59-B81; A59-B82; A59-B83; A59-B84; A59-B85; A59-B86;
A59-B87; A59-B88; A59-B89; A59-B90; A59-B91; A59-B92;
A59-B93; A59-B94; A59-B95; A59-B96; A59-B97; A59-B98;
A59-B99; A59-B100; A59-B101; A59-B102; A59-B103; A59-B104;
A59-B 105; A59-B 106; A59-B107; A59-B 108; A59-B109; A59-B 110;
A59-B111; A59-B112; A59-B113; A59-B114; A59-B115; A59-B116;
A59-B117; A59-B118; A59-B119; A59-B120; A59-B121; A59-B122;
A59-B 123; A59-B124; A59-B125; A59-B 126; A59-B 127; A59-B128;
A59-B 129; A59-B 130; A59-B 131; A59-B132; A59-B 133; A59-B 134;
A59-B 135; A59-B136; A59-B137; A59-B138; A59-B139; A59-B140;
A59-B 141; A59-B 142; A59-B 143; A59-B 144; A59-B 145; A59-B 146;
A59-B147; A59-B148; A59-B149; A59-B150; A59-B151; A59-B152;
A59-B153; A59-B 154; A59-B 155; A59-B156; A59-B 157; A59-B 158;
A59-B 159; A59-B160; A59-B161; A59-B 162; A59-B 163; A59-B164;
A59-B 165; A59-B 166; A59-B 167; A59-B 168; A59-B169; A60-B l;
A60-B2; A60-B3; A60-B4; A60-B5; A60-B6; A60-B7;
A60-B8; A60-B9; A60-B10; A60-B11; A60-B12; A60-B13;
A60-B 14; A60-B 15; A60-B 16; A60-B 17; A60-B 18; A60-B 19;
A60-B20; A60-B21; A60-B22; A60-B23; A60-B24; A60-B25;
A60-B26; A60-B27; A60-B28; A60-B29; A60-B30; A60-B31;
A60-B32; A60-B33; A60-B34; A60-B35; A60-B36; A60-B37;
A60-B38; A60-B39; A60-B40; A60-B41; A60-B42; A60-B43;
A60-B44; A60-B45; A60-B46; A60-B47; A60-B48; A60-B49;
A60-B50; A60-B51; A60-B52; A60-B53; A60-B54; A60-B55;
A60-B56; A60-B57; A60-B58; A60-B59; A60-B60; A60-B61;
A60-B62; A60-B63; A60-B64; A60-B65; A60-B66; A60-B67;
A60-B68; A60-B69; A60-B70; A60-B71; A60-B72; A60-B73;
A60-B74; A60-B75; A60-B76; A60-B77; A60-B78; A60-B79;
A60-B80; A60-B81; A60-B82; A60-B83; A60-B84; A60-B85;
A60-B86; A60-B87; A60-B88; A60-B89; A60-B90; A60-B91;
A60-B92; A60-B93; A60-B94; A60-B95; A60-B96; A60-B97;
A60-B98; A60-B99; A60-B100; A60-B101; A60-B102; A60-B103;
A60-B 104; A60-B 105; A60-B 106; A60-B 107; A60-B 108; A60-B 109;
A60-B 110; A60-B 111; A60-B 112; A60-B 113; A60-B 114; A60-B 115;
A60-B 116; A60-B 117; A60-B 118; A60-B 119; A60-B 120; A60-B 121;
A60-B 122; A60-B 123; A60-B 124; A60-B 125; A60-B126; A60-B 127;
A60-B 128; A60-B 129; A60-B 130; A60-B 131; A60-B132; A60-B 133;
A60-B 134; A60-B 135; A60-B 136; A60-B 137; A60-B 138; A60-B 139;
A60-B 140; A60-B 141; A60-B 142; A60-B 143; A60-B 144; A60-B 145;
A60-B 146; A60-B 147; A60-B 148; A60-B 149; A60-B 150; A60-B 151;
A60-B 152; A60-B 153; A60-B154; A60-B 155; A60-B 156; A60-B 157;
A60-B 158; A60-B 159; A60-B 160; A60-B 161; A60-B 162; A60-B 163;
A60-B 164; A60-B 165; A60-B 166; A60-B 167; A60-B 168; A60-B 169;
A61-B1; A61-B2; A61-B3; A61-B4; A61-B5; A61-B6;
A61-B7; A61-B8; A61-B9; A61-B10; A61-B11; A61-B12;
A61-B13; A61-B14; A61-B15; A61-B16; A61-B17; A61-B18;
A61-B19; A61-B20; A61-B21; A61-B22; A61-B23; A61-B24;
A61-B25; A61-B26; A61-B27; A61-B28; A61-B29; A61-B30;
A61-B31; A61-B32; A61-B33; A61-B34; A61-B35; A61-B36;
A61-B37; A61-B38; A61-B39; A61-B40; A61-B41; A61-B42;
A61-B43; A61-B44; A61-B45; A61-B46; A61-B47; A61-B48;
A61-B49; A61-B50; A61-B51; A61-B52; A61-B53; A61-B54;
A61-B55; A61-B56; A61-B57; A61-B58; A61-B59; A61-B60;
A61-B61; A61-B62; A61-B63; A61-B64; A61-B65; A61-B66;
A61-B67; A61-B68; A61-B69; A61-B70; A61-B71; A61-B72;
A61-B73; A61-B74; A61-B75; A61-B76; A61-B77; A61-B78;
A61-B79; A61-B80; A61-B81; A61-B82; A61-B83; A61-B84;
A61-B85; A61-B86; A61-B87; A61-B88; A61-B89; A61-B90;
A61-B91; A61-B92; A61-B93; A61-B94; A61-B95; A61-B96;
A61-B97; A61-B98; A61-B99; A61-B100; A61-B101; A61-B102;
A61-B103; A61-B104; A61-B105; A61-B106; A61-B107; A61-B108;
A61-B109; A61-B110; A61-B111; A61-B112; A61-B113; A61-B114;
A61-B115; A61-B116; A61-B117; A61-B118; A61-B119; A61-B120;
A61-B121; A61-B122; A61-B123; A61-B124; A61-B125; A61-B126;
A61-B127; A61-B128; A61-B129; A61-B130; A61-B131; A61-B132;
A61-B133; A61-B134; A61-B135; A61-B136; A61-B137; A61-B138;
A61-B139; A61-B140; A61-B141; A61-B142; A61-B143; A61-B144;
A61-B145; A61-B146; A61-B147; A61-B148; A61-B149; A61-B150;
A61-B151; A61-B152; A61-B153; A61-B154; A61-B155; A61-B156;
A61-B157; A61-B158; A61-B159; A61-B160; A61-B161; A61-B162;
A61-B163; A61-B164; A61-B165; A61-B166; A61-B167; A61-B168;
A61-B169; A62-B1; A62-B2; A62-B3; A62-B4; A62-B5;
A62-B6; A62-B7; A62-B8; A62-B9; A62-B10; A62-B11;
A62-B 12; A62-B 13; A62-B 14; A62-B 15; A62-B 16; A62-B 17;
A62-B18; A62-B19; A62-B20; A62-B21; A62-B22; A62-B23;
A62-B24; A62-B25; A62-B26; A62-B27; A62-B28; A62-B29;
A62-B30; A62-B31; A62-B32; A62-B33; A62-B34; A62-B35;
A62-B36; A62-B37; A62-B38; A62-B39; A62-B40; A62-B41;
A62-B42; A62-B43; A62-B44; A62-B45; A62-B46; A62-B47;
A62-B48; A62-B49; A62-B50; A62-B51; A62-B52; A62-B53;
A62-B54; A62-B55; A62-B56; A62-B57; A62-B58; A62-B59;
A62-B60; A62-B61; A62-B62; A62-B63; A62-B64; A62-B65;
A62-B66; A62-B67; A62-B68; A62-B69; A62-B70; A62-B71;
A62-B72; A62-B73; A62-B74; A62-B75; A62-B76; A62-B77;
A62-B78; A62-B79; A62-B80; A62-B81; A62-B82; A62-B83;
A62-B84; A62-B85; A62-B86; A62-B87; A62-B88; A62-B89;
A62-B90; A62-B91; A62-B92; A62-B93; A62-B94; A62-B95;
A62-B96; A62-B97; A62-B98; A62-B99; A62-B100; A62-B101;
A62-B 102; A62-B 103; A62-B 104; A62-B 105; A62-B 106; A62-B 107;
A62-B108; A62-B 109; A62-B 110; A62-B 111; A62-B 112; A62-B 113;
A62-B 114; A62-B 115; A62-B 116; A62-B 117; A62-B 118; A62-B 119;
A62-B 120; A62-B 12 1; A62-B 122; A62-B 123; A62-B 124; A62-B 125;
A62-B 126; A62-B 127; A62-B 128; A62-B 129; A62-B 130; A62-B 13 1;
A62-B 132; A62-B 133; A62-B 134; A62-B 135; A62-B 136; A62-B 137;
A62-B 13 8; A62-B 13 9; A62-B 140; A62-B 141; A62-B 142; A62-B 143;
A62-B 144; A62-B 145; A62-B 146; A62-B 147; A62-B 148; A62-B 149;
A62-B 150; A62-B 15 1; A62-B 152; A62-B 153; A62-B 154; A62-B155;
A62-B 156; A62-B 157; A62-B 158; A62-B 159; A62-B 160; A62-B 161;
A62-B 162; A62-B 163; A62-B 164; A62-B 165; A62-B 166; A62-B 167;
A62-B168; A62-B169; A63-B1; A63-B2; A63-B3; A63-B4;
A63-B5; A63-B6; A63-B7; A63-B8; A63-B9; A63-B10;
A63-B 11; A63-B 12; A63-B 13; A63-B 14; A63-B 15; A63-B 16;
A63-B 17; A63-B 18; A63-B 19; A63-B20; A63-B21; A63-B22;
A63-B23; A63-B24; A63-B25; A63-B26; A63-B27; A63-B28;
A63-B29; A63-B30; A63-B31; A63-B32; A63-B33; A63-B34;
A63-B35; A63-B36; A63-B37; A63-B38; A63-B39; A63-B40;
A63-B41; A63-B42; A63-B43; A63-B44; A63-B45; A63-B46;
A63-B47; A63-B48; A63-B49; A63-B50; A63-B51; A63-B52;
A63-B53; A63-B54; A63-B55; A63-B56; A63-B57; A63-B58;
A63-B59; A63-B60; A63-B61; A63-B62; A63-B63; A63-B64;
A63-B65; A63-B66; A63-B67; A63-B68; A63-B69; A63-B70;
A63-B71; A63-B72; A63-B73; A63-B74; A63-B75; A63-B76;
A63-B77; A63-B78; A63-B79; A63-B80; A63-B81; A63-B82;
A63-B83; A63-B84; A63-B85; A63-B86; A63-B87; A63-B88;
A63-B89; A63-B90; A63-B91; A63-B92; A63-B93; A63-B94;
A63-B95; A63-B96; A63-B97; A63-B98; A63-B99; A63-B100;
A63-B 101; A63-B 102; A63-B103; A63-B 104; A63-B 105; A63-B 106;
A63-B 107; A63-B108; A63-B 109; A63-B 110; A63-B 111; A63-B 112;
A63-B 113; A63-B 114; A63-B 115; A63-B116; A63-B117; A63-B118;
A63-B 119; A63-B 120; A63-B121; A63-B 122; A63-B123; A63-B 124;
A63-B 125; A63-B 126; A63-B 127; A63-B 128; A63-B 129; A63-B 130;
A63-B 131; A63-B 132; A63-B 133; A63-B 134; A63-B 135; A63-B136;
A63-B 137; A63-B 138; A63-B 139; A63-B 140; A63-B 141; A63-B 142;
A63-B 143; A63-B 144; A63-B 145; A63-B 146; A63-B147; A63-B 148;
A63-B149; A63-B150; A63-B151; A63-B152; A63-B153; A63-B154;
A63-B 155; A63-B156; A63-B 157; A63-B 158; A63-B 159; A63-B 160;
A63-B 161; A63-B 162; A63-B 163; A63-B 164; A63-B 165; A63-B 166;
A63-B 167; A63-B168; A63-B 169; A64-B 1; A64-B2; A64-B3;
A64-B4; A64-B5; A64-B6; A64-B7; A64-B8; A64-B9;
A64-B 10; A64-B 11; A64-B 12; A64-B 13; A64-B 14; A64-B 15;
A64-B 16; A64-B 17; A64-B 18; A64-B 19; A64-B20; A64-B21;
A64-B22; A64-B23; A64-B24; A64-B25; A64-B26; A64-B27;
A64-B28; A64-B29; A64-B30; A64-B31; A64-B32; A64-B33;
A64-B34; A64-B35; A64-B36; A64-B37; A64-B38; A64-B39;
A64-B40; A64-B41; A64-B42; A64-B43; A64-B44; A64-B45;
A64-B46; A64-B47; A64-B48; A64-B49; A64-B50; A64-B51;
A64-B52; A64-B53; A64-B54; A64-B55; A64-B56; A64-B57;
A64-B58; A64-B59; A64-B60; A64-B61; A64-B62; A64-B63;
A64-B64; A64-B65; A64-B66; A64-B67; A64-B68; A64-B69;
A64-B70; A64-B71; A64-B72; A64-B73; A64-B74; A64-B75;
A64-B76; A64-B77; A64-B78; A64-B79; A64-B80; A64-B81;
A64-B82; A64-B83; A64-B84; A64-B85; A64-B86; A64-B87;
A64-B88; A64-B89; A64-B90; A64-B91; A64-B92; A64-B93;
A64-B94; A64-B95; A64-B96; A64-B97; A64-B98; A64-B99;
A64-B 100; A64-B 101; A64-B 102; A64-B 103; A64-B 104; A64-B 105;
A64-B 106; A64-B 107; A64-B 108; A64-B 109; A64-B 110; A64-B 111;
A64-B 112; A64-B 113; A64-B 114; A64-B 115; A64-B 116; A64-B 117;
A64-B 118; A64-B 119; A64-B 120; A64-B121; A64-B122; A64-B 123;
A64-B 124; A64-B 125; A64-B 126; A64-B 127; A64-B 128; A64-B 129;
A64-B 13 0; A64-B 13 1; A64-B 132; A64-B 133; A64-B 134; A64-B 13 5;
A64-B 136; A64-B 137; A64-B 138; A64-B 139; A64-B 140; A64-B141;
A64-B142; A64-B 143; A64-B 144; A64-B 145; A64-B 146; A64-B 147;
A64-B 148; A64-B 149; A64-B150; A64-B 151; A64-B 152; A64-B 153;
A64-B 154; A64-B 155; A64-B 156; A64-B 157; A64-B 158; A64-B 159;
A64-B 160; A64-B 161; A64-B 162; A64-B 163; A64-B 164; A64-B 165;
A64-B 166; A64-B 167; A64-B 168; A64-B 169; A65-B l; A65-B2;
A65-B3; A65-B4; A65-B5; A65-B6; A65-B7; A65-B8;
A65-B9; A65-B 10; A65-B 11; A65-B 12; A65-B 13; A65-B 14;
A65-B 15; A65-B 16; A65-B 17; A65-B 18; A65-B 19; A65-B20;
A65-B21; A65-B22; A65-B23; A65-B24; A65-B25; A65-B26;
A65-B27; A65-B28; A65-B29; A65-B30; A65-B31; A65-B32;
A65-B33; A65-B34; A65-B35; A65-B36; A65-B37; A65-B38;
A65-B39; A65-B40; A65-B41; A65-B42; A65-B43; A65-B44;
A65-B45; A65-B46; A65-B47; A65-B48; A65-B49; A65-B50;
A65-B51; A65-B52; A65-B53; A65-B54; A65-B55; A65-B56;
A65-B57; A65-B58; A65-B59; A65-B60; A65-B61; A65-B62;
A65-B63; A65-B64; A65-B65; A65-B66; A65-B67; A65-B68;
A65-B69; A65-B70; A65-B71; A65-B72; A65-B73; A65-B74;
A65-B75; A65-B76; A65-B77; A65-B78; A65-B79; A65-B80;
A65-B81; A65-B82; A65-B83; A65-B84; A65-B85; A65-B86;
A65-B87; A65-B88; A65-B89; A65-B90; A65-B91; A65-B92;
A65-B93; A65-B94; A65-B95; A65-B96; A65-B97; A65-B98;
A65-B99; A65-B 100; A65-B 101; A65-B 102; A65-B 103; A65-B 104;
A65-B 105; A65-B 106; A65-B107; A65-B 108; A65-B 109; A65-B 110;
A65-B 111; A65-B 112; A65-B 113; A65-B 114; A65-B 115; A65-B 116;
A65-B 117; A65-B 118; A65-B 119; A65-B120; A65-B 121; A65-B 122;
A65-B 123; A65-B124; A65-B 125; A65-B 126; A65-B127; A65-B 128;
A65-B129; A65-B130; A65-B131; A65-B132; A65-B133; A65-B 134;
A65-B 135; A65-B 136; A65-B 137; A65-B 138; A65-B139; A65-B140;
A65-B 141; A65-B 142; A65-B 143; A65-B 144; A65-B 145; A65-B146;
A65-B147; A65-B148; A65-B149; A65-B150; A65-B151; A65-B152;
A65-B153; A65-B 154; A65-B 155; A65-B156; A65-B 157; A65-B158;
A65-B159; A65-B160; A65-B161; A65-B162; A65-B163; A65-B164;
A65-B 165; A65-B 166; A65-B 167; A65-B 168; A65-B169; A66-B 1;
A66-B2; A66-B3; A66-B4; A66-B5; A66-B6; A66-B7;
A66-B8; A66-B9; A66-B10; A66-B11; A66-B12; A66-B13;
A66-B 14; A66-B 15; A66-B 16; A66-B 17; A66-B18; A66-B19;
A66-B20; A66-B21; A66-B22; A66-B23; A66-B24; A66-B25;
A66-B26; A66-B27; A66-B28; A66-B29; A66-B30; A66-B31;
A66-B32; A66-B33; A66-B34; A66-B35; A66-B36; A66-B37;
A66-B38; A66-B39; A66-B40; A66-B41; A66-B42; A66-B43;
A66-B44; A66-B45; A66-B46; A66-B47; A66-B48; A66-B49;
A66-B50; A66-B51; A66-B52; A66-B53; A66-B54; A66-B55;
A66-B56; A66-B57; A66-B58; A66-B59; A66-B60; A66-B61;
A66-B62; A66-B63; A66-B64; A66-B65; A66-B66; A66-B67;
A66-B68; A66-B69; A66-B70; A66-B71; A66-B72; A66-B73;
A66-B74; A66-B75; A66-B76; A66-B77; A66-B78; A66-B79;
A66-B80; A66-B81; A66-B82; A66-B83; A66-B84; A66-B85;
A66-B86; A66-B87; A66-B88; A66-B89; A66-B90; A66-B91;
A66-B92; A66-B93; A66-B94; A66-B95; A66-B96; A66-B97;
A66-B98; A66-B99; A66-B 100; A66-B 101; A66-B 102; A66-B 103;
A66-B 104; A66-B 105; A66-B 106; A66-B 107; A66-B 108; A66-B 109;
A66-B 110; A66-B 111; A66-B 112; A66-B 113; A66-B 114; A66-B 115;
A66-B 116; A66-B 117; A66-B118; A66-B 119; A66-B 120; A66-B121;
A66-B 122; A66-B 123; A66-B 124; A66-B 125; A66-B 126; A66-B 127;
A66-B 128; A66-B 129; A66-B 130; A66-B 131; A66-B 132; A66-B 133;
A66-B 134; A66-B 135; A66-B 136; A66-B 137; A66-B 13 8; A66-B 139;
A66-B 140; A66-B 141; A66-B 142; A66-B 143; A66-B 144; A66-B145;
A66-B 146; A66-B 147; A66-B 148; A66-B 149; A66-B 150; A66-B 151;
A66-B 152; A66-B153; A66-B 154; A66-B155; A66-B 156; A66-B 157;
A66-B 15 8; A66-B159; A66-B 160; A66-B 161; A66-B 162; A66-B 163;
A66-B 164; A66-B 165; A66-B 166; A66-B 167; A66-B168; A66-B 169;
A67-B 1; A67-B2; A67-B3; A67-B4; A67-B5; A67-B6;
A67-B7; A67-B8; A67-B9; A67-B10; A67-B11; A67-B12;
A67-B 13; A67-B 14; A67-B 15; A67-B 16; A67-B 17; A67-B 18;
A67-B19; A67-B20; A67-B21; A67-B22; A67-B23; A67-B24;
A67-B25; A67-B26; A67-B27; A67-B28; A67-B29; A67-B30;
A67-B31; A67-B32; A67-B33; A67-B34; A67-B35; A67-B36;
A67-B37; A67-B38; A67-B39; A67-B40; A67-B41; A67-B42;
A67-B43; A67-B44; A67-B45; A67-B46; A67-B47; A67-B48;
A67-B49; A67-B50; A67-B51; A67-B52; A67-B53; A67-B54;
A67-B55; A67-B56; A67-B57; A67-B58; A67-B59; A67-B60;
A67-B61; A67-B62; A67-B63; A67-B64; A67-B65; A67-B66;
A67-B67; A67-B68; A67-B69; A67-B70; A67-B71; A67-B72;
A67-B73; A67-B74; A67-B75; A67-B76; A67-B77; A67-B78;
A67-B79; A67-B80; A67-B81; A67-B82; A67-B83; A67-B84;
A67-B85; A67-B86; A67-B87; A67-B88; A67-B89; A67-B90;
A67-B91; A67-B92; A67-B93; A67-B94; A67-B95; A67-B96;
A67-B97; A67-B98; A67-B99; A67-B 100; A67-B 101; A67-B 102;
A67-B 103; A67-B104; A67-B 105; A67-B 106; A67-B 107; A67-B108;
A67-B 109; A67-B 110; A67-B 111; A67-B 112; A67-B 113; A67-B 114;
A67-B 115; A67-B 116; A67-B 117; A67-B 118; A67-B 119; A67-B 120;
A67-B 121; A67-B 122; A67-B 123; A67-B 124; A67-B 125; A67-B 126;
A67-B 127; A67-B 128; A67-B 129; A67-B 130; A67-B 131; A67-B132;
A67-B 133; A67-B 134; A67-B 135; A67-B 136; A67-B137; A67-B 138;
A67-B 139; A67-B 140; A67-B 141; A67-B 142; A67-B 143; A67-B 144;
A67-B 145; A67-B 146; A67-B 147; A67-B 148; A67-B 149; A67-B150;
A67-B151; A67-B152; A67-B153; A67-B154; A67-B155; A67-B156;
A67-B157; A67-B 158; A67-B 159; A67-B 160; A67-B 161; A67-B 162;
A67-B 163; A67-B 164; A67-B 165; A67-B 166; A67-B 167; A67-B 168;
A67-B169; A68-B1; A68-B2; A68-B3; A68-B4; A68-B5;
A68-B6; A68-B7; A68-B8; A68-B9; A68-B10; A68-B11;
A68-B 12; A68-B 13; A68-B 14; A68-B 15; A68-B 16; A68-B 17;
A68-B18; A68-B 19; A68-B20; A68-B21; A68-B22; A68-B23;
A68-B24; A68-B25; A68-B26; A68-B27; A68-B28; A68-B29;
A68-B30; A68-B31; A68-B32; A68-B33; A68-B34; A68-B35;
A68-B36; A68-B37; A68-B38; A68-B39; A68-B40; A68-B41;
A68-B42; A68-B43; A68-B44; A68-B45; A68-B46; A68-B47;
A68-B48; A68-B49; A68-B50; A68-B51; A68-B52; A68-B53;
A68-B54; A68-B55; A68-B56; A68-B57; A68-B58; A68-B59;
A68-B60; A68-B61; A68-B62; A68-B63; A68-B64; A68-B65;
A68-B66; A68-B67; A68-B68; A68-B69; A68-B70; A68-B71;
A68-B72; A68-B73; A68-B74; A68-B75; A68-B76; A68-B77;
A68-B78; A68-B79; A68-B80; A68-B81; A68-B82; A68-B83;
A68-B84; A68-B85; A68-B86; A68-B87; A68-B88; A68-B89;
A68-B90; A68-B91; A68-B92; A68-B93; A68-B94; A68-B95;
A68-B96; A68-B97; A68-B98; A68-B99; A68-B100; A68-B101;
A68-B 102; A68-B 103; A68-B 104; A68-B 105; A68-B 106; A68-B 107;
A68-B 108; A68-B 109; A68-B 110; A68-B 111; A68-B112; A68-B 113;
A68-B 114; A68-B 115; A68-B 116; A68-B 117; A68-B118; A68-B 119;
A68-B 120; A68-B 121; A68-B 122; A68-B 123; A68-B 124; A68-B 125;
A68-B 126; A68-B 127; A68-B 128; A68-B 129; A68-B 130; A68-B 131;
A68-B132; A68-B133; A68-B 134; A68-B 135; A68-B136; A68-B 137;
A68-B 138; A68-B 139; A68-B140; A68-B 141; A68-B142; A68-B 143;
A68-B 144; A68-B 145; A68-B146; A68-B 147; A68-B148; A68-B 149;
A68-B 150; A68-B 151; A68-B 152; A68-B 153; A68-B154; A68-B 155;
A68-B156; A68-B157; A68-B 158; A68-B 159; A68-B 160; A68-B 161;
A68-B 162; A68-B 163; A68-B 164; A68-B165; A68-B166; A68-B 167;
A68-B 168; A68-B 169; A69-B 1; A69-B2; A69-B3; A69-B4;
A69-B5; A69-B6; A69-B7; A69-B8; A69-B9; A69-B10;
A69-B 11; A69-B 12; A69-B 13; A69-B 14; A69-B 15; A69-B 16;
A69-B 17; A69-B 18; A69-B 19; A69-B20; A69-B21; A69-B22;
A69-B23; A69-B24; A69-B25; A69-B26; A69-B27; A69-B28;
A69-B29; A69-B30; A69-B31; A69-B32; A69-B33; A69-B34;
A69-B35; A69-B36; A69-B37; A69-B38; A69-B39; A69-B40;
A69-B41; A69-B42; A69-B43; A69-B44; A69-B45; A69-B46;
A69-B47; A69-B48; A69-B49; A69-B50; A69-B51; A69-B52;
A69-B53; A69-B54; A69-B55; A69-B56; A69-B57; A69-B58;
A69-B59; A69-B60; A69-B61; A69-B62; A69-B63; A69-B64;
A69-B65; A69-B66; A69-B67; A69-B68; A69-B69; A69-B70;
A69-B71; A69-B72; A69-B73; A69-B74; A69-B75; A69-B76;
A69-B77; A69-B78; A69-B79; A69-B80; A69-B81; A69-B82;
A69-B83; A69-B84; A69-B85; A69-B86; A69-B87; A69-B88;
A69-B89; A69-B90; A69-B91; A69-B92; A69-B93; A69-B94;
A69-B95; A69-B96; A69-B97; A69-B98; A69-B99; A69-B 100;
A69-B 101; A69-B 102; A69-B 103; A69-B104; A69-B 105; A69-B 106;
A69-B107; A69-B 108; A69-B 109; A69-B 110; A69-B 111; A69-B 112;
A69-B 113; A69-B 114; A69-B 115; A69-B 116; A69-B 117; A69-B 118;
A69-B 119; A69-B 120; A69-B 121; A69-B 122; A69-B 123; A69-B 124;
A69-B 125; A69-B 126; A69-B 127; A69-B 128; A69-B 129; A69-B130;
A69-B 13 1; A69-B 132; A69-B133; A69-B 134; A69-B 135; A69-B 136;
A69-B 137; A69-B 138; A69-B 139; A69-B 140; A69-B 141; A69-B 142;
A69-B 143; A69-B 144; A69-B 145; A69-B 146; A69-B 147; A69-B 148;
A69-B 149; A69-B 150; A69-B 151; A69-B 152; A69-B 153; A69-B 154;
A69-B 155; A69-B 156; A69-B 157; A69-B 158; A69-B 159; A69-B 160;
A69-B 161; A69-B 162; A69-B 163; A69-B 164; A69-B 165; A69-B 166;
A69-B 167; A69-B168; A69-B 169; A70-B 1; A70-B2; A70-B3;
A70-B4; A70-B5; A70-B6; A70-B7; A70-B8; A70-B9;
A70-B 10; A70-B 11; A70-B 12; A70-B 13; A70-B 14; A70-B 15;
A70-B 16; A70-B 17; A70-B 18; A70-B 19; A70-B20; A70-B21;
A70-B22; A70-B23; A70-B24; A70-B25; A70-B26; A70-B27;
A70-B28; A70-B29; A70-B30; A70-B31; A70-B32; A70-B33;
A70-B34; A70-B35; A70-B36; A70-B37; A70-B38; A70-B39;
A70-B40; A70-B41; A70-B42; A70-B43; A70-B44; A70-B45;
A70-B46; A70-B47;, A70-B48; A70-B49; A70-B50; A70-B51;
A70-B52; A70-B53; A70-B54; A70-B55; A70-B56; A70-B57;
A70-B58; A70-B59; A70-B60; A70-B61; A70-B62; A70-B63;
A70-B64; A70-B65; A70-B66; A70-B67; A70-B68; A70-B69;
A70-B70; A70-B71; A70-B72; A70-B73; A70-B74; A70-B75;
A70-B76; A70-B77; A70-B78; A70-B79; A70-B80; A70-B81;
A70-B82; A70-B83; A70-B84; A70-B85; A70-B86; A70-B87;
A70-B88; A70-B89; A70-B90; A70-B91; A70-B92; A70-B93;
A70-B94; A70-B95; A70-B96; A70-B97; A70-B98; A70-B99;
A70-B 100; A70-B 101; A70-B 102; A70-B 103; A70-B 104; A70-B 105;
A70-B 106; A70-B 107; A70-B 108; A70-B 109; A70-B 110; A70-B 111;
A70-B 112; A70-B 113; A70-B 114; A70-B 115; A70-B 116; A70-B 117;
A70-B 118; A70-B 119; A70-B120; A70-B 121; A70-B 122; A70-B 123;
A70-B 124; A70-B 125; A70-B126; A70-B 127; A70-B128; A70-B 129;
A70-B130; A70-B131; A70-B132; A70-B133; A70-B134; A70-B135;
A70-B 136; . A70-B137; A70-B138; A70-B 139; A70-B 140; A70-B141;
A70-B 142; A70-B 143; A70-B144; A70-B 145; A70-B146; A70-B 147;
A70-B 148; A70-B149; A70-B150; A70-B 151; A70-B 152; A70-B153;
A70-B 154; A70-B155; A70-B156; A70-B157; A70-B158; A70-B 159;
A70-B 160; A70-B 161; A70-B 162; A70-B 163; A70-B 164; A70-B 165;
A70-B 166; A70-B 167; A70-B168; A70-B 169; A71-B 1; A71-B2;
A71-B3; A71-B4; A71-B5; A71-B6; A71-B7; A71-B8;
A71-B9; A71-B10; A71-B11; A71-B12; A71-B13; A71-B14;
A71-B15; A71-B16; A71-B17; A71-B18; A71-B19; A71-B20;
A71-B21; A71-B22; A71-B23; A71-B24; A71-B25; A71-B26;
A71-B27; A71-B28; A71-B29; A71-B30; A71-B31; A71-B32;
A71-B33; A71-B34; A71-B35; A71-B36; A71-B37; A71-B38;
A71-B39; A71-B40; A71-B41; A71-B42; A71-B43; A71-B44;
A71-B45; A71-B46; A71-B47; A71-B48; A71-B49; A71-B50;
A71-B51; A71-B52; A71-B53; A71-B54; A71-B55; A71-B56;
A71-B57; A71-B58; A71-B59; A71-B60; A71-B61; A71-B62;
A71-B63; A71-B64; A71-B65; A71-B66; A71-B67; A71-B68;
A71-B69; A71-B70; A71-B71; A71-B72; A71-B73; A71-B74;
A71-B75; A71-B76; A71-B77; A71-B78; A71-B79; A71-B80;
A71-B81; A71-B82; A71-B83; A71-B84; A71-B85; A71-B86;
A71-B87; A71-B88; A71-B89; A71-B90; A71-B91; A71-B92;
A71-B93; A71-B94; A71-B95; A71-B96; A71-B97; A71-B98;
A71-B99; A71-B100; A71-B101; A71-B102; A71-B103; A71-B104;
A71-B105; A71-B106; A71-B107; A71-B108; A71-B109; A71-B110;
A71-B111; A71-B112; A71-B113; A71-B114; A71-B115; A71-B116;
A71-B117; A71-B118; A71-B119; A71-B120; A71-B121; A71-B122;
A71-B123; A71-B124; A71-B125; A71-B126; A71-B127; A71-B128;
A71-B129; A71-B130; A71-B131; A71-B132; A71-B133; A71-B134;
A71-B135; A71-B136; A71-B137; A71-B138; A71-B139; A71-B140;
A71-B141; A71-B142; A71-B143; A71-B144; A71-B145; A71-B146;
A71-B147; A71-B148; A71-B149; A71-B150; A71-B151; A71-B152;
A71-B153; A71-B154; A71-B155; A71-B156; A71-B157; A71-B158;
A71-B159; A71-B160; A71-B161; A71-B162; A71-B163; A71-B164;
A71-B165; A71-B166; A71-B167; A71-B168; A71-B169; A72-B1;
A72-B2; A72-B3; A72-B4; A72-B5; A72-B6; A72-B7;
A72-B8; A72-B9; A72-B 10; A72-B 11; A72-B12; A72-B 13;
A72-B 14; A72-B 15; A72-B 16; A72-B 17; A72-B 18; A72-B 19;
A72-B20; A72-B21; A72-B22; A72-B23; A72-B24; A72-B25;
A72-B26; A72-B27; A72-B28; A72-B29; A72-B30; A72-B31;
A72-B32; A72-B33; A72-B34; A72-B35; A72-B36; A72-B37;
A72-B38; A72-B39; A72-B40; A72-B41; A72-B42; A72-B43;
A72-B44; A72-B45; A72-B46; A72-B47; A72-B48; A72-B49;
A72-B50; A72-B51; A72-B52; A72-B53; A72-B54; A72-B55;
A72-B56; A72-B57; A72-B58; A72-B59; A72-B60; A72-B61;
A72-B62; A72-B63; A72-B64; A72-B65; A72-B66; A72-B67;
A72-B68; A72-B69; A72-B70; A72-B71; A72-B72; A72-B73;
A72-B74; A72-B75; A72-B76; A72-B77; A72-B78; A72-B79;
A72-B80; A72-B81; A72-B82; A72-B83; A72-B84; A72-B85;
A72-B86; A72-B87; A72-B88; A72-B89; A72-B90; A72-B91;
A72-B92; A72-B93; A72-B94; A72-B95; A72-B96; A72-B97;
A72-B98; A72-B99; A72-B 100; A72-B 101; A72-B 102; A72-B 103;
A72-B 104; A72-B 105; A72-B 106; A72-B 107; A72-B108; A72-B 109;
A72-B 110; A72-B 111; A72-B 112; A72-B 113; A72-B 114; A72-B 115;
A72-B 116; A72-B 117; A72-B 118; A72-B 119; A72-B 120; A72-B 121;
A72-B 122; A72-B 123; A72-B 124; A72-B 125; A72-B 126; A72-B 127;
A72-B128; A72-B 129; A72-B 130; A72-B 131; A72-B 132; A72-B133;
A72-B 134; A72-B 135; A72-B 136; A72-B 137; A72-B 138; A72-B 139;
A72-B 140; A72-B 141; A72-B 142; A72-B 143; A72-B 144; A72-B 145;
A72-B 146; A72-B 147; A72-B 148; A72-B 149; A72-B150; A72-B 151;
A72-B 152; A72-B 153; A72-B 154; A72-B 155; A72-B 156; A72-B157;
A72-B158; A72-B 159; A72-B 160; A72-B 161; A72-B 162; A72-B 163;
A72-B 164; A72-B 165; A72-B 166; A72-B 167; A72-B 168; A72-B 169;
A73-B1; A73-B2; A73-B3; A73-B4; A73-B5; A73-B6;
A73-B7; A73-B8; A73-B9; A73-B10; A73-B11; A73-B12;
A73-B13; A73-B 14; A73-B 15; A73-B 16; A73-B 17; A73-B 18;
A73-B19; A73-B20; A73-B21; A73-B22; A73-B23; A73-B24;
A73-B25; A73-B26; A73-B27; A73-B28; A73-B29; A73-B30;
A73-B31; A73-B32; A73-B33; A73-B34; A73-B35; A73-B36;
A73-B37; A73-B38; A73-B39; A73-B40; A73-B41; A73-B42;
A73-B43; A73-B44; A73-B45; A73-B46; A73-B47; A73-B48;
A73-B49; A73-B50; A73-B51; A73-B52; A73-B53; A73-B54;
A73-B55; A73-B56; A73-B57; A73-B58; A73-B59; A73-B60;
A73-B61; A73-B62; A73-B63; A73-B64; A73-B65; A73-B66;
A73-B67; A73-B68; A73-B69; A73-B70; A73-B71; A73-B72;
A73-B73; A73-B74; A73-B75; A73-B76; A73-B77; A73-B78;
A73-B79; A73-B80; A73-B81; A73-B82; A73-B83; A73-B84;
A73-B85; A73-B86; A73-B87; A73-B88; A73-B89; A73-B90;
A73-B91; A73-B92; A73-B93; A73-B94; A73-B95; A73-B96;
A73-B97; A73-B98; A73-B99; A73-B100; A73-B101; A73-B102;
A73-B 103; A73-B104; A73-B 105; A73-B 106; A73-B 107; A73-B108;
A73-B 109; A73-B 110; A73-B 111; A73-B 112; A73-B 113; A73-B114;
A73-B 115; A73-B 116; A73-B 117; A73-B118; A73-B 119; A73-B 120;
A73-B 121; A73-B 122; A73-B123; A73-B 124; A73-B125; A73-B 126;
A73-B 127; A73-B 128; A73-B129; A73-B130; A73-B 131; A73-B132;
A73-B 133; A73-B134; A73-B135; A73-B 136; A73-B 137; A73-B 138;
A73-B139; A73-B 140; A73-B141; A73-B 142; A73-B 143; A73-B 144;
A73-B 145; A73-B 146; A73-B 147; A73-B 148; A73-B 149; A73-B 150;
A73-B151; A73-B152; A73-B153; A73-B154; A73-B155; A73-B156;
A73-B157; A73-B158; A73-B159; A73-B160; A73-B161; A73-B162;
A73-B 163; A73-B 164; A73-B 165; A73-B 166; A73-B 167; A73-B 168;
A73-B169; A74-B1; A74-B2; A74-B3; A74-B4; A74-B5;
A74-B6; A74-B7; A74-B8; A74-B9; A74-B 10; A74-B 11;
A74-B 12; A74-B 13; A74-B 14; A74-B 15; A74-B 16; A74-B 17;
A74-B 18; A74-B 19; A74-B20; A74-B21; A74-B22; A74-B23;
A74-B24; A74-B25; A74-B26; A74-B27; A74-B28; A74-B29;
A74-B30; A74-B31; A74-B32; A74-B33; A74-B34; A74-B35;
A74-B36; A74-B37; A74-B38; A74-B39; A74-B40; A74-B41;
A74-B42; A74-B43; A74-B44; A74-B45; A74-B46; A74-B47;
A74-B48; A74-B49; A74-B50; A74-B51; A74-B52; A74-B53;
A74-B54; A74-B55; A74-B56; A74-B57; A74-B58; A74-B59;
A74-B60; A74-B61; A74-B62; A74-B63; A74-B64; A74-B65;
A74-B66; A74-B67; A74-B68; A74-B69; A74-B70; A74-B71;
A74-B72; A74-B73; A74-B74; A74-B75; 'A74-B76; A74-B77;
A74-B78; A74-B79; A74-B80; A74-B81; A74-B82; A74-B83;
A74-B84; A74-B85; A74-B86; A74-B87; A74-B88; A74-B89;
A74-B90; A74-B91; A74-B92; A74-B93; A74-B94; A74-B95;
A74-B96; A74-B97; A74-B98; A74-B99; A74-B100; A74-B101;
A74-B 102; A74-B 103; A74-B 104; A74-B 105; A74-B 106; A74-B 107;
A74-B 108; A74-B109; A74-B 110; A74-B 111; A74-B 112; A74-B 113;
A74-B 114; A74-B 115; A74-B 116; A74-B 117; A74-B 118; A74-B 119;
A74-B 120; A74-B 121; A74-B 122; A74-B 123; A74-B 124; A74-B 125;
A74-B 126; A74-B 127; A74-B 128; A74-B 129; A74-B130; A74-B 131;
A74-B 132; A74-B133; A74-B 134; A74-B135; A74-B 136; A74-B137;
A74-B138; A74-B139; A74-B 140; A74-B 141; A74-B 142; A74-B143;
A74-B 144; A74-B 145; A74-B 146; A74-B 147; A74-B 148; A74-B 149;
A74-B 150; A74-B 151; A74-B 152; A74-B153; A74-B 154; A74-B 155;
A74-B 156; A74-B 157; A74-B 15 8; A74-B 159; A74-B 160; A74-B 161;
A74-B 162; A74-B 163; A74-B 164; A74-B 165; A74-B 166; A74-B 167;
A74-B 168; A74-B 169; A75-B 1; A75-B2; A75-B3; A75-B4;
A75-B5; A75-B6; A75-B7; A75-B8; A75-B9; A75-B10;
A75-B 11; A75-B 12; A75-B13; A75-B 14; A75-B 15; A75-B16;
A75-B 17; A75-B18; A75-B 19; A75-B20; A75-B21; A75-B22;
A75-B23; A75-B24; A75-B25; A75-B26; A75-B27; A75-B28;
A75-B29; A75-B30; A75-B31; A75-B32; A75-B33; A75-B34;
A75-B35; A75-B36; A75-B37; A75-B38; A75-B39; A75-B40;
A75-B41; A75-B42; A75-B43; A75-B44; A75-B45; A75-B46;
A75-B47; A75-B48; A75-B49; A75-B50; A75-B51; A75-B52;
A75-B53; A75-B54; A75-B55; A75-B56; A75-B57; A75-B58;
A75-B59; A75-B60; A75-B61; A75-B62; A75-B63; A75-B64;
A75-B65; A75-B66; A75-B67; A75-B68; A75-B69; A75-B70;
A75-B71; A75-B72; A75-B73; A75-B74; A75-B75; A75-B76;
A75-B77; A75-B78; A75-B79; A75-B80; A75-B81; A75-B82;
A75-B83; A75-B84; A75-B85; A75-B86; A75-B87; A75-B88;
A75-B89; A75-B90; A75-B91; A75-B92; A75-B93; A75-B94;
A75-B95; A75-B96; A75-B97; A75-B98; A75-B99; A75-B100;
A75-B 101; A75-B 102; A75-B 103; A75-B 104; A75-B 105; A75-B 106;
A75-B 107; A75-B 108; A75-B109; A75-B110; A75-B 111; A75-B 112;
A75-B 113; A75-B 114; A75-B115; A75-B 116; A75-B117; A75-B118;
A75-B119; A75-B120; A75-B121; A75-B122; A75-B123; A75-B124;
A75-B 125; A75-B 126; A75-B 127; A75-B 128; A75-B 129; A75-B 130;
A75-B131; A75-B132; A75-B133; A75-B134; A75-B135; A75-B136;
A75-B137; A75-B138; A75-B139; A75-B140; A75-B141; A75-B142;
A75-B 143; A75-B 144; A75-B 145; A75-B 146; A75-B 147; A75-B 148;
A75-B 149; A75-B 150; A75-B 151; A75-B152; A75-B 153; A75-B 154;
A75-B155; A75-B156; A75-B157; A75-B158; A75-B159; A75-B160;
A75-B 161; A75-B 162; A75-B163; A75-B 164; A75-B 165; A75-B 166;
A75-B167; A75-B168; A75-B169; A76-B1; A76-B2; A76-B3;
A76-B4; A76-B5; A76-B6; A76-B7; A76-B8; A76-B9;
A76-B 10; A76-B 11; A76-B12; A76-B 13; A76-B 14; A76-B 15;
A76-B 16; A76-B 17; A76-B 18; A76-B 19; A76-B20; A76-B21;
A76-B22; A76-B23; A76-B24; A76-B25; A76-B26; A76-B27;
A76-B28; A76-B29; A76-B30; A76-B31; A76-B32; A76-B33;
A76-B34; A76-B35; A76-B36; A76-B37; A76-B38; A76-B39;
A76-B40; A76-B41; A76-B42; A76-B43; A76-B44; A76-B45;
A76-B46; A76-B47; A76-B48; A76-B49; A76-B50; A76-B51;
A76-B52; A76-B53; A76-B54; A76-B55; A76-B56; A76-B57;
A76-B58; A76-B59; A76-B60; A76-B61; A76-B62; A76-B63;
A76-B64; A76-B65; A76-B66; A76-B67; A76-B68; A76-B69;
A76-B70; A76-B71; A76-B72; A76-B73; A76-B74; A76-B75;
A76-B76; A76-B77; A76-B78; A76-B79; A76-B80; A76-B81;
A76-B82; A76-B83; A76-B84; A76-B85; A76-B86; A76-B87;
A76-B88; A76-B89; A76-B90; A76-B91; A76-B92; A76-B93;
A76-B94; A76-B95; A76-B96; A76-B97; A76-B98; A76-B99;
A76-B 100; A76-B 101; A76-B 102; A76-B 103; A76-B 104; A76-B 105;
A76-B106; A76-B107; A76-B 108; A76-B109; A76-B 110; A76-B 111;
A76-B 112; A76-B 113; A76-B 114; A76-B 115; A76-B 116; A76-B 117;
A76-B 118; A76-B 119; A76-B 120; A76-B 121; A76-B 122; A76-B 123;
A76-B 124; A76-B 125; A76-B126; A76-B 127; A76-B128; A76-B 129;
A76-B 130; A76-B 131; A76-B 132; A76-B 133; A76-B 134; A76-B 135;
A76-B 136; A76-B 137; A76-B 138; A76-B 139; A76-B140; A76-B 141;
A76-B142; A76-B 143; A76-B 144; A76-B 145; A76-B 146; A76-B 147;
A76-B 148; A76-B 149; A76-B 150; A76-B 151; A76-B 152; A76-B 153;
A76-B 154; A76-B 155; A76-B 156; A76-B 157; A76-B 158; A76-B 159;
A76-B 160; A76-B 161; A76-B162; A76-B 163; A76-B 164; A76-B 165;
A76-B 166; A76-B 167; A76-B 168; A76-B169; A77-B 1; A77-B2;
A77-B3; A77-B4; A77-B5; A77-B6; A77-B7; A77-B8;
A77-B9; A77-B 10; A77-B 11; A77-B 12; A77-B 13; A77-B 14;
A77-B 15; A77-B 16; A77-B17; A77-B 18; A77-B 19; A77-B20;
A77-B21; A77-B22; A77-B23; A77-B24; A77-B25; A77-B26;
A77-B27; A77-B28; A77-B29; A77-B30; A77-B31; A77-B32;
A77-B33; A77-B34; A77-B35; A77-B36; A77-B37; A77-B38;
A77-B39; A77-B40; A77-B41; A77-B42; A77-B43; A77-B44;
A77-B45; A77-B46; A77-B47; A77-B48; A77-B49; A77-B50;
A77-B51; A77-B52; A77-B53; A77-B54; A77-B55; A77-B56;
A77-B57; A77-B58; A77-B59; A77-B60; A77-B61; A77-B62;
A77-B63; A77-B64; A77-B65; A77-B66; A77-B67; A77-B68;
A77-B69; A77-B70; A77-B71; A77-B72; A77-B73; A77-B74;
A77-B75; A77-B76; A77-B77; A77-B78; A77-B79; A77-B80;
A77-B81; A77-B82; A77-B83; A77-B84; A77-B85; A77-B86;
A77-B87; A77-B88; A77-B89; A77-B90; A77-B91; A77-B92;
A77-B93; A77-B94; A77-B95; A77-B96; A77-B97; A77-B98;
A77-B99; A77-B 100; A77-B 101; A77-B 102; A77-B 103; A77-B 104;
A77-B 105; A77-B 106; A77-B 107; A77-B 108; A77-B 109; A77-B 110;
A77-B 111; A77-B 112; A77-B 113; A77-B 114; A77-B 115; A77-B 116;
A77-B 117; A77-B 118; A77-B 119; A77-B 120; A77-B 121; A77-B 122;
A77-B 123; A77-B 124; A77-B 125; A77-B 126; A77-B 127; A77-B128;
A77-B 129; A77-B 130; A77-B 131; A77-B 132; A77-B 133; A77-B 134;
A77-B 135; A77-B 136; A77-B 137; A77-B 138; A77-B 139; A77-B 140;
A77-B 141; A77-B 142; A77-B 143; A77-B 144; A77-B 145; A77-B 146;
A77-B 147; A77-B 148; A77-B 149; A77-B 150; A77-B 151; A77-B 152;
A77-B 153; A77-B 154; A77-B 155; A77-B156; A77-B 157; A77-B 158;
A77-B 159; A77-B 160; A77-B 161; A77-B 162; A77-B 163; A77-B 164;
A77-B165; A77-B 166; A77-B 167; A77-B168; A77-B 169; A78-B 1;
A78-B2; A78-B3; A78-B4; A78-B5; A78-B6; A78-B7;
A78-B8; A78-B9; A78-B10; A78-B11; A78-B12; A78-B13;
A78-B14; A78-B15; A78-B16; A78-B17; A78-B18; A78-B19;
A78-B20; A78-B21; A78-B22; A78-B23; A78-B24; A78-B25;
A78-B26; A78-B27; A78-B28; A78-B29; A78-B30; A78-B31;
A78-B32; A78-B33; A78-B34; A78-B35; A78-B36; A78-B37;
A78-B38; A78-B39; A78-B40; A78-B41; A78-B42; A78-B43;
A78-B44; A78-B45; A78-B46; A78-B47; A78-B48; A78-B49;
A78-B50; A78-B51; A78-B52; A78-B53; A78-B54; A78-B55;
A78-B56; A78-B57; A78-B58; A78-B59; A78-B60; A78-B61;
A78-B62; A78-B63; A78-B64; A78-B65; A78-B66; A78-B67;
A78-B68; A78-B69; A78-B70; A78-B71; A78-B72; A78-B73;
A78-B74; A78-B75; A78-B76; A78-B77; A78-B78; A78-B79;
A78-B80; A78-B81; A78-B82; A78-B83; A78-B84; A78-B85;
A78-B86; A78-B87; A78-B88; A78-B89; A78-B90; A78-B91;
A78-B92; A78-B93; A78-B94; A78-B95; A78-B96; A78-B97;
A78-B98; A78-B99; A78-B100; A78-B101; A78-B102; A78-B103;
A78-B 104; A78-B 105; A78-B 106; A78-B 107; A78-B 108; A78-B 109;
A78-B 110; A78-B 111; A78-B 112; A78-B 113; A78-B 114; A78-B 115;
A78-B116; A78-B 117; A78-B118; A78-B 119; A78-B120; A78-B121;
A78-B122; A78-B 123; A78-B 124; A78-B125; A78-B 126; A78-B127;
A78-B128; A78-B 129; A78-B 130; A78-B 131; A78-B 132; A78-B 133;
A78-B134; A78-B135; A78-B136; A78-B137; A78-B138; A78-B139;
A78-B 140; A78-B141; A78-B142; A78-B 143; A78-B 144; A78-B 145;
A78-B 146; A78-B 147; A78-B 148; A78-B 149; A78-B150; A78-B 151;
A78-B 152; A78-B 153; A78-B154; A78-B 155; A78-B156; A78-B 157;
A78-B 158; A78-B 159; A78-B 160; A78-B 161; A78-B 162; A78-B 163;
A78-B 164; A78-B 165; A78-B 166; A78-B 167; A78-B 168; A78-B 169;
A79-Bl; A79-B2; A79-B3; A79-B4; A79-B5; A79-B6;
A79-B7; A79-B8; A79-B9; A79-B 10; A79-B 11; A79-B 12;
A79-B 13; A79-B 14; A79-B 15; A79-B 16; A79-B 17; A79-B 18;
A79-B19; A79-B20; A79-B21; A79-B22; A79-B23; A79-B24;
A79-B25; A79-B26; A79-B27; A79-B28; A79-B29; A79-B30;
A79-B31; A79-B32; A79-B33; A79-B34; A79-B35; A79-B36;
A79-B37; A79-B38; A79-B39; A79-B40; A79-B41; A79-B42;
A79-B43; A79-B44; A79-B45; A79-B46; A79-B47; A79-B48;
A79-B49; A79-B50; A79-B51; A79-B52; A79-B53; A79-B54;
A79-B55; A79-B56; A79-B57; A79-B58; A79-B59; A79-B60;
A79-B61; A79-B62; A79-B63; A79-B64; A79-B65; A79-B66;
A79-B67; A79-B68; A79-B69; A79-B70; A79-B71; A79-B72;
A79-B73; A79-B74; A79-B75; A79-B76; A79-B77; A79-B78;
A79-B79; A79-B80; A79-B81; A79-B82; A79-B83; A79-B84;
A79-B85; A79-B86; A79-B87; A79-B88; A79-B89; A79-B90;
A79-B91; A79-B92; A79-B93; A79-B94; A79-B95; A79-B96;
A79-B97; A79-B98; A79-B99; A79-B100; A79-B101; A79-B102;
A79-B 103; A79-B104; A79-B105; A79-B106; A79-B 107; A79-B 108;
A79-B 109; A79-B 110; A79-B 111; A79-B 112; A79-B 113; A79-B 114;
A79-B 115; A79-B 116; A79-B 117; A79-B 118; A79-B 119; A79-B 120;
A79-B 121; A79-B 122; A79-B 123; A79-B 124; A79-B 125; A79-B 126;
A79-B 127; A79-B 128; A79-B 129; A79-B 130; A79-B 131; A79-B 132;
A79-B133; A79-B134; A79-B135; A79-B136; A79-B137; A79-B138;
A79-B 139; A79-B 140; A79-B 141; A79-B 142; A79-B 143; A79-B 144;
A79-B 145; A79-B 146; A79-B 147; A79-B 148; A79-B 149; A79-B150;
A79-B 151; A79-B 152; A79-B 153; A79-B 154; A79-B 155; A79-B 156;
A79-B 157; A79-B 158; A79-B 159; A79-B 160; A79-B 161; A79-B 162;
A79-B 163; A79-B 164; A79-B 165; A79-B 166; A79-B 167; A79-B 168;
A79-B169; A80-B1; A80-B2; A80-B3; A80-B4; A80-B5;
A80-B6; A80-B7; A80-B8; A80-B9; A80-B10; A80-B11;
A80-B 12; A80-B 13; A80-B 14; A80-B 15; A80-B 16; A80-B 17;
A80-B 18; A80-B 19; A80-B20; A80-B21; A80-B22; A80-B23;
A80-B24; A80-B25; A80-B26; A80-B27; A80-B28; A80-B29;
A80-B30; A80-B31; A80-B32; A80-B33; A80-B34; A80-B35;
A80-B36; A80-B37; A80-B38; A80-B39; A80-B40; A80-B41;
A80-B42; A80-B43; A80-B44; A80-B45; A80-B46; A80-B47;
A80-B48; A80-B49; A80-B50; A80-B51; A80-B52; A80-B53;
A80-B54; A80-B55; A80-B56; A80-B57; A80-B58; A80-B59;
A80-B60; A80-B61; A80-B62; A80-B63; A80-B64; A80-B65;
A80-B66; A80-B67; A80-B68; A80-B69; A80-B70; A80-B71;
A80-B72; A80-B73; A80-B74; A80-B75; A80-B76; A80-B77;
A80-B78; A80-B79; A80-B80; A80-B81; A80-B82; A80-B83;
A80-B84; A80-B85; A80-B86; A80-B87; A80-B88; A80-B89;
A80-B90; A80-B91; A80-B92; A80-B93; A80-B94; A80-B95;
A80-B96; A80-B97; A80-B98; A80-B99; A80-B 100; A80-B 101;
A80-B 102; A80-B 103; A80-B 104; A80-B 105; A80-B 106; A80-B 107;
A80-B 108; A80-B 109; A80-B 110; A80-B 11 l; A80-B 112; A80-B 113;
A80-B 114; A80-B 115; A80-B 116; A80-B 117; A80-B 118; A80-B 119;
A80-B 120; A80-B 121; A80-B 122; A80-B 123; A80-B 124; A80-B 125;
A80-B 126; A80-B 127; A80-B128; A80-B 129; A80-B130; A80-B 13 1;
A80-B 132; A80-B 133; A80-B 134; A80-B 135; A80-B 136; A80-B 137;
A80-B 138; A80-B139; A80-B 140; A80-B 141; A80-B 142; A80-B 143;
A80-B 144; A80-B 145; A80-B 146; A80-B 147; A80-B 148; A80-B 149;
A80-B 150; A80-B 151; A80-B152; A80-B 153; A80-B 154; A80-B155;
A80-B156; A80-B 157; A80-B158; A80-B 159; A80-B 160; A80-B 161;
A80-B 162; A80-B 163; A80-B 164; A80-B 165; A80-B 166; A80-B 167;
A80-B 168; A80-B 169; A81-B 1; A81-B2; A81-B3; A81-B4;
A81-B5; A81-B6; A81-B7; A81-B8; A81-B9; A81-B10;
A81-B11; A81-B12; A81-B13; A81-B14; A81-B15; A81-B16;
A81-B17; A81-B18; A81-B19; A81-B20; A81-B21; A81-B22;
A81-B23; A81-B24; A81-B25; A81-B26; A81-B27; A81-B28;
A81-B29; A81-B30; A81-B31; A81-B32; A81-B33; A81-B34;
A81-B35; A81-B36; A81-B37; A81-B38; A81-B39; A81-B40;
A81-B41; A81-B42; A81-B43; A81-B44; A81-B45; A81-B46;
A81-B47; A81-B48; A81-B49; A81-B50; A81-B51; A81-B52;
A81-B53; A81-B54; A81-B55; A81-B56; A81-B57; A81-B58;
A81-B59; A81-B60; A81-B61; A81-B62; A81-B63; A81-B64;
A81-B65; A81-B66; A81-B67; A81-B68; A81-B69; A81-B70;
A81-B71; A81-B72; A81-B73; A81-B74; A81-B75; A81-B76;
A81-B77; A81-B78; A81-B79; A81-B80; A81-B81; A81-B82;
A81-B83; A81-B84; A81-B85; A81-B86; A81-B87; A81-B88;
A81-B89; A81-B90; A81-B91; A81-B92; A81-B93; A81-B94;
A81-B95; A81-B96; A81-B97; A81-B98; A81-B99; A81-B100;
A81-B101; A81-B102; A81-B103; A81-B104; A81-B105; A81-B106;
A81-B107; A81-B108; A81-B109; A81-B110; A81-B111; A81-B112;
A81-B113; A81-B114; A81-B115; A81-B116; A81-B117; A81-B118;
A81-B119; A81-B120; A81-B121; A81-B122; A81-B123; A81-B124;
A81-B125; A81-B126; A81-B127; A81-B128; A81-B129; A81-B130;
A81-B131; A81-B132; A81-B133; A81-B134; A81-B135; A81-B136;
A81-B 137; A81-B138; A81-B 139; A81-B 140; A81-B 141; A81-B 142;
A81-B143; A81-B144; A81-B145; A81-B146; A81-B147; A81-B148;
A81-B149; A81-B150; A81-B151; A81-B152; A81-B153; A81-B154;
A81-B155; A81-B156; A81-B157; A81-B158; A81-B159; A81-B160;
A81-B161; A81-B162; A81-B163; A81-B164; A81-B165; A81-B166;
A81-B167; A81-B168; A81-B169; A82-B1; A82-B2; A82-B3;
A82-B4; A82-B5; A82-B6; A82-B7; A82-B8; A82-B9;
A82-B 10; A82-B 11; A82-B12; A82-B 13; A82-B 14; A82-B15;
A82-B 16; A82-B 17; A82-B18; A82-B 19; A82-B20; A82-B21;
A82-B22; A82-B23; A82-B24; A82-B25; A82-B26; A82-B27;
A82-B28; A82-B29; A82-B30; A82-B31; A82-B32; A82-B33;
A82-B34; A82-B35; A82-B36; A82-B37; A82-B38; A82-B39;
A82-B40; A82-B41; A82-B42; A82-B43; A82-B44; A82-B45;
A82-B46; A82-B47; A82-B48; A82-B49; A82-B50; A82-B51;
A82-B52; A82-B53; A82-B54; A82-B55; A82-B56; A82-B57;
A82-B58; A82-B59; A82-B60; A82-B61; A82-B62; A82-B63;
A82-B64; A82-B65; A82-B66; A82-B67; A82-B68; A82-B69;
A82-B70; A82-B71; A82-B72; A82-B73; A82-B74; A82-B75;
A82-B76; A82-B77; A82-B78; A82-B79; A82-B80; A82-B81;
A82-B82; A82-B83; A82-B84; A82-B85; A82-B86; A82-B87;
A82-B88; A82-B89; A82-B90; A82-B91; A82-B92; A82-B93;
A82-B94; A82-B95; A82-B96; A82-B97; A82-B98; A82-B99;
A82-B 100; A82-B 101; A82-B 102; A82-B 103; A82-B 104; A82-B 105;
A82-B 106; A82-B 107; A82-B 108; A82-B 109; A82-B 110; A82-B 111;
A82-B 112; A82-B 113; A82-B 114; A82-B 115; A82-B 116; A82-B 117;
A82-B 118; A82-B 119; A82-B 120; A82-B 121; A82-B 122; A82-B 123;
A82-B124; A82-B 125; A82-B 126; A82-B 127; A82-B 128; A82-B129;
A82-B 130; A82-B 13 1; A82-B 132; A82-B 133; A82-B 134; A82-B 135;
A82-B 136; A82-B 137; A82-B 13 8; A82-B139; A82-B 140; A82-B 141;
A82-B 142; A82-B 143; A82-B 144; A82-B 145; A82-B 146; A82-B 147;
A82-B 148; A82-B149; A82-B 150; A82-B 151; A82-B 152; A82-B 153;
A82-B 154; A82-B 155; A82-B 156; A82-B 157; A82-B 158; A82-B 159;
A82-B 160; A82-B 161; A82-B 162; A82-B 163; A82-B 164; A82-B 165;
A82-B 166; A82-B 167; A82-B 168; A82-B 169; A83-B 1; A83-B2;
A83-B3; A83-B4; A83-B5; A83-B6; A83-B7; A83-B8;
A83-B9; A83-B 10; A83-B 11; A83-B 12; A83-B 13; A83-B 14;
A83-B 15; A83-B 16; A83-B 17; A83-B 18; A83-B19; A83-B20;
A83-B21; A83-B22; A83-B23; A83-B24; A83-B25; A83-B26;
A83-B27; A83-B28; A83-B29; A83-B30; A83-B31; A83-B32;
A83-B33; A83-B34; A83-B35; A83-B36; A83-B37; A83-B38;
A83-B39; A83-B40; A83-B41; A83-B42; A83-B43; A83-B44;
A83-B45; A83-B46; A83-B47; A83-B48; A83-B49; A83-B50;
A83-B51; A83-B52; A83-B53; A83-B54; A83-B55; A83-B56;
A83-B57; A83-B58; A83-B59; A83-B60; A83-B61; A83-B62;
A83-B63; A83-B64; A83-B65; A83-B66; A83-B67; A83-B68;
A83-B69; A83-B70; A83-B71; A83-B72; A83-B73; A83-B74;
A83-B75; A83-B76; A83-B77; A83-B78; A83-B79; A83-B80;
A83-B81; A83-B82; A83-B83; A83-B84; A83-B85; A83-B86;
A83-B87; A83-B88; A83-B89; A83-B90; A83-B91; A83-B92;
A83-B93; A83-B94; A83-B95; A83-B96; A83-B97; A83-B98;
A83-B99; A83-B100; A83-B101; A83-B102; A83-B103; A83-B104;
A83-B 105; A83-B 106; A83-B 107; A83-B 108; A83-B 109; A83-B 110;
A83-B 111; A83-B 112; A83-B 113; A83-B 114; A83-B115; A83-B 116;
A83-B 117; A83-B 118; A83-B 119; A83-B 120; A83-B 121; A83-B 122;
A83-B 123; A83-B 124; A83-B 125; A83-B 126; A83-B 127; A83-B 128;
A83-B 129; A83-B 130; A83-B 131; A83-B 132; A83-B 133; A83-B 134;
A83-B135; A83-B136; A83-B137; A83-B138; A83-B139; A83-B140;
A83-B141; A83-B 142; A83-B 143; A83-B 144; A83-B145; A83-B 146;
A83-B 147; A83-B148; A83-B 149; A83-B 150; A83-B 151; A83-B 152;
A83-B153; A83-B154; A83-B155; A83-B156; A83-B157; A83-B158;
A83-B 159; A83-B 160; A83-B161; A83-B 162; A83-B 163; A83-B 164;
A83-B 165; A83-B 166; A83-B167; A83-B 168; A83-B169; A84-B 1;
A84-B2; A84-B3; A84-B4; A84-B5; A84-B6; A84-B7;
A84-B8; A84-B9; A84-B 10; A84-B 11; A84-B 12; A84-B 13;
A84-B 14; A84-B 15; A84-B 16; A84-B 17; A84-B 18; A84-B 19;
A84-B20; A84-B21; A84-B22; A84-B23; A84-B24; A84-B25;
A84-B26; A84-B27; A84-B28; A84-B29; A84-B30; A84-B31;
A84-B32; A84-B33; A84-B34; A84-B35; A84-B36; A84-B37;
A84-B38; A84-B39; A84-B40; A84-B41; A84-B42; A84-B43;
A84-B44; A84-B45; A84-B46; A84-B47; A84-B48; A84-B49;
A84-B50; A84-B51; A84-B52; A84-B53; A84-B54; A84-B55;
A84-B56; A84-B57; A84-B58; A84-B59; A84-B60; A84-B61;
A84-B62; A84-B63; A84-B64; A84-B65; A84-B66; A84-B67;
A84-B68; A84-B69; A84-B70; A84-B71; A84-B72; A84-B73;
A84-B74; A84-B75; A84-B76; A84-B77; A84-B78; A84-B79;
A84-B80; A84-B81; A84-B82; A84-B83; A84-B84; A84-B85;
A84-B86; A84-B87; A84-B88; A84-B89; A84-B90; A84-B91;
A84-B92; A84-B93; A84-B94; A84-B95; A84-B96; A84-B97;
A84-B98; A84-B99; A84-B100; A84-B101; A84-B102; A84-B103;
A84-B 104; A84-B 105; A84-B 106; A84-B 107; A84-B 108; A84-B 109;
A84-B 110; A84-B 111; A84-B 112; A84-B 113; A84-B 114; A84-B 115;
A84-B 116; A84-B 117; A84-B 118; A84-B 119; A84-B 120; A84-B 121;
A84-B 122; A84-B 123; A84-B 124; A84-B 125; A84-B 126; A84-B 127;
A84-B 128; A84-B 129; A84-B 130; A84-B 13 1; A84-B132; A84-B 133;
A84-B 134; A84-B 13 5; A84-B 136; A84-B 137; A84-B 13 8; A84-B 139;
A84-B 140; A84-B 141; A84-B 142; A84-B 143; A84-B 144; A84-B 145;
A84-B 146; A84-B 147; A84-B 148; A84-B149; A84-B 150; A84-B 151;
A84-B 152; A84-B 153; A84-B 154; A84-B 155; A84-B 156; A84-B157;
A84-B 158; A84-B 159; A84-B 160; A84-B 161; A84-B 162; A84-B 163;
A84-B 164; A84-B 165; A84-B 166; A84-B 167; A84-B 168; A84-B 169;
A85-B 1; A85-B2; A85-B3; A85-B4; A85-B5; A85-B6;
A85-B7; A85-B8; A85-B9; A85-B10; A85-B11; A85-B12;
A85-B 13; A85-B14; A85-B 15; A85-B 16; A85-B 17; A85-B 18;
A85-B19; A85-B20; A85-B21; A85-B22; A85-B23; A85-B24;
A85-B25; A85-B26; A85-B27; A85-B28; A85-B29; A85-B30;
A85-B31; A85-B32; A85-B33; A85-B34; A85-B35; A85-B36;
A85-B37; A85-B38; A85-B39; A85-B40; A85-B41; A85-B42;
A85-B43; A85-B44; A85-B45; A85-B46; A85-B47; A85-B48;
A85-B49; A85-B50; A85-B51; A85-B52; A85-B53; A85-B54;
A85-B55; A85-B56; A85-B57; A85-B58; A85-B59; A85-B60;
A85-B61; A85-B62; A85-B63; A85-B64; A85-B65; A85-B66;
A85-B67; A85-B68; A85-B69; A85-B70; A85-B71; A85-B72;
A85-B73; A85-B74; A85-B75; A85-B76; A85-B77; A85-B78;
A85-B79; A85-B80; A85-B81; A85-B82; A85-B83; A85-B84;
A85-B85; A85-B86; A85-B87; A85-B88; A85-B89; A85-B90;
A85-B91; A85-B92; A85-B93; A85-B94; A85-B95; A85-B96;
A85-B97; A85-B98; A85-B99; A85-B 100; A85-B 101; A85-B 102;
A85-B 103; A85-B 104; A85-B105; A85-B 106; A85-B 107; A85-B 108;
A85-B109; A85-B 110; A85-B 111; A85-B 112; A85-B 113; A85-B 114;
A85-B 115; A85-B 116; A85-B 117; A85-B 118; A85-B 119; A85-B 120;
A85-B121; A85-B122; A85-B123; A85-B124; A85-B125; A85-B126;
A85-B 127; A85-B 128; A85-B 129; A85-B 130; A85-B131; A85-B 132;
A85-B133; A85-B134; A85-B135; A85-B136; A85-B137; A85-B138;
A85-B139; A85-B140; A85-B141; A85-B142; A85-B143; A85-B144;
A85-B 145; A85-B 146; A85-B 147; A85-B 148; A85-B 149; A85-B 150;
A85-B 151; A85-B 152; A85-B 153; A85-B 154; A85-B 155; A85-B 156;
A85-B157; A85-B158; A85-B159; A85-B160; A85-B161; A85-B162;
A85-B163; A85-B164; A85-B165; A85-B166; A85-B167; A85-B168;
A85-B169; A86-B1; A86-B2; A86-B3; A86-B4; A86-B5;
A86-B6; A86-B7; A86-B8; A86-B9; A86-B10; A86-B11;
A86-B 12; A86-B 13; A86-B 14; A86-B 15; A86-B 16; A86-B 17;
A86-B 18; A86-B 19; A86-B20; A86-B21; A86-B22; A86-B23;
A86-B24; A86-B25; A86-B26; A86-B27; A86-B28; A86-B29;
A86-B30; A86-B31; A86-B32; A86-B33; A86-B34; A86-B35;
A86-B36; A86-B37; A86-B38; A86-B39; A86-B40; A86-B41;
A86-B42; A86-B43; A86-B44; A86-B45; A86-B46; A86-B47;
A86-B48; A86-B49; A86-B50; A86-B51; A86-B52; A86-B53;
A86-B54; A86-B55; A86-B56; A86-B57; A86-B58; A86-B59;
A86-B60; A86-B61; A86-B62; A86-B63; A86-B64; A86-B65;
A86-B66; A86-B67; A86-B68; A86-B69; A86-B70; A86-B71;
A86-B72; A86-B73; A86-B74; A86-B75; A86-B76; A86-B77;
A86-B78; A86-B79; A86-B80; A86-B81; A86-B82; A86-B83;
A86-B84; A86-B85; A86-B86; A86-B87; A86-B88; A86-B89;
A86-B90; A86-B91; A86-B92; A86-B93; A86-B94; A86-B95;
A86-B96; A86-B97; A86-B98; A86-B99; A86-B100; A86-B101;
A86-B102; A86-B 103; A86-B 104; A86-B 105; A86-B 106; A86-B 107;
A86-B108; A86-B 109; A86-B 110; A86-B 111; A86-B 112; A86-B 113;
A86-B 114; A86-B 115; A86-B 116; A86-B 117; A86-B 118; A86-B 119;
A86-B 120; A86-B 121; A86-B 122; A86-B 123; A86-B 124; A86-B 125;
A86-B 126; A86-B127; A86-B128; A86-B 129; A86-B 130; A86-B 131;
A86-B132; A86-B 133; A86-B 134; A86-B135; A86-B136; A86-B137;
A86-B138; A86-B139; A86-B140; A86-B141; A86-B142; A86-B143;
A86-B 144; A86-B 145; A86-B 146; A86-B 147; A86-B148; A86-B149;
A86-B 150; A86-B 151; A86-B 152; A86-B153; A86-B 154; A86-B155;
A86-B156; A86-B157; A86-B158; A86-B159; A86-B160; A86-B161;
A86-B162; A86-B 163; A86-B164; A86-B 165; A86-B 166; A86-B167;
A86-B 168; A86-B 169; A87-B 1; A87-B2; A87-B3; A87-B4;
A87-B5; A87-B6; A87-B7; A87-B8; A87-B9; A87-B10;
A87-B 11; A87-B 12; A87-B 13; A87-B 14; A87-B15; A87-B16;
A87-B 17; A87-B 18; A87-B 19; A87-B20; A87-B21; A87-B22;
A87-B23; A87-B24; A87-B25; A87-B26; A87-B27; A87-B28;
A87-B29; A87-B30; A87-B31; A87-B32; A87-B33; A87-B34;
A87-B35; A87-B36; A87-B37; A87-B38; A87-B39; A87-B40;
A87-B41; A87-B42; A87-B43; A87-B44; A87-B45; A87-B46;
A87-B47; A87-B48; A87-B49; A87-B50; A87-B51; A87-B52;
A87-B53; A87-B54; A87-B55; A87-B56; A87-B57; A87-B58;
A87-B59; A87-B60; A87-B61; A87-B62; A87-B63; A87-B64;
A87-B65; A87-B66; A87-B67; A87-B68; A87-B69; A87-B70;
A87-B71; A87-B72; A87-B73; A87-B74; A87-B75; A87-B76;
A87-B77; A87-B78; A87-B79; A87-B80; A87-B81; A87-B82;
A87-B83; A87-B84; A87-B85; A87-B86; A87-B87; A87-B88;
A87-B89; A87-B90; A87-B91; A87-B92; A87-B93; A87-B94;
A87-B95; A87-B96; A87-B97; A87-B98; A87-B99; A87-B 100;
A87-B 101; A87-B 102; A87-B 103; A87-B 104; A87-B 105; A87-B 106;
A87-B 107; A87-B108; A87-B 109; A87-B 110; A87-B 111; A87-B 112;
A87-B 113; A87-B 114; A87-B 115; A87-B 116; A87-B 117; A87-B 118;
A87-B 119; A87-B 120; A87-B 121; A87-B 122; A87-B 123; A87-B 124;
A87-B125; A87-B 126; A87-B 127; A87-B 128; A87-B 129; A87-B 130;
A87-B 13 1; A87-B 132; A87-B 133; A87-B 134; A87-B 135; A87-B 136;
A87-B 137; A87-B 13 8; A87-B 139; A87-B 140; A87-B 141; A87-B 142;
A87-B 143; A87-B 144; A87-B 145; A87-B 146; A87-B 147; A87-B148;
A87-B 149; A87-B 150; A87-B 151; A87-B 152; A87-B 153; A87-B 154;
A87-B155; A87-B 156; A87-B 157; A87-B 158; A87-B 159; A87-B 160;
A87-B161; A87-B 162; A87-B 163; A87-B 164; A87-B 165; A87-B 166;
A87-B 167; A87-B168; A87-B 169; A88-B 1; A88-B2; A88-B3;
A88-B4; A88-B5; A88-B6; A88-B7; A88-B8; A88-B9;
A88-B 10; A88-B 11; A88-B 12; A88-B 13; A88-B14; A88-B15;
A88-B16; A88-B17; A88-B18; A88-B19; A88-B20; A88-B21;
A88-B22; A88-B23; A88-B24; A88-B25; A88-B26; A88-B27;
A88-B28; A88-B29; A88-B30; A88-B31; A88-B32; A88-B33;
A88-B34; A88-B35; A88-B36; A88-B37; A88-B38; A88-B39;
A88-B40; A88-B41; A88-B42; A88-B43; A88-B44; A88-B45;
A88-B46; A88-B47; A88-B48; A88-B49; A88-B50; A88-B51;
A88-B52; A88-B53; A88-B54; A88-B55; A88-B56; A88-B57;
A88-B58; A88-B59; A88-B60; A88-B61; A88-B62; A88-B63;
A88-B64; A88-B65; A88-B66; A88-B67; A88-B68; A88-B69;
A88-B70; A88-B71; A88-B72; A88-B73; A88-B74; A88-B75;
A88-B76; A88-B77; A88-B78; A88-B79; A88-B80; A88-B81;
A88-B82; A88-B83; A88-B84; A88-B85; A88-B86; A88-B87;
A88-B88; A88-B89; A88-B90; A88-B91; A88-B92; A88-B93;
A88-B94; A88-B95; A88-B96; A88-B97; A88-B98; A88-B99;
A88-B 100; A88-B 101; A88-B 102; A88-B103; A88-B 104; A88-B 105;
A88-B 106; A88-B 107; A88-B 108; A88-B 109; A88-B 110; A88-B 111;
A88-B 112; A88-B 113; A88-B 114; A88-B 115; A88-B 116; A88-B117;
A88-B118; A88-B 119; A88-B 120; A88-B 121; A88-B122; A88-B123;
A88-B 124; A88-B 125; A88-B 126; A88-B 127; A88-B128; A88-B 129;
A88-B130; A88-B131; A88-B132; A88-B133; A88-B134; A88-B135;
A88-B 136; A88-B137; A88-B 138; A88-B 139; A88-B140; A88-B141;
A88-B 142; A88-B 143; A88-B 144; A88-B 145; A88-B 146; A88-B 147;
A88-B 148; A88-B 149; A88-B 150; A88-B 151; A88-B 152; A88-B153;
A88-B154; A88-B155; A88-B156; A88-B157; A88-B158; A88-B159;
A88-B 160; A88-B 161; A88-B 162; A88-B 163; A88-B 164; A88-B165;
A88-B 166; A88-B 167; A88-B 168; A88-B 169; A89-B 1; A89-B2;
A89-B3; A89-B4; A89-B5; A89-B6; A89-B7; A89-B8;
A89-B9; A89-B 10; A89-B 11; A89-B 12; A89-B 13; A89-B 14;
A89-B 15; A89-B 16; A89-B 17; A89-B 18; A89-B19; A89-B20;
A89-B21; A89-B22; A89-B23; A89-B24; A89-B25; A89-B26;
A89-B27; A89-B28; A89-B29; A89-B30; A89-B31; A89-B32;
A89-B33; A89-B34; A89-B35; A89-B36; A89-B37; A89-B38;
A89-B39; A89-B40; A89-B41; A89-B42; A89-B43; A89-B44;
A89-B45; A89-B46; A89-B47; A89-B48; A89-B49; A89-B50;
A89-B51; A89-B52; A89-B53; A89-B54; A89-B55; A89-B56;
A89-B57; A89-B58; A89-B59; A89-B60; A89-B61; A89-B62;
A89-B63; A89-B64; A89-B65; A89-B66; A89-B67; A89-B68;
A89-B69; A89-B70; A89-B71; A89-B72; A89-B73; A89-B74;
A89-B75; A89-B76; A89-B77; A89-B78; A89-B79; A89-B80;
A89-B81; A89-B82; A89-B83; A89-B84; A89-B85; A89-B86;
A89-B87; A89-B88; A89-B89; A89-B90; A89-B91; A89-B92;
A89-B93; A89-B94; A89-B95; A89-B96; A89-B97; A89-B98;
A89-B99; A89-B 100; A89-B 101; A89-B 102; A89-B 103; A89-B 104;
A89-B 105; A89-B 106; A89-B 107; A89-B 108; A89-B109; A89-B 110;
A89-B111; A89-B112; A89-B113; A89-B114; A89-B115; A89-B116;
A89-B 117; A89-B 118; A89-B 119; A89-B 120; A89-B 121; A89-B 122;
A89-B 123; A89-B124; A89-B 125; A89-B 126; A89-B127; A89-B128;
A89-B 129; A89-B 130; A89-B 131; A89-B 132; A89-B 133; A89-B 134;
A89-B 135; A89-B 136; A89-B 137; A89-B138; A89-B 139; A89-B 140;
A89-B 141; A89-B 142; A89-B 143; A89-B 144; A89-B 145; A89-B 146;
A89-B 147; A89-B 148; A89-B 149; A89-B 150; A89-B 15 1; A89-B 152;
A89-B 153; A89-B 154; A89-B 155; A89-B 156; A89-B157; A89-B 158;
A89-B 159; A89-B 160; A89-B 161; A89-B 162; A89-B 163; A89-B 164;
A89-B 165; A89-B 166; A89-B 167; A89-B168; A89-B 169; A90-B 1;
A90-B2; A90-B3; A90-B4; A90-B5; A90-B6; A90-B7;
A90-B8; A90-B9; A90-B 10; A90-B 11; A90-B 12; A90-B 13;
A90-B 14; A90-B 15; A90-B 16; A90-B 17; A90-B 18; A90-B 19;
A90-B20; A90-B21; A90-B22; A90-B23; A90-B24; A90-B25;
A90-B26; A90-B27; A90-B28; A90-B29; A90-B30; A90-B31;
A90-B32; A90-B33; A90-B34; A90-B35; A90-B36; A90-B37;
A90-B38; A90-B39; A90-B40; A90-B41; A90-B42; A90-B43;
A90-B44; A90-B45; A90-B46; A90-B47; A90-B48; A90-B49;
A90-B50; A90-B51; A90-B52; A90-B53; A90-B54; A90-B55;
A90-B56; A90-B57; A90-B58; A90-B59; A90-B60; A90-B61;
A90-B62; A90-B63; A90-B64; A90-B65; A90-B66; A90-B67;
A90-B68; A90-B69; A90-B70; A90-B71; A90-B72; A90-B73;
A90-B74; A90-B75; A90-B76; A90-B77; A90-B78; A90-B79;
A90-B80; A90-B81; A90-B82; A90-B83; A90-B84; A90-B85;
A90-B86; A90-B87; A90-B88; A90-B89; A90-B90; A90-B91;
A90-B92; A90-B93; A90-B94; A90-B95; A90-B96; A90-B97;
A90-B98; A90-B99; A90-B 100; A90-B 101; A90-B 102; A90-B 103;
A90-B 104; A90-B 105; A90-B 106; A90-B 107; A90-B108; A90-B 109;
A90-B110; A90-B 111; A90-B 112; A90-B 113; A90-B 114; A90-B 115;
A90-B 116; A90-B 117; A90-B 118; A90-B 119; A90-B 120; A90-B 121;
A90-B 122; A90-B 123; A90-B 124; A90-B 125; A90-B 126; A90-B 127;
A90-B128; A90-B129; A90-B 130; A90-B 131; A90-B 132; A90-B 133;
A90-B 134; A90-B 135; A90-B 136; A90-B 137; A90-B 138; A90-B 139;
A90-B 140; A90-B 141; A90-B 142; A90-B 143; A90-B 144; A90-B 145;
A90-B 146; A90-B 147; A90-B 148; A90-B 149; A90-B150; A90-B 151;
A90-B 152; A90-B 153; A90-B 154; A90-B 155; A90-B156; A90-B157;
A90-B 158; A90-B 159; A90-B 160; A90-B 161; A90-B 162; A90-B 163;
A90-B 164; A90-B 165; A90-B 166; A90-B 167; A90-B 168; A90-B 169;
A91-B1; A91-B2; A91-B3; A91-B4; A91-B5; A91-B6;
A91-B7; A91-B8; A91-B9; A91-B10; A91-B11; A91-B12;
A91-B13; A91-B14; A91-B15; A91-B16; A91-B17; A91-B18;
A91-B19; A91-B20; A91-B21; A91-B22; A91-B23; A91-B24;
A91-B25; A91-B26; A91-B27; A91-B28; A91-B29; A91-B30;
A91-B31; A91-B32; A91-B33; A91-B34; A91-B35; A91-B36;
A91-B37; A91-B38; A91-B39; A91-B40; A91-B41; A91-B42;
A91-B43; A91-B44; A91-B45; A91-B46; A91-B47; A91-B48;
A91-B49; A91-B50; A91-B51; A91-B52; A91-B53; A91-B54;
A91-B55; A91-B56; A91-B57; A91-B58; A91-B59; A91-B60;
A91-B61; A91-B62; A91-B63; A91-B64; A91-B65; A91-B66;
A91-B67; A91-B68; A91-B69; A91-B70; A91-B71; A91-B72;
A91-B73; A91-B74; A91-B75; A91-B76; A91-B77; A91-B78;
A91-B79; A91-B80; A91-B81; A91-B82; A91-B83; A91-B84;
A91-B85; A91-B86; A91-B87; A91-B88; A91-B89; A91-B90;
A91-B91; A91-B92; A91-B93; A91-B94; A91-B95; A91-B96;
A91-B97; A91-B98; A91-B99; A91-B100; A91-B101; A91-B102;
A91-B 103; A91-B 104; A91-B 105; A91-B 106; A91-B 107; A91-B 108;
A91-B109; A91-B110; A91-B111; A91-B112; A91-B113; A91-B114;
A91-B115; A91-B116; A91-B117; A91-B118; A91-B119; A91-B120;
A91-B121; A91-B122; A91-B123; A91-B124; A91-B125; A91-B126;
A91-B127; A91-B128; A91-B129; A91-B130; A91-B131; A91-B132;
A91-B133; A91-B134; A91-B135; A91-B136; A91-B137; A91-B138;
A91-B139; A91-B140; A91-B141; A91-B142; A91-B143; A91-B144;
A91-B145; A91-B146; A91-B147; A91-B148; A91-B149; A91-B150;
A91-B151; A91-B152; A91-B153; A91-B154; A91-B155; A91-B156;
A91-B157; A91-B158; A91-B159; A91-B160; A91-B161; A91-B162;
A91-B163; A91-B164; A91-B165; A91-B166; A91-B167; A91-B168;
A91-B169; A92-B1; A92-B2; A92-B3; A92-B4; A92-B5;
A92-B6; A92-B7; A92-B8; A92-B9; A92-B10; A92-B11;
A92-B 12; A92-B 13; A92-B 14; A92-B 15; A92-B 16; A92-B17;
A92-B 18; A92-B 19; A92-B20; A92-B21; A92-B22; A92-B23;
A92-B24; A92-B25; A92-B26; A92-B27; A92-B28; A92-B29;
A92-B30; A92-B31; A92-B32; A92-B33; A92-B34; A92-B35;
A92-B36; A92-B37; A92-B38; A92-B39; A92-B40; A92-B41;
A92-B42; A92-B43; A92-B44; A92-B45; A92-B46; A92-B47;
A92-B48; A92-B49; A92-B50; A92-B51; A92-B52; A92-B53;
A92-B54; A92-B55; A92-B56; A92-B57; A92-B58; A92-B59;
A92-B60; A92-B61; A92-B62; A92-B63; A92-B64; A92-B65;
A92-B66; A92-B67; A92-B68; A92-B69; A92-B70; A92-B71;
A92-B72; A92-B73; A92-B74; A92-B75; A92-B76; A92-B77;
A92-B78; A92-B79; A92-B80; A92-B81; A92-B82; A92-B83;
A92-B84; A92-B85; A92-B86; A92-B87; A92-B88; A92-B89;
A92-B90; A92-B91; A92-B92; A92-B93; A92-B94; A92-B95;
A92-B96; A92-B97; A92-B98; A92-B99; A92-B100; A92-B101;
A92-B 102; A92-B 103; A92-B 104; A92-B 105; A92-B 106; A92-B 107;
A92-B108; A92-B 109; A92-B 110; A92-B 111; A92-B 112; A92-B 113;
A92-B 114; A92-B 115; A92-B 116; A92-B 117; A92-B 118; A92-B 119;
A92-B 120; A92-B 121; A92-B 122; A92-B 123; A92-B 124; A92-B 125;
A92-B 126; A92-B 127; A92-B 128; A92-B 129; A92-B 130; A92-B 131;
A92-B 132; A92-B133; A92-B 134; A92-B135; A92-B 136; A92-B 137;
A92-B 13 8; A92-B 13 9; A92-B 140; A92-B 141; A92-B 142; A92-B 143;
A92-B 144; A92-B 145; A92-B 146; A92-B 147; A92-B 148; A92-B 149;
A92-B 150; A92-B 151; A92-B 152; A92-B 153; A92-B 154; A92-B 155;
A92-B 156; A92-B 157; A92-B 158; A92-B 159; A92-B 160; A92-B 161;
A92-B 162; A92-B 163; A92-B 164; A92-B165; A92-B 166; A92-B 167;
A92-B168; A92-B 169; A93-B 1; A93-B2; A93-B3; A93-B4;
A93-B5; A93-B6; A93-B7; A93-B8; A93-B9; A93-B10;
A93-B 11; A93-B12; A93-B 13; A93-B 14; A93-B15; A93-B 16;
A93-B 17; A93-B 18; A93-B 19; A93-B20; A93-B21; A93-B22;
A93-B23; A93-B24; A93-B25; A93-B26; A93-B27; A93-B28;
A93-B29; A93-B30; A93-B31; A93-B32; A93-B33; A93-B34;
A93-B35; A93-B36; A93-B37; A93-B38; A93-B39; A93-B40;
A93-B41; A93-B42; A93-B43; A93-B44; A93-B45; A93-B46;
A93-B47; A93-B48; A93-B49; A93-B50; A93-B51; A93-B52;
A93-B53; A93-B54; A93-B55; A93-B56; A93-B57; A93-B58;
A93-B59; A93-B60; A93-B61; A93-B62; A93-B63; A93-B64;
A93-B65; A93-B66; A93-B67; A93-B68; A93-B69; A93-B70;
A93-B71; A93-B72; A93-B73; A93-B74; A93-B75; A93-B76;
A93-B77; A93-B78; A93-B79; A93-B80; A93-B81; A93-B82;
A93-B83; A93-B84; A93-B85; A93-B86; A93-B87; A93-B88;
A93-B89; A93-B90; A93-B91; A93-B92; A93-B93; A93-B94;
A93-B95; A93-B96; A93-B97; A93-B98; A93-B99; A93-B100;
A93-B 101; A93-B102; A93-B 103; A93-B 104; A93-B 105; A93-B 106;
A93-B 107; A93-B 108; A93-B 109; A93-B 110; A93-B 111; A93-B 112;
A93-B 113; A93-B114; A93-B 115; A93-B 116; A93-B117; A93-B 118;
A93-B119; A93-B120; A93-B121; A93-B122; A93-B123; A93-B124;
A93-B 125; A93-B 126; A93-B 127; A93-B 128; A93-B129; A93-B 130;
A93-B 131; A93-B132; A93-B 133; A93-B134; A93-B135; A93-B 136;
A93-B137; A93-B138; A93-B139; A93-B140; A93-B141; A93-B142;
A93-B 143; A93-B 144; A93-B 145; A93-B 146; A93-B 147; A93-B 148;
A93-B 149; A93-B 150; A93-B 151; A93-B 152; A93-B 153; A93-B 154;
A93-B 155; A93-B 156; A93-B 157; A93-B158; A93-B159; A93-B 160;
A93-B 161; A93-B 162; A93-B 163; A93-B 164; A93-B 165; A93-B 166;
A93-B167; A93-B 168; A93-B169; A94-B l; A94-B2; A94-B3;
A94-B4; A94-B5; A94-B6; A94-B7; A94-B8; A94-B9;
A94-B 10; A94-B 11; A94-B 12; A94-B 13; A94-B 14; A94-B 15 ;
A94-B 16; A94-B 17; A94-B 18; A94-B 19; A94-B20; A94-B21;
A94-B22; A94-B23; A94-B24; A94-B25; A94-B26; A94-B27;
A94-B28; A94-B29; A94-B30; A94-B31; A94-B32; A94-B33;
A94-B34; A94-B35; A94-B36; A94-B37; A94-B38; A94-B39;
A94-B40; A94-B41; A94-B42; A94-B43; A94-B44; A94-B45;
A94-B46; A94-B47; A94-B48; A94-B49; A94-B50; A94-B51;
A94-B52; A94-B53; A94-B54; A94-B55; A94-B56; A94-B57;
A94-B58; A94-B59; A94-B60; A94-B61; A94-B62; A94-B63;
A94-B64; A94-B65; A94-B66; A94-B67; A94-B68; A94-B69;
A94-B70; A94-B71; A94-B72; A94-B73; A94-B74; A94-B75;
A94-B76; A94-B77; A94-B78; A94-B79; A94-B80; A94-B81;
A94-B82; A94-B83; A94-B84; A94-B85; A94-B86; A94-B87;
A94-B88; A94-B89; A94-B90; A94-B91; A94-B92; A94-B93;
A94-B94; A94-B95; A94-B96; A94-B97; A94-B98; A94-B99;
A94-B 100; A94-B 101; A94-B 102; A94-B103; A94-B 104; A94-B 105;
A94-B 106; A94-B 107; A94-B 108; A94-B 109; A94-B 110; A94-B 111;
A94-B 112; A94-B 113; A94-B 114; A94-B 115; A94-B 116; A94-B 117;
A94-B 118; A94-B 119; A94-B 120; A94-B 121; A94-B 122; A94-B 123;
A94-B 124; A94-B 125; A94-B 126; A94-B 127; A94-B 128; A94-B 129;
A94-B130; A94-B 131; A94-B 132; A94-B 133; A94-B 134; A94-B 135;
A94-B 13 6; A94-B 137; A94-B 13 8; A94-B 13 9; A94-B 140; A94-B 141;
A94-B 142; A94-B 143; A94-B 144; A94-B 145; A94-B 146; A94-B 147;
A94-B 148; A94-B 149; A94-B 150; A94-B 15 1; A94-B 152; A94-B153;
A94-B 154; A94-B 155; A94-B156; A94-B 157; A94-B 158; A94-B 159;
A94-B 160; A94-B 161; A94-B 162; A94-B 163; A94-B 164; A94-B 165;
A94-B 166; A94-B 167; A94-B168; A94-B169; A95-B 1; A95-B2;
A95-B3; A95-B4; A95-B5; A95-B6; A95-B7; A95-B8;
A95-B9; A95-B 10; A95-B 11; A95-B 12; A95-B 13; A95-B14;
A95-B15; A95-B 16; A95-B 17; A95-B 18; A95-B 19; A95-B20;
A95-B21; A95-B22; A95-B23; A95-B24; A95-B25; A95-B26;
A95-B27; A95-B28; A95-B29; A95-B30; A95-B31; A95-B32;
A95-B33; A95-B34; A95-B35; A95-B36; A95-B37; A95-B38;
A95-B39; A95-B40; A95-B41; A95-B42; A95-B43; A95-B44;
A95-B45; A95-B46; A95-B47; A95-B48; A95-B49; A95-B50;
A95-B51; A95-B52; A95-B53; A95-B54; A95-B55; A95-B56;
A95-B57; A95-B58; A95-B59; A95-B60; A95-B61; A95-B62;
A95-B63; A95-B64; A95-B65; A95-B66; A95-B67; A95-B68;
A95-B69; A95-B70; A95-B71; A95-B72; A95-B73; A95-B74;
A95-B75; A95-B76; A95-B77; A95-B78; A95-B79; A95-B80;
A95-B81; A95-B82; A95-B83; A95-B84; A95-B85; A95-B86;
A95-B87; A95-B88; A95-B89; A95-B90; A95-B91; A95-B92;
A95-B93; A95-B94; A95-B95; A95-B96; A95-B97; A95-B98;
A95-B99; A95-B 100; A95-B 101; A95-B 102; A95-B103; A95-B 104;
A95-B 105; A95-B106; A95-B107; A95-B108; A95-B 109; A95-B 110;
A95-B 111; A95-B112; A95-B113; A95-B114; A95-B 115; A95-B 116;
A95-B 117; A95-B 118; A95-B 119; A95-B 120; A95-B 121; A95-B122;
A95-B123; A95-B124; A95-B125; A95-B126; A95-B127; A95-B128;
A95-B 129; A95-B130; A95-B 131; A95-B 132; A95-B 133; A95-B 134;
A95-B135; A95-B136; A95-B137; A95-B138; A95-B139; A95-B140;
A95-B141; A95-B 142; A95-B 143; A95-B144; A95-B 145; A95-B 146;
A95-B147; A95-B148; A95-B149; A95-B150; A95-B151; A95-B152;
A95-B153; A95-B 154; A95-B155; A95-B 156; A95-B157; A95-B158;
A95-B159; A95-B160; A95-B161; A95-B162; A95-B163; A95-B164;
A95-B 165; A95-B 166; A95-B 167; A95-B 168; A95-B 169; A96-B 1;
A96-B2; A96-B3; A96-B4; A96-B5; A96-B6; A96-B7;
A96-B8; A96-B9; A96-B 10; A96-B 11; A96-B 12; A96-B 13;
A96-B 14; A96-B 15; A96-B 16; A96-B 17; A96-B 18; A96-B 19;
A96-B20; A96-B21; A96-B22; A96-B23; A96-B24; A96-B25;
A96-B26; A96-B27; A96-B28; A96-B29; A96-B30; A96-B31;
A96-B32; A96-B33; A96-B34; A96-B35; A96-B36; A96-B37;
A96-B38; A96-B39; A96-B40; A96-B41; A96-B42; A96-B43;
A96-B44; A96-B45; A96-B46; A96-B47; A96-B48; A96-B49;
A96-B50; A96-B51; A96-B52; A96-B53; A96-B54; A96-B55;
A96-B56; A96-B57; A96-B58; A96-B59; A96-B60; A96-B61;
A96-B62; A96-B63; A96-B64; A96-B65; A96-B66; A96-B67;
A96-B68; A96-B69; A96-B70; A96-B71; A96-B72; A96-B73;
A96-B74; A96-B75; A96-B76; A96-B77; A96-B78; A96-B79;
A96-B80; A96-B81; A96-B82; A96-B83; A96-B84; A96-B85;
A96-B86; A96-B87; A96-B88; A96-B89; A96-B90; A96-B91;
A96-B92; A96-B93; A96-B94; A96-B95; A96-B96; A96-B97;
A96-B98; A96-B99; A96-B 100; A96-B 101; A96-B 102; A96-B 103;
A96-B 104; A96-B 105; A96-B 106; A96-B 107; A96-B 108; A96-B 109;
A96-B 110; A96-B 11 1; A96-B 112; A96-B 113; A96-B 114; A96-B 115;
A96-B 116; A96-B 117; A96-B 118; A96-B 119; A96-B 120; A96-B 121;
A96-B 122; A96-B 123; A96-B 124; A96-B125; A96-B 126; A96-B 127;
A96-B 128; A96-B 129; A96-B 130; A96-B 131; A96-B 132; A96-B 133;
A96-B 134; A96-B 135; A96-B 136; A96-B137; A96-B 138; A96-B 139;
A96-B 140; A96-B141; A96-B 142; A96-B 143; A96-B 144; A96-B 145;
A96-B 146; A96-B 147; A96-B 148; A96-B 149; A96-B150; A96-B 151;
A96-B 152; A96-B 153; A96-B 154; A96-B 155; A96-B 156; A96-B 157;
A96-B158; A96-B159; A96-B160; A96-B 161; A96-B 162; A96-B 163;
A96-B164; A96-B 165; A96-B 166; A96-B 167; A96-B 168; A96-B 169;
A97-B l; A97-B2; A97-B3; A97-B4; A97-B5; A97-B6;
A97-B7; A97-B8; A97-B9; A97-B10; A97-B11; A97-B12;
A97-B 13; A97-B 14; A97-B 15; A97-B 16; A97-B17; A97-B 18;
A97-B19; A97-B20; A97-B21; A97-B22; A97-B23; A97-B24;
A97-B25; A97-B26; A97-B27; A97-B28; A97-B29; A97-B30;
A97-B31; A97-B32; A97-B33; A97-B34; A97-B35; A97-B36;
A97-B37; A97-B38; A97-B39; A97-B40; A97-B41; A97-B42;
A97-B43; A97-B44; A97-B45; A97-B46; A97-B47; A97-B48;
A97-B49; A97-B50; A97-B51; A97-B52; A97-B53; A97-B54;
A97-B55; A97-B56; A97-B57; A97-B58; A97-B59; A97-B60;
A97-B61; A97-B62; A97-B63; A97-B64; A97-B65; A97-B66;
A97-B67; A97-B68; A97-B69; A97-B70; A97-B71; A97-B72;
A97-B73; A97-B74; A97-B75; A97-B76; A97-B77; A97-B78;
A97-B79; A97-B80; A97-B81; A97-B82; A97-B83; A97-B84;
A97-B85; A97-B86; A97-B87; A97-B88; A97-B89; A97-B90;
A97-B91; A97-B92; A97-B93; A97-B94; A97-B95; A97-B96;
A97-B97; A97-B98; A97-B99; A97-B 100; A97-B 101; A97-B 102;
A97-B 103; A97-B 104; A97-B 105; A97-B 106; A97-B 107; A97-B 108;
A97-B 109; A97-B 110; A97-B 111; A97-B 112; A97-B 113; A97-B 114;
A97-B 115; A97-B 116; A97-B 117; A97-B 118; A97-B 119; A97-B 120;
A97-B 121; A97-B 122; A97-B 123; A97-B 124; A97-B 125; A97-B 126;
A97-B 127; A97-B 128; A97-B 129; A97-B130; A97-B 131; A97-B 132;
A97-B 133; A97-B 134; A97-B 135; A97-B 136; A97-B 137; A97-B 138;
A97-B 139; A97-B 140; A97-B141; A97-B 142; A97-B 143; A97-B 144;
A97-B 145; A97-B 146; A97-B 147; A97-B 148; A97-B 149; A97-B 150;
A97-B 151; A97-B 152; A97-B153; A97-B 154; A97-B 155; A97-B156;
A97-B 157; A97-B158; A97-B 159; A97-B 160; A97-B 161; A97-B 162;
A97-B 163; A97-B 164; A97-B 165; A97-B 166; A97-B 167; A97-B 168;
A97-B169; A98-B1; A98-B2; A98-B3; A98-B4; A98-B5;
A98-B6; A98-B7; A98-B8; A98-B9; A98-B10; A98-B11;
A98-B 12; A98-B 13; A98-B 14; A98-B 15; A98-B 16; A98-B17;
A98-B18; A98-B19; A98-B20; A98-B21; A98-B22; A98-B23;
A98-B24; A98-B25; A98-B26; A98-B27; A98-B28; A98-B29;
A98-B30; A98-B31; A98-B32; A98-B33; A98-B34; A98-B35;
A98-B36; A98-B37; A98-B38; A98-B39; A98-B40; A98-B41;
A98-B42; A98-B43; A98-B44; A98-B45; A98-B46; A98-B47;
A98-B48; A98-B49; A98-B50; A98-B51; A98-B52; A98-B53;
A98-B54; A98-B55; A98-B56; A98-B57; A98-B58; A98-B59;
A98-B60; A98-B61; A98-B62; A98-B63; A98-B64; A98-B65;
A98-B66; A98-B67; A98-B68; A98-B69; A98-B70; A98-B71;
A98-B72; A98-B73; A98-B74; A98-B75; A98-B76; A98-B77;
A98-B78; A98-B79; A98-B80; A98-B81; A98-B82; A98-B83;
A98-B84; A98-B85; A98-B86; A98-B87; A98-B88; A98-B89;
A98-B90; A98-B91; A98-B92; A98-B93; A98-B94; A98-B95;
A98-B96; A98-B97; A98-B98; A98-B99; A98-B100; A98-B101;
A98-B 102; A98-B 103; A98-B 104; A98-B 105; A98-B 106; A98-B107;
A98-B108; A98-B109; A98-B110; A98-B111; A98-B112; A98-B113;
A98-B114; A98-B 115; A98-B 116; A98-B117; A98-B118; A98-B 119;
A98-B 120; A98-B 121; A98-B 122; A98-B 123; A98-B124; A98-B125;
A98-B 126; A98-B 127; A98-B 128; A98-B 129; A98-B 130; A98-B 131;
A98-B132; A98-B133; A98-B 134; A98-B 135; A98-B136; A98-B 137;
A98-B138; A98-B139; A98-B140; A98-B141; A98-B142; A98-B143;
A98-B 144; A98-B145; A98-B 146; A98-B147; A98-B 148; A98-B 149;
A98-B150; A98-B 151; A98-B 152; A98-B153; A98-B154; A98-B 155;
A98-B156; A98-B157; A98-B158; A98-B159; A98-B160; A98-B161;
A98-B 162; A98-B 163; A98-B 164; A98-B165; A98-B166; A98-B 167;
A98-B168; A98-B169; A99-B1; A99-B2; A99-B3; A99-B4;
A99-B5; A99-B6; A99-B7; A99-B8; A99-B9; A99-B10;
A99-B 11; A99-B 12; A99-B 13; A99-B 14; A99-B 15; A99-B 16;
A99-B17; A99-B18; A99-B19; A99-B20; A99-B21; A99-B22;
A99-B23; A99-B24; A99-B25; A99-B26; A99-B27; A99-B28;
A99-B29; A99-B30; A99-B31; A99-B32; A99-B33; A99-B34;
A99-B35; A99-B36; A99-B37; A99-B38; A99-B39; A99-B40;
A99-B41; A99-B42; A99-B43; A99-B44; A99-B45; A99-B46;
A99-B47; A99-B48; A99-B49; A99-B50; A99-B51; A99-B52;
A99-B53; A99-B54; A99-B55; A99-B56; A99-B57; A99-B58;
A99-B59; A99-B60; A99-B61; A99-B62; A99-B63; A99-B64;
A99-B65; A99-B66; A99-B67; A99-B68; A99-B69; A99-B70;
A99-B71; A99-B72; A99-B73; A99-B74; A99-B75; A99-B76;
A99-B77; A99-B78; A99-B79; A99-B80; A99-B81; A99-B82;
A99-B83; A99-B84; A99-B85; A99-B86; A99-B87; A99-B88;
A99-B89; A99-B90; A99-B91; A99-B92; A99-B93; A99-B94;
A99-B95; A99-B96; A99-B97; A99-B98; A99-B99; A99-B 100;
A99-B 101; A99-B 102; A99-B 103; A99-B 104; A99-B 105; A99-B 106;
A99-B 107; A99-B108; A99-B109; A99-B 110; A99-B 111; A99-B 112;
A99-B 113; A99-B 114; A99-B 115; A99-B 116; A99-B 117; A99-B 118;
A99-B 119; A99-B 120; A99-B 121; A99-B 122; A99-B 123; A99-B 124;
A99-B 125; A99-B 126; A99-B 127; A99-B 128; A99-B 129; A99-B130;
A99-B 131; A99-B 132; A99-B 133; A99-B 134; A99-B 135; A99-B 136;
A99-B 137; A99-B 13 8; A99-B139; A99-B 140; A99-B 141; A99-B 142;
A99-B 143; A99-B 144; A99-B 145; A99-B 146; A99-B 147; A99-B 148;
A99-B149; A99-B 150; A99-B 15 1; A99-B 152; A99-B 153; A99-B 154;
A99-B 155; A99-B 156; A99-B 157; A99-B 158; A99-B 159; A99-B 160;
A99-B 161; A99-B 162; A99-B 163; A99-B 164; A99-B 165; A99-B 166;
A99-B167; A99-B168; A99-B169; A100-B1; A100-B2; A100-B3;
A100-B4; A100-B5; A100-B6; A100-B7; A100-B8; A100-B9;
A100-B10; A100-B11; A100-B12; A100-B13; A100-B14; A100-B15;
A100-B16; A100-B17; A100-B18; A100-B19; A100-B20; A100-B21;
A100-B22; A100-B23; A100-B24; A100-B25; A100-B26; A100-B27;
A100-B28; A100-B29; A100-B30; A100-B31; A100-B32; A100-B33;
A100-B34; A100-B35; A100-B36; A100-B37; A100-B38; A100-B39;
A100-B40; A100-B41; A100-B42; A100-B43; A100-B44; A100-B45;
A100-B46; A100-B47; A100-B48; A100-B49; A100-B50; A100-B51;
A100-B52; A100-B53; A100-B54; A100-B55; A100-B56; A100-B57;
A100-B58; A100-B59; A100-B60; A100-B61; A100-B62; A100-B63;
A100-B64; A100-B65; A100-B66; A100-B67; A100-B68; A100-B69;
A100-B70; A100-B71; A100-B72; A100-B73; A100-B74; A100-B75;
A100-B76; A100-B77; A100-B78; A100-B79; A100-B80; A100-B81;
A100-B82; A100-B83; A100-B84; A100-B85; A100-B86; A100-B87;
A100-B88; A100-B89; A100-B90; A100-B91; A100-B92; A100-B93;
A100-B94; A100-B95; A100-B96; A100-B97; A100-B98; A100-B99;
A100-B100; A100-B101; A100-B102; A100-B103; A100-B104; A100-B105;
A100-B106; A100-B107; A100-B108; A100-B109; A100-B110; A100-Blll;
A100-B 112; A100-B 113; A100-B 114; A100-B 115; A100-B 116; A100-B117;
A100-B118; A100-B119; A100-B120; A100-B121; A100-B122; A100-B123;
A100-B124; A100-B125; A100-B126; A100-B127; A100-B128; A100-B129;
A100-B130; A100-B131; A100-B132; A100-B133; A100-B134; A100-B135;
A100-B136; A100-B137; A100-B138; A100-B139; A100-B140; A100-B141;
A100-B142; A100-B143; A100-B144; A100-B145; A100-B146; A100-B147;
A100-B148; A100-B149; A100-B150; A100-B151; A100-B152; A100-B153;
A100-B154; A100-B155; A100-B156; A100-B157; A100-B158; A100-B159;
A100-B160; A100-B161; A100-B162; A100-B163; A100-B164; A100-B165;
A100-B166; A100-B167; A100-B168; A100-B169; A101-B1; A101-B2;
A101-B3; A101-B4; A101-B5; A101-B6; A101-B7; A101-B8;
A101-B9; A101-B10; A101-B11; A101-B12; A101-B13; A101-B14;
A101-B15; A101-B16; A101-B17; A101-B18; A101-B19; A101-B20;
A101-B21; A101-B22; A101-B23; A101-B24; A101-B25; A101-B26;
A101-B27; A101-B28; A101-B29; A101-B30; A101-B31; A101-B32;
A101-B33; A101-B34; A101-B35; A101-B36; A101-B37; A101-B38;
A101-B39; A101-B40; A101-B41; A101-B42; A101-B43; A101-B44;
A101-B45; A101-B46; A101-B47; A101-B48; A101-B49; A101-B50;
A101-B51; A101-B52; A101-B53; A101-B54; A101-B55; A101-B56;
A101-B57; A101-B58; A101-B59; A101-B60; A101-B61; A101-B62;
A101-B63; A101-B64; A101-B65; A101-B66; A101-B67; A101-B68;
A101-B69; A101-B70; A101-B71; A101-B72; A101-B73; A101-B74;
A101-B75; A101-B76; A101-B77; A101-B78; A101-B79; A101-B80;
A101-B81; A101-B82; A101-B83; A101-B84; A101-B85; A101-B86;
A1 1-B87; A101-B88; A101-B89; A101-B90; A101-B91; A101-B92;
A101-B93; A101-B94; A101-B95; A101-B96; A101-B97; A101-B98;
A101-B99; A101-B100; A101-Bl01; A101-B102; A101-B103; A101-B104;
A101-B105; A101-B106; A101-B107; A101-B108; A101-B109; A101-B110;
A101-B11l; A101-B112; A101-B113; A101-B114; A101-B115; A101-B116;
A101-B117; A101-B118; A101-B119; A101-B120; A101-B121; A101-B122;
A101-B123; A101-B124; A101-B125; A101-B126; A101-B127; A101-B128;
A101-B129; A101-B130; A101-B131; A101-B132; A101-B133; A101-B134;
A101-B135; A101-B136; A101-B137; A101-B138; A101-B139; A101-B140;
A101-B141; A101-B142; A101-B143; A101-B144; A101-B145; A101-B146;
A101-B147; A101-B148; A101-B149; A101-B150; A101-B151; A101-B152;
A101-B153; A101-B154; A101-B155; A101-B156; A101-B157; A101-B158;
A101-B159; A101-B160; A101-B161; A101-B162; A101-B163; A101-B164;
A101-B165; A101-B166; A101-B167; A101-B168; A101-B169; A102-B1;
A102-B2; A102-B3; A102-B4; A102-B5; A102-B6; A102-B7;
A102-B8; A102-B9; A102-B10; A102-Bll; A102-B12; A102-B13;
A102-B14; A102-B15; A102-B16; A102-B17; A102-B18; A102-B19;
A102-B20; A102-B21; A102-B22; A102-B23; A102-B24; A102-B25;
A102-B26; A102-B27; A102-B28; A102-B29; A102-B30; A102-B31;
A102-B32; A102-B33; A102-B34; A102-B35; A102-B36; A102-B37;
A102-B38; A102-B39; A102-B40; A102-B41; A102-B42; A102-B43;
A102-B44; A102-B45; A102-B46; A102-B47; A102-B48; A102-B49;
A102-B50; A102-B51; A102-B52; A102-B53; A102-B54; A102-B55;
A102-B56; A102-B57; A102-B58; A102-B59; A102-B60; A102-B61;
A102-B62; A102-B63; A102-B64; A102-B65; A102-B66; A102-B67;
A102-B68; A102-B69; A102-B70; A102-B71; A102-B72; A102-B73;
A102-B74; A102-B75; A102-B76; A102-B77; A102-B78; A102-B79;
A102-B80; A102-B81; A102-B82; A102-B83; A102-B84; A102-B85;
A102-B86; A102-B87; A102-B88; A102-B89; A102-B90; A102-B91;
A102-B92; A102-B93; A102-B94; A102-B95; A102-B96; A102-B97;
A102-B98; A102-B99; A102-B100; A102-B101; A102-B102; A102-B103;
A102-B104; A102-B105; A102-B106; A102-B107; A102-B108; A102-B109;
A102-B110; A102-B111; A102-B112; A102-B113; A102-B114; A102-B115;
A102-B116; A102-B117; A102-B118; A102-B119; A102-B120; A102-B121;
A102-B122; A102-B123; A102-B124; A102-B125; A102-B126; A102-B127;
A102-B128; A102-B129; A102-B130; A102-B131; A102-B132; A102-B133;
A102-B134; A102-B135; A102-B136; A102-B137; A102-B138; A102-B139;
A102-B140; A102-B141; A102-B142; A102-B143; A102-B144; A102-B145;
A102-B146; A102-B147; A102-B148; A102-B149; A102-B150; A102-B151;
A102-B152; A102-B153; A102-B154; A102-B155; A102-B156; A102-B157;
A102-B158; A102-B159; A102-B160; A102-B161; A102-B162; A102-B163;
A102-B164; A102-B165; A102-B166; A102-B167; A102-B168; A102-B169;
A103-B1; A103-B2; A103-B3; A103-B4; A103-B5; A103-B6;
A103-B7; A103-B8; A103-B9; A103-B10; A103-B11; A103-B12;
A103-B13; A103-B14; A103-B15; A103-B16; A103-B17; A103-B18;
A103-B19; A103-B20; A103-B21; A103-B22; A103-B23; A103-B24;
A103-B25; A103-B26; A103-B27; A103-B28; A103-B29; A103-B30;
A103-B31; A103-B32; A103-B33; A103-B34; A103-B35; A103-B36;
A103-B37; A103-B38; A103-B39; A103-B40; A103-B41; A103-B42;
A103-B43; A103-B44; A103-B45; A103-B46; A103-B47; A103-B48;
A103-B49; A103-B50; A103-B51; A103-B52; A103-B53; A103-B54;
A103-B55; A103-B56; A103-B57; A103-B58; A103-B59; A103-B60;
A103-B61; A103-B62; A103-B63; A103-B64; A103-B65; A103-B66;
A103-B67; A103-B68; A103-B69; A103-B70; A103-B71; A103-B72;
A103-B73; A103-B74; A103-B75; A103-B76; A103-B77; A103-B78;
A103-B79; A103-B80; A103-B81; A103-B82; A103-B83; A103-B84;
A103-B85; A103-B86; A103-B87; A103-B88; A103-B89; A103-B90;
A103-B91; A103-B92; A103-B93; A103-B94; A103-B95; A103-B96;
A103-B97; A103-B98; A103-B99; A103-B100; A103-B101; A103-B102;
A103-B103; A103-B104; A103-B105; A103-B106; A103-B107; A103-B108;
A103-B109; A103-B110; A103-B111; A103-B112; A103-B113; A103-B114;
A103-B115; A103-B116; A103-B117; A103-B118; A103-B119; A103-B120;
A103-B121; A103-B122; A103-B123; A103-B124; A103-B125; A103-B126;
A103-B127; A103-B128; A103-B129; A103-B130; A103-B131; A103-B132;
A103-B133; A103-B134; A103-B135; A103-B136; A103-B137; A103-B138;
A103-B139; A103-B140; A103-B141; A103-B142; A103-B143; A103-B144;
A103-B145; A103-B146; A103-B147; A103-B148; A103-B149; A103-B150;
A103-B151; A103-B152; A103-B153; A103-B154; A103-B155; A103-B156;
A103-B157; A103-B158; A103-B159; A103-B160; A103-B161; A103-B162;
A103-B163; A103-B164; A103-B165; A103-B166; A103-B167; A103-B168;
A103-B169; A104-B1; A104-B2; A104-B3; A104-B4; A104-B5;
A104-B6; A104-B7; A104-B8; A104-B9; A104-B10; A104-B11;
A104-B12; A104-B13; A104-B14; A104-B15; A104-B16; A104-B17;
A104-B18; A104-B19; A104-B20; A104-B21; A104-B22; A104-B23;
A104-B24; A104-B25; A104-B26; A104-B27; A104-B28; A104-B29;
A104-B30; A104-B31; A104-B32; A104-B33; A104-B34; A104-B35;
A104-B36; A104-B37; A104-B38; A104-B39; A104-B40; A104-B41;
A104-B42; A104-B43; A104-B44; A104-B45; A104-B46; A104-B47;
A104-B48; A104-B49; A104-B50; A104-B51; A104-B52; A104-B53;
A104-B54; A104-B55; A104-B56; A104-B57; A104-B58; A104-B59;
A104-B60; A104-B61; A104-B62; A104-B63; A104-B64; A104-B65;
A104-B66; A104-B67; A104-B68; A104-B69; A104-B70; A104-B71;
A104-B72; A104-B73; A104-B74; A104-B75; A104-B76; A104-B77;
A104-B78; A104-B79; A104-B80; A104-B81; A104-B82; A104-B83;
A104-B84; A104-B85; A104-B86; A104-B87; A104-B88; A104-B89;
A104-B90; A104-B91; A104-B92; A104-B93; A104-B94; A104-B95;
A104-B96; A104-B97; A104-B98; A104-B99; A104-B100; A104-B101;
A104-B102; A104-B103; A104-B104; A104-B105; A104-B106; A104-B107;
A104-B108; A104-B109; A104-B110; A104-B111; A104-B112; A104-B113;
A104-B114; A104-B115; A104-B116; A104-B117; A104-B118; A104-B119;
A104-B120; A104-B121; A104-B122; A104-B123; A104-B124; A104-B125;
A104-B126; A104-B127; A104-B128; A104-B129; A104-B130; A104-B131;
A104-B132; A104-B133; A104-B134; A104-B135; A104-B136; A104-B137;
A104-B138; A104-B139; A104-B140; A104-B141; A104-B142; A104-B143;
A104-B144; A104-B145; A104-B146; A104-B147; A104-B148; A104-B149;
A104-B150; A104-B151; A104-B152; A104-B153; A104-B154; A104-B155;
A104-B156; A104-B157; A104-B158; A104-B159; A104-B160; A104-B161;
A104-B162; A104-B163; A104-B164; A104-B165; A104-B166; A104-B167;
A104-B168; A104-B169; A105-B1; A105-B2; A105-B3; A105-B4;
A105-B5; A105-B6; A105-B7; A105-B8; A105-B9; A105-B10;
A105-B11; A105-B12; A105-B13; A105-B14; A105-B15; A105-B16;
A105-B17; A105-B18; A105-B19; A105-B20; A105-B21; A105-B22;
A105-B23; A105-B24; A105-B25; A105-B26; A105-B27; A105-B28;
A105-B29; A105-B30; A105-B31; A105-B32; A105-B33; A105-B34;
A105-B35; A105-B36; A105-B37; A105-B38; A105-B39; A105-B40;
A105-B41; A105-B42; A105-B43; A105-B44; A105-B45; A105-B46;
A105-B47; A105-B48; A105-B49; A105-B50; A105-B51; A105-B52;
A105-B53; A105-B54; A105-B55; A105-B56; A105-B57; A105-B58;
A105-B59; A105-B60; A105-B61; A105-B62; A105-B63; A105-B64;
A105-B65; A105-B66; A105-B67; A105-B68; A105-B69; A105-B70;
A105-B71; A105-B72; A105-B73; A105-B74; A105-B75; A105-B76;
A105-B77; A105-B78; A105-B79; A105-B80; A105-B81; A105-B82;
A105-B83; A105-B84; A105-B85; A105-B86; A105-B87; A105-B88;
A105-B89; A105-B90; A105-B91; A105-B92; A105-B93; A105-B94;
A105-B95; A105-B96; A105-B97; A105-B98; A105-B99; A105-B100;
A105-B101; A105-B102; A105-B103; A105-B104; A105-B105; A105-B106;
A105-B107; A105-B108; A105-B109; A105-B110; A105-B111; A105-B112;
A105-B113; A105-B114; A105-B115; A105-B116; A105-B117; A105-B118;
A105-B119; A105-B120; A105-B121; A105-B122; A105-B123; A105-B124;
A105-B125; A105-B126; A105-B127; A105-B128; A105-B129; A105-B130;
A105-B131; A105-B132; A105-B133; A105-B134; A105-B135; A105-B136;
A105-B137; A105-B138; A105-B139; A105-B140; A105-B141; A105-B142;
A105-B143; A105-B144; A105-B145; A105-B146; A105-B147; A105-B148;
A105-B149; A105-B150; A105-B151; A105-B152; A105-B153; A105-B154;
A105-B155; A105-B156; A105-B157; A105-B158; A105-B159; A105-B160;
A105-B161; A105-B162; A105-B163; A105-B164; A105-B165; A105-B166;
A105-B167; A105-B168; A105-B169; A106-B1; A106-B2; A106-B3;
A106-B4; A106-B5; A106-B6; A106-B7; A106-B8; A106-B9;
A106-B10; A106-B11; A106-B12; A106-B13; A106-B14; A106-B15;
A106-B16; A106-B17; A106-B18; A106-B19; A106-B20; A106-B21;
A106-B22; A106-B23; A106-B24; A106-B25; A106-B26; A106-B27;
A106-B28; A106-B29; A106-B30; A106-B31; A106-B32; A106-B33;
A106-B34; A106-B35; A106-B36; A106-B37; A106-B38; A106-B39;
A106-B40; A106-B41; A106-B42; A106-B43; A106-B44; A106-B45;
A106-B46; A106-B47; A106-B48; A106-B49; A106-B50; A106-B51;
A106-B52; A106-B53; A106-B54; A106-B55; A106-B56; A106-B57;
A106-B58; A106-B59; A106-B60; A106-B61; A106-B62; A106-B63;
A106-B64; A106-B65; A106-B66; A106-B67; A106-B68; A106-B69;
A106-B70; A106-B71; A106-B72; A106-B73; A106-B74; A106-B75;
A106-B76; A106-B77; A106-B78; A106-B79; A106-B80; A106-B81;
A106-B82; A106-B83; A106-B84; A106-B85; A106-B86; A106-B87;
A106-B88; A106-B89; A106-B90; A106-B91; A106-B92; A106-B93;
A106-B94; A106-B95; A106-B96; A106-B97; A106-B98; A106-B99;
A106-B100; A106-B101; A106-B102; A106-B103; A106-B104; A106-B105;
A106-B106; A106-B107; A106-B108; A106-B109; A106-B110; A106-B111;
A106-B112; A106-B113; A106-B114; A106-B115; A106-B116; A106-B117;
A106-B118; A106-B119; A106-B120; A106-B121; A106-B122; A106-B123;
A106-B124; A106-B125; A106-B126; A106-B127; A106-B128; A106-B129;
A106-B130; A106-B131; A106-B132; A106-B133; A106-B134; A106-B135;
A106-B136; A106-B137; A106-B138; A106-B139; A106-B140; A106-B141;
A106-B 142; A106-B 143; A106-B144; A106-B145; A 106-B 146; A106-B 147;
A106-B148; A106-B149; A106-B150; A106-B151; A106-B152; A106-B153;
A106-B154; A106-B155; A106-B156; A106-B157; A106-B158; A106-B159;
A106-B160; A106-B161; A106-B162; A106-B163; A106-B164; A106-B165;
A106-B166; A106-B167; A106-B168; A106-B169; A107-B1; A107-B2;
A107-B3; A107-B4; A107-B5; A107-B6; A107-B7; A107-B8;
A107-B9; A107-B10; A107-B11; A107-B12; A107-B13; A107-B14;
A107-B15; A107-B16; A107-B17; A107-B18; A107-B19; A107-B20;
A107-B21; A107-B22; A107-B23; A107-B24; A107-B25; A107-B26;
A107-B27; A107-B28; A107-B29; A107-B30; A107-B31; A107-B32;
A107-B33; A107-B34; A107-B35; A107-B36; A107-B37; A107-B38;
A107-B39; A107-B40; A107-B41; A107-B42; A107-B43; A107-B44;
A107-B45; A107-B46; A107-B47; A107-B48; A107-B49; A107-B50;
A107-B51; A107-B52; A107-B53; A107-B54; A107-B55; A107-B56;
A107-B57; A107-B58; A107-B59; A107-B60; A107-B61; A107-B62;
A107-B63; A107-B64; A107-B65; A107-B66; A107-B67; A107-B68;
A107-B69; A107-B70; A107-B71; A107-B72; A107-B73; A107-B74;
A107-B75; A107-B76; A107-B77; A107-B78; A107-B79; A107-B80;
A107-B81; A107-B82; A107-B83; A107-B84; A107-B85; A107-B86;
A107-B87; A107-B88; A107-B89; A107-B90; A107-B91; A107-B92;
A107-B93; A107-B94; A107-B95; A107-B96; A107-B97; A107-B98;
A107-B99; A107-B100; A107-B101; A107-B102; A107-B103; A107-B104;
A107-B105; A107-B106; A107-B107; A107-B108; A107-B109; A107-B110;
A107-B111; A107-B112; A107-B113; A107-B114; A107-B115; A107-B116;
A107-B117; A107-B118; A107-B119; A107-B120; A107-B121; A107-B122;
A107-B123; A107-B124; A107-B125; A107-B126; A107-B127; A107-B128;
A107-B129; A107-B130; A107-B131; A107-B132; A107-B133; A107-B134;
A107-B135; A107-B136; A107-B137; A107-B138; A107-B139; A107-B140;
A107-B141; A107-B142; A107-B143; A107-B144; A107-B145; A107-B146;
A107-B147; A107-B148; A107-B149; A107-B150; A107-B151; A107-B152;
A107-B153; A107-B154; A107-B155; A107-B156; A107-B157; A107-B158;
A107-B159; A107-B160; A107-B161; A107-B162; A107-B163; A107-B164;
A107-B165; A107-B166; A107-B167; A107-B168; A107-B169; A108-B1;
A108-B2; A108-B3; A108-B4; A108-B5; A108-B6; A108-B7;
A108-B8; A108-B9; A108-B10; A108-B11; A108-B12; A108-B13;
A108-B14; A108-B15; A108-B16; A108-B17; A108-B18; A108-B19;
A108-B20; A108-B21; A108-B22; A108-B23; A108-B24; A108-B25;
A108-B26; A108-B27; A108-B28; A108-B29; A108-B30; A108-B31;
A108-B32; A108-B33; A108-B34; A108-B35; A108-B36; A108-B37;
A108-B38; A108-B39; A108-B40; A108-B41; A108-B42; A108-B43;
A108-B44; A108-B45; A108-B46; A108-B47; A108-B48; A108-B49;
A108-B50; A108-B51; A108-B52; A108-B53; A108-B54; A108-B55;
A108-B56; A108-B57; A108-B58; A108-B59; A108-B60; A108-B61;
A108-B62; A108-B63; A108-B64; A108-B65; A108-B66; A108-B67;
A108-B68; A108-B69; A108-B70; A108-B71; A108-B72; A108-B73;
A108-B74; A108-B75; A108-B76; A108-B77; A108-B78; A108-B79;
A108-B80; A108-B81; A108-B82; A108-B83; A108-B84; A108-B85;
A108-B86; A108-B87; A108-B88; A108-B89; A108-B90; A108-B91;
A108-B92; A108-B93; A108-B94; A108-B95; A108-B96; A108-B97;
A108-B98; A108-B99; A108-B100; A108-B101; A108-B102; A108-B103;
A108-B104; A108-B105; A108-B106; A108-B107; A108-B108; A108-B109;
A108-B110; A108-B111; A108-B112; A108-B113; A108-B114; A108-B115;
A108-B116; A108-B117; A108-B118; A108-B119; A108-B120; A108-B121;
A108-B122; A108-B123; A108-B124; A108-B125; A108-B126; A108-B127;
A108-B128; A108-B129; A108-B130; A108-B131; A108-B132; A108-B133;
A108-B134; A108-B135; A108-B136; A108-B137; A108-B138; A108-B139;
A108-B140; A108-B141; A108-B142; A108-B143; A108-B144; A108-B145;
A108-B146; A108-B147; A108-B148; A108-B149; A108-B150; A108-B151;
A108-B152; A108-B153; A108-B154; A108-B155; A108-B156; A108-B157;
A108-B158; A108-B159; A108-B160; A108-B161; A108-B162; A108-B163;
A108-B164; A108-B165; A108-B166; A108-B167; A108-B168; A108-B169;
A109-B1; A109-B2; A109-B3; A109-B4; A109-B5; A109-B6;
A109-B7; A109-B8; A109-B9; A109-B10; A109-B11; A109-B12;
A109-B13; A109-B14; A109-B15; A109-B16; A109-B17; A109-B18;
A109-B19; A109-B20; A109-B21; A109-B22; A109-B23; A109-B24;
A109-B25; A109-B26; A109-B27; A109-B28; A109-B29; A109-B30;
A109-B31; A109-B32; A109-B33; A109-B34; A109-B35; A109-B36;
A109-B37; A109-B38; A109-B39; A109-B40; A109-B41; A109-B42;
A109-B43; A109-B44; A109-B45; A109-B46; A109-B47; A109-B48;
A109-B49; A109-B50; A109-B51; A109-B52; A109-B53; A109-B54;
A109-B55; A109-B56; A109-B57; A109-B58; A109-B59; A109-B60;
A109-B61; A109-B62; A109-B63; A109-B64; A109-B65; A109-B66;
A109-B67; A109-B68; A109-B69; A109-B70; A109-B71; A109-B72;
A109-B73; A109-B74; A109-B75; A109-B76; A109-B77; A109-B78;
A109-B79; A109-B80; A109-B81; A109-B82; A109-B83; A109-B84;
A109-B85; A109-B86; A109-B87; A109-B88; A109-B89; A109-B90;
A109-B91; A109-B92; A109-B93; A109-B94; A109-B95; A109-B96;
A109-B97; A109-B98; A109-B99; A109-B100; A109-B101; A109-B102;
Al09-B103; A109-B104; A109-B105; A109-B106; A109-B107; A109-B108;
A109-B109; A109-B110; A109-B111; A109-B112; A109-B113; A109-B114;
A109-B 115; A109-B 116; A109-B 117; A109-B 118; A109-B119; A109-B 120;
A109-B121; A109-B122; A109-B123; A109-B124; A109-B125; A109-B126;
A109-B127; A109-B128; A109-B129; A109-B130; A109-B131; A109-B132;
A109-B133; A109-B134; A109-B135; A109-B136; A109-B137; A109-B138;
A109-B139; A109-B140; A109-B141; A109-B142; A109-B143; A109-B144;
A109-B145; A109-B146; A109-B147; A109-B148; A109-B149; A109-B150;
A109-B151; A109-B152; A109-B153; A109-B154; A109-B155; A109-B156;
A109-B157; A109-B158; A109-B159; A109-B160; A109-B161; A109-B162;
A109-B163; A109-B164; A109-B165; A109-B166; A109-B167; A109-B168;
A109-B169; AllO-B1; A110-B2; A110-B3; A110-B4; A110-B5;
A110-B6; A110-B7; A110-B8; A110-B9; A110-BlO; A110-B11;
A110-B12; A110-B13; A110-B14; A110-B15; A110-B16; A110-B17;
A110-B18; A110-B19; A110-B20; A110-B21; A110-B22; A110-B23;
A110-B24; A110-B25; A110-B26; A110-B27; A110-B28; A110-B29;
A110-B30; Al10-B31; A110-B32; A110-B33; A110-B34; A110-B35;
A110-B36; A110-B37; A110-B38; A110-B39; A110-B40; A110-B41;
A110-B42; A110-B43; A110-B44; A110-B45; A110-B46; A110-B47;
A110-B48; A110-B49; A110-B50; A110-B51; A110-B52; A110-B53;
Al10-B54; A110-B55; A110-B56; A110-B57; A110-B58; A110-B59;
A110-B60; A110-B61; A110-B62; A110-B63; A110-B64; A110-B65;
A110-B66; A110-B67; A110-B68; A110-B69; A110-B70; A110-B71;
A110-B72; A110-B73; A110-B74; A110-B75; A110-B76; A110-B77;
A110-B78; A110-B79; A110-B80; A110-B81; A110-B82; A110-B83;
A110-B84; A110-B85; A110-B86; A110-B87; A110-B88; A110-B89;
A110-B90; A110-B91; A110-B92; A110-B93; A110-B94; A110-B95;
A110-B96; A110-B97; A110-B98; A110-B99; A110-B100; A110-B101;
A110-B102; A110-B103; A110-B104; A110-B105; A110-B106; A110-B107;
A110-B108; A110-B109; A110-B110; A110-B111; A110-B112; A110-B113;
A110-B114; A110-B115; A110-B116; A110-B117; A110-B118; A110-B119;
A110-B120; A110-B121; A110-B122; A110-B123; A110-B124; A110-B125;
A110-B126; A110-B127; A110-B128; A110-B129; A110-B130; A110-B131;
A110-B132; A110-B133; A110-B134; Al10-B135; A110-B136; A110-B137;
A110-B138; A110-B139; A110-B140; A110-B141; A110-B142; A110-B143;
A110-B144; A110-B145; A110-B146; A110-B147; A110-B148; A110-B149;
A110-B150; A110-B151; A110-B152; A110-B153; A110-B154; A110-B155;
A110-B156; A110-B157; A110-B158; A110-B159; A110-B160; A110-B161;
A110-B162; A110-B163; A110-B164; A110-B165; A110-B166; A110-B167;
A110-B168; A110-B169.

Thus, for example, in the above list the compound denoted as A9-B9 is the product of the combination of group A9 in Table 1 and B9 in Table 2, namely ,~ N
I / \ NH

, Example 230(a) hereinafter described.
Particular compounds of the invention of formula (Ix) for the inhibition of SYK are:
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole=5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid N-phenethylamide;
5,6-dimethyl-2-(5-methylsulfanyl-lH-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-methylsulfanyl-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1 H-pyrazol-3-yl)-5-methyl-lH-benzoimidazole;
2-(5 -methylsulfanyl- 1 H-pyrazol-3-yl)-5-trifluoromethyl-1 H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1 H-pyrazol-3-yl)-5,6-dimethyl-1 H-benzoimidazole;
2-(5-ethylsulfanyl-lH-pyrazol-3-yl)-5,6-dimethyl-lH-benzoimidazole;
5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5-fluoro-2-[5-methylsulfanyl)-1 H-pyrazol-3-yl]-1H-benzoimidazole;
5,6-dimethyl-2-(5-phenethylsulfanyl-1 H-pyrazol-3-yl)-1H-benzoimidazole;
4-methyl-2-(5-methylsulfanyl-1 H-pyrazol-3 -yl)-1 H-b enzoimidazole;
5,6-dimethyl-2-(5-benzylsulfanyl-lH-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5 -methyl-2-(5 -morpholin-4-yl-1 H-pyrazol-3 -yl)-1 H-b enzoimidazole;
5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1 H-benzoimidazole;
2-(5-ethylsulfanyl-lH-pyrazol-3-yl)-5-methoxy-lH-benzoimidazole hydrochloride;
5-methyl-2-(5-methylsulfanyl-4-propyl-1 H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-lH-pyrazol-3-yl)- 5-methyl-lH-benzoimidazole;
2-(5-benzylsulfanyl-4-isopropyl-1 H-pyrazol-3-yl)-5-methyl-lH-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-lH-pyrazol-3-yl)-5-methoxy-1 H-benzoimidazole;
2 -(5-methylsulfanyl-4-methyl-1 H-pyrazol-3-yl)-5-methyl-1 H-benzoimidazole;
3-(5-chloro-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5,6-dichloro-lH-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(6-chloro-5-methoxy-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5-methoxy-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5 -fluoro-6-methyl-1 H-benzoiinidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5-trifluoromethoxy-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
2-(4-amino-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-methoxy-1 H-benzoimidazol-2-yl)-1 H-indazole;
[2-(indazol-3-yl)-1 H-benzoimidazol-5-yl]-phenyl-methanone;
2-(1 H-indazol-3-yl)-3H-benzoimidazol-4-ol;
2-phenyl-1 H-imidazol[4,5-b]pyrazine;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole;
2-(1 H-indazol-3 -yl)-3 H-imidazo [4, 5 -c]pyridine;
2-(1 H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine;
2-(1 H-pyrazol-3y1)-1 H-benzoimidazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methoxy-1 H-indazole;
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-5-methoxy-lH-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-fluoro-1 H-indazole;
3 -(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-6-fluoro-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-6-methoxy-lH-indazole;
5,6-dimethyl-2-(4-phenyl-lH-pyrazol-3-yl)-1H-benzoimidazole;
3-(5 -ethyl-1 H-b enzo imi dazo l-2 -yl)-1 H-indazo le;
3-( 5-ethyl-6-methyl-1 H-b enzo imi dazo l-2-yl) -1 H-indazo le;
3-(5-isopropyl-6-methyl-1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-6-methyl-lH-benzoimidazol-2-yl)-1 H-indazole;
3-(5-bromo-lH-benzoimidazol-2-yl)-1H-indazole;
3-(5 -(3 -cyano)phenyl-1 H-b enzoimidazol-2-yl)-1 H-indazo le;
3 -(5 -(pyrid-3 -yl)-1 H-b enzoimidazol-2-yl)-1 H-indazole;
3-(6-methyl-5-phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3 -(5 -(2-fluoro)phenyl-1 H-b enzoimidazol-2-yl)-1 H-indazole;
3-(5-(5,6-methylenedioxy)phenyl-lH-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-methoxy)phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3 -(5-(4-chloro)phenyl-1 H-b enzoimidazol-2-yl)-1 H-indazole;
3-(5-(4-methyl)phenyl-1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5-benzyloxy-1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-methylenedioxy-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5, 6-dixnethoxy-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5,6-diethyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(4, 5-dimethyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carbonitrile;
3-(5-methoxycarbonyl-lH-benzoimidazol-2-yl)-1H-indazole;
3-(5, 6-dimethyl-1 IH-benzoimidazol-2-yl)-5-ethoxy- H-indazole;
3-(5,6-dimethyl-lH-benzoiinidazol-2-yl)-pyrazole-4-carboxylic acid ethyl ester;
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-[5-(2-morpholin-4-yl-ethoxy)-1 H-benzoimidazol-2-yl]-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1 H-indazole-5-carbonitrile;
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
2-( 5-methyl-1 H-pyrazol-3 -yl)-1 H-b enzoimidazol e;
2-(5 -ethoxy-1 H-pyrazol-3 -yl)-1 H-benzoimidazole;
2-(5-methylsulfanyl-isoxazol-3-yl)-1 H-benzoimidazole;
5-chloro-2-(4-nitro-1 H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dichloro-2-(4-nitro-lH-pyrazol-3-yl)-1H-benzoimidazole;
(benzoimidazol-2-yl)-5-methylthio-3-pyrazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1 H-indazole;
2-(5-isopropyl-1 H-pyrazol-3-yl)-5,6-dimethyl-1 H-benzoimidazole;
2-(5-ethyl-1 H-pyrazol-3-yl)-5,6-dimethyl-1 H-benzoimidazole;
5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1 H-benzoimidazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-4-fluoro-lH-indazole;
4-chloro-3 -(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-chloro-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazol-5-ol;
3-(5-n-propyl-1 H-benzoimidazo 1-2-yl)-1 H-indazole;
2-(1H-indazol-3-yl)-lH-benzoimidazole-5-sulfonic acid benzylamide;
3 -(5 -methane sulfonyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
[2-(indazol-3-yl)-1 H-benzoimidazol-5-yl]-phenyl-methanol;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide;
IH-benzoimidazol-5-yl]-carboxylic acid, benzylamide;
[2-(indazol-3-yl)-1 H-benzoimidazol-5-yl]-carboxylic acid, benzamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(4-isopropylcarbamoyl-IH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid cyclopropylamide;
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;
2-(1H-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide;
2-(IH-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;
3-(5, 6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid tert-butylamide;
3-(5,6-dimethyl-lH-benzoiinidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide;
2-(4-isobutyrylamino-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
3-(5,6-dimethyl-lH-benzoimidazol-5-yl)-pyrazole-4-carboxylic acid;
2-(4-isopropylcarbamoyl-1 H-pyrazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid;
N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-isobutyramide ;
N-[3-(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-methyl-butyramide;
N-[3-(5,6-dimethyl-lH-benzoiinidazol-2-yl)-1 H-pyrazol-4-yl]-2-phenyl-acetamide;
cyclopropanecarboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-y1)-1H-pyrazol-4-yl]-amide;
N-[3 -(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl] -4-methyl-benzamide;
5, 6-dimethyl-2-(4-nitro-1 H-pyrazo 1-3 -yl)-1 H-benzoimidazole;
5-ethyl-6-methyl-2-(4-nitro-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
6-chloro-5-methoxy-2-(4-nitro-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
5-fluoro-6-methyl-2-(4-nitro-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
2-(4-nitro-lH-pyrazol-3-yl)-5-trifluoromethoxy-lH-benzoimidazole;
2-(4-nitro-1 H-pyrazol-3-yl)-5-trifluoromethyl-lH-benzoimidazole;
5 -chloro-6-methyl-2-(4-nitro-1 H-pyrazol-3 -yl)-1 H-benzoimidazole;
2-(4-nitro-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
cyclopropyl-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;
isopropyl-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-l-one;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine;
3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridine;
3-[5-(2-morpholin-4-yl-ethoxy)-1 H-benzoimidazol-2-yl]-4,5,6,7-tetrahydro-1 H-pyrazolo [4,3-c]pyridine;
3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
5-methoxy-2-(4-nitro-lH-pyrazol-3-yl)-1H-benzoimidazole;
5-ethoxy-2-(4-nitro-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
3-(5-chloro-6-methyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole;
3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
2-dimethylamino-N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-acetamide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3 -( 5, 6-dimethyl-1 H-b enzoimidazol-2 -yl)-1 H-pyrazol-4-yl] -acetamide;
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl] -3-phenyl-urea;
1-benzyl-3-[3-(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-urea;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1 H-pyrazol-4-ylamine;
4-methylpiperazine-l-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
l,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl] urea;
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazole-4-yl] amide;
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
5-methoxy-2-(4-nitro-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;
3-[3-(5-difluoromethoxy-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-l-carboxylic acid [3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-l-yl-methanone;
[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-l-yl-methanone;
[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;
3-(5-chloro-6-methyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[5-(2-morpholin-4-yl-ethoxy)-1 H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [2-(2H-tetrazol-5-yl)-ethyl]-amide;
1-cyc lopropyl-3 -[3 -( 5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl] -urea;
1-[3-(5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-methyl-urea;
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-urea;
1-[3-(5 -chloro-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-l-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea;
4-methyl-piperazine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3 -(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl] -urea;
3-(5-chloro-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid;
2-(4-isobutyrylamino-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid;
3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
3-(5-nitro-1 H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide;
N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide;
N-[3-(5,6-Dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide;
2-(1 H-indazol-3-yl)-3H-benzoimidazol-5-amine;
piperidine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
5,6-dimethyl-2-(5-methylsulfanyl-lH-pyrazol-3-yl)-1 H-benzoimidazole;
6-chloro-5-methyl-2-(5-methylsulfanyl-lH-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1 H-pyrazol-3-yl)-5-methyl-1 H-benzoimidazole;
2-(5-methylsulfanyl-lH-pyrazol-3-yl)-5-trifluoromethyl-1 H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1 H-pyrazol-3-yl)-5, 6-dimethyl-1 H-benzoimidazole;
2-(5-ethylsulfanyl-1 H-pyrazol-3-yl)-5,6-dimethyl-1 H-benzoimidazole;
5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5-fluoro-2-[ 5-methylsulfanyl)-1 H-pyrazol-3 -yl] -1 H-b enzo imidazo le;
5, 6-dimethyl-2-(5-phenethylsulfanyl-1 H-pyrazol-3 -yl)-1 H-b enzoimidazole;
4-methyl-2-(5 -methylsulfanyl-1 H-pyrazol-3 -yl)-1 H-b enzoimidazole;
5,6-dimethyl-2-(5-benzylsulfanyl-1 H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
2-(5-ethylsulfanyl-lH-pyrazol-3-yl)-5-methoxy-lH-benzoimidazole hydrochloride;
5-methyl-2-(5-methylsulfanyl-4-propyl-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-lH-pyrazol-3-yl)- 5-methyl-lH-benzoimidazole;
2-(5-benzylsulfanyl-4-isopropyl-1 H-pyrazol-3-yl)-5-methyl-1 H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1 H-pyrazol-3-yl)-5-methoxy-1 H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-lH-pyrazol-3-yl)-5-methyl-lH-benzoimidazole;
3 -(5 -chloro-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylamine;
3-(5, 6-dichloro-1 H-benzoimidazol-2-yl)-1 H-pyrazo 1-4-ylamine;
5,6-dimethyl-2-(4-phenyl-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
2-(5-ethoxy-1 H-pyrazol-3-yl)-1 H-benzoimidazole;
(benzoimidazol-2-yl)-5-methylthio-3 -pyrazole;
2-(5-isopropyl-1 H-pyrazol-3-yl)-5,6-dimethyl-lH-benzoimidazole;
2-(5-ethyl-lH-pyrazol-3-yl)-5,6-dimethyl-lH-benzoimidazole;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid cyclopropylamide;
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;
3-(5, 6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid tert-butylamide;
2-(4-isobutyrylamino-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide;
cyclopropanecarboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tef-t-butylacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-4-methyl-benzamide;
N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
2-dimethylamino-N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-acetamide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
4-methylpiperazine-l-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl] amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1 H-pyrazol-4-yl]urea;
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1 H-benzimidazol-2-yl)-1 H-pyrazole-4-yl]amide;
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;
3-[3-(5-difluoromethoxy-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-l-carboxylic acid [3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[ 3-(5 -methoxy-1 H-b enzoimidazol-2 -yl)-1 H-pyrazo 1-4-y1]-1,1-dimethyl-urea;
piperidine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-fluoro-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-1,1-dimethyl-urea;
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-methyl-urea;
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-urea;
1-[3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-l-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[ 3-(5, 6-dimethyl-1 H-b enzo imi dazo l-2-yl)-1 H-pyrazol-4-yl] -3 -ethyl-ure a;
4-methyl-piperazine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
N-[2-(1 H-indazol-3 -yl)-1 H-b enzoimidazol-5 -yl] -isobutyramide;
N-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide;
2-(1H-indazol-3-yl)-IH-benzimidazole-5-carboxylic acid N-morpholinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide;
2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid N-(isobutyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide;
methyl2-(1H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
5,6-dimethyl-2-(1 H-indazol-3-yl)-1H-benzimidazole;
2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid;
2-(5-ethoxy-2H-pyrazol-3-yl)-1 H-benzimidazole-4-carboxylic acid;
5, 6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1 H-benzimidazole;
5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole;
2-(4-bromo-2H-pyrazol-3-yl)-5, 6-dimethyl-lH-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5, 6-dimethyl-1 H-b enzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4, 5-ethylenedioxy-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1 H-benzimidazole 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1 H-benzimidazole;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-2-(1H-indazol-3-yl)-IH-benzimidazole-5-carboxylic acid benzylamide, Example 1;
2-(1H-indazol-3-yl)-IH-benzimidazole-5-carboxylic acid N-methylamide, Example 2;
2-(1H-indazol-3-yl)-IH-benzimidazole-5-carboxylic acid N-ethylamide, Example 3;
2-(1H-indazol-3-yl)-IH-benzimidazole-5-carboxylic acid N-isopropylamide, Example 4;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide, Example 5;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acidN-phenethylamide, Example 6 5,6-dimethyl-2-(5-methylsulfanyl-lH-pyrazol-3-yl)-1H-benzoimidazole, (compound denoted as A9-B9), Example 230(a);
6-chloro-2-(5-methylsulfanyl-lH-pyrazol-3-yl)-5-methyl-lH-benzoimidazole, (compound denoted as A12-B9), Example 230(b);
6-chloro-2-(5-ethylsulfanyl-lH-pyrazol-3-yl)-5-methyl-lH-benzoimidazole, (compound denoted as A12-B10), Example 230(c);
2-(5-methylsulfanyl-lH-pyrazol-3-yl)-5-trifluoromethyl-lH-benzoimidazole, (compound denoted as A4-B9), Example 230(d);
2-(5-cyclopropylmethylsulfanyl-lH-pyrazol-3-yl)-5,6-dimethyl-lH-benzoimidazole, (compound denoted as A9-B11), Example 230(e);
2-(5-ethylsulfanyl-lH-pyrazol-3-yl)-5,6-dimethyl-lH-benzoimidazole, (compound denoted as A9-B10), Example 230(f);
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah);
3-(5-methoxy-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide, Example 235(ak);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide, Example 235(al);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am);
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ao);
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ap);
3-(6-ethyl-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(aq);
2-(5-isopropyl-lH-pyrazol-3-yl)-5,6-dimethyl-lH-benzoimidazole, (compound denoted as A9-B83), Example 241(b);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, (compound denoted as A9-B106), Example 246(g);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, (compound denoted as A9-B25), Example 246(h);
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, (compound denoted as A40-B 106), Example 246(i);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid cyclopropylamide, (compound denoted as A9-B 105), Example 246(j);
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106), Example 246(k);
3-(5, 6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v);

3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 246(w);

3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide, Example 246(x);

3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid tert-butylamide, Example 246(y);
2-(4-isobutyrylamino-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide, Example 246(aa);

N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, (compound denoted as A9-B85), Example 248(a);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide, (compound denoted as A9-B86), Example 248(b);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide, (compound denoted as A9-B36), Example 248(c);
cyclopropanecarboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B89), Example 248(d);
methoxyacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B94), Example 248(e);
cyclopentanecarboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B87), Example 248(f);
trimethylacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B88), Example 248(g);
tert-butylacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B90), Example 248(h);
butanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B91), Example 248(i);
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B96), Example 248(j);
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B93), Example 248(k);
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A55-B89), Example 248(1);
piperidine-l-carboxylic acid[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(m);

3-[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea, Example 248(n);

cyclopropanecarboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(o);

cyclopropanecarboxylic acid [3-(5-ethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(p);

cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(q);
cyclopropanecarboxylic acid [3-(S-trifluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(r);

cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(s);
N-[3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-y1]-isobutyramide, Example 248(t);
cyclopropanecarboxylic acid [3-(S-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(u);

3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Exainple 248(v);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide, Example 248(w);
furan-3-carboxylic acid [3-(S-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(x);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide, Example 248(y);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide, (compound denoted as A9-B99), Example 253;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide, (compound denoted as A9-B97), Example 254(a);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
Example 254(b);
2-cyclopropyl-N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; Example 254(c);

1-[3-(5,6-dimethyl-lH-benzoimidazol-2-y1)-1H-pyrazol-4-yl]-3-methyl-urea, (compound denoted as A9-B38), Example 255(a);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea, (compound denoted as A9-B103), Example 255(b);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea, (compound denoted as A9-B40), Example 255(c);
1-benzyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, (compound denoted as A9-B39), Example 255(d);
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a);
4-methylpiperazine-l-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 256(c);
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d);
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(a);
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide, Example 257(b);
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(c);
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d);
3-[6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e);
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-ylmethyl]-amide, Example 257(g);
3-[3-(5-difluoroinethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);
piperidine-l-carboxylic acid [3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i);
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(a);
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b);
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(c);
piperidine-l-carboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d);
3-[3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(e);
piperidine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f);
3-[3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(g);
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(h);
morpholine-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(n);
piperidine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o);
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-urea, Example 260(a);
1-[3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-3-methyl-urea, Example 260(b);
4-methyl-piperazine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(c);
piperidine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide, Example 260(d);
1-[3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(e);
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(f);
4-methyl-piperazine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(g);
1-methyl-3-[3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(h);
1-[3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(i);
4-methyl-piperazine-l-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(j);
1-tert-butyl-3-[3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k);
1-[3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea, Example 260(1);
4-methyl-piperazine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(m);
1-cyclopropyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-urea, Example 260(n);
3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-3-isobutyl-urea, Example 260(p);
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q);
3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(r);
2-(IH-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide, Example 246(ab);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide, Example 246(ac);
N-[3-(5,6-Dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide, Example 253(c);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Especially preferred compounds of formula (Ixa), denoted as the product of the combination of group Al in Table 1 and Bl in Table 2, of the invention for the inhibition of SYK
are:-3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah);
3-(5-methoxy-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide, Example 235(ak);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide, Example 235(al);
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am);
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ao);
3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ap);
3-(6-ethyl-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(aq);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, (compound denoted as A9-B106), Example 246(g);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-l,l-dimethyl-ethyl)-amide, (compound denoted as A9-B25), Example 246(h);
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, (compound denoted as A40-B106), Exainple 246(i);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid cyclopropylamide, (compound denoted as A9-B 105), Example 246(j);
2-(4-isopropylcarbamoyl-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106), Example 246(k);
3-(5, 6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 246(w);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide, Example 246(x);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-pyrazole-4-carboxylic acid tert-butylamide, Example 246(y);
2-(4-isobutyrylamino-lH-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide, Example 246(aa);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, (compound denoted as A9-B85), Example 248(a);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide, (compound denoted as A9-B86), Example 248(b);
cyclopropanecarboxylic acid [3-(5,6-dimethyl-lH-benzoiinidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B89), Example 248(d);
methoxyacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B94), Example 248(e);
cyclopentanecarboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B87), Example 248(f);
trimethylacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B88), Example 248(g);
tert-butylacetic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B90), Example 248(h);
butanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B91), Example 248(i);
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B96), Example 248(j);
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B93), Example 248(k);
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A55-B89), Example 248(1);
piperidine-l-carboxylic acid[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(m);
3-[3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea, Example 248(n);
cyclopropanecarboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(o);
cyclopropanecarboxylic acid [3-(5-ethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(p);
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(q);
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(s);
N-[3-(5-trifluoromethyl-1 H-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-isobutyramide, Example 248(t);
cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(u);
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(v);
furan-3-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(x);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide, (compound denoted as A9-B99), Example 253;
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide, (compound denoted as A9-B97), Example 254(a);
N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
Example 254(b);
2-cyclopropyl-N-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; Example 254(c);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, (compound denoted as A9-B38), Example 255(a);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea, (compound denoted as A9-B103), Example 255(b);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea, (compound denoted as A9-B40), Example 255(c);
1-benzyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, (compound denoted as A9-B39), Example 255(d);
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a);
4-methylpiperazine-l-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 256(c);
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d);
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(a);
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide, Example 257(b);
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(c);
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d);
3-[6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e);
3-[3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);
piperidine-l-carboxylic acid [3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i);
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-lH-benzoimidazol-2-yl)-1 H-pyrazol-4-yl]-amide, Example 258(a);
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b);
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(c);
piperidine-l-carboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d);
3-[3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(e);
piperidine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f);
3-[3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(g);
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(h);
morpholine-4-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(n);
piperidine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o);
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a);
1-[3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(b);
4-methyl-piperazine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(c);
piperidine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d);
1-[3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(e);
morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(f);
1-methyl-3-[3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(h);
1-[3-(5-chloro-6-inethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(i);
4-methyl-piperazine-l-carboxylic acid [3-(5-chloro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(j);
1-tert-butyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea, Example 260(1);
4-methyl-piperazine-l-carboxylic acid [3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(m);
1-cyclopropyl-3-[3-(5,6-dimethyl-lH-benzoiinidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n);
3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o);
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea, Example 260(p);
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q); 3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, (compound denoted as A9-B 142), Example 25 8(r);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
More especially preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-3-(5-methoxy-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai);
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am);
3-(5, 6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v);
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a);
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d);
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d);
3-[6-ethoxy-5-fluoro-lH-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e);
3-[3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);
piperidine-l-carboxylic acid [3-(5-difluoromethoxy-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i);
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b);
piperidine-l-carboxylic acid [3-(5-methoxy-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-amide, Example 258(d);
piperidine-l-carboxylic acid [3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f);
piperidine-l-carboxylic acid [3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o);
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a);
piperidine-l-carboxylic acid [3-(5-fluoro-6-methyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d);
1-tert-butyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k);
1-cyclopropyl-3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n);
3-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-IH-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o);
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-IH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q);
3-[3-(5,6-dimethyl-lH-benzoiinidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(r);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixb) of the invention for the inhibition of SYK are:-3-(1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-indazole;
[2-(indazol-3-yl)-1 H-benzoimidazol-5-yl] -phenyl-methanone;
2-(1 H-indazol-3-yl)-3H-benzoimidazol-4-ol;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine;
2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine;
3 -(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-5 -methoxy-1 H-indazole;
3-(5, 6-dimethyl-1 H-b enzoimidazol-2-yl)-5-fluoro-1 H-indazole;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-6-fluoro-lH-indazole;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-5-methyl-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-6-methoxy-lH-indazole;
3 -(5 -ethyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-isopropyl-6-methyl-lH-benzoimidazol-2-yl)-1 H-indazole;
3-(5-bromo-6-methyl-1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-(3-cyano)phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-(pyrid-3-yl)-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(6-methyl-5-phenyl-1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5-phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-(2-fluoro)phenyl- 1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-methoxy)phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-(4-chloro)phenyl- 1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-(4-methyl)phenyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5 -benzyloxy- 1 H-benzoimidazol-2-yl)- 1 H-indazole;
3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5, 6-dimethoxy-1 H-b enzo imidazol-2-yl)-1 H-indazole;
3-(5,6-diethyl-1 H-benzoimidazol-2 -yl)-1 H-indazole;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carbonitrile;
3-(5-methoxycarbonyl- 1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-ethoxy-lH-indazole;
3-[5-(2-morpholin-4-yl-ethoxy)-1 H-benzoimidazol-2-yl] -1 H-indazole;
3-(5-ethyl-6-methyl-1 H-benzoimidazol-2-yl)-1 H-indazole-5-carbonitrile;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1 H-indazole-5-carbonitrile;
3-(5,6-dimethyl- 1 H-benzoimidazol-2-yl)-4-fluoro-1 H-indazole;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-chloro-lH-indazole;
3-(5-n-propyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide;
3-(5-methanesulfonyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
[2-(indazol-3 -yl)-1 H-benzoimidazol-5-yl] -phenyl-methanol;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-lH-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-l,l-dimethyl-ethyl)-amide;
2-(lH-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide;
[2-(indazol-3-yl)-1 H-benzoimidazol-5-yl]-carboxylic acid;
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixb), denoted as the product of the combination of group Al in Table 1 and B 1 in Table 2, of the invention for the inhibition of SYK
are:-3-(1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A1-B63), Example 234(a);
3-(5-methoxy-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A6-B63), Example 234(b);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A9-B63), Example 234(f);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methoxy-lH-indazole, (compound denoted as A9-B68), Example 235(b);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-fluoro-lH-indazole, (compound denoted as A9-B70), Example 235(d);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-6-fluoro-lH-indazole, (compound denoted as A9-B71), Example 235(e);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methyl-lH-indazole, (compound denoted as A9-B64), Example 235(f);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-6-methoxy-lH-indazole, (compound denoted as A9-B69), Example 235(g);

3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A27-B63), Example 235(i);
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A55-B63), Example 235(j);

3-(5-isopropyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A54-B63), Example 235(k);
3-(5-bromo-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A58-B63), Example 235(1);
3-(5-bromo-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A32-B63), Example 235(m);
3-(5-(3-cyano)phenyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A68-B63), Example 235(n);
3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A69-B63), Example 235(o);
3-(6-methyl-5-phenyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A57-B63), Example 235(p);
3-(5-phenyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A60-B63), Example 235(q);
3-(5-(2-fluoro)phenyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A65-B63), Example 235(r);
3-(5-(3,4 -methylenedioxy)phenyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A66-B63), Example 235(s);
3-(5-benzyloxy-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A74-B63), Example 235(w);
3-(5,6-methylenedioxy-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A22-B63), Example 235(x);
3-(5,6-dimethoxy-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A23-B63), Example 235(y);
3-(5,6-diethyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A56-B63), Example 235(z);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile, (compound denoted as A33-B63), Example 235(ab);
3-(5-methoxycarbonyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A35-B63), Example 235(ac);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-ethoxy-lH-indazole, (compound denoted as A9-B63), (compound denoted as A9-B 112), Example 235(ad);
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole, Example 235(aj);
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile, Example 235(an);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile, Example 235(ar);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-4-fluoro-lH-indazole, (compound denoted as A9-B110), Example 242(a);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-chloro-lH-indazole, (compound denoted as A9-B109), Example 242(c);
3-(5-n-propyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A28-B63), Example 244(a);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide, Example244(b);
3-(5-methanesulfonyl-lH-benzoimidazol-2-yl)-1H-indazole; Example 244(c) [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol, (compound denoted as A34-B63), Example 245;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, ethylamide, (compound denoted as A36-B63), Example 246(a);
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide, (compound denoted as A15-B63), Example 246(b);
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide, (compound denoted as A16-B63), Example 246(d);
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide, (compound denoted as A17-B63), Example 246(e);
[2-(indazol-3-yl)-1H-benzoimidazol-5-y1]-carboxylic acid, benzamide, (compound denoted as A52-B63), Example 246(f);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, Exainple 246(m);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide, Example 246(n);
2-(1H-indazol-3-yl)-lH-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide, Example 246(o);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide, Example 246(p);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide, Example 246(q);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide, Example 246(r);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide, Example 246(s);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, Example 246(t);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide, Example 246(u), 3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide, Example 246(x);
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, (compound denoted as A14-B63), Example 247(a);
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride, Example 262;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (Ixb) of the invention for the inhibition of SYK are:-3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-5-methoxy-lH-indazole, (compound denoted as A9-B68), Example 235(b);
3-(5-ethyl-6-methyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A55-B63), Example 235(j);
3-(5,6-diethyl-lH-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A56-B63), Example 235(z);
3-(5,6-diinethyl-lH-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide, Example 246(x);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixc) of the invention for the inhibition of SYK are:-3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-4, 5, 6,7-tetrahydro-1 H-indazole;
5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1 H-benzoimidazole;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixc), denoted as the product of the combination of group Al in Table 1 and B 1 in Table 2, of the invention for the inhibition of SYK
are:-3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-lH-indazole, (compound denoted as A9-B59), Example 241(a);
5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole, (compound denoted as A9-B56), Example 241(d);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixd) of the invention for the inhibition of SYK are:-3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
cyclopropyl-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;
isopropyl-[3-(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4, 3-c]pyridin-5-yl]-methanone;
1-[3-(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl] -ethanone;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-methyl-propan-l-one;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide;
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-3-methyl-butan-l-one;
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-l-one;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-l-yl-methanone;
[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-l-yl-methanone;
[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;
3 -(5-chloro-6-methyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dietllylamide;
3-[5-(2-morpholin-4-yl-ethoxy)-1 H-benzoimidazol-2-y1]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylainide;
1-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-5-(propane-2-sulfonyl)-4,5,6,7-tetrahydro-lH-pyrazolo[4,3-c]pyridine;
3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixd), denoted as the product of the combination of group Al in Table 1 and B 1 in Table 2, of the invention for the inhibition of SYK
are:-3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, (compound denoted as A9-B121), Example 250(a);
cyclopropyl-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone, (compound denoted as A9-B 122);
isopropyl-[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;
1-[3-(5, 6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-p rop an-l-one;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; 26(e) prepared 3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-l-yl-methanone;
[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-l-yl-methanone;
[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;
3-(5-chloro-6-methyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
3-[5-(2-morpholin-4-yl-ethoxy)-1 H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo [4,3-c]pyridine-5-carboxylic acid diethylamide;
3-(5-trifluoromethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide, (compound denoted as A9-B 119);
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4, 6,7-tetrahydro-pyrazolo [4,3-c]pyridin-5-yl] -2-methyl-propan-l-one, (compound denoted as A9-B117);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester, (compound denoted as A9-B 120);
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-3-methyl-butan-l-one, (compound denoted as A9-B118);
1-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-l-one, (compound denoted as A9-B123);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (Ixd), denoted as the product of the combination of group Al in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK
are:-3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, (compound denoted as A9-B121), Example 250(a);
cyclopropyl-[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4, 6,7-tetrahydro-pyrazolo [4,3-c]pyridin-5-yl]-methanone, (compound denoted as A9-B 122); Example 250(b);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, Example 255(e);
prepared 3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide, Example 258(i);
[3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-l-yl-methanone, Example 258(j);
[3-(5,6-dimethyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3 -c]pyridin-5-yl]-piperidin-l-yl-methanone, Example 258(k);
3-(5-chloro-6-methyl-1 H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo [4,3-c]pyridine-5-carboxylic acid diethylamide, Example 258(m);
3-(5,6-dimethyl-lH-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide, (compound denoted as A9-B 119);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Particular compounds of formula (Ix) of the invention for the inhibition of KDR are:-2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide;
methyl2-(1H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole;
5-methoxy-2-(1 H-indazol-3-yl)-1H-benzimidazole;
2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid;
5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole;
2-(5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid;
5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole;
5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1 H-benzimidazole;
2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1 H-benzimidazole 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1 H-benzimidazole;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide;
4-( { [2-(1 H-indazol-3-y1)-1H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-l-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-lH-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-lH-pyrazol-4-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (5-chloro-benzo[b]thiophen-3-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 3-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-lH-benzoimidazol-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1 H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide;
2-(1 H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-dimethylamino-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-phenoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-chloro-benzylamide;
2-(1 H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenethyl-amide;
3-(6-phenyl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(2,4-dichloro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-(6-naphthalen-1-yl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-chloro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-chloro-4-fluoro-phenyl)-1 H-benzoimidazol-2-yl] -2H-indazole;
3-[6-(3,5-dichloro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-(6-thianthren-l-yl-lH-benzoimidazol-2-yl)-2H-indazole;
3-(6-biphenyl-4-yl-l H-benzoimidazol-2-yl)-2H-indazole;
3 -(6-p-tolyl-1 H-benzoimidazol-2-yl)-2 H-indazole;
3-(6-m-tolyl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-(6-o-tolyl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-(6-thiophen-3-yl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3-trifluoromethyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3 -[6-(4-trifluoromethyl-phenyl)-1 H-benzoimidazol-2-yl] -2H-indazole;
3-[6-(3-chloro-phenyl)-1 H-benzoimidazol-2-yl] -2H-indazole;
3-[6-(3 -methoxy-phenyl)- 1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,5-dimethyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,4-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-benzo[ 1,3] dioxol-5-yl-lH-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-tert-butyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3 -(6-hex-l-enyl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3,4-dimethoxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl] -phenol;
4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl] -phenol;
3-[6-(3,4-dichloro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-trifluoromethoxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
1- {4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl } -ethanone;
3-(6-benzo[b]thiophen-2-yl-lH-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3,4,5-trimethoxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
1- { 5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl } -ethanone;
1-{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl} -ethanone;
3-[6-(4-benzyloxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(2-fluoro-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2H-indazole;
3 -(6-b enzo [b] thiophen-3 -yl-1 H-benzoimidazol-2-yl)-2H-indazole;
{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl } -methanol;
3-[6-(4-ethylsulfanyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(2,4-difluoro-phenyl)-1 H-b enzoimidazol-2-yl] -2H-indazole;
3-[6-(3-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-fluoro-2-methyl-phenyl)-1 H-benzoimidazol-2-yl] -2H-indazole;
3-{6-[2-(4-fluoro-phenyl)-vinyl]-1 H-benzoimidazol-2-yl} -2H-indazole;
3-{6-[2-(4-chloro-phenyl)-vinyl]-1 H-benzoimidazol-2-yl} -2H-indazole;
3-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-propionic acid;
{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;
3 -(6-furan-2-yl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3-benzyloxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-isopropyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3 -[6-(4-methane sulfonyl-phenyl)-1 H-benzoimidazol-2-yl] -2H-indazole;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid isopropylamide;
[2-(1 H-indazol-3-yl)-1 H-benzoimidazol-5-yl]-morpholin-4-yl-methanone;
[2-(1 H-indazol-3-yl)-1 H-benzoimidazol-5-yl]-(4-methyl-piperazin-l-yl)-methanone;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4'-chloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3',5'-dichloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4'-fluoro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2'-chloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-ainide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;
4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-l-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[ 5-(3 -phenyl-allyloxy)2H-pyrazol-3-yl] -1 H-benzoimidazole;
2-[5-(2-methyl-allyloxy)2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,7-dimethyl-octa-2, 6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-bromo-benzyloxy)-2 H-pyrazol-3-yl]-1 H-benzoimidazole;
3-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile;
2-[5-(4-trifluoromethyl-benzyloxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[ 5 -(3,4-dichloro-b enzyloxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[5-pentafluorophenylmethoxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[5-(4-tert-butyl-benzyloxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
4-[5 -(1 H-benzoimidazol-2-yl)-1 H-pyrazol-3-yloxymethyl] -benzonitrile;
2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2,3-dichioro-benzenesulfonic acid 5-(1 H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2-[5-(2-morpholin-4-yl-ethoxy)-2 H-pyrazol-3-yl]-1H-benzoiniidazole;
2-[5-(2-piperidin-1-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1 -p-tolyl-ethanone;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3,4,4,4-pentafluoro-butan-2-one;
2-[5-(1 H-benzoimidazol-2-yl)-1 H-pyrazol-3 -yloxy] -1-biphenyl-4-yl-ethanone;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-butan-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1 H-pyrazol-3-yloxy]-1-(4-dimethylamino-phenyl)-ethanone;
2-[5-(1 H-b enzo imidazol-2-yl)-1 H-pyrazol-3-yloxy]-1-(3 -phenyl-isoxazol-5-yl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-N-phenyl-acetamide;
1-[5-(1H-benzoimidazol-2-yl)-1 H-pyrazol-3-yloxy]-3,3-dimethyl-butan-2-one;
1-adamantan-1-yI-2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-naphthalen-2-yl-ethanone;
4-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl} -benzonitrile;
6- {2-[5-(IH-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-3,4-dihydro-lH-quinolin-2-one;
2-[5-(1 H-benzoimidazol-2-yl)-1 H-pyrazol-3-yloxy]-1-(4-trifluoromethoxy-phenyl)-ethanone;
5-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-2-chloro-benzenesulfonamide;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-methoxy-phenyl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1 -cyclopropyl-ethanone;
isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,2-dimethyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzyloxy-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
4-methoxy-benzoic acid 5-(1H-benzoimidazol-2-yI)-1H-pyrazol-3-yl ester;
phenyl-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,3,4,5,6-Pentafluoro-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
cyclopropanecarboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,2,3,3,4,4,4-heptafluoro-butyric acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
cyclopentanecarboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yI)-1H-pyrazol-3-yl ester;
biphenyl-4-carboxylic acid 5-(1H benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3,5-bis-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
4-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
thiophene-2-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixa), denoted as the product of the combination of group Al in Table 1 and B 1 in Table 2, of the invention for the inhibition of KDR are:-2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-lH-benzimidazole, (compound denoted as A9-B3);
2-(5-methyl-2H-pyrazol-3-yl)-5,6-dimethyl-lH-benzimidazole (compound denoted as A9-B2);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically accelftable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixb), denoted as the product of the combination of group Al in Table 1 and B 1 in Table 2, of the invention for the inhibition of KDR are:-2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide, (compound denoted as A17-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide, (compound denoted as A15-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide, (compound denoted as A36-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide, (compound denoted as A37-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide, (compound denoted as A52-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide, (compound denoted as A51-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide, (compound denoted as A92-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide, (compound denoted as A93-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide, (compouiid denoted as A91-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide, (compound denoted as A82-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide, (compound denoted as A83-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide, (compound denoted as A84-B63);
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide, (compound denoted as A90-B63);
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide;
4-( { [2-(1H-indazol-3-yl)-1 H-benzoimidazole-5-carbonyl]-amino} -methyl)-piperidine- 1 -carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-lH-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (1-methyl-lH-pyrazol-4-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide;
2-(IH-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-lH-benzoimidazol-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide;
2-(1 H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide;
3-[6-(4-fluoro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-methoxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-m-tolyl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-(6-o-tolyl-1 H-b enzoimidazol-2-yl)-2H-indazole;
3-(6-thiophen-3-yl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3-chloro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,5-dimethyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-(6-benzo[ 1,3]dioxol-5-yl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-(6-hex-l-enyl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3,4-dimethoxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;
4-[2-(2H-indazol-3-yl)-3H-benzoiinidazol-5-yl]-phenol;
3-[6-(3,4,5-trimethoxy-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
1-{5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl} -ethanone;
{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl} -methanol;
3-[6-(2,4-difluoro-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-fluoro-2-methyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl } -methanol;
3-(6-furan-2-yl-1 H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-isopropyl-phenyl)-1 H-benzoimidazol-2-yl]-2H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid isopropylamide;
[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-morpholin-4-yl-methanone;
[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-(4-methyl-piperazin-1-yl)-methanone;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide;
2-(lH-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2'-chloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-l-yl-propyl)-amide;
4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-l-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[5 -(3-phenyl-allyloxy)2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[5-(3,7-dimethyl-octa-2, 6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5 -(3-bromo-benzyloxy)-2H-pyrazol-3-yl]-1 H-benzoimidazole;
2-[5-(3,4-dichloro-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3 -yl]-1H-benzoimidazole;
isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yn-lH-pyrazol-3-yl ester;
methyl2-(1 H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
5 -methoxy-2-(1 H-indazol-3 -yl)-1 H-benzimidazole;
5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole, (compound denoted as A32-B63);
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Particularly preferred compounds of formula (Ixb) of the invention for the inhibition of KDR are:-2-(1 H-indazol-3-yl)- 1 H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-lH-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-lH-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(lH-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(lH-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoiinidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particular compounds of formula (Ix) of the invention for the inhibition of ITK are:-2-(IH-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide, Example 246(ab);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide, Example 246(ac);
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide, Example 246(ad);
N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide, Example 246(ae) N-[3-(5,6-Dimethyl-lH-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide, Example 253(c) and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

The compounds of formula (Ix) of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of formula (Ix) of the invention and compositions containing compounds of formula (Ix) of the invention for use in therapy.

Compounds of formula (Ix) within the scope of the present invention block kinase catalytic activity according to tests described in the literature and in vitro procedures described hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of forinula (Ix) of the invention and compositions containing compounds of formula (Ix) of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of protein kinase inhibitors (e.g. Syk, KDR, tie2 or ITK). For example, compounds of formula (Ix) of the present invention are useful in the treatment of inflammatory diseases, for example asthma: atopic dermatitis, inflammatory dermatoses (e.g. psoriasis, dematitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease, acute and chronic urticaria,); allergic rhinitis and allergic conjunctivitis; joint inflainmation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. The compounds of formula (Ix) are also useful in the treatment of Chronic Obstructive Pulmonary Disease (COPD), adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, collitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, viral infections, bacterial infections, parasitic infections, graft v host disease and other transplant associated rejection events, reperfusion injury, Crohn's disease and ulcerative colitis, cancers and tumours (such as colorectal, prostate, breast, thyroid, colon and lung cancers), atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, fibrotic diseases of the viscera, and inflammatory bowel disease.
The products of the present patent application as SYK inhibitors may be used for the treatment of diseases chosen from the following: asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, acute and chronic urticaria, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, systemic lupus erythromatosis, viral infections, bacterial infections, parasitic infections, graft vs. host disease, organ transplant rejection, reperfusion injury, Crohn's disease and ulcerative colitis.
The products of the present patent application as KDR inhibitors may be used especially for the treatment or prevention of diseases chosen from the following group: cancers, especially breast, colon, lung and prostate cancer, atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and fibrotic diseases of the viscera.

A special embodiment of the therapeutic methods of the present invention is the treating of asthma.
Another special embodiment of the therapeutic methods of the present invention is the treating of psoriasis.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.
Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

Another special embodiment of the therapeutic methods of the present invention is the treating of cancers and tumours.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of a protein kinase inhibitor (e.g. . Syk, KDR, tie2 or ITK) for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. "Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting the catalytic activity a protein kinase, such as. Syk, KDR, tie2 or ITK, and thus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.

The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of formula (Ix) of the invention, as defined above, or a pharmaceutically acceptable salt or a prodrug, in association, where appropriate, with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical compositions of the present invention for the treatment of KDR
or tie2 associated disease states can also, where appropriate, contain active principles of other antimitotic medicinal prbducts such as, in particular, those based on taxol, cis-platin, DNA-intercalating agents and the like.
Compounds of formula (Ix) of the invention may be administered by any suitable means. In practice compounds of formula (Ix) of the present invention may generally be administered parenterally, locally by topical application to the skin and mucous membranes, rectally, orally, by inhalation, or by intravenous or intramuscular injection, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents.
The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets.
To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols.
When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used.
The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of formula (Ix) of the invention may be used. Compounds of formula (Ix) of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

For administration by inhalation compounds of formula (Ix) of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.
Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inllalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds of formula (Ix) according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds of formula (Ix) of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH
publishers, 1989.
In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P.G.M.Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

Compounds of formula (Ix) wherein W, X, Y, Z and R1 are as hereinbefore defined for compounds of formula (Ix) and A5 is H, may be prepared by reaction of compounds of formula (IIx):-Y~ ~ NH, X\ , (IIx) W NHZ

in which W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with acids of formula (IIIx):-Rl COZH (IIIx) in which Rl is as hereinbefore defined for compounds of formula (Ix), at a temperature at about 160 C.
Alternatively the reaction may (i) be carried in the presence of hydrochloric acid at about reflux temperature, or polyphosphoric acid at a temperature at about 160 C or (ii) be carried out in a microwave oven.

Compounds of formula (Ix) wherein W, X, Y, Z and Rl are as hereinbefore defined and A5 is H, may =
be prepared by reaction of compounds of formula (IIx) in which W, X, Y and Z
are as hereinbefore defined for compounds of formula (Ix), with aldehydes of formula (IVx):-Rl CHO (IVx) in which RI is as hereinbefore defined for compounds of formula (Ix), in the presence of in inert solvent, such as dimethylformamide or nitrobenzene, and at a temperature up to about 145 C.
Alternatively the reaction may (i) be carried in the presence of sodium bisulfite at a temperature at about reflux temperature or (ii) be carried out in a microwave oven at a temperature up to about 200 C.

Compounds of formula (Ix) wherein W, X, Y, Z and RI are as hereinbefore defined for compounds of formula (Ix) and A5 is H, may be prepared by cyclisation of compounds of formula (Vx):-I-lZ NH, 11 ~
X~w/ "kRi (Vx) wherein W, X, Y, Z and R1 are as hereinbefore defined for compounds of formula (Ix). The cyclisation may be carried out by heating in the presence of an acid catalyst, such as acetic acid, and at a temperature up to about 120 C.

Compounds of formula (Ixa) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and Rl is in which R9 is as hereinbefore defined for compounds of formula (Ix), R7is hydrogen and R8 is SR4, i.e. compounds of formula (Ixaa), may be prepared as shown in scheme 1.

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME DE

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims (94)

WE CLAIM:
1. A compound of general formula (Ix) wherein X, Y, Z, and W are carbon atoms;
A5 represents H or alkyl;

R1 is a pyrazolyl moiety in which R7 is hydrogen or alkyl, R8 is selected from the group consisting of hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R14, -C(=O)R4, -C(=O)NY1Y2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -N(R6)SO2NY1Y2, -NY1Y2, -OR4, -OC(=O)R4, -OC(=O)NY1Y2, -S(O)n R4 and -S(O)2NY1Y2, and R9 is selected from the group consisting of hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NY1Y2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -N(R6)SO2NY1Y2, -NY1Y2, -OR4, -OC(=O)R4, -OC(=O)NY1Y2, -S(O)n R4 and -S(O)2NY1Y2; or R8 and R9 together with the carbon atoms to which they are attached form (i) a 5 to 8 membered carbocyclic ring optionally substituted by one or more carbocyclic ring substituents; (ii) a phenyl ring optionally substituted by one or more aryl group substituents; (iii) a 5 or 6 membered heteroaromatic ring in which one or more of the ring members is/are nitrogen, oxygen or sulfur and which is optionally substituted by one or more groups selected from haloalkyl, hydroxy, halo, cyano, nitro, R4, -C(=O)NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)SO2R4, -NY1Y2 and -OR5; or (iv) a 5 or 6 membered heterocyclic ring unsubstituted or substituted by alkyl or oxo, and comprising a heteroatom-containing group selected from O, S, SO2, and NY5 where Y5 is hydrogen, R4, -C(=O)R4, -C(=O)NY1Y2, -C(=O)OR4 or -SO2R4;

R2 and R3 are attached to X, Y, Z, or W but they are not attached to the same atom simultaneously;

R2 and R3 are independently H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R24, -C(=O)R4, -C(=O)NY1Y2, -C(=O)OR4, -NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -N(R6)SO2NY1Y2, -OR4, -OCF2H, -OCF3, -OC(=O)R4, -OC(=O)NY1Y2, -S(O)n R4, -S(O)n NY1Y2 or -S(O)n OR4, provided that R2 and R3 are not both H simultaneously; or R2 represents H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R4, -C(=O)R4, -C(=O)NY1Y2, -C(=O)OR4, -NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -N(R6)SO2NY1Y2, -OR4, -OCF2H, -OCF3, -OC(=O)R4, -OC(=O)NY1Y2, -S(O)n R4, -S(O)n NY1Y2 or -S(O) n OR4 and R3 represents alkyl, haloalkyl, halogen and OR6;

R4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each optionally substituted with one or more substituents selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, halo, hydroxy, hydroxyalkyl, -C(=O)NY3Y4, -C(=O)OR6, -N(R6)C(=O)NY1Y2, -NY1Y2, -OR5 or alkyl substituted by -NY3Y4;

R14 is alkyl with more than one carbon atom, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each optionally substituted with one or more substituents selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, halo, hydroxy, hydroxyalkyl, -C(=O)NY3Y4, -C(=O)OR6, -N(R6)C(=O)NY1Y2, -NY1Y2, -OR5 or alkyl substituted by -NY3Y4;

R24 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl, each optionally substituted with one or more substituents selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, halo, hydroxy, hydroxyalkyl, -C(=O)NY3Y4, -C(=O)OR6, -N(R6)C(=O)NY1Y2 -NY1Y2, -OR5 or alkyl substituted by -NY3Y4;

R5 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R6 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
n is zero or an integer 1 or 2;

Y1 and Y2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, heterocycloalkylalkyl or alkyl optionally substituted by one or more groups selected from cyano, aryl, heteroaryl, hydroxy, -C(=O)OR6, -C(=O)NY3Y4 -NY3Y4 and -OR5, or the group NY1Y2 may form a cyclic amine;

Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may form a cyclic amine;
where all the alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals are optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino (NH-COalk), -C(=O)OR6, -C(=O)R6, hydroxyalkyl, carboxyalkyl, S(O)n-alk, S(O)n-NH2, S(O)n-NH(alk), S(O)n-N(alk)2, CF3, OCF3, NO2, arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, -C(=O)-NY3Y4 and NY3Y4 radicals, the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(O)R5;

or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of said compound; or an N-oxide, prodrug, or acid bioisostere of said salt or solvate.
2. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier or excipient.
3. A compound according to claim 1 of formula (Ixa) wherein R7 is hydrogen or alkyl;

R8 and R9 are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R14, -C(=O)R4, -C(=O)NY1Y2, -C(=O)OR4, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -N(R6)C(=O)OR4, -N(R6)SO2R4, -NY1Y2, -OR4, -OC(=O)R4, -OC(=O)NY1Y2, -S(O)n R4 and -S(O)2NY1Y2, where X,Y,Z, W, R4, R6, Y1, Y2, and n are defined in claim 1; or an N-oxide, prodrug, acid bioisostere, pharmaceutically acceptable salt or solvate of such compound; or an N-oxide, prodrug, or acid bioisostere of such salt or solvate.
4. A compound according to claim 3 wherein R2 and R3 are independently alkyl, aryl, CN, NO2, halo, halo-alkyl, heteroaryl, OR4, C(=O)R4, C(=O)NY1Y2, C(=O)OR4, NHC(=O)R4 CH(OH) aryl, S(O)2NY1Y2, or S(O)n R4, where R4, R6, Y1, Y2, and n are defined in claim 1.
5. A compound according to claim 3 wherein R2 is attached to X and R3 is attached to Y;
R2 is CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, Br, or Cl;

R3 is CH3, CH2CH3, OCH3, Br, Cl, F,
6. A compound according to claim 3 wherein R2 is CH3 and is attached to Y and R3 is CH3 and is attached to Z.
7. A compound according to claim 3 wherein CR2 is attached to X; CR3 is attached to Y, and R2 and R3 form the group -CH2-O-CH2.
8. A compound according to claim 3 wherein CR2 is attached to X; CR3 is attached to Y, and R2 and R3 form the group -CH2-CH2-CH2.
9. A compound according to claim 3 wherein R7 represents hydrogen.
10. A compound according to claim 3 wherein R8 represents hydrogen, C1-4alkyl,-SR4, -NY1Y2 or -OR5.
11. A compound according to claim 3 wherein R9 represents hydrogen, C1-7alkyl, aryl, -C(=O)NY1Y2, -N(R)C(=O)R4, where R4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, or where R4 is NY1Y2 or -OR5 , or where R4 is aryl , or where R4 is cycloalkyl, or where R4 is heteroaryl, or where R4 is heterocycloalkyl;
or R9 represents -N(R)C(=O)NY1Y2, -NY1Y2, or alkyl substituted by -N(R6)C(=O)NY1Y2.
12. A compound according to claim 3 wherein R2 is H;
R3 is H; or R3 is CH3 and is attached to Z;
R7 represents hydrogen;

R8 represents hydrogen, C24alkyl, -SR4,-NY1Y2; and R9 represents hydrogen, C2-7alkyl, aryl, -C(=O)NY1Y2, -N(R6)C(=O)R4, -NHC(=O)R4, -N(R6)C(=O)NY1Y2, -NY1Y2, or alkyl substituted by -N(R6)C(=O)NY1Y2.
13. A compound according to claim 3 wherein R2 is H;
R3 is attached to Y and Y-R3 represents C-C1-4alkyl, C-aryl, C-CN, C-NO2, C-halo, C-haloalkyl, C-heteroaryl, C-OR4, C-C(=O)R4, C-C=O)NY1Y2, C-C(=O)OR4, or C-CH(OH)aryl;

R8 represents hydrogen, C2-4alkyl, -SR4,-NY1Y2 or -OR5 ; and R9 represents hydrogen, C2-7alkyl, aryl, -C(=O)NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -NY1Y2, or alkyl substituted by -N(R6)C(=O)NY1Y2.
14. A compound according to claim 3 wherein R2 is attached to X and X-R2 represents C-CH3, C-CH2CH3, C-CH(CH3)2, C-OCH3, C-OCH2CH3, C-Br or C-Cl;

R3 is attached to Y and Y-R3 represents C-CH3, C-CH2CH3, C-OCH3, C-Br, C-Cl, C-F, R7 represents hydrogen;

R8 represents hydrogen, C2-4alkyl, -SR4,-NY1Y2, or -OR5; and R9 represents hydrogen, C2-7alkyl, aryl, -C(=O)NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -NY1Y2, or alkyl substituted by -N(R6)C(=O)NY1Y2.
15. A compound according to claim 3 wherein R2 and R3 are CH3 and attached to Y and Z, respectively;
R7 represents hydrogen;

R8 represents hydrogen, C2-4alkyl, -SR4,-NY1Y2, or -OR5; and R9 represents hydrogen, C2-7alkyl, aryl, -C(=O)NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -NY1Y2, or alkyl substituted by -N(R6)C(=O)NY1Y2
16. A compound according to claim 3 wherein CR2 is attached X and CR3 is attached to Y, where R2 and R3 form the group -CH2-O-CH2-;

R7 represents hydrogen;

R8 represents hydrogen, C2-4alkyl, -SR4,-NY1Y2, or -OR5; and R9 represents hydrogen, C2-7alkyl, aryl, -C(=O)NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -NY1Y2, or alkyl substituted by -N(R6)C(=O)NY1Y2
17. A compound according to claim 3 wherein CR2 is attached to X and CR3 is attached to Y, where R2 and R3 form the group -CH2-CH2-CH2-;

R7 represents hydrogen;

R8 represents hydrogen, C2-4alkyl, -SR4 ,-NY1Y2, or -OR5; and R9 represents hydrogen, C2-7alkyl, aryl, -C(=O)NY1Y2, -N(R6)C(=O)R4, -N(R6)C(=O)NY1Y2, -NY1Y2 or alkyl substituted by -N(R6)C(=O)NY1Y2.
18. A compound according to claim 3 wherein R8 is hydrogen or -CH3; and R9 is -CH2-CH2-CH(CH3)2, -C(=O)-NH-CH2CH3, -C(=O)-NH-CH2CH2CH3, -C(=O)-NH-CH(CH3)2, -C(=O)-NH-C(CH3)3, -C(=O)-NH-C(CH3)2CH2OH, -C(=O)-NH-CH2CH2OCH3, -C(=O)-N(CH3)2, -C(=O)-N(CH2CH3)2, -NH-C(=O)-CH3, -NH-C(=O)-(CH2)2CH3, -NH-C(=O)-CH(CH3)2, -NH-C(=O)-C(CH3)3, -NH-C(=O)-CH2CH(CH3)2, -NH-C(=O)-CH(CH3)CH2CH3, -NH-C(=O)-CH2C(CH3)3, -NH-C(=O)-CH~N(CH3)2, -NH-C(=O)-CH2OCH3, -NH-C(=O)-NHCH3, -NH-C(=O)-NHCH2CH3, -NH-C(=O)-NHCH(CH3)2, -NH-C(=O)-NHC(CH3)3, -NH-C(=O)-N(CH3)2, -NH-C(=O)-N(CH2CH3)2, -CH2-NH-C(=O)-CH(CH3)2 or
19. A compound according to claim 3 wherein R9 represents hydrogen and R8 represents -CH(CH3)2, -S-CH3, -S-CH2CH3 or
20. A compound according to claim 3 wherein R2 is attached to Y; and Y-R2 is CH, C-CH2CH3, C-CH2CH2CH3, C-CN, C-Br, C-CF3, C-OCH3, C-OCH2CH3, C-OCHF2, C-OCF3, C-C(=O)-NH-CH3, C-C(=O)-NH-CH2CH3, C-C(=O)-NH-CH(CH3)2, C-C(=O)-NH-C(CH3)2-CH2OH, C-C(=O)-NH-CH2CH2CN, C-C(=O)-NH-CH2CH2OCH3 C-C(=O)OCH3, C-C(=O)OH, and and Z is CH.
21. A compound according to claim 3 wherein R2 is attached to X and X-R2 is C-CH3 or C-CH2CH3; R3 is attached to Y and Y-R3 is C-CH3, C-CH2CH3, C-CH(CH3)2, C-Br , C-Cl, C-F, or
22. A compound according to claim 3 wherein R2 is attached to X and X-R2 is C-OCH3;
and R3 is attached to Y and Y-R3 is CH, C-CH3, C-CH2CH3, C-Cl or C-OCH3.
23. A compound according to claim 3 wherein R2 is attached to X and X-R2 is C-OCH2CH3; and R3 is attached to Y and Y-R3 is C-F.
24. A compound according to claim 3 wherein R2 is attached to X and R3 is attached to Y, where R2 and R3 atoms form the group -CH2-CH2-CH2.
25. A compound according to claim 3 wherein R2 is attached to X and R3 is attached to Y, where R2 and R3 form the group -CH2-O-CH2.
26. A compound according to claim 13 wherein R8 is hydrogen; and R9 is -C(=O)-NH-CH2CH3, -C(=O)-NH-CH2CH2CH3, -C(=O)-NH-CH(CH3)2, -C(=O)-NH-CH2CH(CH3)2, -C(=O)-NH-C(CH3)3, -C(=O)-NH-C(CH3)2CH2OH, -C(=O)-N(CH2CH3), -C(=O)-NH-CH2CH2OCH3, -NH-C(=O)-(CH2)2CH3, -NH-C(=O)-CH(CH3)2, -NH-C(=O)-C(CH3)3, -NH-C(=O)-CH2CH(CH3)2, -NH-C(=O)-CH(CH3)CH2CH3, -NH-C(=O)-CH2C(CH3)3, -NH-C(=O)-CH2OCH3, -NH-C(=O)-NHCH3, -NH-C(=O)-NHCH2CH3, -NH-C(=O)-NHCH(CH3)2, -NH-C(=O)-NHC(CH3)3, -NH-C(=O)-N(CH3)2, -NH-C(=O)-N(CH2CH3)2
27. A compound according to claim 3 wherein R2 is H and is attached to X; and R3 is attached to Y and Y-R3 is C-OCH3, C-OCH2CH3, C-OCHF2, C-CF3, or and Z is CH.
28. A compound according to claim 3 wherein R2 is CH3 or CH2CH3 and is attached to X;
and R3 is attached to Y and Y-R3 is C-CH3 or C-CH2CH3, C-Cl or C-F.
29. A compound according to claim 3 wherein R2 is attached to X and X-R2 is C-OCH3;
R3 is attached to Y and Y-R3 is C-CH3, C-CH2CH3, C-Cl, C-F, or C-OCH3.
30. A compound according to claim 3 wherein R2 is attached to X and X-R2 is C-OCH2CH3; and R3 is attached to Y and Y-R3 is C-Cl or C-F.
31. A compound according to claim 3 wherein R2 is attached to X and R3 is attached to Y, where R2 and R3 form the group -CH2-CH2-CH2.
32. A compound according to claim 3 wherein R2 is attached to X and R3 is attached to Y
where R2 and R3 form the group -CH2-O-CH2.
33. A compound according to claim 1 selected from the group consisting of:
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;

5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5-fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride;

5-methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-1H-pyrazol-3-yl)- 5-methyl-1H-benzoimidazole;
2-(5-benzylsulfanyl-4-isopropyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
3-(5-chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
2-(4-amino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone;
2-(1H-indazol-3-yl)-3H-benzoimidazol-4-ol;

2-phenyl-1H-imidazol[4,5-b]pyrazine;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine;
2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine;
2-(1H-pyrazol-3yl)-1H-benzoimidazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole;
5,6-dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-isopropyl-6-methyl-1 H-benzoimidazol-2-yl)-1 H-indazole;
3-(5-bromo-6-methyl-1 H-benzoimidazol-2-yl)-1H-indazole;
3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole;
3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(2-methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(4-chloro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-(4-methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(4,5-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile;
3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid ethyl ester;

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3 -(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile;
2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-methylsulfanyl-isoxazol-3-yl)-1H-benzoimidazole;
5-chloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dichloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
(benzoimidazol-2-yl)-5-methylthio-3-pyrazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole;
2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole;
4-chloro-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazol-5-ol;
3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide;
3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide;
1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide;

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide;
2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid;
3-(5,6-dimethyl-1H-benzoimidazol-5-yl)-pyrazole-4-carboxylic acid;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide ;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide;

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;

cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide;

5,6-dimethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
5-ethyl-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
5-fluoro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethoxy-1H-benzoimidazole;
2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;
5-chloro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;
isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
5-ethoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole;
3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
2-dimethylamino-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-ylamine;
4-methylpiperazine-l-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;

cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;

tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide;

morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;

piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;

3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;

3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;

morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;

piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone;

[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone;
3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [2-(2H-tetrazol-5-yl)-ethyl]-amide;
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3 -ethyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid;
2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
3-(5-nitro-1H-benzoimidazol-2-yl)-1H-indazole;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide; N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide;
N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide;
2-(1H-indazol-3-yl)-3H-benzoimidazol-5-amine; and piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
34. A compound according to claim 1 selected from the group consisting of:
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5-fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;

4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride;

5-methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-benzylsulfanyl-4-isopropyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole;
2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
3-(5-chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine;
5,6-dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
2-(5-ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole;
(benzoimidazol-2-yl)-5-methylthio-3-pyrazole;
2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide;

2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide;

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

piperidine-1-carboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;

cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;

cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

N- [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
2-dimethylamino-N-[3-(5,6-dimethyl- 1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;

4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;

1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;

cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide;

morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;

piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;

3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;

3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;

morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;

piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide;
N-[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide;

methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5- carboxylate;

5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole;
2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid;
2-(5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid;
5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole;
5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole;
2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole; and 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole.
35. A compound according to claim 1 selected from the group consisting of:
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide, Example 3;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole;
6-chloro-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole;
2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole;
2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;

3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106);
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide;
2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide;

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;

cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]- 2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;

1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide;
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide;
3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h);
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;

morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1- [3 -(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide;
2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide; and N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide.
36. A compound according to claim 1 selected from the group consisting of:
3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;
3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide;
2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide;

2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide;

2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide;

cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea;
cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide;

cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide;
N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide;

N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide;
2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea;
1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;
cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide;
morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea;

morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea;

4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea;
4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;

1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; and 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea.
37. A compound according to claim 1 selected from the group consisting of:
3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide;

3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide;

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide;
3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide;
cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide;
1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea;
piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide;
3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea;
3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide;
piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide;
1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;
1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea;

3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea;
1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; and 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea.
38. A compound according to claim 1 selected from the group consisting of:
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide;

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(N'-methylpiperazino)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide;
2-(1 H-indazol-3-yl)-1 H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide;
2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide;

methyl 2-(IH-indazol-3-yl)-3H-benzimidazole-5- carboxylate;
,6-dimethyl-2-(1 H-indazol-3-yl)-1 H-benzimidazole;
5-methoxy-2-(1 H-indazol-3-yl)-1 H-benzimidazole;
2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid;
5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole;
2-(5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid;
5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole;
5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1 H-benzimidazole;
2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-IH-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5, 6-dimethyl-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-lH-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1 H-benzimidazole;
2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1 H-benzimidazole 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1 H-benzimidazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide;
2-(1I-I-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide;
4-({ [2-(1 H-indazol-3-yl)-1 H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-l-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-IH-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide;
2-(IH-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2']bithiophenyl-5-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-chloro-benzo[b]thiophen-3-ylmethyl)-amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-benzoimidazol-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (3-ethoxy-propyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-bromo-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (naphthalen-1-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-dimethylamino-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-bromo-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide;

2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-phenoxy-benzylamide;

2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethoxy-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide;

2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-chloro-benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid benzylamide;
2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenethyl-amide;
3-(6-phenyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(2,4-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-naphthalen-1-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,5-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-thianthren-1-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-biphenyl-4-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-p-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-m-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-o-tolyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-(6-thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3-trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,5-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3,4-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-benzo[1,3]dioxol-5-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(4-tert-butyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3 -(6-hex-1-enyl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3,4-dimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[2-(214-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;

4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol;
3-[6-(3,4-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
1-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone;
3-(6-benzo[b]thiophen-2-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3,4,5-trimethoxy-phenyl)-1H-benzoimidazol-2-y1]-2H-indazole;
1-{5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl}-ethanone;
1-{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone;
3-[6-(4-benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(2-fluoro-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-(6-benzo[b]thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole;
{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;
3-[6-(4-ethylsulfanyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(2,4-difluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(3-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-fluoro-2-methyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-{6-[2-(4-fluoro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole;
3-{6-[2-(4-chloro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole;
3-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-propionic acid;
{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol;
3-(6-furan-2-yl-1H-benzoimidazol-2-yl)-2H-indazole;
3-[6-(3-benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-isopropyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
3-[6-(4-methanesulfonyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid isopropylamide;
[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-morpholin-4-yl-methanone;
[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-(4-methyl-piperazin-l-yl)-methanone;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4'-chloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3',5'-dichloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4'-fluoro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2'-chloro-biphenyl-4-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide;
4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide;

2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide;
2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide;
2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-phenyl-allyloxy)2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-methyl-allyloxy)2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,7-dimethyl-octa-2,6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-bromo-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
3-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile;
2-[5-(4-trifluoromethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3,4-dichloro-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-pentafluorophenylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(4-tert-butyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
4-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile;
2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2,3-dichioro-benzenesulfonic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2-[5-(2-morpholin-4-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(2-piperidin-1-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-p-tolyl-ethanone;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3,4,4,4-pentafluoro-butan-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-biphenyl-4-yl-ethanone;

1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-butan-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-dimethylamino-phenyl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(3-phenyl-isoxazol-5-yl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-N-phenyl-acetamide;
1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3-dimethyl-butan-2-one;
1-adamantan-1-yl-2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-naphthalen-2-yl-ethanone;
4-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-benzonitrile;
6-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-3,4-dihydro-1H-quinolin-2-one;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-trifluoromethoxy-phenyl)-ethanone;

5-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-2-chloro-benzenesulfonamide;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-methoxy-phenyl)-ethanone;
2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-cyclopropyl-ethanone;

isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,2-dimethyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzyloxy-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
4-methoxy-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
phenyl-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,3,4,5,6-Pentafluoro-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
cyclopropanecarboxylic acid5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
2,2,3,3,4,4,4-heptafluoro-butyric acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
cyclopentanecarboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
biphenyl-4-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
3,5-bis-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester;
4-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; and thiophene-2-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester.
39. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any one of claims 3 to 38, together with one or more pharmaceutically acceptable carriers or excipients.
40. A use of a compound according to any one of claims 1 and 3 to 38 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk.
41. A use of a composition according to claims 2 or 39 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk.
42. A use of a compound according to any one of claims 1 and 3 to 38 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of KDR.
43. A use of a composition according to claims 2 or 39 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of KDR.
44. A use of a compound according to any one of claims 1 and 3 to 38 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of tie2.
45. A use of a composition according to claims 2 or 39 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of tie2.
46. A use of a compound according to any one of claims 1 and 3 to 38 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of ITK.
47. A use of a composition according to claims 2 or 39 for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of ITK.
48. A use of a compound according to any one of claims 1 and 3 to 38 for treating inflammatory disease.
49. A use of a composition according to claims 2 or 39 for treating inflammatory disease.
50. A use of a compound according to any one of claims 1 and 3 to 38 for treating cancer.
51. A use of a composition according to claims 2 or 39 for treating cancer.
52. A use of a compound according to any one of claims 1 and 3 to 38 for treating Chronic Obstructive Pulmonary Disease.
53. A use of a composition according to claims 2 or 39 for treating Chronic Obstructive Pulmonary Disease.
54. A use of a compound according to any one of claims 1 and 3 to 38 for treating asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, acute and chronic urticaria, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, systemic lupus erythromatosis, viral infections, bacterial infections, parasitic infections, graft vs. host disease, organ transplant rejection, reperfusion injury, Crohn's disease or ulcerative colitis.
55. A use of a composition according to claims 2 or 39 for treating asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, acute and chronic urticaria, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, systemic lupus erythromatosis, viral infections, bacterial infections, parasitic infections, graft vs. host disease, organ transplant rejection, reperfusion injury, Crohn's disease or ulcerative colitis.
56. A use of a compound according to any one of claims 1 and 3 to 38 for treating cancers, atherosclerosis, degenerative muscle disease, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, or fibrotic diseases of the viscera.
57. A use of a composition according to claims 2 or 39 for treating cancers, atherosclerosis, degenerative muscle disease, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, or fibrotic diseases of the viscera.
58. A use of a compound according to any one of claims 1 and 3 to 38 for treating asthma, atopic dermatitis, psoriasis, dermatitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease, acute and chronic urticaria, allergic rhinitis or allergic conjunctivitis, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, colitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, viral infections, bacterial infections, parasitic infections, graft v host disease and other transplant associated rejection events, reperfusion injury, Crohn's disease, ulcerative colitis, cancers, tumours, atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, fibrotic diseases of the viscera or inflammatory bowel disease.
59. A use of a composition according to claims 2 or 39 for treating asthma, atopic dermatitis, psoriasis, dermatitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease, acute and chronic urticaria, allergic rhinitis or allergic conjunctivitis, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, colitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, viral infections, bacterial infections, parasitic infections, graft v host disease and other transplant associated rejection events, reperfusion injury, Crohn's disease, ulcerative colitis, cancers, tumours, atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, fibrotic diseases of the viscera or inflammatory bowel disease.
60. A use of a compound according to any one of claims 1 and 3 to 38 for inhibiting angiogenesis.
61. A use of a composition according to claims 2 or 39 for inhibiting angiogenesis.
62. A use according to claim 50 or 51 wherein the cancer being treated is colorectal, prostrate, breast, thyroid, skin, colon or lung cancer.
63. A use of a compound according to any one of claims 1 and 3 to 38 for treating asthma.
64. A use of a composition according to claims 2 or 39 for treating asthma.
65. A use of a compound according to any one of claims 1 and 3 to 38 for treating psoriasis.
66. A use of a composition according to claims 2 or 39 for treating psoriasis.
67. A use of a compound according to any one of claims 1 and 3 to 38 for treating joint inflammation.
68. A use of a composition according to claims 2 or 39 for treating joint inflammation.
69. A use of a compound according to any one of claims 1 and 3 to 38 for treating inflammatory bowel disease.
70. A use of a composition according to claims 2 or 39 for treating inflammatory bowel disease.
71. A use of a compound according to any one of claims 1 and 3 to 38 for the preparation of a medicinal product intended for inhibiting the activity of a kinase protein.
72. A use of a compound according to any one of claims 1 and 3 to 38 for the preparation of a medicinal product for treating or preventing a disease characterized by deregulation of the activity of a kinase protein.
73. Use according to claims 71 or 72, in which the kinase protein is a tyrosine kinase protein.
74. Use according to claims 71 or 72, in which the kinase protein is chosen from the following group: FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2 and VEGFR.
75. Use according to claims 71 or 72, in which the kinase protein is KDR.
76. Use according to claims 71 or 72, in which the kinase protein is tie2.
77. Use according to claims 71 or 72, in which the kinase protein is in a cell culture.
78. Use according to claims 71 or 72, in which the kinase protein is in a mammal.
79. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of a medicinal product for treating or preventing a disease chosen from the following group:
disorders of the proliferation of blood vessels, fibrotic disorders, disorders of the proliferation of "mesangial" cells, metabolic disorders, allergies, asthma, thrombosis, diseases of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
80. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of a medicinal product for treating or preventing a disease chosen from the following group:
disorders of the proliferation of blood vessels, fibrotic disorders, disorders of the proliferation of "mesangial" cells, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
81. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of a medicinal product for preventing or treating diseases associated with an uncontrolled angiogenesis.
82. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of a medicinal product for treating diseases in oncology.
83. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of a medicinal product for treating cancers.
84. Use according to claim 82, for the treatment of solid tumours.
85. Use according to claims 83 or 84, for the treatment of cancers that are resistant to cytotoxic agents.
86. Use according to claims 83 or 84, for the treatment of breast cancer, stomach cancer, cancer of the ovaries, cancer of the colon, lung cancer, brain cancer, cancer of the larynx, cancer of the lymphatic system, cancer of the genito-urinary tract, bladder cancer, prostrate cancer, bone cancer and cancer of the pancreas.
87. Use according to claims 83 or 84, for the treatment of breast cancer, cancer of the colon or lung cancer.
88. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of medicinal products intended for cancer chemotherapy.
89. A use of a compound according to any one of claims 1 and 3 to 38, for the preparation of medicinal products intended for cancer chemotherapy alone or in combination.
90. Compounds according to any one of claims 1 and 3 to 38, as kinase inhibitors.
91. Compounds according to any one of claims 1 and 3 to 38, as KDR inhibitors.
92. Compounds according to any one of claims 1 and 3 to 38, as tie2 inhibitors.
93. A use according to claim 50 or 51 wherein the cancer being treated is breast cancer, stomach cancer, cancer of the ovaries, cancer of the colon, lung cancer, brain cancer, cancer of the larynx, cancer of the lymphatic system, cancer of the genito-urinary tract, bladder, prostrate, bone cancer or cancer of the pancreas.
94. A process for preparing a compound of formula (Ix) according to claim 1, characterized in that an acid of formula (D):
R1'-COOH (D) in which R1' has the meaning given in claim 1 for R1, in which the possible reactive functions are optionally protected with protecting groups, is subjected to an esterification reaction to give an acid ester of formula (II):
R1'-COOalk (II) in which R1' has the meaning given above and alk represents an alkyl radical, is subjected to a reduction reaction to give the alcohol of formula (III):
R1'-CH2OH (III) in which R1' has the meaning given above, which is oxidized to the aldehyde of formula (IV):
R1'-CHO (IV) in which R1' has the meaning given above, and the compound of formula (D) or compound of formula (IV) as defined above is reacted with a diamine of formula (V):

in which W', X', Y' and Z' have the meanings given in claim 1, respectively, for W, X, Y and Z, in which the possible reactive functions are optionally protected with protecting groups, to give a compound of formula (I'):

in which A5' has the meaning given in claim 1 for A5, in which the possible reactive functions are optionally protected with protecting groups, and R1', W', X', Y' and Z' have the meanings given above, the compound of formula (I') being a compound which may be a compound of formula (Ix) and which, in order to obtain a compound or other compound of formula (Ix), may be subjected, if desired and if necessary, to one or more of the following conversion reactions, in any order:
a) an esterification reaction of an acid function, b) a saponification reaction of an ester function to an acid function, c) an oxidation reaction of an alkylthio group to the corresponding sulphoxide or sulphone, d) a reaction for conversion of a ketone function to an oxime function, e) a reaction for reduction of the free or esterified carboxyl function to an alcohol function, f) a reaction for conversion of the alkoxy function to a hydroxyl function, or alternatively, of the hydroxyl function to an alkoxy function, g) a reaction for oxidation of an alcohol function to an aldehyde, acid or ketone function, h) a reaction for conversion of a nitrile radical to a tetrazolyl, i) a reaction for removal of the protecting groups that may be borne on the protected reactive functions, j) a salification reaction with a mineral or organic acid or with a base to give the corresponding salt, k) a reaction for resolution of the racemic forms into resolved products, the said compound of formula (Ix) this being obtained in any possible racemic, enantiomeric or diastereomeric isomer form.
CA2465247A 2001-10-26 2002-10-24 Benzimidazoles and analogues and their use as protein kinases inhibitors Expired - Fee Related CA2465247C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
FR0113868A FR2831537B1 (en) 2001-10-26 2001-10-26 NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF
FR01/13868 2001-10-26
GB0206893A GB0206893D0 (en) 2002-03-22 2002-03-22 Chemical compounds
GB0206893.0 2002-03-22
GB0206895A GB0206895D0 (en) 2002-03-22 2002-03-22 Chemical compounds
GB0206895.5 2002-03-22
US39506002P 2002-07-11 2002-07-11
US39515102P 2002-07-11 2002-07-11
US60/395,060 2002-07-11
US60/395,151 2002-07-11
PCT/GB2002/004763 WO2003035065A1 (en) 2001-10-26 2002-10-24 Benzimidazoles and analogues and their use as protein kinases inhibitors

Publications (2)

Publication Number Publication Date
CA2465247A1 CA2465247A1 (en) 2003-05-01
CA2465247C true CA2465247C (en) 2010-05-18

Family

ID=27515325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2465247A Expired - Fee Related CA2465247C (en) 2001-10-26 2002-10-24 Benzimidazoles and analogues and their use as protein kinases inhibitors

Country Status (9)

Country Link
EP (1) EP1441725A1 (en)
JP (1) JP5039268B2 (en)
AU (1) AU2002334217B2 (en)
BR (1) BR0213562A (en)
CA (1) CA2465247C (en)
IL (1) IL161576A0 (en)
MX (1) MXPA04003954A (en)
UY (1) UY27516A1 (en)
WO (1) WO2003035065A1 (en)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007697A (en) * 2002-02-06 2004-11-10 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3.
DE10227668A1 (en) * 2002-06-20 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicines for the treatment of systemic inflammatory response syndrome
CA2494421A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
JP2004189738A (en) * 2002-11-29 2004-07-08 Nippon Nohyaku Co Ltd Substituted anilide derivative, its intermediate, agricultural horticultural chemical and usage of the same
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
KR101190964B1 (en) * 2003-07-03 2012-10-12 아스텍스 테라퓨틱스 리미티드 Benzimidazole derivatives and their use as protein kinases inhibitors
AR045037A1 (en) * 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
RS51846B (en) * 2003-09-08 2012-02-29 Aventis Pharmaceuticals Inc. Thienopyrazoles
ES2319539T3 (en) * 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv HETEROCICLICAL COMPOUNDS CONDENSED AS SEROTONINE RECEPTOR MODULATORS.
EP1694671A2 (en) 2003-12-04 2006-08-30 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005065686A1 (en) * 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Differentiation modulating agents and uses therefor
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
ITTO20040125A1 (en) * 2004-03-01 2004-06-01 Rotta Research Lab NEW HETEROCYCLIC AMIDINS INHIBITIVE THE PRODUCTION OF NITROGEN OXIDE (NO) FOR ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY
DE102004010207A1 (en) 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
DE102004010194A1 (en) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-one derivatives, their preparation and use in medicaments
GT200500208A (en) * 2004-08-03 2006-03-02 USEFUL INDAZOLS TO TREAT CARDIOVASCULAR DISEASES
EP1797072A4 (en) 2004-09-17 2009-09-09 Exelixis Inc Pyrazole kinase modulators and methods of use
JP2008513508A (en) 2004-09-21 2008-05-01 シンタ ファーマシューティカルズ コーポレーション Compounds used for inflammation and immunity related applications
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
DE602005026037D1 (en) * 2004-10-27 2011-03-03 Janssen Pharmaceutica Nv TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS
CN101830899A (en) * 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
US20100160324A1 (en) * 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EP1833819A1 (en) * 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
JPWO2006080450A1 (en) * 2005-01-27 2008-06-19 協和醗酵工業株式会社 IGF-1R inhibitor
CN101160312A (en) * 2005-04-14 2008-04-09 霍夫曼-拉罗奇有限公司 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
MX2007012477A (en) 2005-04-14 2007-11-08 Hoffmann La Roche Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents.
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2007001939A1 (en) * 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
CA2614156A1 (en) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
JP2009503001A (en) * 2005-08-01 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー Heterocyclic benzylamino derivatives, their production and use as pharmaceuticals
JP2009519279A (en) * 2005-12-15 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー Three-membered lactam derivatives, methods for their production and use as pharmaceutical agents
JP5474354B2 (en) * 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
EP1984370A4 (en) * 2006-01-23 2010-03-31 Crystalgenomics Inc Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
CN101466374B (en) * 2006-04-14 2012-03-21 雅培制药有限公司 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1(VR1) receptors
EP2049119A2 (en) * 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
DE102006030479A1 (en) 2006-07-01 2008-03-20 Merck Patent Gmbh indazole
FR2903406B1 (en) * 2006-07-04 2012-08-10 Aventis Pharma Sa PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
CL2007002617A1 (en) 2006-09-11 2008-05-16 Sanofi Aventis COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO.
MX2009004140A (en) 2006-10-21 2009-07-10 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors.
DE102006060598A1 (en) * 2006-12-21 2008-06-26 Merck Patent Gmbh New tetrahydrobenzoisoxazole compounds are mitotic motor protein Eg5 modulators useful to treat and prevent cancer, and to treat e.g. monocyte leukemia, glioblastoma, colon carcinoma, myelotic leukemia and lymphatic leukemia
BRPI0817527A2 (en) 2007-10-01 2017-05-02 Isis Pharmaceuticals Inc antisense modulation of human fibroblast growth factor receptor expression 4
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2294065B1 (en) 2008-01-22 2014-03-19 Vernalis (R&D) Ltd. Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
GB0803018D0 (en) * 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009138799A1 (en) * 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
CA2724430A1 (en) * 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
BRPI0914006A2 (en) 2008-07-03 2015-10-27 Sirtris Pharmaceuticals Inc benzimidazoles and related analogues as sirtuin modulators
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
CN101619058A (en) * 2009-01-08 2010-01-06 上海交通大学 Benzimidazole-4-acid amide type derivant
BR112012000254A2 (en) 2009-07-08 2016-02-16 Dermira Canada Inc tofa analogues useful in treating dermatological disorders or conditions.
KR101529767B1 (en) 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 Aminopyrazole derivative
ES2835553T3 (en) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Indazole Inhibitors of the Wnt Signaling Pathway and Their Therapeutic Uses
BR112012002942A2 (en) * 2009-08-10 2015-10-13 Epitherix Llc indazoles as inhibitors of the wnt / b-catenin signaling pathway and their therapeutic uses.
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
NZ731621A (en) 2009-12-04 2019-01-25 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
CA2986631C (en) 2009-12-21 2020-06-02 Samumed, Llc 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
GB2482501A (en) * 2010-08-04 2012-02-08 Summit Corp Plc Novel compounds for use in the treatment of Clostridium Difficile and associated diseases
WO2012020725A1 (en) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Heterocyclic derivative having npy y5 receptor antagonism
CN102372674A (en) * 2010-08-17 2012-03-14 上海药明康德新药开发有限公司 Synthesis method for pharmaceutical intermediate 3-formyl-4-halogeno pyrazole
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
JP5998142B2 (en) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012135799A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted 3-(1h-benzo{d}imidazol-2-yl)-1h-indazole-analogs as inhibitors of the pdk1 kinase
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
DE102011111400A1 (en) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclic heteroaromatic compounds
MX341504B (en) 2011-09-14 2016-08-19 Samumed Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors.
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
RU2641693C2 (en) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед 5-(pyridine-2-ylamino)-pyrasin-2-carbonitrile compounds and their therapeutic application
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
BR112014024284B1 (en) 2012-05-04 2021-08-31 Samumed, Llc 1H-PIRAZOLO[3,4-B]PYRIDINES COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING SUCH COMPOUNDS AND THERAPEUTIC USES THEREOF
MX358819B (en) 2012-05-15 2018-09-05 Cancer Research Tech Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridy l]amino]pyrazine-2-carbonitrile and therapeutic uses thereof.
US9120792B2 (en) * 2012-05-31 2015-09-01 Sumitomo Chemical Company, Limited Fused heterocyclic compound
UA119315C2 (en) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Inhibitors of hepatitis c virus
JP2015535227A (en) * 2012-10-26 2015-12-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 3,4-disubstituted 1H-pyrazole and 4,5-disubstituted thiazole inhibitors of SYK
MX370487B (en) 2013-01-08 2019-12-16 Samumed Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof.
GB201302927D0 (en) * 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
EP2970205B1 (en) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2735355T3 (en) 2013-03-15 2019-12-18 Gilead Sciences Inc Hepatitis C virus macrocyclic and bicyclic inhibitors
CN104447701B (en) * 2013-09-17 2019-03-22 广东东阳光药业有限公司 Pyrazole derivatives and application thereof
EP3581179A1 (en) 2013-12-27 2019-12-18 Chugai Seiyaku Kabushiki Kaisha Fgfr gatekeeper mutant gene and drug targeting same
CN104098513B (en) * 2014-07-30 2016-08-24 天津市斯芬克司药物研发有限公司 A kind of indazole compound derivative and preparation method thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
US9550779B2 (en) * 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
AU2016264958B2 (en) * 2015-05-21 2020-10-29 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as PAD4 inhibitors
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
WO2016202758A1 (en) * 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
MA43169B1 (en) 2015-11-06 2022-05-31 Incyte Corp Heterocyclic compounds as pi3k-gamma inhibitors
AU2016348639B2 (en) 2015-11-06 2022-09-08 Samumed, Llc Treatment of osteoarthritis
AR107030A1 (en) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc AZA-BENCIMIDAZOL INHIBITORS OF PAD4
TW201734003A (en) 2016-01-05 2017-10-01 英塞特公司 Pyridine and pyridimine compounds as PI3K-gamma inhibitors
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
MD3464285T2 (en) 2016-06-01 2023-01-31 Biosplice Therapeutics Inc Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
JP7187437B2 (en) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク Compounds and compositions and uses thereof
MA45795A (en) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS, AND ASSOCIATED USES
KR102593742B1 (en) 2016-10-21 2023-10-24 사뮤메드, 엘엘씨 Methods of using indazole-3-carboxamide and their use as WNT/B-catenin signaling pathway inhibitors
KR102558716B1 (en) 2016-11-07 2023-07-21 사뮤메드, 엘엘씨 Single-dose, ready-to-use injectable formulation
CA3055292A1 (en) 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP7146782B2 (en) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク Methods of treating schizophrenia
MX2020000523A (en) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof.
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
CN108546266B (en) * 2018-07-25 2020-09-22 上海毕得医药科技有限公司 Synthesis method of 1,4,6, 7-tetrahydropyrane [4,3-C ] pyrazole-3-carboxylic acid
MX2021000977A (en) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same.
DK3847175T3 (en) 2018-09-05 2024-03-18 Incyte Corp CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
CA3125353A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
WO2020150552A2 (en) * 2019-01-17 2020-07-23 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
KR20210139376A (en) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 Salts of isochromanyl compounds, and crystalline forms thereof, methods of preparation, therapeutic uses and pharmaceutical compositions
WO2021060307A1 (en) * 2019-09-25 2021-04-01 富士フイルム株式会社 Imidazopyridine compound or salt thereof, and pharmaceutical composition
JP2023507138A (en) * 2019-12-20 2023-02-21 ファイザー・インク benzimidazole derivative
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
CN112239452B (en) * 2020-10-14 2022-05-10 武汉尚赛光电科技有限公司 Electron transport type heteroanthracene derivative and organic electroluminescent device thereof
CN114478511B (en) * 2022-02-24 2023-06-20 中国药科大学 Benzoxazole compound and preparation method, pharmaceutical composition and application thereof
WO2023234970A1 (en) * 2022-06-01 2023-12-07 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130029A1 (en) * 1971-06-18 1972-12-21 Bayer Ag Anthelmintic 2-pyrazolyl-benzimidazoles prodn - from 2-hydroxy -benzimidazoles and pyrazoles with phosphorus halides
DE2130030A1 (en) * 1971-06-18 1972-12-21 Bayer Ag Fungicidal and bactericidal agents
BE793501A (en) * 1971-12-31 1973-06-29 Ciba Geigy HETEROCYCLIC COMPOUNDS AND PHYTOPHARMACEUTICAL PRODUCTS WHICH CONTAIN IT
WO1996014843A2 (en) * 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
JP4357004B2 (en) * 1997-04-11 2009-11-04 あすか製薬株式会社 Pyrazole derivative and COX inhibitor containing the same
CN1168727C (en) * 1999-06-23 2004-09-29 阿文蒂斯药物德国有限公司 Substituted benzimidazole
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
YU54202A (en) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds

Also Published As

Publication number Publication date
BR0213562A (en) 2004-08-31
EP1441725A1 (en) 2004-08-04
WO2003035065A1 (en) 2003-05-01
MXPA04003954A (en) 2004-11-29
CA2465247A1 (en) 2003-05-01
JP5039268B2 (en) 2012-10-03
AU2002334217B2 (en) 2008-07-03
IL161576A0 (en) 2004-09-27
JP2005509633A (en) 2005-04-14
UY27516A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
CA2465247C (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
US6897208B2 (en) Benzimidazoles
AU2002334217A1 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
US10995078B2 (en) Compounds and compositions for inhibition of FASN
CA2451678C (en) Azaindoles
CA2395593C (en) Azaindoles
AU2004253338B2 (en) Benzimidazole derivatives and their use as protein kinases inhibitors
JP4377228B2 (en) Benzimidazole derivatives and their use as KDR kinase protein inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141024